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Abstract 
Understanding of appetite regulation has advanced in recent years. A complex network of 
CNS neuropeptides has been identified. Peripheral adipocyte hormones such as leptin 
regulate energy homeostasis, at least in part via CNS appetite circuits 
". 
Hormones secreted 
by the gut also modulate energy intake, and may signal via the CNS. The experiments 
described in this thesis investigate the effects of various gut hormones on energy 
homeostasis in rodents and man. 
Pairs of gut hormones, known to reduce food intake individually, were co-administered to 
rodents in order to investigate the hypothesis that gut hormones reduce feeding additively., 
The combinations OF PYY3-36 + CCK, and PYY3-36 + GLP-17-36 inhibited food intake 
additively. In contrast no such additive effect was observed with PYY3, -36 + 
PP- C-0- 
administration of PYY3-36 + GLP-17-36 stimulated c-fos staining in the arcuate nucleus of 
the hypothalamus, indicating an anatomical location of neuronal activation. ' PYY3-36 and 
GLP-17-36 were administered to healthy lean human volunteers via intravenous infusion 
over 120 minutes. The combined treatment of 0.4pmol/kg/min PYY3-36 + 0.4pmol/kg1min 
GLP-17-36 was associated with a 28% reduction in energy intake at an unlimited buffet 
meal compared with saline control, which was significantly greater than that following 
either peptidc alone. 
'nie gastric hormone ghrelin was known to increase energy intake in rodents and healthy 
humans. A study was performed to investigate the hypothesis that ghrclin would 
stimulate energy intake in patients with elevated endogenous circulating ghrelin. 
Intravenous infusion of ghrelin (Spmol/kglmin) to cancer patients with loss of appetite 
resulted in a significant 3 1% increase in energy intake. In a further study, subcutaneous 
administration of ghrelin (3.6nmol/kg) to healthy volunteers was associated with a 27% 
increase in energy intake, which suggested that ghrelin might be effective via this more 
practical route. Finally, in order to investigate mechanism of action, ghrelin was 
administered intravenously to patients with vagotomy. Although the GH response was 
present, there was no significant change in energy intake. Thus an intact vagus ncrvc may 
be required to enable ghrelin to stimulate feeding. 
data may enable greater understanding of gut hormone physiology and contribute to 
the quest to devclop cffectivc anti-obesity and appetite-stimulatory treatments. 
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Chapter I 
General Introduction 
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1.1 Obesity 
The survival of our species depends upon the drive to find food. Our ancestors are likely 
to have been those who were best able to survive famine by laying down fat in times of 
plenty, and conserving energy in timesof food deprivation. Ironically in present times 
these survival attributes make us particularly susceptible to the dangers of excess food. 
Obesity is a disease which is causally associated with a number of serious medical 
conditions, including diabetes mellitus, coronary heart disease and several cancers (Daling 
et al, 2001). The prevalence of obesity is increasing. Figures from the Health Survey for 
England show that in 1980 8% women and 6% men were classified as obese, as defined 
by a body mass index (BMI) of greater than 30 k g/M 2. By 2004 these proportions had 
increased to 24% in both sexes, with an additional 35% of women and 44% of men being 
overweight (BMI 25 - 30 kg/m2) (Health Survey for England, 2004), reflecting a 
worldwide trend which is most marked in, but not restricted to, the developed world. The 
rising prevalence of obesity in children and adolescents is of particular concern (Chinn & 
Rona, 2001) not least because obese children are at significantly increased risk of 
becoming obese adults. The prevalence of obesity in 11-15 year olds almost doubled 
between 1995 and 2004 (Health Survey for England, 2004). In this age group the 
prevalence of obesity in boys increased from 14% in 1995 to 24% in 2004, and in girls 
from 15% to 26%. There was also an increase in the number of obese younger children. 
Obesity prevalence in boys aged 2-10 increased from 10% in 1995 to 16% in 2004 and for 
girls from 10% to I I% (Health Survey for England, 2004). 
These data indicate a significant shift in the weight of the population over two decades. 
Such a rapid alteration is unlikely to be explained by genetic change and is more likely to 
be attributable to changes in the environment such as more readily available energy dense 
foods and more sedentary lifestyles. There is a great range of weights between individuals 
in similar environments and this may be attributable at least in part to differences in 
genetic makeup. Children whose parents are obese are at increased risk of developing 
obesity themselves (Reilly et al, 2005). In an observational study in twins, concordance 
rates for different degrees of overweight were twice as high for monozygotic twins as for 
12 
dizygotic twins (Stunkard et al, 1986a). Further evidence of the relative importance of 
genetic makeup in the determination of individual body weight comes from a study which 
compared the 'weight class' (thin, medium weight, overweight and obese) in Danish 
adoptees with those of their biological and adoptive parents (Stunkard et al, 1986b). 
There were significant correlations between the weight class of the adoptees and both 
biological parents but not with their adoptive parents. 
1.2 Energy homeostasis 
Energy homeostasis is the regulation of energy balance to maintain a relatively constant 
weight in the face of short term changes in energy intake and output. The majority of 
healthy humans retain their weight remarkably accurately despite considerable variation in 
day to day energy intake (Edholm, 1977). Disorder of energy homeostasis may lead to 
obesity. If the energy content of the food ingested is less than the energy output, then 
endogenous energy stores are utilised. Glycogen, protein and fat are catabolised and the 
individual loses weight. Conversely if energy intake exceeds energy output, then the 
excess energy is stored, predominantly as glycogen and fat and the individual gains 
weight. Energy output or expenditure results from basal energy metabolism, 
thermoregulation and physical activity. Basal metabolism sustains essential bodily 
functions and growth and accounts for approximately 45-70% of daily energy expenditure 
(Ganong, 2003). 
There is an intimate relationship between energy intake and expenditure and between 
energy stores and reproductive capacity. The hypothalamus has been thought to be 
critical in the regulation of energy homeostasis since the late 1940s, when it was noted 
that animals with lesions to the medial hypothalamus became hyperphagic and obese, and 
animals with lesions to the lateral hypothalamus became hypophagic and thin (Brobeck, 
1946; Anand & Brobeck, 1951). In the 1960s, it was reported that rats with bilateral 
lesions to the ventral medial hypothalamus not only ate more but also displayed reduced 
locomotor activity as assessed by movement on a running wheel (Kennedy & Mitra, 
1963a). Thus the hypothalamus may regulate energy expenditure in addition to food 
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intake. In another study, these authors observed that lesions to the ventrornedial 
hypothalamus of female rats sometimes caused disruption to the oestrus cycle and always 
prevented mating behaviour (Kennedy & Mitra, 1963b). This latter study suggested that 
the ventromedial hypothalamus modulates reproduction in female rats in addition to 
energy balance. 
1.3 Afferent signals of energy stores 
1.3.1 Insulin ' 
Over 50 years ago, Kennedy postulated that there was a circulating factor, related to or 
arising from adipose tissue, that regulated the control of food intake to achieve long-term 
stability of body weight and fat mass (Kennedy, 1953). Insulin was the first hormone 
postulated to act in this way. Insulin is a 51 amino acid molecule consisting of two 
peptide chains joined by disulphide bonds which is secreted from the pancreatic 0-cells. 
Insulin secretion increases rapidly after a meal. Plasma insulin concentrations also depend 
on peripheral insulin sensitivity which is related to fat mass. Insulin is best known for its 
promotion of glucose transport into cells, stimulation of hepatic glycogen storage and 
increase in muscle protein and glycogen synthesis. 
There is considerable evidence that insulin acts as an anorectic signal within the central 
nervous system (CNS). Insulin infusion into the Yd ventricle in rodents (Ikeda et al, 1986) 
or the lateral ventricle in primates (Woods et al, 1979) reduces food intake in a dose- 
dependent fashion leading to weight loss over a period of weeks. Insulin antibodies 
injected into the ventromedial nuclei of the hypothalamus of rats stimulate food intake 
(Strubbe & Mein, 1977) and neuronal specific deletion of insulin receptors results in 
obesity with increased circulating leptin (Bruning et al, 2000). 
Insulin reaches the CNS via saturable receptor-mediated transport across the blood-brain 
barrier at levels proportional to circulating insulin concentrations (Baura et al, 1993). 
Peripheral injection of insulin leads to hypoglycaemia, which itself is a potent stimulus of 
food intake. However when glucose concentrations are maintained in hyperinsulinaernic, 
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euglycaemic clamp studies, a reduction in food, intake in rodents has, been observed 
(Nicolaidis & Rowland, 1976). 
Insulin binds to a cell-surface insulin receptor resulting in tyrosine phosphorylation of 
several insulin receptor substrates (IRSs) which include IRS-I and IRS-2. IRS-I appears 
to play a dominant role in the periphery but has a less clear role in the CNS (Porte, Jr. et 
al, 2005). However insulin administration rapidly induces tyrosine phosphorylation of 
IRS-2 within the CNS. Further evidence that IRS-2 plays a role in the CNS signalling of 
insulin comes from IRS-2 knockout mice. Female IRS-2 knockout mice are obese and 
hyperphagic with impaired fertility (Burks et al, 2000). Targeted deletion of 
hypothalamic IRS-2 results in an obese insulin resistant phenotype (Kubota el al, 2004). 
These studies suggest that the IRS-2 receptor may mediate the feeding effect of insulin. 
1.3.2 Leptin 
In 1994 the obese (ob) gene was identified from examination of naturally occurring 
mutant obese oblob mice which are hyperphagic, hyperinsulinaemic and very obese 
(Zhang et al, 1994). The 16 kilodalton (kD) protein which is absent in the oblob mouse 
was named leptin from the Greek leptos meaning thin. Leptin is synthesised 
predominantly in adipose tissue (Zhang et al, 1994) but is also expressed at lower levels in 
the placenta (Masuzaki et al, 1997) and in gastric epithelium (Bado et al, 1998). Plasma 
leptin levels are highly correlated with adipose tissue mass in rodents and humans (Maffei 
et al, 1995). Food restriction results in suppression of circulating leptin which can be 
reversed by re-feeding (Frederich et al, 1995). Acute peripheral leptin administration 
reduces food intake and body weight in mice, and chronic peripheral and central leptin 
administration leads to a sustained suppression of food intake and a reduction in fat mass 
and body weight (Halaas et al, 1995; Halaas et al, 1997). Chronic administration of leptin 
to oblob mice results in reduced food intake and sustained reduction in body weight 
(Halaas et al, 1995). 
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The leptin receptor (Ob-R) is a large single membrane spanning protein that belongs to the 
GP130 family of cytokine class I receptors. In mice at least 6 alternatively spliced 
isoforms have been identified, all of which are products of the Ob-R gene (Lee et al, 
1996). In humans there are four known isoforms of the leptin receptor, each with different 
C-terminal cytoplasmic domains (Barr et al, 1999). In all species, Ob-R isoforms may be 
divided into threes classes - long, short and soluble. 
On binding with leptin, the long form of the leptin receptor (Ob-Rb) associates with the 
Janus family of tyrosine kinases (JAK) (Ghilardi & Skoda, 1997). Subsequently the 
tyrosine residues located on the intracellular tail of Ob-Rb are phosphorylated (Bjorbaek 
et al, 1997). This results in the activation of signalling cascades incorporating various 
'signal transducer and activator of transcription' (STAT) proteins. These activated STAT 
proteins dimerise and translocate to the nucleus where specific gene responses are elicited 
(Ghilardi et al, 1996) (figure 1.1). The long form of the leptin receptor (Ob-Rb) is thought 
to be the major signalling isoform since it is the only receptor that can transmit the leptin 
signal via the janus; kinase 2 (Ghilardi et al, 1996). 
The dbldb mouse is deficient in the long form of the leptin receptor (Ob-R) and has a 
similar obese phenotype to the ob/ob mouse (Chua, Jr. et al, 1996). This supports the 
hypothesis that the Ob-R plays a critical role in leptin signalling. Consistent with leptin's 
role in appetite regulation and energy homeostasis, the Ob-R is present in the 
hypothalamus, choroid plexus and adjacent CNS tissues (Tartaglia et al, 1995). The Ob-R 
is also located in organs involved in energy storage and metabolism such as skeletal 
muscle, adipose tissue, pancreas and liver and in reproductive organs such as ovaries, 
uterus and testes. It is also present in the immune system including the spleen, thymus, 
lymph nodes, haematopoietic cells and T-cells (Fruhbeck, 2001). Circulating leptin 
crosses the blood brain barrier via a saturable process (Banks et al, 1996), and the short 
and soluble forms of the leptin receptor may play a role in this active transport process 
(Hileman et al, 2002). 
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Figure 1.1 
Schematic Representation of the Leptin Ob-Rb post-receptor signalling cascade. Adapted 
from Central nervous system control offood intake (Schwartz M et al, 2000). 
The importance of leptin pathways in the control of human body weight was first 
demonstrated by the discovery of congenital leptin deficiency in a child with severe early- 
onset obesity and hyperphagia (Farooqi et al, 1999). Treatment of three leptin-deficient 
children with recombinant leptin for up to four years has led to a significant reduction in 
hyperphagia and fat mass. Leptin therapy also increased plasma thyroid levels and 
facilitated appropriately timed pubertal development (Farooqi et al, 2002). 
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However, the vast majority of obese people have high circulating leptin concentrations 
which reflect their increased fat mass and normally functioning ob genes (Considine et al, 
1996). While subcutaneous recombinant leptin treatment appears to be safe and well- 
tolerated, it has only modest effect on body weight in obese people (Mantzoros & Flier, 
2000). Thus obesity may be associated with relative leptin resistance. One mechanism 
that has been proposed to explain leptin resistance is through saturation of active transport 
of leptin across the BBB (Banks & Farrell, 2003). An alternative explanation is that obese 
people may have altered post leptin receptor signalling within the CNS (BJorbaek et al, 
1998). Suppressor of cytokine signalling-3 (Socs-3) is a molecule which modulates 
cytokine signalling and inhibits leptin signalling in vitro (BJorbaek et al, 1998). Socs-3 
haplo-insufficient mice have increased leptin sensitivity and are significantly protected 
against the development of diet-induced obesity (Howard et al, 2004). 
Humans and rodents are acutely sensitive to the effects of loss of weight with reduced 
circulating leptin. In starvation there is suppression of reproduction, the thyroid axis and 
the immune system (Lord et al, 1998; Ahima et al, 1996). These changes may all reduce 
energy expenditure and thus prolong life when limited or no food is available. Prevention 
of the starvation-induced fall in leptin in mice substantially blunts the changes in the 
immune system (Lord et al, 1998) and in the gonadal and thyroid axes (Ahima et al, 
1996). Thus leptin may play a more critical physiological role in times of food 
deprivation than in those of food excess. 
1.3.3,4diponectin 
Adiponectin belongs to the collagen super-family sharing structural homology with 
collagen, complement factors and TNF-<x. Adiponectin is specifically and abundantly 
expressed in adipose tissue. It is a 3-kDa monomer protein with a collagen-like domain 
that permits building of secondary and tertiary structures. The resulting trimers further 
associate through disulphide bonds to form larger polymeric complexes (Koerner et al, 
2005). 
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The effects of adiponectin are mediated by at least two receptors. These receptors were 
originally identified predominantly on muscle cells (AdipoRI) and liver cells (AdipoR2). 
Adiponectin binds to both receptors and mediates activation of AMP kinase, peroxisome 
proliferators-activated receptor (PPAR) -cc activation and consequently, glucose uptake 
and fatty acid oxidation (Koerner et al, 2005). Interestingly, in obese mice and humans, 
there is a reduction in the expression of adiponectin receptors which may contribute to the 
insulin resistance (Kadowaki & Yamauchi, 2005). - 
Adiponectin expression is restricted to mature adipocytes and increasing adiponectin 
expression and secretion occur during human adipocyte differentiation (Korner A et al, 
2005a). Higher levels of adiponectin mRNA and protein expression have been detected in 
subcutaneous compared with visceral fat in humans (Matsuzawa et al, 2004). In contrast 
with leptin, decreased circulating adiponectin levels are observed in patients with obesity, 
insulin resistance and diabetes (Matsuzawa et al, 2004). Weight loss results in increased 
adiponectin expression with associated improvements in insulin sensitivity. 
Although adiponectin knockout mice were reported to have normal body weight, they 
exhibited moderate insulin resistance with glucose intolerance (Kubota et al, 2002). The 
knockout mice also showed increased neointimal formation, a marker of atherosclerosis, 
in response to vascular cuff injury. Thus adiponectin may play a protective role against 
insulin resistance and atherosclerosis. 
Polymorphisms in the adiponectin receptor gene have been reported in patients with type 
2 diabetes (Wang et al, 2004a). This supports the notion that adiponectin plays a role in 
insulin signalling and sensitivity. However the mechanism is not fully understood. The 
PPAR-1 agonists, the thiazolidinediones, improve insulin sensitivity. Interestingly these 
compounds have been reported to increase circulating adiponectin in rodent models of 
obesity (Combs et al, 2002) and in patients with obesity and type 2 diabetes (Maeda et al, 
2001), and this may contribute to the improved insulin sensitivity. 
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1.3.4 Resistin 
Resistin is a 12.5-kD cysteine-rich protein which has a tendency to form dimers. Murine 
and human resistin display 59% homology in their amino acid sequences. However their 
tissue expression varies between species. In the mouse, resistin is predominantly 
expressed by white adipose tissue in proportion to adipocyte differentiation and to the 
mass of adipocyte tissue (Steppan et al, 2001). Resistin was only released from human 
adipocytes in neglible quantities compared with that released from non-fat omental cells 
(Fain et al, 2003). However, resistin expression and secretion have been observed in 
human bone marrow, lung and pancreatic P-cells (Koerner et al, 2005). 
There is conflicting evidence regarding the relationship between resistin expression and 
energy balance. Elevation of serum resistin levels were initially reported to be elevated in 
rodent models of obesity including oblob mice, dbldb mice and diet-induced obesity 
(Eýteppan et al, 2001). In contrast a subsequent study reported decreased expression of 
resistin in adipose tissue in these models (Way et al, 200 1). 
The role of resistin in human obesity is also controversial. Interpretation of the data from 
human studies is difficult because resistin occurs in different isoforms that may be 
selectively detected by immunoassays. While some studies have reported a positive 
association between body fat mass and circulating resistin, others have found no such 
correlation (Rea & Donnelly, 2004). In a large clinical study, the -420G/G genotype was 
associated with susceptibility to type 2 diabetes (Osawa et al, 2004). In other human 
genetic studies, there has generally been no clear association between resistin 
polymorphisms with obesity or diabetes (Koerner et al, 2005; Osawa et al, 2002). 
1.4 Afferent signals from the gut 
Gut-derived hormones play an important role in appetite signalling and energy 
homeostasis. In 1973 Gibbs et aL postulated that 'satiety factors' generated during a 
meal, such as peptides released from the gut, inhibit feeding leading to meal termination 
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(Gibbs et al, 1973). It is now known that gut-derived hormones may stimulate appetite in 
the absence of nutrients in addition to suppressing food intake following a meal. Satiety 
factors include peptide YY, glucagon-like peptide-1, cholecystokinin and pancreatic 
polypeptide, while one orexigenic hormone, ghrelin, has so far been described. The 
principle hormones secreted by the gut which are known to regulate food intake are 
illustrated below (figure 1.2). 
1.4.1 Ghrelin 
In 1984 Bowers et al. described non-naturally occurring short peptides which were 
modifications of enkephalins, without opioid activity which released GH (Bowers et al, 
1984). Subsequently these growth hormone secretagogues (GHSs), as they became 
known, were reported to stimulate feeding in rats when administered 
intracerebroventricularly (ICV) (Okada et al, 1996) and subcutaneously (Torsello et al, 
1998). In 1996, Howard et aL identified the GHS receptor (GHS-R) from human and 
swine cDNA libraries (Howard et al, 1996). The structure was a G-coupled protein 
receptor with seven transmembrane domains. Two receptor clones were identified, a full- 
length clone (GHS-Rla) and a truncated clone (GHS-Rlb). No function of the truncated 
GHS-Rlb has been identified to date. In situ hybridisation studies have revealed that the 
GHS-R is widely expressed in the hypothalamus (Mitchell V et al, 2001b). The GHS-R is 
also present in the pituitary and at lower concentration in the myocardium, pancreas, 
spleen, thyroid and adrenal glands (Gnanapavan et al, 2002). 
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Figure 1.2 
Schematic diagram showing the main location of synthesis of gut-derived hormones. 
Following nutrient intake, ghrelin release is inhibited (1) whereas release of 
cholecystokinin (CCK), pancreatic polypeptide (PP), glucagon-like peptide-I (GLP-1) and 
peptide YY (PYY) are stimulated (T). 
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An endogenous ligand to the GHS-R was identified in 1999 and named ghrelin (Kojima et 
al, 1999) from the Proto-Indo-European route 'ghre' meaning to grow. Ghrelin is 
synthesised predominantly in the gastric oxyntic cells, but is also found at lower 
concentrations in the duodenum, ileum, caecum and colon (Date et al, 2000). Acylated 
ghrelin has a unique biological structure comprising a series of 28 amino acids with an 
acyl group on the third amino acid, serine. Des-acylated ghrelin, with an identical 28 
amino acid chain but without the acyl side chain, is also present in the circulation 
(Marzullo et al, 2004). Des-acylated ghrelin has no binding affinity for the GHS-R 
(Kojima et al, 1999). Rat and mouse ghrelin are identical to one another and differ from 
human ghrelin by only two amino acids. This conservation across species (figure 1.3) 
suggests that ghrelin may play an important physiological role. 
O=C-(CH, )6-CH3 
I 
O=C-(CH2)6-CH3 
I 
0 
Figure 1.3 
Diagramatic representation of the amino acid sequence of murine and rat and human 
acylated ghrelin (non-homologous amino acids shown in orange, identical amino acids 
shown in yellow). Amino acids are identified by a one-letter symbol code - see appendix 
1. 
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Endogenous levels of ghrelin in man rise on fasting and fall rapidly on re-feeding with 
sharp peaks occurring just before each meal (Cummings et al, 2001). In rodents, 
expression of ghrelin from the gastric mucosa falls after ingestion of either fat or 
carbohydrate. However the suppression of mRNA expression is short-lived after fat 
intake and has returned to normal after 45 minutes whereas mRNA expression remains 
suppressed 45 minutes after carbohydrate ingestion (Sanchez et al, 2004). Circulating 
ghrelin levels are unchanged by ingestion of water (Tschop et al, 2000) which suggests 
that gastric distension does not inhibit ghrelin release. 
Exogenous acylated ghrelin has been reported to stimulate GH release and feeding in 
rodents when given lCV and peripherally via intra-peritoneal (IP) injection (Wren et al, 
2000). These effects of ghrelin on feeding appear to be independent of its actions on GH 
as ghrelin administration stimulates feeding in the GH-deficient mouse (Tschop et al, 
2000). Ghrelin analogues also display dissociation between the feeding effect and 
stimulation of GH (Torsello, et al, 1998). 
The orexigenic action of exogenous ghrelin and the rise in endogenous ghrelin prior to a 
meal support -the hypothesis that ghrelin acts as a meal initiator. Anti-ghrelin 
immunoglobulin attenuates re-feeding after a fast (Nakazato et al, 2001), which provides 
further evidence that ghrelin is an endogenous regulator of food intake. Ghrelin may 
stimulate food intake via CNS hypothalamic -appetite circuits (see section 1.5.3) and 
through stimulation of gastric motility (Asakawa et al, 2001). There is evidence that des- 
acylated ghrelin plays a role in appetite signalling despite its lack of binding to the GHS- 
Rla. lCV and peripheral administration of des-acylated ghrelin were reported to inhibit 
feeding and gastric motility (Asakawa el al, 2005). Des-acylated ghrelin may mediate 
these effects via an alternative receptor. Recently another post-translational product of 
proghrelin has been isolated from the stomach and named obestatin. Obestatin is an 
endogenous ligand for the orphan GPR39 receptor and has been reported to suppress food 
intake and inhibit body weight gain in mice (Zhang JV et al, 2005). Thus the balance of 
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the post-translational products of pre-pro-ghrelin, which include acylated ghrelin, 
desacylated ghrelin and obestatin, may be critical to energy homeostasis. 
In addition to influencing acute food intake, acylated ghrelin appears to play a role in 
longer-term appetite regulation and energy balance. Circulating ghrelin is elevated in 
patients with anorexia nervosa. and reduced in obesity compared with normal weight 
controls (Rigamonti et al, 2002; Tschop et al, 200 1). Plasma ghrelin levels increased after 
obese subjects had lost weight (Cummings et al, 2002). Repeated peripheral exogenous 
ghrelin administration to rats, leads to an increase in food intake (Wren et al, 2001b) and 
an increase in body weight (Fschop et al, 2000; Wren et al, 200 1 b). 
Despite the potent action of ghrelin on food intake in animals and humans, the ghrelin-null 
mouse was initially reported to be of equivalent size to WT littermates with normal 
appetite, body composition and reproduction. The ghrelin-null mouse displayed similar 
responses to starvation and to exposure to a high fat diet (35% total energy from fat) as 
WT controls (Sun et al, 2003). The authors subsequently reported that mice deficient in 
the GHSR-la ghrelin receptor have modestly reduced body weight from 16 weeks of age 
but without significant change in food intake (Sun et al, 2004). One explanation for the 
absence of a phenotype in the ghrelin-null mouse and only a mild phenotype in the 
GHSR-la-null mouse could be that there is redundancy in the systems underlying 
orexigenic signalling and in the absence of ghrelin other appetite signalling circuits are 
altered. Alternatively these results could suggest that ghrelin does not play a critical role 
in the regulation of energy homeostasis. 
More recently the effects of exposing ghrelin-null mice to high fat diet at an earlier age 
have been examined. When male ghrelin knockout mice consumed a high fat diet (45% 
energy from fat) from 6 weeks of age, they were protected from the rapid weight gain and 
accumulation of adipose tissue observed in their WF littermates (Wortley et al, 2005). 
Although no significant differences in food intake were observed, there was increased 
energy expenditure and locomotion in the knockout animals. However, no difference 
from WT females was observed in the weight of ghrelin knockout female mice when both 
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consumed high-fat diet. In another study GHS-R knockout mice were fed high fat diet 
(40% energy from fat) from 4 weeks of age. Significantly less weight gain was observed 
in both male and female knockout mice with a significant reduction in fat mass. This was 
sustained until study completion at 19 weeks of age (Zigman et al, 2005). These studies 
suggest that ghrelin signalling is required for the full development of diet-induced obesity. 
In addition to the earlier commencement of HFD, the higher fat content of this diet used 
by Zigman et al. and Wortly et aL (45% and 40% respectively) compared with Sun et aL 
(35%) may explain the ability of the former two groups to detect a phenotype. 
The effect of gbrelin over-expression has been examined in traiisgenic mice models. in a 
mouse model in which plasma acylated ghrelin was increased 14-fold but with increased 
ghrelin expression in the pancreas rather than in the stomach, no significant difference in 
phenotype was observed (Wei et al, 2006). Interestingly, a similar orexigenic response to 
exogenous; ghrelin was observed as that seen in WT controls. In two studies, transgenic 
mice were created which over-expressed des-acylated ghrelin rather than acylated ghrelin. 
In both studies the des-acylated ghrelin over-expressing mice had reduced body weight 
and shorter nose to anus length compared with controls (Ariyasu et al, 2005; Asakawa et 
al, 2005). As discussed above, acute administration of des-acylated ghrelin was reported 
to inhibit food intake (Asakawa et al, 2005). Together these studies suggest that the 
balance of acylated to des-acylated ghrelin may be important and that, despite its lack of 
binding to the GHS-Rla, des-acylated ghrelin may play a role in energy homeostasis and 
GH regulation. 
Acylated ghrelin has been reported to stimulate food intake in man. An intravenous 
ghrelin infusion in healthy volunteers was associated with a 28% increase in food intake 
from a free buffet meal in healthy volunteers compared with saline control (Wren et al, 
2001a). Additionally there were increases in subjective hunger as measured by visual 
analogue scales. Ghrelin has also been reported to stimulate energy intake in obese 
subjects (Druce et al, 2005b). Ghrelin may act as a pro-kinetic in humans, as ghrelin 
infusion stimulated gastric motility in diabetic patients suffering from gastroparesis 
(Murray et al, 2005). 
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There is some evidence for the involvement of ghrelin in the aetiology of human obesity. 
Prader-Willi syndrome (PWS) is the commonest genetic syndromal cause of human 
obesity, and is characterised by insatiable hunger from childhood, mental retardation, 
hypogonadism, and GH deficiency (Holm et al, 1993). The molecular genetic defect is 
due to the failure of expression of paternal genes in the PWS region on chromosome 
15ql 1-13 (Nicholls et al, 1998). Regulation of leptin secretion is normal in PWS with 
elevated leptin ý levels in proportion to their obesity, as seen in non-PWS BMI-matched 
controls (Considine et al, 1996). In contrast, plasma ghrelin levels in children with PWS 
are significantly higher than in obese BMI- and age- matched controls (Haqq et al, 2003). 
The elevation in plasma ghrelin could explain, at least in part, the increased appetite and 
weight associated with PWS. 
There is conflicting evidence regarding mutations in the ghrelin gene in non-syndromic 
obesity. Variations in the pre-pro-ghrelin gene, the ghrelin gene and the GHS-R gene 
have been described in lean and obese subjects One study has reported evidence of a 
relationship between a low-frequency sequence variation in the ghrelin gene and obesity 
in adult female (Ukkola et al, 2001). However other authors have suggested that there is 
no relationship between the incidence of obesity and mutations of the pre-pro-ghrelin 
(Larsen et al, 2005) or the GHS-R genes (Wang et al, 2004b). 
1.4.2 Peptide YY 
Peptide YY (PYY) is secreted from the endocrine L-cells of the small and large bowel, 
and released into the circulation after meals. The L-cell has a slender triangular form, 
with the base resting on the basal lamina and a long cytoplasmic process reaching the gut 
lumen. This process is equipped with microvilli that protrude into the lumen (Eissele et al, 
1992) and thus the L-cell may secrete PYY in response to nutrients in the gut. PYY is a 
member of the neuropeptide Y (NPY) family and consists of a linear chain of 36 amino 
acids. At least 6 CNS receptor subtypes have been proposed to date (Bard et al, 1995; 
Grandt et al, 1994). PYY is named after its tyrosine residues (Y), which are the first and 
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last amino acids of the peptide chain. The enzyme dipeptidyl peptidase IV (DPPIV) 
truncates full length PYYI-36 at the N-terminus to PYY3-36, and both forms of PYY are 
present in the circulation (Grandt et al, 1994). Both PYYI-36 and PYY3-36 bind to the YI, 
Y2 and Y5 receptors, but PYY3-36 is relatively selective for the Y2-receptor (Gerald et al, 
1995). 
PYY release is correlated with caloric intake and circulating levels rise to a plateau in 
humans 1-2 hours after a meal and remain elevated for 6 hours (Adrian et al, 1985a). 
Circulating PYY concentrations are lower in the obese than in lean controls in rodents and 
humans in both fasting and post-prandial states (le Roux. et al, 2006). A human peptide 
extraction study revealed that PYY concentration increases down the gastrointestinal tract 
with the lowest detectable levels in the duodenum and the highest in the rectum (Adrian et 
al, 1985a). No alteration in circulating PYY was observed following ingestion of water in 
humans (Pedersen-Bjergaard et al, 1996) which suggests that PYY release is independent 
of gastric distension. 
In the 1980s, PYYI-36 was reported to delay gastric emptying (Allen el al, 1984) and 
suppress gastric acid secretion (Adrian et al, 1985c). In 1993 Okada et al. presented in an 
abstract their observation that peripheral administration Of PYYI-36 to rodents was 
associated with a reduction in food intake (Okada et al, 1993). It was not until 2002 that 
the effect of peripheral administration Of PYYX-36 on food intake was reported formally in 
the literature. Batterharn et al. observed that peripheral administration of PYY3-36 led to a 
dose-dependent decrease in food intake in mice and rats (Batterharn et al, 2002). 
Subsequently several other groups have reported a reduction in energy intake in rodents 
following peripheral PYY3-36 administration (Challis et al, 2003; Halatchev et al, 2004; 
Pittner et al, 2004). However other authors have not observed a reduction in food intake 
following acute PW3-36 administration (Tschop et al, 2004). This disparity could be 
explained by differences in the stress levels in the rodents studied. In an elegant study, 
PYY3-36 was administered to mice accustomed and unaccustomed to the experimental 
protocol (Halatchev et al, 2004). A reduction in food intake was only observed in the 
acclimated mice. Thus one explanation for the apparently contradictory reports in the 
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literature could be that the animals which failed to respond to PYY3-36 had not been 
adequately acclimatised to the experimental protocol. - 
Recently transgeneic PYY knockout mice , have been reported to develop 
hyperinsulinaemia and obesity (Boey et al, 2006). In female knockout mice there was an 
increase in body weight on normal chow from 4-28 weeks of age. Although no significant 
differences in body weight were seen in male knockouts on normal or high fat (HF) diet, 
at 14 weeks on high fat diet there was an increase in body fat. The authors suggested that 
an increase in circulating IGF-I seen in the male but not the female mice could account 
for the difference in phenotypes between female and male PYY knockout mice (Boey et 
al, 2006). 
It is also pertinent to examine data on Y2-receptor knockout mice. The first described 
Y2-R knockout mice were of a Balb/c background and were heavier than their WT 
littermates with increased food intake and fat mass (Naveilhan et al, 1999). This 
phenotype is consistent with the hypothesis that the Y2 receptor mediates feeding 
inhibition and negative energy balance. Subsequently Y2-R knockout mice were bred on 
a C57BL/6 background and reported to have an identical birth weights to their 
heterozygote and WT littermates (Sainsbury el al, 2002). Surprisingly both male and 
females had a lower body weight from 4 weeks until the end of monitoring at 16 weeks. 
In the male Y2-R knockout mice, an increase in circulating pancreatic polypeptide (PP) 
was observed and this could explain the reduction in body weight. The difference in 
phenotype between these two models could be due to difference in the mouse strains. In a 
conditional knockout model on a C57BU6 background in which the Y2-R was only 
absent in the hypothalamus, there was an initial reduction in the body weight in both sexes 
which, unlike the germ-line knockout of the same strain, was not subsequently sustained 
(Sainsbury et al, 2002). Developmental or extra-hypothalamic mechanisms could explain 
the different phenotypes between these two C57BU6 mice models. When PYY3-36 was 
administered to germ-line deleted Y2-R mice of normal weight, a reduction in food intake 
was only observed in the WT mice (Batterham et al, 2002). This supports the hypothesis 
that PYY3-36 inhibits food intake through the Y2-R. 
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PYY3-36 administration has been reported to inhibit food intake and subjective hunger in 
man (Batterham et al, 2002). An intravenous infusion Of PYY3-36 reduced energy intake 
at a buffet meal by 36% compared with saline control. The inhibitory effect of PYY on 
food intake was sustained over the following 12 hours as assessed by food diaries. 
Overall there was a 33% reduction in cumulative energy intake (buffet meal + food diary 
for 24 hours) following PYY3-36 infusion. PYY3-36 infusion also reduced energy intake in 
obese subjects by a similar proportion as observed in lean subjects (Batterharn et al, 
2003a). Thus Y2-R activation by PYY3-36 or an analogue Of PYY3-36 could provide a 
useful therapeutic target for the treatment of obesity. 
1.4.3 Glucagon- like peptide- 1, glucagon-like peptide-2 and oxyntomodulin 
Glucagon-like-peptide I (GLP-1) is co-secreted with PYY in response to nutrients in the 
endocrine L-cells of the small and large bowel (Anini et al, 1999). Circulating PYY and 
GLP-I rise within 30 minutes of nutrient ingestion (Anini et al, 1999), before nutrients 
would be expected to have reached the large bowel, where the highest concentrations of 
these hormones are synthesised (Adrian et al, 1985a). Thus the release of PYY and GLP- 
I may also be under neural control. 
The precursor of GLP-I, pre-pro-glucagon, is cleaved tissue-specifically - in the pancreas 
it forms glucagon whereas in the intestinal L-cells it gives rise to GLP-I, glucagon like 
peptide-2 and oxyntomodulin (Merchenthaler et al, 1999) (figure 1.4). GLP-l is also 
expressed at lower concentration within the CNS (Merchenthaler et al, 1999). The active 
form of GLP-I, GLP-17-36, binds to the GLP-I receptor (GLP-IR), a G-protein coupled 
receptor which is widely expressed in the CNS including the brainstem and hypothalamus 
(Merchenthaler et al, 1999). GLP-IR expression had also been reported in the pancreatic 
islets (Horsch et al, 1997), kidney and throughout the gastrointestinal tract (Dunphy et al, 
1998). 
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GLP-17-36 is rapidly inactivated by the enzyme DPP-IV and has a very short circulating 
half-life of approximately 1-3 minutes in a number of species (Pridal et al, 1996; Deacon 
el al, 1996; Kieffer el al, 1995). Consequently much of the peripheral work examining 
the GLP-l system has been performed with the naturally occurring GLP-l receptor 
agonist, exendin-4, which has a longer half-life. Exendin-4 was identified from the 
salivary glands of the Gila monster lizard and found to be a potent agonist at the GLP-l 
receptor (Goke el al, 1993). 
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Figure 1.4 
The products of pre-pro-glucagon cleavage. Numbers denote amino acid residues at 
which cleavage occurs. Abbreviations: GLP-l and GLP-2, glucagon-like peptides I and 
2; GRPP, glicentin-related polypeptide; IP-1 and IP-2, intervening peptides I and 2; 
MPGF, major pro glucagon fragment. Adapted from Gastrointestinal Hormones 
Regulating Appetite (Chaudhri et al, 2006). 
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lCV injection of GLP-17-36 powerfully inhibits feeding in rodents (Turton et al, 1996), and 
repeated ICV GLP-17-36 has been reported to reduce body weight (Meeran et al, 1999). 
Peripheral administration of GLP-17-36 (Dakin et al, 2004) and exendin4 (Szayna et al, 
2000) have been reported to inhibit feeding. Following repeated peripheral administration 
of exendin4 to Zucker fatty rats, sustained reductions in food intake and body weight 
were observed (Szayna et al, 2000). There were also reductions in fasting glucose, long- 
term glycaemic control (HbAlc) and insulin levels. 
GLP-I receptor knockout mice are glucose intolerant but exhibit normal food intake and 
body weight (Scrocchi et al, 1996). Compensatory up-regulation of alternative satiety 
pathways or alternative GLP-I receptor types could explain the lack of alteration in food 
intake or body weight. 
Human data on whether peripheral administration of GLP-17-36 inhibits feeding are more 
conflicting. A recent meta-analysis showed that GLP-17-36 causes a small dose dependent 
inhibition of food intake in both lean and overweight subjects (Verdich et at, 2001a). 
Reduction in the rate of gastric emptying (Meier et al, 2003) may contribute to the 
increased satiety induced by GLP- 17-36- 
GLP-17-36 plays an additional role in enhancing insulin secretion and suppressing 
glucagon secretion after a meal, functioning as an incretin (Kreymann et al, 1987). An 
incretin is a substance which enhances insulin release in response to oral glucose. The 
plasma insulin response to a given rise in plasma glucose is greater after an oral glucose 
load than after an intravenous glucose infusion, and this difference may be attributed to 
the rise in circulating GLP-I and gastric inhibitory polypeptide (GIP) stimulated by the 
oral glucose. 
The combination of enhanced insulin release with reduction of food intake makes GLP-17. 
36 an attractive treatment for patients with type 2 diabetes mellitus. A six-week trial of 
three subcutaneous pre-meal GLP-17-36 injections per day improved glycaemic control by 
increasing insulin levels and inhibiting glucagon compared with placebo control, with no 
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adverse effects (Todd et al, 1997). Exendin4 has undergone clinical trials in man and has 
been found to be a potent insulotropic agent in diabetic and non-diabetic subjects (Egan et 
al, 2002). In 2005 the FDA approved exenatide as an adjunctive treatment to existing oral 
medications in patients with type 2 diabetes (Medical news today, 2005). An alternative 
therapeutic strategy is to target enzymes such as dipeptidyl peptidase-IV (DPPIV) that 
catalyse the breakdown of GLP-17-36. After 4 weeks of three subcutaneous pre-meal 
injections of the DPPIV inhibitor NVP DPP728 in patients with type 2 diabetes there was 
an improvement in glycaemic control compared with placebo, but without the additional 
benefit of weight loss (Ahren et al, 2002). Interestingly, DPPIV also catalyses the 
cleavage Of PYYI-36 to PYY3-36 (Mentlein et al, 1993). 
ICV injection of GLP-2 (Tang-Christensen et al, 2000) and oxyntomodulin (Dakin et al, 
2001) have also been reported to inhibit feeding in rodents. Peripheral GLP-2 
administration has been reported to stimulate gut mucosal growth (Baggio & Drucker, 
2004), but has not been reported to alter food intake to date. Following peripheral 
oxyntomodulin, a significant reduction in food intake was observed in rats, and following 
repeated peripheral oxyntomodulin injection there was a reduction in body weight (Dakin 
et al, 2004). Administration of GLP-17-36 (Scrocchi et al, 1996) and oxyntomodulin 
(Baggio et al, 2004) to the GLP-1 receptor knockout mouse resulted in no alteration in 
food intake but did inhibit food intake in wild-type mice. This suggests that both GLP-17- 
36 and oxyntomodulin modulate food intake exclusively through the GLP-1 receptor 
system. In a study in rats, the GLP-1 receptor antagonist, exendin 9-39, was injected into 
the arcuate nucleus of the hypothalamus prior to peripheral injection of GLP-17-36 and 
oxyntomodulin. While the effect of GLP-17-36 on food intake was blocked by exendin 9- 
39, oxyntomodulin inhibited feeding (Dakin et al, 2004). This latter contradictory study 
raises the possibility of the presence of an alternative receptor to the GLP-l receptor 
through which oxyntomodulin inhibits feeding. 
The effect of oxyntomodulin on energy homeostasis has recently been examined in man. 
Following acute oxyntomodulin administration a 19% reduction in energy intake was 
observed at a buffct meal (Cohen et al, 2003). Repeated subcutaneous injection of 
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oxyntomodulin to obese humans three times per day for 4 weeks was reported to lead to a 
significant reduction in body weight (Wynne et al, 2005b). Trials running over a longer 
period could now be performed in order to investigate the therapeutic potential of 
oxyntomodulin as an anti-obesity treatment. 
1.4.4 Cholecystokinin 
Cholecystokinin (CCK) is widely distributed within the GI tract, but is present at highest 
concentrations within the duodenum and jejunum (Moran, 2000). Cholecystokinin (CCK) 
was the first gut hormone shown to inhibit feeding following exogenous administration in 
rodents (Gibbs et al, 1973). CCKA receptors, present on the vagus nerve and pyloric 
sphincter, are bound exclusively by the sulphated. forms of CCK, and are active in 
reducing food intake (Moran, 2000). Other well characterised functions of CCK include 
the stimulation of pancreatic enzyme secretion and gallbladder contraction and inhibition 
of gastric emptying (Varga et al, 2004). CCK is released rapidly into the circulation 
following nutrient ingestion in rodents (Liddle et al, 1984) and man (Liddle et al, 1985). 
Peripheral CCK has a rapid but relatively short-lived effect on feeding in rodents, exerting 
its maximum inhibition within * 30 minutes post injection (Moran, 2000) which is 
consistent with a role in mediating satiety and meal termination. High dose CCK may 
also cause nausea, vomiting and taste aversion, although lower doses have been shown to 
inhibit feeding without inducing these effects (West et al, 1987). Tolerance is exhibited 
following prolonged administration of low dose CCK to rats after 24 hours (Crawley & 
Beinfeld, 1983). Although meal size was persistently reduced with the CCK infusion, 
there was compensatory increase in meal number. CCK may however play a role in 
longer-term energy regulation by enhancing the . actions of leptin. CNS leptin 
administration potentiates the feeding inhibition of peripheral CCK, and the CCK/leptin 
combination results in greater weight loss than with leptin alone over 24 hours (Matson et 
al, 1997). 
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Examination of naturally occurring Otsuka Long-Evans Tokushima Fatty (OTLEF) rats 
which are deficient in CCK-A receptors supports the notion that CCK plays a 
physiological role in appetite regulation. These rats are hyperphagic and obese (Moran et 
al, 1998). However the CCK-A receptor knockout mouse has a normal phenotype (Bi el 
al, 2004). The difference in phenotypes between OTLEF rats and CCK-A receptor 
knockout mice suggests that CCK signalling could differ between species. Alternatively 
the OTLEF rat could have other alterations from intact rats in addition to deficiency in 
CCK-A receptors. 
1.4.5 Pancreatic polypeptide 
Pancreatic polypeptide (PP) is a 36 amino acid peptide belonging to the PP-fold family 
which also includes NPY and PYY. PYY, NPY and PP share a characteristic structure 
consisting of propyl/propyl helix followed by a0 turn and an a helical region (Beck- 
Sickinger & Jung, 1995). NPY and PYY exhibit 70% homology with each other and 
about 50% with PP (Kimmel el al, 1975). In this family, PP is the least conserved across 
the species (Yonekura el al, 1988) which suggests that it may have been modified later in 
evolution. Human and rodent PP have high binding affinity for the Y4 receptor (Bard et 
al, 1995) whereas only human PP is thought to have significant affinity for the Y5 
receptor (Asakawa et al, 2003). 
PP is primarily produced in PP cells in the periphery of the pancreatic islets of 
Langerhans, but is also secreted by the exocrine pancreas and distal gastrointestinal tract 
(Larsson et al, 1975). Like PYY and GLP-I, PP is released into the circulation after the 
ingestion of food. However post-prandial PP release is biphasic (Track el al, 1980) and 
circulating concentrations are elevated for approximately 6 hours (Adrian el al, 1977). 
Total PP release is proportional to energy intake with the contribution of the first phase 
increasing with consecutive meals (Track el al, 1980). PP secretion is also increased 
following gastric distension (Christofides el al, 1979). Following exogenous ghrelin 
administration to human healthy volunteers, a rise in the first phase in PP release was 
observed although the mechanism remains unclear (Arosio et al, 2003). 
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Plasma PP concentrations have been reported to be inversely proportional to adiposity, 
with elevated levels following a fat-rich meal in human subjects with anorexia nervosa 
(Fujimoto et al, 1997). Obese subjects have reduced fasting PP plasma levels and a 
reduced rise in second phase of PP release following a meal (Lassmann et al, 1980). 
Humans with Prader-Willi syndrome have reduced basal and blunted post-prandial PP 
release compared with BMI-matched controls (Zipf et al, 1981) which may contribute to 
their hyperphagia and obesity. 
The effect of exogenous PP on food intake is dependent upon its route of administration. 
Injection of human PP into the 3d ventricle of rats stimulates food intake (Clark et al, 
1984). In contrast peripheral administration of PP inhibits food intake in rodents 
(Asakawa et al, 1999) and increases energy expenditure (Asakawa. et al, 2003). This 
disparity could be explained by preferential stimulation of Y5 receptors in the following 
ICV administration (increasing food intake) and predominant Y4 receptor stimulation 
following peripheral administration (reducing food intake). Peripheral PP also has local 
effects on the gut, which may contribute to its anorectic effect, including reduction in the 
rate of gastric emptying (Asakawa et al, 2003) and inhibition of pancreatic exocrine 
secretion. 
Acute administration of peripheral PP reduces food intake in oblob mice. Repeated 
peripheral administration of PP to oblob mice is associated with a reduction in body 
weight (Asakawa el al, 2003). Thus PP appears to inhibit food intake and reduce body 
weight independently of leptin signalling. Consistent with the reduction in food intake 
and body weight associated with peripheral PP administration, a transgenic mouse over- 
expressing PP has a lower body weight than WT littermates and reduced food intake 
(Ueno et al, 1999). 
PP administration has also been reported to inhibit food intake in humans. Intravenous 
infusion of PP was associated with a 22% reduction in energy intake in lean healthy 
volunteers at a buffet meal (Batterham et al, 2003b). Energy intake, as assessed by food 
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diary, was reduced over the 24 hours following PP infusion, suggesting that PP may be 
associated with sustained reduction in energy intake. Twice daily PP administration to 
patients with Prader-Willi syndrome was associated with, a significantly reduced food 
intake (Berntson et al, 1993). However the effect of PP in non-syndromic obesity remains 
to be investigated. 
1.4.6 Neural sensory gut signals 
Both the vagus and non-vagal splanchnic nerves supply the upper gastrointestinal tract. 
Within the gut wall the myenteric and submucosal plexuses may alter GI muscular tone 
(Schwartz G, 2000). To date there is little knowledge of the role of non-vagal splanchnic 
nerves in the mediation of satiety. There is far greater understanding of the role of the 
vagus nerve, which appears to be the major component of the neuronal brain-gut axis. 
Vagal afferents have been reported to be sensitive to meal related stimuli including 
mechanical distension of the gut lumen, chemical properties of luminal contents such as 
gastric acid secretion and alterations in gut hormone concentrations (Schwartz GJ, 2000; 
Date et al, 2002). The cell bodies of these afferent vagal neurones are located in the 
nodose ganglion, the inferior cranial ganglion of the vagus (Harding & Leek, 1973). 
Anterograde tracer studies after injection of tracer compounds into the upper GI tract have 
demonstrated target neurones in the vagal nodose ganglion and in the nucleus of the 
solitary tract of the brainstem (Altschuler et al, 1989). Thus the vagus may signal from 
the GI tract to the CNS via the nodose ganglion. 
1.5 CNS appetite-regulating circuitry 
1.5.1 The brainstem 
The major input of viscerosensory transmission to the CNS comes through the afferent 
portion of the vagus nerve (Williams et al, 2001), which terminates in the nucleus of the 
solitary tract (NTS) and the area postrema (AP) (Berthoud & Neuhuber, 2000). The area 
postrema is a circumventricular organ with an incomplete blood brain-barrier enabling the 
brainstern to access the peripheral circulation. The NTS lies in close proximity to the area 
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postrema and contains neuropeptide Y (NPY), melanocortin and GLP-I neuronal circuits. 
There are extensive reciprocal connections between the hypothalamus and brainstem, 
particularly to and from the NTS (Ricardo & Koh, 1978; van der Kooy et al, 1984). 
Within the CNS, GLP-I is synthesised exclusively within the caudal NTS, and these pre- 
pro-glucagon neurones also express leptin receptors (Goldstone et al, 1997). GLP-I 
immunoreactive fibres project widely from the NTS to the areas in the forebrain including 
the hypothalamus, thalamus and cortex. Densely distributed GLP-I fibres are present in 
the PVN and DNM with fewer fibres in the ARC (Larsen et al, 1997). 
The role of the brainstem in appetite and feeding regulation has been examined using 
experimental decerebrate rats in which connections between the brainstem and forebrain 
are severed surgically (Grill & Smith, 1988). The decerebrate rats were able to 
compensate for changes in the composition of individual meals offered to them. 
However, when challenged with a reduction in meal number from 3 to 2 per day, intact 
rats compensated by increasing their food intake at each meal, but the decerebrate rats 
failed to adjust their meal size. Thus while the brainstem plays a role in individual meal 
size, the hypothalamus may be required for long term energy balance and appetite 
regulation. 
1.5.2 Ae hypothalamus 
The hypothalamus has been thought to play an important role in energy homeostasis for 
several decades since animals with lesions to the medial hypothalamus were noted to 
develop hyperphagia and obesity, and those with lesions to the lateral hypothalamus 
became hypophagic and thin (Brobeck, 1946; Anand & Brobeck,, 1951) (see section, 1.2). 
More recently the hypothalamus has been subdivided into nuclei consisting of collections 
of neurones with discrete functions (figure 1.5) (KaIra et al, 1999)., Neuronal projections 
between these nuclei and to and from other areas in the brain enable the hypothalamus to 
integrate signals from the brain, the peripheral circulation and the autonomic nervous 
system to regulate energy intake and expenditure. 
38 
Lateral View of Hypothalamic Nuclei 
Snout 
i 
Figure 1.5 
Hypothalamic nuclei involved in energy homeostasis (lateral view) 
ARC - arcuate nucleus (known as the infundibular nucleus in humans) 
PVN - paraventricular nucleus 
VMH - ventromedial hypothalamus 
DMH - dorsomedial hypothalamus 
LH - lateral hypothalamic area 
OC - optic chiasm 
The arcuate nucleus (ARC), termed infundibular nucleus in man, is situated at the base of 
the hypothalamus. This is an elongated arc shaped collection of neuronal cell bodies, 
which express receptors for many of the hormones and neuropeptides that are known to 
regulate feeding. The arcuate nucleus is thought to have access to the peripheral 
circulation through semi-permeable capillaries in the underlying median eminence (Cone 
et al, 2001), and is thus in an ideal position to integrate hormonal signals for energy 
homeostasis. Within the ARC, key neuropeptides are expressed which regulate appetite 
and energy balance. These include NPY, the melanocortins (Agrp and POMQ and CART 
(see sections 1.6.1,1.6.2 and 1.6.3). Neurones in the medial ARC express the orexigenic 
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neuropeptides, NPY and Agrp (Broberger et al, 1998), and these project primarily to the 
ipsilateral paraventricular nucleus (PVN) (Bai et al, 1985). In the lateral ARC, a second 
group of neurones inhibit food intake via expression of POMC and CART (Elias et al, 
1999) (figure 1.6). This group of neurones project more widely within the CNS to 
hypothalamic nuclei such as the dorsomedial hypothalamus (DMH) and lateral 
hypothalamic area (LH) in addition to the PVN (Elias el al, 1998). 
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Figure 1.6 
NPY/AGRP (green) and POMC/CART (red) neurons in the arcuate nucleus (ARC) are 
regulated by leptin and project to the paraventricular nucleus (PVN) and to the lateral 
hypothalamus (LHA) and pre-fomical area (PFA). Adapted from Central nervous system 
control offood intake (Schwartz M et al, 2000). 
The paraventricular nucleus (PVN) is adjacent to the superior part of the 
P ventricle in 
the anterior hypothalamus. The PVN is the main site of corticotrophin releasing hormone 
(CRH) and thyrotrophin releasing hormone (TRH) synthesis in addition to being richly 
supplied with neuronal projections from the arcuate nucleus (Kalra et al, 1999). Thus the 
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PVN plays a role in the integration of nýtritional signals with the thyroid and the 
hypothalamic-pituitary-adrenal (HPA) axes. 
The lateral hypothalamus is situated dorsally and laterally to the ventromedial. 
hypothalamus and contains the medial forebrain bundle in addition to sparsely distributed 
neuronal subpopulations (Kalra et al, 1999), including melanin-concentrating hormone 
(MCH) expressing neurones (Marsh et al, 2002). 
1.5.3 Integration of adipocyte and gut-derived hormones with the hypothalamus 
Several lines of evidence indicate that circulating leptin modulates appetite via arcuate 
neurones. Ob-Rb mRNA is expressed on arcuate, NPY, Agrp, POMC and CART 
neurones (Baskin et al, 1999; Wilson et al, 1999; Cheung et al, 1997; Kristensen et al, 
1998). Leptin inhibits arcuate NPY/Agrp neurones (Schwartz MW et al, 1996; Kristensen 
et al, 1998) but stimulates POMC/CART neurones (Elias et al, 1999). Absence of NPY 
ameliorates the obesity of the oblob mouse. Thus the full response to leptin appears to 
require NPY signalling (Erickson et al, 1996b). 
First order NPY/Agrp and CART/POMC neurones Project to other areas in the CNS 
relaying peripheral circulating signals of energy stores and satiety to other brain effector 
pathways (Schwartz MW et al, 2000). Arcuate neurones also project within the nucleus to 
create important local regulatory circuits. The inhibitory neurotransmitter GABA is co- 
expressed in a subpopulation of NPY neurones in the ARC (Horvath et al, 1997). 
Electron microscopy revealed that NPY and GABA are co-localised in synaptic terminals 
engaging with POMC neurones. ARC NPY neurones express the auto-inhibitory Y2 
receptor and locally released NPY may inhibit its own release via this receptor, 
attenuating GABA release and activating POMC neurones. 
There is recent evidence that leptin modulates POMC and NPY neurones at the 
electrophysiological level. In oblob mice expressing variants of green fluorescent protein 
in POMC and NPY neurones, there was marked alteration in excitatory and inhibitory 
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synaptic inputs to POMC and NPY neurones (Pinto et al, 2004). Compared with WT 
littermates, there were increases in excitatory inputs to NPY neurones and increases in 
inhibitory inputs to POMC/CART neurones. When leptin was administered rapid re- 
wiring in POMC and NPY neurones was observed indicating significant plasticity in the 
neuronal circuitry. Leptin may be critical to hypothalamic neuronal growth in 
development, particularly in the projections from the ARC to the PVN which develop 
relatively late in mice from post-natal days 8-10. A 10-fold reduction in the number of 
fibres projecting to the PVN was observed at day 10 in oblob mice compared with WT 
controls (Bouret et al, 2004). However when oblob mice were treated with recombinant 
leptin from day 4 there was a significant increase in ARC fibres projecting to the PVN 
which was comparable with WT mice. 
There is considerable evidence that gut-derived hormones signal via the ARC. Following 
peripheral ghrelin administration, a significant increase in the early gene product, c-fos, 
(see section 1.8) in the ventro-medial ARC was observed, and approximately 90% of the 
c-fos positive neurones expressed NPY (Wang et al, 2002). The knockout mouse lacking 
both NPY and Agrp is completely insensitive to the feeding effects of ghrelin (Chen et al, 
2004). Thus NPY and Agrp neurones may be critical to the orexigenic signalling of 
ghrelin. In contrast PYY3-36 has been reported to inhibit hypothalamic NPY mRNA 
expression (Batterham et al, 2002). PYY3-36 also increased c-fos expression by 2-fold in 
POMC neurones within the ARC. However subsequently PYY3-36 has been administered 
to POMC knockout mice and no reduction in hyperphagia observed. Thus melanocortin 
signalling may not be critical in the regulation of food intake by PYY3-36- 
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Figure 1.6 
Schematic diagram of stimulatory and inhibitory hypothalamic and circulating hormones. 
Green represents CNS appetite-stimulatory neurones, red represents CNS appetite- 
inhibitory neurones, filled black arrow represents stimulatory peripheral stimulatory 
hormonal action and dotted black arrows represent inhibitory neuronal signals from the 
periphery. 
1.6 CNS Neuropeptides which regulate appetite 
1.6 1 Neuropeptide Y (NPY) 
Neuropeptide Y (NPY) is one of the most abundant neurotransmitters within the CNS 
(Allen et al, 1983). Within the hypothalamus, the ARC is the major site of NPY 
expression (Morris, 1989). Hypothalamic NPY levels are sensitive to nutritional status. 
Hypothalamic NPY mRNA expression and NPY release increase with fasting and 
decrease with re-feeding (Kalra et al, 199 1; Sanacora et al, 1990; Swart et al, 2002). 
NPY is a member of the PP-fold family of peptides which bind to the G-protein coupled 
YI -Y6 receptors (Larhammar, 1996). The YI -Y5 receptors are found in the CNS of mice, 
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rats and primates. However, the Y6 receptor has only been identified as an active receptor 
in mice, being absent in rats and inactive in primates (Inui, 1999). The hypothalamic Yl, 
Y2, Y4 and Y5 have all been hypothesised to mediate the feeding effect of NPY (Stanley 
et al, 2005). 
NPY is the most potent short-term orexigen identified to date. A single 
intracerebroventricular QCV) NPY injection acutely stimulates feeding in rodents 
(Gehlert, 1999). Chronic administration of NPY into the PVN leads to sustained 
hyperphagia and weight gain, and CNS injection of NPY receptor antagonists or 
antiserum decreases food intake in the dark phase when rats normally eat readily (Kalra et 
al, 1999). Thus NPY may play a role in the CNS control of energy homeostasis. In 
addition to its effect on food intake and energy balance, NPY has multiple actions within 
the CNS including modulation of the hypothalamic-pituitary axes (Suda et al, 1993), 
seizure activity (Woldbye et at, 1997) and responses to stress and anxiety (Broqua et al, 
1996). Such diverse effects may limit the use of NPY as a drug target for the treatment of 
obesity. 
Despite the potent effect of exogenous NPY on food intake, NPY null mice have normal 
food intake, body weight and response to a fast (Erickson et al, 1996a). The only reported 
abnormality in energy homeostasis in NPY null mice is impaired re-feeding after a fast 
(Bannon et al, 2000). This essentially normal phenotype could be explained by 
redundancy in orexigenic signalling, such as by Agrp neurones or by developmental 
compensation. - 
1.6.2 The melanocortins 
The melanocortin system consists of the peptide products of POMC cleavage, their 
receptors and the endogenous melanocortin antagonists, agouti protein and agouti-related 
protein (Agrp). In the anterior pituitary, POMC gives rise to ACTH, which acts via the 
melanocortin 2 (MC2) receptor to stimulate adrenal steroidogenesis. In the CNS, POMC 
gives rise to the melanocortins ((x, 0 andy-MSH) and the endogenous opioid, P-endorphin 
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(Ellacott & Cone, 2004). Five melanocortin receptors (MC-Rs) have been cloned 
although only the MC3 and MC4 receptors are thought to play a role in the regulation of 
appetite and body weight (Ollmann et al, 1997). Alpha, beta and gamma-MSH are 
agonists of the MC3 and MC4 receptors. The MC3 receptor is found in the arcuate and 
ventromedial nuclei of the hypothalamus whereas the MC4 receptor is found more widely, 
including in the cortex, thalamus, hypothalamus, brainstem, and spinal cord. Within the 
hypothalamus, the MC4-receptor is expressed in the ARC, VMH and PVN. Acute ICV 
administration of (x-MSH and y -MSH inhibits feeding in rodents (Millington et al, 200 1). 
Although rodents do not process fý-MSH, ICV injection of human fý-MSH to rats has been 
reported to inhibit feeding (Abbott et al, 2000). Recently a missense mutation has been 
described within the coding region of the POMC-derived peptide P-MSH (Y5C-fý-MSH) 
which is associated with early-onset human obesity (Biebermann et al, 2006). This 
suggests that P-MSH may play a role in human energy homeostasis. 
In addition to endogenous agonists at the melanocortin receptors, there are also 
endogenous antagonists. Agouti protein is an antagonist at the MC I and MC4 receptors in 
rodents (Lu et al, 1994). Its expression is normally restricted to the hair follicle in rodents 
where by antagonising the MCI receptor, it results in a yellow pigment. The agouti 
mouse has yellow hair, hyperphagia and obesity which may be explained by ectopic 
expression of agouti protein (Wolff et al, 1999). Ectopic heterozygote expression of 
agouti outside the hair follicle in the AY/a mouse results in an obese phenotype whereas 
hornozygous expression is lethal (Barsh et al, 1990). Subsequently a gene was isolated in 
mice and humans that encodes a protein which is nearly identical to agouti which 
antagonises the MC3 and MC4 receptors. This protein was named agouti-related protein 
(Agrp) (Ollmann et al, 1997). Agrp is expressed in the CNS, primarily in the medial part 
of the ARC. Interestingly within the ARC, virtually all neurones expressing Agrp co- 
express NPY (Hahn et al, 1998). Like NPY, Agrp expression is increased with fasting. 
However in contrast, while NPY expression is reduced 6 hours following re-feeding, Agrp 
expression remains elevated (Swart et al, 2002). In contrast to the potent but relatively 
short-lived effect of NPY, CNS administration of Agrp to rodents leads to an increase in 
food intake for up to 24 hours (Rossi et al, 1998). Agrp is thought to increase food intake 
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through antagonism of the melanocortin MC3 and MC4 receptors and opposition of the 
anorexic effect of a-MSH. Agrp has also been reported to reduce energy expenditure 
(Small et al, 2003). Chronic CNS administration of Agrp to rodents causes sustained 
hyperphagia and leads to obesity (Small et al, 2001) and transgenic mice over-expressing 
Agrp are obese (Ollmann et al, 1997). 
The Agrp-null mouse has a normal phenotype as does the Agrp, NPY-dual null mouse 
(Qian et al, 2002). Thus the normal phenotype of the NPY knockout mouse cannot be 
explained by compensation Agrp and vice versa. ' The lack of a phenotype in these 
knockout models could however be due to developmental compensation. Selective 
ablation of Agrp expressing neurones in adult mice (which have undergone normal 
development) results in reductions in food intake and body weight (Gropp et al, 2005; 
Bewick et al, 2005). This suggests that NPY/Agrp neurones are important regulators of 
energy balance in the adult. 
The MC4 receptor, in particular, is thought to be critical to body weight regulation. The 
MC4-R knockout mouse is hyperphagic and very obese, and insensitive to a-MSH 
(Huszar et al, 1997). Functional mutations of the MC4 receptor are the most commonly 
recognised cause of monogenic human obesity being found in up to 4% of people with 
severe childhood-onset obesity (Farooqi et al, 2000). The minority with homozygous 
mutations tend to be more severely obese (Farooqi el al, 2003). For the majority of obese 
patients who have intact melanocortin receptors, agonists at these receptors and in 
particular the MC4 receptor could reduce appetite and food intake. The prolonged action 
of the endogenous antagonist Agrp suggests that manipulation of the melanocortin system 
could have long-lasting effects. 
The importance of the melanocortin pathways in human body weight regulation has also 
been demonstrated by childhood-onset obesity associated with rare mutations in POMC 
(Krude et al, 1998). Two such individuals have been found who have red hair (as a result 
of lack of melanocortin signalling at MCI-R), adrenal insufficiency (as a result of 
deficient ACTH signalling at MC2-R), and childhood-onset obesity (presumed as a result 
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of deficient melanocortin signalling at MOR and/or MC4R). Prohormone convertase-I 
mutations also produce severe childhood onset obesity that may be related to impaired 
POMC and other neuropeptide processing (Jackson et al, 1997). 
1.6 3 Cocaine- and amphetamine- related transcript 
The CNS neuropeptide cocaine- and amphetamine- related transcript (CART) is co- 
expressed in ARC neurones with POMC (Aja et al,, 2001). ICV administration of CART 
has been reported to inhibit food intake, but may also alter behaviour (Aja et al, 2001). 
CART mRNA expression is reduced in starvation and increased by peripheral leptin 
administration and ICV administration of CART antibodies increases food intake 
(Kristensen et al, 1998). Therefore CART has been proposed as an anorectic 
hypothalamic neuropeptide. Subsequently lower doses of CART administered directly 
into hypothalamic nuclei were reported to increase food intake (Abbott et al, 2001). Intra- 
hypothalamic CART was not associated with movement abnormalities which were 
reported following ICV CART (Abbott et al, 2001). Aversive locomotion behaviour 
could possibly have masked feeding stimulation following ICV CART. 
1.6.4 Melanin concentrating hormone and the orexins 
MCH-expression is sensitive to nutritional status and is increased in the fasting state. 
Acute ICV administration of MCH increases food intake (Qu et al, 1996; Rossi et al, 
1997) and repeated administration leads to an increase in adiposity in rats (Marsh et al, 
2002). Targeted deletion of MCH results in a lean phenotype (Shimada et al, 1998), and 
MCH over-expression results in an obese and insulin resistant phenotype (Ludwig et al, 
2001). These findings suggest that MCH plays a role in body weight regulation in 
addition to food intake. 
The LH also contains neurones expressing pre-pro-orexin which release the peptide 
products orexin A and B. These neurones. are distinct from MCH expressing neurones, 
and project widely through the CNS including areas associated with arousal as well as 
feeding (Sakurai et al, 1998). Pre-pro-orexin is up-regulated in the fasting state, and ICV 
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administration of orexin A increases food intake. However subsequent work has 
suggested that the orexins have a more important role in promoting arousal. Orexin 
knockout mice have been described to behave similarly to human narcolepsy patients 
(Chemelli et al, 1999). Thus deficiency of orexin signalling may be implicated in the 
pathogenesis of narcolepsy. 
1.7 Reward and appetite regulation 
The rewarding nature of food may stimulate feeding. However the degree of reward is 
related to nutritional status and energy balance (Saper et al, 2002). In an 
electrophysiological study, the effectiveness of electrical stimulation in lateral 
hypothalamic neurones thought to signal reward was enhanced by chronic food restriction 
but attenuated by ICV infusion of leptin (Fulton et al, 2000). Thus leptin may integrate 
nutritional status with the degree of pleasure associated with eating. - 
There is considerable evidence that food rewards and drug rewards may share some 
common neural substrates (Saper et al, 2002), including evidence that opiod receptors 
play key roles in both feeding and reward (Kelley et at, 1996). Opiod receptor antagonists 
such as naloxone block the stimulatory feeding effect of Agrp (Hagan et al, 2001). The 
nucleus accumbens and its doparninergic inputs have also been implicated in drug 
addiction and may play a role in feeding. The nucleus accumbens has extensive reciprocal 
connections with the lateral hypothalamus, which have been hypothesised to regulate 
feeding behaviour (Saper et al, 2002). Microinjection of GABA antagonists and opiod 
agonists has been reported to stimulate feeding and to increase the consumption of 
palatable foods such as salt, sucrose and saccharin (Reynolds & Berridge, 2001; Zhang & 
Kelley, 2002). Selective inactivation of tyrosine hydroxyolase in dopaminergic neurons 
results in mice that cannot make dopamine. These mice are born of normal weight but 
gradually become hypoactive and hypophagic and usually die at 3 weeks of age (Szczypka 
et al, 1999). Thus doparnine appears to be a critical orexigenic neuropeptide. 
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The endogenous cannabinoids (endocannabinoids), including anandamide and 2- 
arachidonoyl glycerol (2-AG), may also play a role in the mediation of food-motivated 
behaviour, in addition to modulating analgesia, excitotoxicity and cognition (Lichtman & 
Cravatt, 2005). These effects are thought to be mediated via CBI receptors in the 
hypothalamus which are co-localised with CART, MCH and orexin peptides (Cota et al, 
2003). CB, receptors are also present on adipocytes where they appear to act directly to 
increase lipogenesis (Cota et al, 2003). CB2 receptors are found primarily on cells of the 
immune system (Lichtman & Cravatt, 2005). CB I knockout mice pups do not ingest milk 
on the first day of life, unlike their WT littermates, but subsequently feed and mature 
normally (Fride et al, 2003). This could be explained by the development of compensatory 
mechanisms which might involve additional cannabinoid receptors. However, in response 
to an 18-hour fast, CB, knockout mice eat less than their wild-type littermates (Di, V et al, 
2001). Thus the endocannabinoids may play a role in promoting and sustaining 
hyperphagia after a fast. The CB, selective receptor antagonist, rimonobant, is currently 
being developed as an anti-obesity therapy. In a phase 3 clinical trial in obese subjects, 
rimonabant was associated with a significant reduction in weight (Despres el al, 2005). 
1.8 c-fos quantification and analysis 
The technique of c-fos staining and quantification has enhanced our understanding of the 
mechanism of action of neuropeptides regulating appetite. 
C-fos was the first protein to be charactcrised from the fos protein family and was 
originally cloned from mouse liver DNA in studies of homologues to the osteogenic 
sarcoma virus, v-fos (Hoffinan el al, 1993). C-fos encodes a 55-kDa product which is 
modified post-translationally to yield a product which migrates as a 62-kDa product. The 
c-fos protein includes several leucine residues, known as the leucine zipper motif, which 
promote dimerisation with other oncogene products, most commonly with members of the 
Jun family. The resulting dimers bind within the nucleus to a specific site on the DNA, 
known as the API binding domain, and may subsequently regulate transcription. 
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In the late 1980s it was discovered that neurones transiently expressed c-fos when 
stimulated, allowing scientists to identify specific neurones that were 'activated' by a 
stimulus (Hoffman et al, 1993). This technique has allowed functional and anatomical 
mapping of hypothalamic and other brain regions stimulated following exogenous 
administration of hormones. Staining techniques have been developed for fos protein 
which has a significantly longer half-life than its mRNA (Morgan et al, 1987). The 
protein product reaches a maximum between 60 and 90 minutes following stimulation and 
persists for between 2 and 5 hours (Morgan et al, 1987; Verbalis et al, 1986). The fact 
that the fos protein is intranuclear has ftirther permitted double-labelling of activated 
neurones for identity of their extra-nuclear transmitter. 
While each neurone can be either positive or negative for fos protein (on-off 
phenomenon), a graded response in the total number of fos-positive neurones per brain 
section has been observed in response to increasing concentrations of a stimulus. For 
example, increasing doses of peripheral CCK were associated with an increasing intensity 
of fos protein in the PVN (Hoffman et al, 1993). 
Although c-fos is the most widely researched intra-nuclear intermediate gene product, 
there are alternatives. Egr-1, a nuclear protein with a zinc finger binding domain, has also 
been used as a marker of neuronal activation. Egr-I shows similar induction kinetics to c- 
fos following mitogenic stimulation and, like fos, increased egr-I protein has been 
observed in the arcuate nucleus of the hypothalamus following peripheral ghrelin 
administration (Hewson & Dickson, 2000). 
There are, however, a number of limitations in the interpretation of neuronal function 
through quantification of intermediate gene products such as c-fos. Whilst these gene 
products are usually good indicators of neuronal stimulation, they are poor indicators of 
neuronal inhibition because baseline expression and transcription is usually low. In 
addition, while c-fos is sensitive to acute stimuli, it may be dissociated by persistent or 
recurrent stimuli such as in lactation with persistent suckling (Hoffman et al, 1993). It is 
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also difficult to determine when a stimulatory signal ceases because there is little 
correlation between the half-life of fos protein and the duration of the signal. 
1.9 Efferent gastrointestinal regulation of food intake 
Within the GI tract, the rate of gastric emptying, gastric acid secretion and the rate of 
intestinal transit modulate nutrient intake. The rate of gastric emptying also plays a role in 
afferent appetite signalling. Gastric emptying of liquids is mediated primarily via a 
pressure gradient between the stomach and duodenum. Gastric emptying of solid food is 
thought to be mediated via a co-ordinated action of the antrurn of the stomach and the 
pylorus. In vagotomised dogs such post-prandial co-ordination was absent (Ueno T et al, 
2005) which suggests that the efferent vagus plays a critical role in the gastric emptying of 
solids. Gastric emptying is also, under hormonal regulation by both CNS neural 
mechanisms and gut-derived hormones. Central injection of NPY inhibits both gastric 
emptying and intestinal transit time. This effect is attenuated by pre-treatment with the 0- 
adrenergic antagonist, propranolol, but not by the a-adrenergic agent, phentolamine 
(Matsuda et al, 1993). Thus NPY may inhibit gastric emptying via the P-adrenergic 
receptor. In contrast, ICV and intravenous ghrelin administration stimulate duodenal 
motility (Fujino et al, 2003). 
Peripheral GLP-I, PYY and PP administration inhibit gastric emptying and gastric acid 
secretion (OHalloran et al, 1990; Allen et al, 1984; Adrian et al, 1985c; Asakawa et al, 
2003) which may contribute to their inhibitory effects on food intake. Interestingly the 
inhibitory effects of PYY and GLP-1 on gastric acid secretion have been reported to be 
additive (Wettergren et al, 1997). 
The term "ileal brake" describes the primary inhibitory feedback mechanism to control 
transit of a meal through the gastrointestinal tract in order to optimise nutrient digestion. 
This brake initiates a distal to proximal feedback loop that inhibits upper gut motility and 
secretion, thus preventing malabsorption. GLP-I is secreted by the distal intestine and 
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leads to a reduction in gastric emptying and gastric acid secretion and has been proposed 
as an important mediator of the ileal brake (Schirra, et al, 1997).. 
While the parasympathetic vagus nerve displays important sensory and motor functions in 
the regulation of food intake, the sympathetic nervous system also plays a role. CRH 
neurones, project from the PVN to several brain regions including the median eminence to 
regulate ACTH secretion and to the spinal cord to activate sympathetic outflow 
(Sawchenko & Swanson, 1985). Leptin administration has been reported to stimulate 
sympathetic neurones to a number of organs including brown adipose tissue (BAT), the 
kidneys and the adrenals., Sympathetic nerve activity was attenuated when leptin 
treatment was preceded by a CRH receptor antagonist (Bamshad et al, 1998). Thus leptin 
may stimulate the sympathetic nervous system (SNS) via CRH neurones. The 
sympathetic nervous system also supplies white adipose tissue (WAT) (Barnshad et al, 
1998). - Interestingly sympathetic nerve stimulation by leptin leads to suppression of leptin 
mRNA expression and secretion from WAT (Rayner & Trayhurn, 2001). Thus leptin in 
the CNS may inhibit its own expression in adipocytes via the SNS, a pathway known as 
the leptin-sympathetic-leptin feedback loop. 
Brown adipose tissue (BAT) contains numerous mitochondria and is characteriscd by the 
presence of uncoupling protein 1, UCPl, which is thought to be important in regulating 
energy expenditure (Rothwell & Stock, 1979). Uncoupling proteins play an important 
role as free fatty acid transporters enabling protons to dissipate energy as heat instead of 
the energy being used to produce adenosine triphosphate (ATP) (Nicholls & Locke, 
1984). The regulation of energy expenditure in BAT is under the control of the SNS and 
higher brain structures (Yasuda et al, 2003). Dietary-restriction results in reduced BAT 
thermogenesis which conserves energy reserves (Widdowson et al, 1997). Recruitment of 
brown adipocytes and upregulation of UCPI in mitochondria depends on thyroid function 
and in particular on high tissue tri-iodo-thyronine (TO concentrations (Laurberg et al, 
2005). Orexigenic and anorexigenic neuropeptides may also regulate BAT energy 
expenditure through changes in the activity of efferent sympathetic neurones. However 
unlike rodents which retain BAT throughout life, humans do not maintain BAT beyond 
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infancy (Laurberg et al, 2005). Thus rodent BAT data may have limited applicability to 
humans. 
ICV ghrelin administration has been reported to increase the respiratory quotient (RQ) in 
rodents (Tschop et al, 2000) indicating a relative increase in the metabolism of 
carbohydrate with preservation of fat and protein. This may be explained by inhibition of 
sympathetic nerve activity in brown adipose tissue (Yasuda et al, 2003). Repeated 
peripheral administration of ghrelin has been reported to be associated with an increase in 
epididymal fat pad (WAT) and decrease in BAT UCP-1 expression (Tsubone et al, 2005). 
Thus ghrelin appears to promote fat storage. ICV ghrelin administration has also been 
reported to inhibit sympathetic activity to the kidney (Matsumura, et al, 2002) and this 
may explain at least in part its blood pressure lowering effect (Nagaya et al, 2001a). 
While ICV ghrelin stimulates circulating ACTH and corticosterone in rats, no significant 
effect was observed following peripheral ghrelin administration (Wren et al, 2002b). This 
suggests a hypothalamic mechanism for the effect of ghrelin on the stress axis. 
GLP-I may also modulate the SNS. Central and peripheral administration of the GLP-I 
receptor agonist, exendin4 to rats increases blood pressure 'and heart rate (Yamamoto H 
et al, 2002a). GLINIR activation induced c-fos expression in the rat in the adrenal 
medulla and in autonomic control sites in the brain thought to be important in the 
regulation of automonic control including medullary catecholamine, neurons. CNS 
administration of GLP-IR agonists rapidly activated tyrosine hydroxylase transcription in 
brainstern catecholamine neurons (Yamamoto H et al, 2002a). Thus GLP-l may regulate 
sympathetic outflow leading to alteration of the cardiovascular system. 
1.10 Obesity and current anti-obesity treatments 
Obesity is a severe pandernic which is accelerating and is associated with significant 
morbidity and mortality (see section 1.1). Tbus effective treatments are required. 
However the system of appetite regulation and body weight regulation is extremely 
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complex and cannot be safely modulated without adequate knowledge and understanding. 
Appetite circuits are closely integrated with other neuroendocrine systems and knowledge 
of these interactions is required in order to develop specific anti-obesity therapies. There 
are powerful evolutionary reasons for the maintenance of body weight in order to avoid 
starvation, and weight loss is powerfully resisted. This may explain why many obese 
people find it difficult to achieve and maintain weight loss through life-style changes such 
as caloric restriction and increasing energy expenditure through exercise, and why current 
pharmacological therapies have limited efficacy. Study of the endocrine alterations 
associated with a proven weight reducing treatment such as gastric bypass surgery may 
facilitate the development of more effective pharmacological treatments. 
1.10.1 Pharmacological anti-obesity treatments 
The two drugs currently licensed for weight loss in the UK are sibutramine and orlistat. 
Sibutramine, a serotonin (5-HT) and noradrenaline re-uptake inhibitor, is recommended 
by the National Institute of Clinical Excellence (NICE) for the treatment of obesity in 
patients with a BMI of over 30 k g/m 2 or the presence of an obesity-related disease and a 
BMI of over 27 kg/M2 (National Institute for Clinical Excellence, 2004a). Serotonin (5- 
HT) is a short-acting widely distributed neurotransmitter which acts on a number of 
receptor subtypes found at high density in the limbic system and Raphe nuclei, as well as 
in the hypothalamus (Blundell, 1984). Sibutramine is thought to inhibit appetite through 
primarily through increasing the concentration of intra-synaptic serotonin. In general, 
agonists at the 5-HT receptors and drugs that inhibit the re-uptake of serotonin reduce 
feeding (Blundell, 1992). Additionally serotonin stimulates noradrenaline release and 
modifies behaviour and mood. In a recent European trial, following a 6-month run-in 
period on sibutramine, patients who achieved a 5% reduction in weight were randomised 
either to'continue with sibutramine or to receive placebo. At 18 months, 69% of patients 
on sibutramine compared with 42% of controls retained this modest 5% reduction in 
weight (James et al, 2000). Sibutramine may cause an increase in blood pressure and 
pulse (acting as a sympathomimetic) and is therefore unsuitable for hypertensive patients. 
In normotensive patients, treatment with sibutramine may achieve moderate weight loss 
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although it is only currently licensed to be prescribed for one year (National Institute for 
Clinical Excellence, 2004a). 
Orlistat acts locally in the gut by binding to gastrointestinal lipases to inhibit fat 
absorption. Patients who take orlistat with meals or one hour after eating excrete 
approximately one third of their ingested dietary fat in their stools, thereby reducing 
calorie intake. Consequently they may have flatulence and offensive stools after a fatty 
meal. Orlistat is licensed for patient with a BMI greater than 30 k g/M 2 or over 28 kg/m' 
with an obesity-related complication (National Institute for Clinical Excellence, 2004b). 
Trials show that orlistat can also achieve mild weight loss of 9% at I year compared with 
5% of placebo and may slow the regain of weight for a second year of use (Yanovski & 
Yanovski, 2002). 
1.10.2 Surgical anti-obesity treatment 
The only treatment which has been so far proven to achieve lasting weight reduction is 
gastric and intestinal bypass surgery. The jejuno-intestinal bypass was performed in obese 
patients in the 1960s and 1970s and was associated with impressive weight loss (Frandsen 
et al, 1998). However its use was limited by serious complications including liver failure, 
electrolyte imbalance, renal calculi, osteomalacia and bypass enteritis. 
The Roux-en-Y gastric bypass has superseded the jejuno-intestinal bypass. This 
technique involves cutting the jejunum, and joining the distal end to the fundus of the 
stomach (the Roux-en-Y) and the proximal part to another part of jejunurn distal to the 
Roux-en-Y (figure 1.7). The stomach is stapled across leaving a 10-15 ml fundal pouch, 
which drains directly into the jejunum. The advantages of the gastric bypass over the 
jejuno-intestmal bypass are that there is no blind loop, the bile can drain through the 
duodenum and into the jejunum, and there is less severe malabsorption. In one series 
mean weight loss at 15 years post gastric bypass surgery was 30 kg (Mitchell JE et al, 
2001a) compared with 43 kg in another study following jejuno-intestinal surgery 
(Frandsen et al, 1998), but with the benefit of fewer complications. Nonetheless, the 
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morbidity associated with gastric bypass surgery, in addition to practical and financial 
constraints, usually limit this approach to severely obese patient (BMI > 40 kg/m2). 
Figure 1.7 
Roux-en-Y Gastric Bypass. Adapted from Ghrelin and gastric bypass: Is there a 
hormonal contribution to surgical weight loss? (Cummings & Shannon, 2003). 
Other'surgical options include laparoscopic gastric banding and the endoscopic placement 
of a gastric balloon. Laparoscopic banding is usually performed using an internally 
adjustable silicone band around the stomach. The most serious complication of erosion of 
the stomach around the band occurs in approximately 1% of cases. Although impressive 
weight loss may be seen up to two years, weight loss at 5 years is significantly less than 
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with gastric bypass (Szold & Abu-Abeid, 2002). Thus banding may be used as an interim 
measure. 
There are significant alterations in the concentrations of gut-derived hormones following 
gastric bypass surgery which may explain, at least in part, the sustained reduction in body 
weight. In 2002 it was reported that circulating ghrelin levels were suppressed in patients 
with gastric bypass and the usual pre-meal peaks in circulating ghrelin were absent 
(Cummings et al, 2002). Subsequently other authors have measured serial ghrelin 
concentrations before and after gastric bypass (Stoeckli et al, 2004). Although no changes 
in ghrelin levels were observed following surgery, the patients lost weight and the usual 
associated rise in ghrelin levels was not observed. Thus it appears that the elevation in 
circulating ghrelin associated with negative energy balance, which may act to oppose 
weight change, is lost in patients who have undergone gastric bypass. In addition to 
suppressed ghrelin levels, gastric, bypass patients have been reported to have an 
exaggerated early post-prandial PYY response (Korner J et al, 2005b) and this may 
contribute to their reduction in appetite. If the hormonal changes observed following 
gastric bypass surgery could be achieved using pharmacological therapy this might lead to 
an effective and more widely available anti-obesity therapy without the morbidity and 
mortality associated with surgery. 
1.11 Cachexia 
Cachexia is a state of negative energy balance due to illness such as cancer, cystic fibrosis, 
AIDS, rheumatoid arthritis and renal failure (Tisdale, 1997b). In contrast with simple 
starvation in which there is a compensatory reduction in energy expenditure and 
predominant loss of fat mass, cachexia is associated with a decrease in appetite, an 
increase in metabolic rate and a pathological loss of lean body mass (Tisdale, 1997a). 
Cachexia has long been known to have a severe impact on quality of life and mortality. In 
patients with AIDS, the preservation of a normal body weight had a stronger correlation 
with survival than did other measures of the disease (Kotler et al, 1989). Loss of appetite 
and loss of weight are also major causes of morbidity and mortality in post-surgical 
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patients, cancer patients (Dell, 2002) and patients with chronic renal failure (Owen, Jr. et 
al, 1993). 
It has been hypothesised that in patients with cancer, host/tumour competition for 
nutrients could explain the pathophysiology of their cachexia, with the aggressive tumour 
succeeding at the expense of the host. However there is no evidence for a relationship 
between the size of the tumour and the degree of weight loss (Hollander et al, 1986). 
Moreover cachexia is observed in conditions other than cancer without a tumour bearing 
load. 
Cytokines such as TNF-a and IL-6 have been implicated in the development of cachexia. 
Exogenous administration of TNF-a has been reported to cause an initial drop in weight in 
animals and man. Acute administration of TNF-a to healthy human volunteers led to a 
similar metabolic alteration to that seen in patients with cachexia with significant 
increases in glycerol, fatty acid and whole-body protein turnover and increased total 
amino acid efflux (Stames, Jr. et al, 1988). However in a rodent study, after repeated 
daily TNF-a administration for 5 days, the major weight loss occurred over the first 24 
hours and thereafter the weight of the TNF-a treated mice increased towards that of the 
controls (Mahony & Tisdale, 1988). Thus alternative or additional factors to TNF-a may 
contribute to the development of cachexia. 
Evidence that IL-6 could be implicated in cancer cachexia came initially from a murine 
adenocarcinoma cell line (colon-26 adenocarcinoma). When this cell line was 
transplanted into mice, levels of IL-6 correlated with the development and degree of 
cachexia (Strassmann et al, 1992). In addition, anti-IL-6 antibody but not anti-TNFa 
attenuated the development of weight loss. However a subsequent study reported that IL- 
6 administration to non-tumour bearing mice resulted in lipolysis and proteolysis but 
without significant alteration in body weight or food intake (Soda et al, 1995). It may be 
that the cachectic process depends on alterations on several cytokines and factors rather 
than on one factor alone. 
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There is evidence of a role for the melanocortin system in the mediation of cachexia. In 
mice bearing a sarcoma, ICV administration of the endogenous MC3 and MC4 receptor 
antagonist, Agrp, prevented the weight loss observed in control-treated tumour bearing 
animals (Marks et al, 2001). Moreover MC4-R knockout mice bearing adenocarcinoma 
gained carcass weight following tumour implantation whereas wild-type mice lost weight. 
There was no significant difference in the final tumour mass between groups, suggesting 
that the MC4 receptor plays a role in the mediation of cachexia rather than modulating 
tumour growth (Marks et al, 2001). The MC3 receptor may also be implicated in 
cachexia. MC3 receptor knockout animals may be considered to have some features of 
cachexia at baseline including a reduction in lean body mass, reduced activity and 
increased adiposity. In response to the cytokines, LPS (lipopolysaccharide) and IL-10, 
enhanced anorexia and weight loss with an increase in metabolic rate were observed in 
MC3-R knockout mice compared with WT controls (Marks & Cone, 2003). In another 
study the effect of ICV administration of NPY and the synthetic melanocortin receptor 
antagonist, SHU9119, were compared in tumour-bearing rats. NPY failed to reverse 
anorexia whereas feeding following SHU9119 was equivalent to non-tumour bearing 
controls (Wisse et al, 2001). This finding suggests that cachexia is mediated via the 
melanocortins rather than the NPY-system. These authors also administered ICV ghrelin 
to tumour-bearing animals and reported an increase in food intake but not to the degree of 
non-tumour bearing controls. It remains to be seen whether this anti-cachectic effect of 
ghrelin is mediated solely through inhibition of the melanocortin system or whether 
ghrelin has additional anti-cachectic effects. 
LI 1.1 Current appetite-stimulating treatments 
Current appetite enhancing therapies for patients with cachexia include fish oils, the 
synthetic progestogen, megestrol acetate (megace), and the synthetic corticosteroid, 
dexamethasone. Fish oil, rich in omega-3 fatty acids, has been shown to suppress the 
cytokines, interleukinI (IL-1) and tumour necrosis factor (TNF) from peripheral 
lymphocytes in healthy volunteers. However a recent randomised controlled trial has 
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reported that taking regular fish oil for two weeks did not significantly influence appetite, 
nutritional status or well-being in patients with advanced cancer (Bruera et al, 2003). 
The progestogen, megestrol acetate, may be used as second or third line therapy as a 
treatment for breast cancer. It may also be prescribed f6r patients with loss of appetite and 
loss of weight, achieving modest weight gain. A recent meta-analysis has reported a mean 
weight gain of 0.49 kg with megestrol acetate compared to weight loss of 1.1 kg with 
placebo control (Ruiz-Garcia et al, 2002). However, megestrol acetate may cause water 
retention and increases the already elevated risk of venous thrombosis. An alternative 
therapeutic strategy is to exploit the weight gain associated with glucocorticoids. In a 
randomised controlled trial, megestrol acetate and dexamethasone were found to achieve 
similar modest weight gains (Loprinzi et al, 1999). However the side-effect profile of 
dexamethasone was more severe, and included immunosuppression, glucose intolerance, 
osteoporosis and psychosis. While dexamethasone should probably be reserved as a 
short-term treatment, megestrol acetate is more suitable as a longer-term therapy and may 
achieve modest weight gain, at least in its initial phase. There remains a need for a more 
effective, better-tolerated therapy. 
1.12 Hypothesis and p urpose of this thesis 
This thesis investigates the two arms of gut-derived afferents in appetite signalling - 
orexigenic and anorexigenic. 
There are a number of gut hormones which are released in response to a meal (see figure 
1.2) and which have been reported to inhibit food intake when administered individually. 
In physiology it may be that alterations in several hormones are acting in concert leading 
to changes in appetite and energy homeostasis. For example PYY and GLP-I are co- 
released from the L-cell in response to nutrients in the gut and thus might inhibit appetite 
additively. In order to investigate this hypothesis, pairs of gut hormones were 
administered to rodents at high and low doses and food intake measured. The purpose of 
the high dose studies was to investigate whether the maximum inhibitory feeding effect of 
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one peptide could be exceeded with the addition of another, which might suggest 
independent mechanisms. The purpose of the low dose studies was to investigate whether 
an additive effect was observed at doses closer to the physiological range. The 
combination Of PYY3-36 and GLP-17-36 was found to be the most effective and was also 
studied at low doses in rats. In order to investigate anatomical location of inhibition of 
food intake by this pair of peptides, c-fos was quantified in the brain and brain-stem 
following peripheral PYY3-36 and GLP-17-36. Finally, in order to determine whether these 
hormones would inhibit food additively in man, PYY3-36 and GLP-17-36 Were CO- 
administered to healthy volunteers at doses lower than previously reported to alter food 
intake individually in a double-blind randomised controlled trial and energy intake 
measured. The purpose of the human study was to gain greater understanding of PYY and 
GLP-I combined signalling in human physiology and to consider whether this 
combination of peptides might be a putative future anti-obesity therapy. 
The gastric hormone ghrelin is the only known orexigenic gut-derived hormone, and 
exogenous ghrelin administration increases energy intake in rodents (rschop et al, 2000) 
and healthy human volunteers (Wren et al, 2001a). While ghrelin has been reported to 
ameliorate cancer associated cachexia. in rodents (Wisse et al, 2001), the effect of ghrelin 
in humans with appetite loss was unknown. This thesis explores the hypothesis that 
exogenous administration of ghrelin to patients with cancer and appetite loss stimulates 
energy intake. A double-blind placebo-controlled trial was performed to investigate the 
effect of intravenous ghrelin on energy intake in cancer patients with appetite loss. 
However intravenous ghrelin is unsuitable for patient use, and therefore a subsequent 
study was performed in order to investigate whether ghrelin would stimulate appetite 
when administered subcutaneously. 
While these trials were in progress, it was reported that rodents with vagotomy did not 
respond to the appetite stimulating effect of ghrelin (Date et al, 2002). This suggested that 
a functioning vagus nerve might be required to mediate the feeding effects of ghrelin. In 
order to investigate this hypothesis in humans, a cohort of patients with 
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oesphagogastrectomy and vagotomy were recruited in whom to evaluate the effect of 
ghrelin infusion. 
In summary, the purpose of this work was to gain a greater understanding of the role of 
gut hormones in physiology and pathology, and to determine whether they might provide 
suitable therapeutic targets in the treatment of obesity and cachexia. 
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Chapter 2 
Co-administration of Gut Hormones in 
Rodents 
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2.1 Introduction 
Many gut hormones have been reported to inhibit feeding when administered 
exogenously. These hormones include PYY3-36, GLP-17-36, CCK-8 and PP. In contrast, 
ghrelin is the only gut hormone reported to increase feeding. In the light of these studies, 
many authors have sought to extrapolate their results to the physiological role of gut 
hormones (Gibbs et al, 1973; Wren et al, 2000; Batterham et al, 2002). It may be that this 
model is over simplistic. For example, the endogenous rise in the plasma concentration of 
a gut hormone is likely to follow a different time course than the exogenous rise following 
a bolus injection. 
Another limitation of the model could be that each hormone is usually studied in isolation. 
After a meal, plasma levels of PYY, GLP-I (Anini et al, 1999), PP (Batterham et al, 
2003b) and CCK (Lieverse et al, 1994) rise in an orchestrated fashion, and are thought to 
play a part in meal termination (Bloom et al, 2005). Peripheral administration of each 
hormone individually has been reported to inhibit feeding (Dakin et al, 2004; Asakawa et 
al, 2003;. Gibbs et al, 1973). However the effects of combinations of these hormones on 
appetite have not been investigated. In addition to improving our understanding of gut 
hormone physiology, co-administration of these hormones might have pharmacological 
benefits. It might be that, as with anti-hypertensives, treatment with two or more gut 
hormones is more effective at inhibiting appetite than one and has a more favourable side- 
effect profile. % 
There is some prior evidence that co-administration of appetite-related peptides inhibit 
feeding synergistically in rodents. The gut hormone cholecystokinin (CCK) has been 
reported to potentiate the appetite inhibitory effects of the adipocyte, hormone, leptin, in 
rodents. Peripheral administration of low dose CCK-8 alone did not alter food intake and 
peripheral administration of low dose leptin only significantly inhibited food intake from 
5-7 hours post-injection (Barrachina et al, 1997). When CCK-8 was co-administered with 
leptin, a marked reduction in cumulative food intake was observed from I to 7 hours 
(Barrachina et al, 1997). 
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The aim of the experiments in this chapter was to investigate the hypothesis that 
combinations of gut hormones inhibit feeding additively. For simplicity, these hormones 
were investigated in pairs. PYY3-36 had only recently been reported to inhibit feeding 
(Batterham et al, 2002), but its effect in combination with other inhibitory gut hormones 
was unknown. Therefore PYY3-36 was investigated in combination with other inhibitory 
gut hormones. The following pairs of gut hormones were investigated - PYY3-36 and 
CCK-8, PYY3-36 and PP, and PYY3-36 and GLP-17-36. Before commencing these studies, a 
dose response study was performed for each peptide individually. It was important to 
know how much feeding inhibition was caused by each peptide alone before combining 
them. In each of the co-administration studies food intake following combined treatment 
was compared with saline control and with each peptide alone. In the light of these 
results, the combination Of PYY3-36 and GLP-17-36 was considered to be sufficiently 
promising to merit further study. 
Given the synergistic inhibition of feeding observed following CCK-8 and leptin 
(Barrachina et al, 1997) one might predict that the oblob mouse, which is deficient in 
leptin, would have reduced sensitivity to CCK-8 administration. However in practice, 
oblob and WT mice display similar sensitivity to CCK-8 administration (Strohmayer & 
Smith, 1986) which suggests that CCK may signal independently of leptin. Alternatively 
it is possible that oblob mice have altered CCK signalling in response to the absence of 
leptin. Other gut hormones may also inhibit feeding independently of leptin. Acute 
administration of PP leads to a reduction in food intake and repeated PP administration 
leads to a reduction in cumulative food intake and body weight in oblob mice (Asakawa et 
al, 2003). Continuous PYY3-36 administration to oblob mice resulted in a significant 
reduction in body weight but without a significant difference in cumulative food intake 
(Pittner et al, 2004). This suggests that PYY3-36 may increase energy expenditure in oblob 
mice. Repeated administration of the GLP-IR agonist, exendin4, also leads to a 
reduction in weight gain in oblob mice (Ding et al, 2006). However the effect of acute 
PYY3-36 and GLP-17-36 administration to oblob mice was unknown. 
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In the current series of experiments it was hypothesiscd that the combined feeding cffect 
observed following acute PYY3, -36 and 
GLP-17-36 administration was independent of leptin 
signalling. In order to investigate this hypothesis, PYY3-36 and GLP-17-36 were 
administered alone and in combination to oblob and dbldb mice and their effect on food 
intake compared with that of WT controls. 
A chronic study was performed in lean mice in order to investigate whether the inhibitory 
feeding effect would be sustained following repeated administration and lead to an 
alteration in body weight. PYY3-36 and GLP-17-36 were injected alone and in combination 
twice per day for 7 days and food intake and body weight measured. 
To determine whether these hormones would inhibit feeding in another species and in 
another feeding phase, PYY3-36 and GLP-17-36 were co-administered to mts in the dark 
phase. In order to elucidate potential mechanisms for the observed acute alterations in 
feeding, fos-like immunoreactivity was quantified following peripheral PYY3-36 and GLP- 
17-36 alone and following IPYY3-36 + GLP-17-36 co-administration. 
2.2 Methods 
2.2.1 Materials 
Synthetic human PYY3-36,, CCK-8, PP and GLP-17-36 were purchased from Phoenix 
Pharmaceuticals (Belmont, CA, USA). These peptides were purchased freeze-dried, and 
kept at -200C. Unless stated otherwise all chemicals were purchased from Merck (Poole, 
Dorset, UK). 
ZZ2 Animals 
All animal procedures were approved by the British Home Office Animals (Scientific 
Procedures) Act 1986 (Project License numbers 70/5516 and 70/5281). Male C57BL/6 
wild-type (WT), ob/ob and db/db mice, and Wistar rats were purchased from Charles 
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River Laboratories UK (Margate, Kent, UK) were maintained in individual cages under 
controlled temperature (21-23C) with ad libitum access to standard chow (RM I diet, SDS 
Ltd, Witham, Essex, UK) and to water. The ages of the animals at the time of the 
experiments are described with the study protocols below. The light cycle for the mice 
was 14 hours light and 10 hours dark with 'dawn' at 07: 00, lights full on at 07: 30, 'dusk' 
at 21: 00 with lights off at 21: 30. The light cycle for the rats was 12 hours light and 12 
hours dark with 'dawn' at 07: 00, lights full on at 07: 30, 'dusk' at 19: 00 with lights off at 
19: 30. These times were fixed in the animal facility. The light cycle is particularly 
relevant to feeding studies as rodents are nocturnal feeders and eat only a small proportion 
of their daily caloric intake during the light phase with a dramatic increase in food intake 
after the onset of darkness (Lu et al, 2002). 
All animals were handled daily for at least 2 minutes for seven days prior to the first 
study. This is particularly important in the light of recent evidence that peripheral PYY3-36 
does not inhibit food intake in stressed animals unaccustomed to their experimental 
conditions but does so in well-handled, acclimatised animals (Halatchev et al, 2004). 
During the acclimatisation period, each animal received two saline injections in order to 
minimise stress on the study days. 
22.3 Intra-peritoneal (IP) injections 
Peptides were weighed using a Sartorius Ultramicro balance (Sartorius Ltd, Epsom, 
Surrey, UK) which is sensitive to O. Ipg. Peptides were dissolved in 200pl of distilled 
water and diluted in saline to achieve the required concentration. IP injections were 
administered to mice via a 0.5ml syringe with a 29-gauge needle (maximum injection 
volume 0.1ml) and to rats via a Iml syringe with a 25-gauge needle (maximum volume 
0.5ml). IP injections were given in the lower half of the abdomen to avoid the liver with 
the head of the animal below the legs in order to minimise the risk of injecting into the 
bowel. 
The IP route was initially chosen for peptide administration because this is the peripheral 
route with which the laboratory had the most experience. While this does involve 
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penetration of the intra-peritoneal cavity, the animals appeared well following injection 
without signs of infection. In a pilot study early in the course of this thesis, PYY was 
administered to freely feeding male Wistar rats via the subcutaneous route prior to the 
dark feeding phase (figure 2.1). While subcutaneous PYY3-36 significantly inhibited 
feeding, the reduction was only seen at 7.5nmol/kg and not at lower doses (n=1 1-12 per 
treatment group). In comparison, IP administration of PYY had been reported to reduce 
dark-phase feeding in male Wistar rats from a 10-fold lower dose of 0.3ýtg/100g 
(0.75nmol/kg) (Batterham el al, 2002). Therefore it was decided that the IP route should 
be used for subsequent studies. One limitation of this conclusion was that the 
subcutaneous route was not compared with the IP route in the same group of animals. 
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Figure 2.1 
Food intake in the first hour of the dark phase in freely feeding male Wistar rats following 
subcutaneous injection Of PYY3-36 (n=1 1-12). *P<0.05 vs. saline. 
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For the combination treatments in the current studies, peptides were pre-mixed and drawn 
up in a single syringe. In each study, animals received one injection with the volume 
adjusted linearly according to body weight., The minimum interval between studies was 
three days in order to allow the animals to recover from their fast and from the effects of 
the peptides administered. 
2.2.4 Studies in lean mice 
C5713116 mice aged 7-9 weeks (20-25g) were injected following a 20-hour fast. A 
Sartorius TE412 balance which was calibrated to weigh to 0.0 1g to a maximum weight of 
410g was used to weigh the chow. In order to investigate the repeatability of food weight 
measurement, 64.50g chow was weighed 10 times and a 95% confidence interval of 64.49 
- 64.50g was observed. Thus the repeatability of food weight measurements was within 
0.0 1g with a confidence of ?: 95%. 
A pre-weighed quantity of chow weighing 60-70g was presented to the mice immediately 
after injection. In order to minimise the risk of small pieces of food falling through the 
hopper, only full size chow pieces were used. The remaining food was weighed at pre- 
specified time points following injection (see below) and food intake calculated. The cage 
was inspected to check that no un-eaten chow was left outside the hopper. 
in order to determine suitable doses for the combined studies, a dose response study was 
performed for each peptide individually. The doses selected for the individual peptides 
included doses of similar magnitude that had previously been reported to inhibit food 
intake in fasted rodents when administered via the IP route. PYY3-36 has been reported to 
inhibit food intake in mice from a dose of 3pg/lOOg (8nmol/kg). In another study PP 
inhibited feeding at 8 and 80nmol/kg in mice (Asakawa et al, 2003). CCK-8 inhibited 
feeding in rats from llig/kg (Inmol/kg) (Moran et al, 1988) and GLP-17-36 inhibited 
feeding in rats from I 00nmol/kg (Dakin et al, 2004). 
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The current dose response studies were carried out on separate days and are described in 
table 2.1. In all studies, a saline control group was included in addition to the doses 
below. 'Me number of animals per group was determined by the total number of animals 
available with a minimum number per treatment group of 8. The studies were performed 
at 09: 00 in the early light-phase. Mice were fasted from 15: 00 from the day before studies 
until following the injection when they were presented with pre-weighed chow. Each 
study was performed only once. Following injection, the remaining food was weighed at 
1,2,4,6 and 24 hours for the PYY and PP dose response studies. Due to other 
experimental commitments and the previously documented short duration of action of 
CCK (Moran, 2000), in the CCK dose response study, food intake was only measured at I 
and 2 hours post injection. In the GLP-17-36 study, food was weighed at 1,2,4,8 and 24 
hours. 
Gut hormone Doses (nmol/kg) number of animals per group 
(n number) 
PYY3-36 30,100,150 and 300 11-12 
PYY3-36 3,10,30 and 100 8 
CCK-8 0.3,1,3 and 10 9-10 
PP 10,30,100,300 8 
GLP-17-36 30,100,300 and 900 9-10 
Table 2.1 
IP dose response studies in lean fasted mice in the early light phase. Each line of the table 
represents a separate experiment. PYY3-36 was investigated twice in order to assess the 
response to a wider range of doses. 
All combined studies were performed in lean fasting mice in the early light phase and 
included a saline control group. The following combinations were investigated (see 
section 2.3.1) - PYY3-36 + CCK-8, PYY3-36 + PR, and PYY3-36 + GLP-17-36. The doses 
administered for each of these combinations are listed below. Each study was performed 
only once, although combinations of peptides were investigated at different doses. Please 
70 
see the results section (2.3.2-2.3.5) for explanation of the doses selected for peptide 
administration in the combined studies. 
PM36 and CCK-8 
CCK-8 and PYY3-36 were administered at the following doses - 30nmOl/kg PYY3-36,, 
10nmol/kg CCK, 30nmol/kg PYY3-36 + l0nmol/kg CCK (n=l 1-12) and food, intake 
measured. A further study was performed in order to assess whether the combined 
peptide would be more effective than twice the individual doses of the peptides and 
included the following groups - 60nmoVkg PYY3-36,20mnoVkg CCK-8,30nmol/kg PYY3- 
36 +I Onmol/kg CCK-8 (n-- I 1- 12). Finally a CCK-8 and PYY3-36 study was performed in 
order to investigate these peptides; at lower doses - 3nmol/kg PYY3-36, Inmol/kg CCK-8, 
3nmol/kg PYY3-36 +I nmol/kg CCK-8 (n=9-1 0). The remaining food was weighed at 1,2, 
4,6 and 24 hours post injection. 
PM36 and PP 
PYY3-36 and PP were administered at the following doses - 30nmol/kg PYY3-36, 
30nmol/kg PP, 30nmol/kg PYY3-36 + 30nmol/kg PP (n=10). In a further study PYY3-36 
and PP were administered at lower doses - 3nmol/kg PP, 6nmol/kg PP, 3nmol/kg PYY3-36, 
6nmol/kg PYY3-36 and 3nmol/kg PP + 3nmol/kg PYY3-36 (n=7-8). The remaining food 
was weighed at 1,2,4,6 and 24 hours post injection. 
PYY3-36 and GLP-17-36 
PYY3-36 and GLP-17-36 were administered at the following doses - 100nmol/kg PYY3-36, 
200nmol/kg PYY3-36,100nmol/kg GLP-17-36,200nmol/kg GLP-17-36 and 100nmol/kg 
PYY3-36 + 100nmol/kg GLP-17-36 (n=8-9). The remaining food was weighed at 1,2,4,8 
and 24 hours post injection. 
Following these studies (see results section), further studies were performed with the 
PYY3-36 + GLP-17-36 combination. 
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2. Z5 Co-administration ofPYY3-36 and GLP-17-36 in oblob and dbldb mice 
10 oblob mice and 10 WT littermates, and 9 dbldb and 10 WT littermates, both on a 
C57BIJ6 background were acquired aged 20 weeks. During their acclimatisation period, 
body weight and 24-hour food intake were measured in order to determine baseline data in 
these genetically obese mice prior to peptide administration. PYY3-36 and GLP-17-36 were 
co-administered in a 4-way cross-over design in order to increase the statistical power 
with the limited numbers of mice available. Therefore four studies were performed; and 
each mouse received all four treatments in randomised order. There was a time interval of 
72 hours between studies. In each study, following a 20-hour fast, mice were IP injected 
with saline, 200nmol/kg PYY3-36,200nmoVkg GLP-17-36 or 100nmoYkg PYY3-36 + 
100nmol/kg GLP-17-36. Due to the limited number of genetically obese mice available, 
doses of the individual peptides (100runol/kg GLP-17-36 and 100nmol/kg PYY3-36) which 
had been administered to lean mice were not included in the studies in oblob and dbldb 
mice. 
Z2.6 Chronic administration OfPYY3-36 and GLP-17-36 in lean mice 
Freely feeding WT C5713116 mice aged 8 weeks were randomised into 4 groups - saline, 
200nmol/kg PYY3-36,200nmol/kg GLP-17-36, and 100nmol/kg PYY3-36 + 100nmol/kg 
GLP-17-36, n--12 per treatment group. Each mouse received two IP injections per 24-hours 
of saline or peptide(s). Between 20: 30 and 21: 00 and 08: 00 and 08: 30 each day, the mice 
were weighed. Their remaining food was weighed in order to allow calculation of intake. 
Then all mice received an IP injection. In order to standardise peptide doses across the 
study, in preparation for the study, the total amount of peptides required had been 
dissolved in small volumes of distilled water (Inmol per 2pl), aliquoted into vials and 
freeze-dried using an Edwards Modulyo 4K freeze drier with an RV5 pump (Edwards 
High Vacuum international, Sussex UK). Immediately prior to each injection period, 
freeze-dried PYY3-36 and GLP-17-36 were dissolved in 200PI distilled water, dissolved in 
saline and drawn-up in individual syringes. As in all the co-administration studies, the 
two peptides were pre-mixed for the combined group and drawn up in a single syringe. 
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The mean weight of the mice was 22.2 ± 0.2g and there were no statistical differences in 
baseline body weights between the four groups. 
The first injection was given prior to the dark-phase, as this was when the larger acute 
reduction in food intake was expected. The duration of the study was 7 days. The first 
evening injection time was called dark-phase 0, and the following morning's day injection 
time was called light-phase 1. The primary outcome in this study was change in body 
weight. Secondary outcomes were food intake following injection and cumulative food 
intake throughout the study. Animals were weighed twice a day and their remaining food 
weighed prior to their morning and evening injections. On dark-phase 0,1,2,4,5 and 7 
the remaining food was measured and food intake calculated I hour after the onset of the 
dark phase. On light-phase 1,2,3,4,6,7 the remaining food was measured and food 
intake calculated I hour following the morning injection. 
Prior to dark-phase 3, behaviour was assessed. For further description and rationale for 
behaviour experiments please see the methods for the behavioural studies in rats (section 
2.2.9). Following their injections of saline or peptide(s), mice were returned as usual to 
their home cages and a colleague who was unaware of which treatment they had received 
assessed their behaviour over the subsequent 30 minutes. She assessed behaviour in each 
mouse for 15 seconds every 5 minutes during this period. These 15-second periods were 
subdivided into three 5-second periods. In each of these periods she used standard 
behaviour analysis sheets (appendix 2) from which to select the behaviour which most 
closely represented that what the mouse was doing. 
2.2.7 Feeding studies in rats 
In order to examine the effect Of PYY3-36 and GLP-17-36 in another species and during a 
different feeding phase, these peptides were co-administered to male Wistar rats in the 
dark phase. Rats, like mice, are nocturnal feeders and eat the majority of their food during 
the dark-phase (Lu et al, 2002). Freely feeding rats aged 6-7 weeks (150-200g) were IP 
injected in the hour before lights off and their food replaced with a pre-weighed quantity 
73 
of chow (60-70g). The remaining food was weighed at 1,2,4,8 and 24 hours following 
injection. As in the mouse studies, prior to the combination study, dose response studies 
were performed for each peptide individually. These included IP doses of PYY3-36 
(Batterham et al, 2002) and GLP-17-36 (Dakin et al,, 2004) which had previously been 
reported to inhibit feeding in freely feeding rats in the dark-phase. 
For the PYY3-36 dose response study, animals received IP saline, 1,3 or l0nmoVkg PYY3. 
36 (n=12-13). For GLP-17-36, rats received saline, 3,10,30,100nmol/kg GLP-17-36 (n--12- 
13). In order to investigate the combined effect of low doses which did not individually 
alter feeding, InmoVkg PYY3-36 and 10nmol/kg GLP-17-36 were chosen for the joint study 
(see results section). On two evenings, 72 hours apart, animals were randomised and 
injected IP with saline, I0nmoI/kg GLP-17-36,20nmoI/kg GLP-17-36,, 'Inmol/kg PYY3-363, 
2nmol/kg PYY3-36 or I fUMOI/kg PYY3-36 +I Onmol/kg GLP- 17-36 (total n= 19-20 per group) 
prior to the dark phase. 
2.2.8 Immunocytochemistry 
Male Wistar rats aged 8-9 weeks (240-265g) were each handled for 5 minutes per day for 
one week to minimise the stress of the procedure and therefore to reduce non-specific 
neuronal activation (Valles et al, 2003). The co-administration acute feeding studies had 
already been performed on these rats when they were 6-7 weeks old. A nine day washout 
period was allowed between studies. The reason that the same cohort of rats was used for 
two studies was to minimise the numbers of animals required. Doses of peptides were 
chosen at which significant reduction in intake had been observed in the feeding studies 
(see results section 2.3.7). Following an overnight fast, rats received IP injections of 
saline, 10nmol/kg GLP-17-36, lnmol/kg PYY3-36 or Inmol/kg PYY3-36 + lOnrnol/kg GLP- 
17-36 (n=5-6 per group). 
Ninety minutes later, rats were terminally anaesthetised with IP sodium pentobarbitone 
(200mg) (Rhone Mdrieux, Harlow, UK). While deeply anaesthetised but prior to 
cessation of the heartbeat, an incision was made through the chest wall and the heart 
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exposed. Rats then underwent cardiac perfusion. A blunt needle attached to an 
intravenous giving set (Baxter Healthcare Ltd., Northampton, UK) was clamped into the 
ascendingaorta. Fifty ml of O. OlMphosphate-buffered saline (PBS) (PBS tablets, Sigma, 
Poole, Dorset, UK) was perfused through the ascending aorta in order to flush the blood 
out of the circulation, followed by 200 ml PBS-formalin 4% (4 % v/v formalin (approx. 
38%) in 0.01M PBS, pH 7.4) in order to fix the brain tissue. A three-way tap allowed 
interchange between fluids without altering the tubing. Once the PBS was switched on, 
the atria were snipped in order to allow blood and fluids to leave the circulation and the 
perfasates to flow. 
Brains were placed immediately into phosphate buffered saline (PBS) containing 4% 
paraformaldehyde (PFA) and left overnight. After 24 hours brains were placed into 
PBS/4% PFA containing 20% sucrose for a further 24 hours. Brains were then blotted dry, 
cut into forebrain and brainstern parts and stored at -70*C until sectioning. 
Coronal sections were cut at 40gm on a freezing microtome and collected into a 24-well 
plate containing O. IM Phosphate buffered saline (PBS). Sections were transferred into 
custom plates and washed in PBS three times for five minutes before incubation in 0.1% 
H202 for ten minutes to quash endogenous peroxidase enzymes. Sections were then 
washed a further three times in PBS before incubation overnight in primary antibody 
solution, consisting of 1: 20,000 dilution of AB-5 rabbit anti c-fos antibody (Oncogene, 
San Diego USA), 0.01% Triton X and 0.3% BSA in O. IM PBS. After overnight 
incubation, sections were washed three times in PBS before incubation for 2 hours in 
secondary antibody solution consisting of 1: 400 dilution of goat anti rabbit antibody 
(Vector laboratories, New Jersey, USA), 0.01% Triton X and 0.3% BSA in O. IM PBS. 
Sections were then washed three times in PBS and incubated for one hour in Avidin- 
Biotin Complex solution containing 1: 200 dilution of avidin biotin complex (vectastain 
elite, Vector laboratories) in PBS. Finally sections were washed in PBS followed by three 
washes in acetate buffer (0.1 M) before being incubated in chromagen solution containing 
0.2 mg/ml Diamino-Benzidine (DAB), 0.01% H202 and 0.01M Nickel (11) Sulphate in 
0.1 M acetate buffer. Incubation was continued until the appearance of blue-black dots in 
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the cortex. The sections were then mounted on poly-L-lysine-coated slides, and 
dehydrated in increasing concentrations of ethanol. Cover slips were applied using DPX 
mounting medium (BDH, Karlsruhe, Germany). 
Fos-positive nuclei were counted using a light microscope (Nikon Eclipse E800) by a 
colleague who was unaware of which treatment had been given. The nuclei examined 
were the medial pre-optic area (MPOA), paraventricular (PVN), arcuate (ARC), 
ventromedial (VMH) and dorsomedial (DIAN) of the hypothalamus, and the nucleus of 
the tractus solitarius (NTS) and the area postrema (AP) of the brainstem. 
2. Z9 Behavioural studies in rats 
Peptides may inhibit feeding through specific appetite circuits or as part of an aversive 
response. The most validated method of investigating aversive effects is through 
conditioned taste aversion studies (Seeley et al, 2000; Talsania et al, 2005). This involves 
acclimatising the animals to drinking for a limited period during a 24-hour period. 
Subsequently animals are injected with peptide or saline'and given one flavoured 
saccharin drink and then on a separate day injected with saline and given another 
flavoured saccharin drink. This is repeated so that each flavour is presented with its 
associated injection on two occasions. Finally all animals are offered both drinks without 
injection and the volume of each drink consumed measured. If the flavours are equally 
palatable the group injected with saline should drink equal proportions of the two drinks. 
if the animals previously injected with peptide consume significantly less of the 
associated flavoured drink, then the peptide is thought to have caused taste aversion. 
PYY3-36 has been reported to lead to taste aversion in mice from a dose of 1.5gg/100g or 
40nmol/kg (Halatchev & Cone, 2005). ICV injection of GLP-17-36 is also associated with 
taste aversion (Seeley et al, 2000). However the effect of peripheral GLP-17-36 
administration on taste aversion has not been reported in the literature. In the current 
study it was hypothesised that the combined inhibitory effect Of PYY3-36 and GLP-17-36 on 
food intake was due to a specific appetite effect rather than aversive effects. It would 
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have been desirable to investigate this using a conditioned taste aversion study. However 
the project animal licenses did not permit temporary fluid restriction of animals which is 
an essential part of the taste aversions study protocol. Therefore, observational behaviour 
and locomotion studies were performed as alternatives, as in previously reported studies 
(Wren et al, 2002a; Talsania et al, 2005). Aversive responses would be expected to result 
in altered behaviours and to disrupt the normal satiety sequence. 
The protocol for the behaviour study in rats was similar to the behaviour study in mice 
(section 2.2.6) (Wren et al, 2002a). Behaviour was classified into seven different 
categories: feeding, drinking, grooming, rearing (defined as stationary with front paws 
elevated), head down (defined as stationary with all four paws on the cage bottom), 
locomotion (defined as moving around the cage, with all four paws moving), or sleeping 
(Wren et al, 2002a). Following an overnight fast, rats aged 6 weeks (150-170g) were 
injected IP with saline, lOmnol/kg GLP-17-36,, lnmol/kg PYY3, -36,, 
InmOl/kg PYY3-36 + 
10nmol/kg GLP-17-36,10nmol/kg exendin4, lithium chloride (IM), n=10 per treatment 
group, and their food replaced. Lithium chloride and exendin4 were included as positive 
controls. Lithium chloride has been previously reported to cause conditioned taste 
aversion and elicits vomiting in species with an emetic reflexes (Seeley et al, 2000). In 
another study, exendin4 led to a reduction in observed activity at doses of 0.3 and 3pg 
per mouse (3 and 30nmol/kg respectively). When the 30nmol/kg dose was formally 
investigated, reduction in locomotion was confirmed and significant conditioned taste 
aversion was noted (Talsania et al, 2005). Therefore lithium chloride and exendin4 were 
expected to be associated with observable behavioural change in the current studies and 
were included as positive controls to confirm the validity of the paradigm in the current 
experimental conditions. 
In the current study, behaviour was assessed for 60 minutes following IP injection by two 
observers who were unaware of which treatment had been given. Each observer recorded 
behaviours of 30 animals (n=5 per treatment group per observer). Each rat was observed 
for 15 seconds in every 5 minutes. The 15-second periods were subdivided into three 5- 
second periods in which the observers assigned the behaviour which most closely 
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represented the animal's behaviour. The number of behavioural observations in each 
group was compared following administration of peptides and saline. Lack of significant 
difference compared with saline would indicate the absence of observable behavioural 
change associated with peptide administration. Certain behaviours may suggest a 
physiological phenotype. For example, in addition to its primary role in caring for the 
body surface, grooming in rodents has been associated with a de-arousal process that 
develops during habituation to stress (Spruijt et al, 1992). Exposure to novelty and stress 
has also been reported to trigger grooming (Windle et al, 1997). 
In a ftirther experiment, freely feeding rats were IP injected prior to the dark phase with 
saline, 10nmoVkg GLP-17-36, Inmol/kg PYY3-36, Inmol/kg PYY3-36 + l0nmol/kg GLP-17- 
36 or 10nmol/kg exendin-4 (n--9-10 per treatment group). Infira-red beam breaks in two 
planes x-tot (horizontal movement) and z-tot (vertical movement) were counted for one 
hour following injection using an Opto-Max system (Columbus Instruments, Columbus, 
OH, USA) in order to assess locomotion. 
Z 2.10 Statistical analysis 
Results are shown as mean values ± SEM. Data from the repeated food weight 
measurements are reported as a 95% confidence interval. Data from the animal feeding, 
immunocytochemistry and locomotion studies were analysed using a one-way ANOVA 
with a Dunnett's 2-sided post hoc test. In the behavioural study, the numbers of 
observations of a particular behaviour category would not be expected to be normally 
distributed, therefore non-parametric statistics are appropriate. These data were analysed 
using the Kruskal-Wallis test. The Kruskal-Wallis test is a non-parametric test which 
allows comparisons between 3 or more groups (Altman, 1991) and may be regarded as an 
extension of the Mann-Witney non-parametric test which only permits comparison of 2 
groups. In all statistical tests P<0.05 was considered to be significant. 
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2.3 Results 
2.3.1 Dose response studies in lean fasted mice 
In the higher range PYY3-36 dose response study, food intake in the first hour was 
significantly inhibited by all doses Of PYY3-36 administered (figure 2.2a). PYY3-36 
appeared to cause maximal feeding inhibition from doses of 30nmol/kg and above. 
Inhibition of cumulative feeding was sustained for up to 6 hours post injection but not up 
to 24 hours following all doses Of PYY3-36 administered in this study (figure 2.2b) 
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Figure 2.2a 
Food intake in the first hour following increasing doses of IP PYY3-36 to lean fasted mice, 
n=1 1-12 per group. *P<0.05 vs. saline. 
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Figure 2.2b 
Cumulative food intake up to 24 hours following increasing doses Of IP PYY3-36 to lean 
fasted mice, n=1 1-12 per group. * P<0.05 for all groups vs. saline 
In order to determine the minimum dose Of PYY3-36 that would significantly inhibit 
feeding, a further dose response study was performed using lower doses. Food intake in 
the first hour was significantly inhibited from a dose of 10nmol/kg compared with saline 
(P<0.05) (figure 2.3a). Cumulative food intake was significantly inhibited for up to 6 
hours but not up to 24 hours post-injection by the 10,30 and 100nmol/kg doses (figure 
2.3b). 
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Figure 2.3a 
Food intake in the first hour following lower doses Of PYY3-36 to lean fasted mice, n=8 per 
group. * P<0.05 vs. saline. 
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Figure 2.3b, 
Cumulative food intake up to 24 hours following lower doses Of PYY3-36, n=8 per group. 
* P<0.05 for 10,30 and I 00nmol/kg vs. saline. 
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In the CCK-8 dose response study, food intake in the first hour was inhibited from a dose 
of 3nmol/kg (figure 2.4a). This inhibition in food intake was not significantly sustained 
beyond the first hour at any of the doses of CCK-8 administered (figure 2.4b). 
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Figure 2.4a 
Food intake in the first hour following IP CCK-8 to lean fasted mice, n=9-10 per group. 
*P<0.05 vs. saline. 
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Figure 2.4b 
Cumulative food intake in the first 2 hours following IP CCK-8 in lean fasted mice, n=9- 
10 per group. 
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In the PP dose response study, food intake was inhibited from a dose of IOnmoI/kg (figure 
2.5a). There appeared to be an increase in food intake with the 100nmol/kg dose 
compared with the 30nmoVkg dose (P-0.05). Food intake was inhibited up to 6 hours 
compared with saline by both the 30nmol/kg and 100nmol/kg doses. However with the 
30nmol/kg dose, but not with the 100nmol/kg dose, inhibition of cumulative food intake 
was sustained up to 24 hours post-injection (figure 2.5b). 
Saline 3 
Výý 
10 
PP (nmoUkg) 
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Figure 2.5a 
Food intake in the first hour following increasing doses of IP PP in lean fasted mice, n=8 
per group. * P<0.001 vs. saline. § P--0.05 vs. 30nmoVkg dose. 
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Figure 2.5b 
Cumulative 24 hour food intake following increasing doses of IP PP in lean fasted mice, 
n=8 per group. * P<0.05 for 10,30 and 100nmol/kg PP vs. saline. t P<0.05 for 30 and 
I 00nmol/kg PP vs. saline. § P<0.05 for 30nmol/kg vs. saline. 
In the GLP-17-36 dose response study, food intake in the first hour was significantly 
inhibited by 100,300 and 900nmol/kg GLP-17-36 but not by the 30nmol/kg dose (figure 
2.6a). In contrast with the PYY and PP studies, greater inhibition of feeding was observed 
with increasing doses of GLP- 17-36 (P<0.05 for I 00nmol/kg vs. 30nmol/kg GLP- 17-36 and 
for 300nmol/kg vs. 100nmol/kg GLP-17-36)- Inhibition in cumulative feeding was 
sustained up to 6 hours post injection following the 100,300 and 900 nmol/kg doses 
(P<0.05) (figure 2-6b). 
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Figure 2.6a 
Food intake in the first hour following increasing doses of GLP-I 7-36 in lean fasted mice, 
n=]O per group. *P<0.05 vs. saline. § P<0.05 for 100nmol/kg vs. 30nmol/kg GLP-17-36 
and for 300nmol/kg vs. I 00nmong GLP- 17-36- 
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Figure 2.6b 
Cumulative 24-hour food intake following increasing doses of IP GLP- 17-36 in lean fasted 
mice, n=10 per group. * P<0.05 for 100,300 and 900nmol/kg GLP-I vs. saline. 
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In the light of the results of the individual dose response studies, studies were planned in 
which two peptides would be administered together and individually and their effect on 
food intake compared with saline. PYY3-36 had consistently been observed to lead to a 
reduction in food intake of approximately 30% in the first hour following injection at 
doses of l0nmol/kg and above. However, higher doses Of PYY3-36 did not lead to 
significantly greater reductions in food intake. In order to test the hypothesis that further 
reduction in food intake would be observed with the addition of another gut hormone, 
PYY3-36 was co-administered with other gut hormones from the dose response studies. 
Z 3.2 Co-administration of CCK-8 and PY436 in leanfasted mice 
Doses of CCK-8 and PYY3-36 that appeared to achieve maximal inhibition of feeding in 
the first hour were chosen from the dose response studies. Fasted mice were injected with 
10nmol/kg CCK-8,30nmol/kg PYY3-36 or 10nmol/kg CCK-8 + 30nmol/kg PYY3-36- All 
peptide groups inhibited feeding in the first hour compared with saline (figure 2.7a). 
Food intake was significantly further inhibited by the combined CCK-8 + PYY3-36 group 
compared with saline and either peptide alone (P<0.05). Cumulative food intake was 
inhibited up to 6 hours compared with saline by the combined treatment and by PYY3-36 
alone but not beyond 2 hours by CCK-8 alone (figure 2.7b). 
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Figure 2.7 
Food intake following IP saline, l0nmol/kg CCK-8,30nmol/kg PYY3-36 or lOnmol/kg 
CCK-8 + 30nmol/kg PYY3-36 (n=l 1-12) a) in the first hour * P<0.05 vs. saline. t P<0.05 
vs. all other groups; b) cumulative 24 hour food intake t P<0.05 for PYY+CCK vs. all 
other groups, § P<0.05 for PYY and PYY+CCK-8 vs. saline. 
In order to determine whether the combination of CCK-8 and PYY3-36 would be more 
effective than twice the doses of the individual peptides, a further study was performed. 
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As in the single dose study, all peptide groups inhibited food intake in the first hour 
compared with saline (figure 2.8a). However while the combined group (30nmol/kg 
PYY3-36 + lOmnol/kg CCK-8) inhibited feeding in the first hour more than 60nmol/kg 
PYY3-36 (P<0.05), it did not do so compared with 20nmol/kg CCK-8 (P=0.17). In this 
study, food intake was measured up to 4 hours (figure 2.8b). Cumulative 2 hour food 
intake was inhibited more by the combined group than 20nmol/kg CCK-8 but not more 
than 60nmol PYY3-36- 
CCK-8 and PYY3-36 were also co-administered at lower doses. Doses from the dose 
response studies that were three-fold lower than those observed to significantly inhibit 
feeding were selected. Thus fasted mice were injected with saline, InmoVkg CCK-8, 
3nmoUkg PYY3-36 or I nmol/kg CCK-8 + 3nmol/kg PYY3-36. At these low doses, neither 
PYY3-36 nor CCK-8 alone inhibited feeding compared with saline. However the combined 
PYY3-36 + CCK-8 group inhibited food intake in the first hour compared with all other 
groups (P<0.001) (figure 2.9). At these low doses, significant inhibition in food intake 
was not observed beyond the first hour following injection. 
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Figure 2.8 
Food intake following IP saline, 20nmol/kg CCK-8 (2*CCK), 60nmol/kg PYY3-36 
(2*PYY) or I Onmol/kg CCK-8 + 30 nmol/kg PYY3-36 (CCK+PYY) (n= I ]- 12) a) in the 
first hour * P<0.05 vs. saline, t P<0.05 vs. saline and vs. 2*PYY; b) cumulative 4-hour 
food intake, *P<0.05 for all groups vs. saline, §P<0.05 for 2*PYY and PYY+CCK vs. 
saline. 
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Figure 2.9 
Food intake in the first hour following saline, lnmol/kg CCK-8,3nmol/kg PYY3-36 or 
I nmol/kg CCK-8 + 3nmol/kg PYY3-36 (n=9- 10). t P<0.05 vs. all other groups. 
2.3.3 Co-administralion of PP and PYY3-36 in leanfasted mice 
For the high dose co-administration study, doses of PP and PYY3-36 which appeared to 
cause maximal inhibition of feeding were selected from the dose response studies. Fasted 
mice were injected with saline, 30nmol/kg PP, 30nmol/kg PYY-3-36 and 30nmol/kg PP + 
30 nmol/kg PYY3-36. All peptide groups inhibited food intake in the first hour compared 
with saline (P<0.05). However there were no statistical differences between the combined 
PP+ PYY3-36 group compared with either peptide alone (figure 2.1 Oa). PP alone and PP+ 
PYY3-36 inhibited cumulative food intake for up to 24 hours (figure 2.10b). 
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Figure 2.10 
Food intake following IP 30nmol/kg PP, 30nmol/kg PYY3-36 or 30nmol/kg PP + 
30nmol/kg PYY3-36 (n=10) a) in the first hour, *P<0.05 vs. saline; b) cumulative 24 hour 
data *P<0.05 for all groups vs. saline, § P<0.05 for PP and PYY+PP vs. saline 
In the low dose PP and PYY3-36 co-administration study, doses of the individual peptides 
were selected from the dose response studies which were 3-fold lower than those 
statistically observed to inhibit feeding. Fasted mice were injected with saline, 3nmol/kg 
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PP, 6nmol/kg PP, 3nmol/kg PYY, 6nmol/kg PYY or 3nmol/kg PP + 3nmol/kg PYY. 
Food intake in the first hour was significantly inhibited by the 6nmol/kg PP and 6nmol/kg 
PYY groups compared with saline (P<0.05) (figure 2.1 la). However the combined group 
did not significantly inhibit feeding in the first hour compared with saline (P=0.34). At 
these low doses there were no significant differences in cumulative 4 hour food intake in 
any treatment group (figure 2.11 b). 
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Figure 2.11 
Cumulative food intake following IP saline, 3nmol/kg PP (PP), 6nmol/kg PP (2*PP). 
3nmol/kg PYY3-36 (PYY) 6nmol/kg PYY3-36 (2*PYY) or 3nmol/kg PP + 3nmol/kg IIYY; 
; (, (n 7-8)a) in the first hour and b) in the first flour hOUrs, * P--, 0.05 vs. saline. 
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Z 3.4 Co-administration OfPYY3-36 and GLP-1 7-36 in lean mice 
For the PYY3-36 and GLP-17-36 co-administration study, a dose Of PYY3-36 Was selected 
from the dose response study which appeared to have led to maximum inhibition of 
feeding in the first hour compared with saline. In the GLP-17-36 dose response study, 
increasing doses were associated with increasing inhibition of feeding down to an 
inhibition of 76% with a dose of 900nmol/kg. It might have been difficult to achieve any 
further reduction in feeding. Therefore a dose of GLP-17-36 which was associated with 
approximately a 50% reduction in food intake in the first hour was selected (100nmol/kg). 
Fasted mice were injected with saline, 100nmol/kg PYY3-36,200nmol/kg PYY3-36,. 
100nmol/kg GLP-17-36,200nmol/kg GLP-17-36 or 100nmol/kg PYY3-36 + 100nmol/kg 
GLP-17-36. All peptides inhibited feeding in the first hour compared with saline. Co- 
administration Of PYY3-36 with GLP-17-36 led to significantly greater feeding inhibition 
than all other groups (P<0.05) (figure 2.12a). Feeding inhibition following the 
combination treatment was sustained up to 24 hours post injection (figure 2.12b). 
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Figure 2.12 
Food intake following IP 100nmol/kg PYY3-36 (PYY), 200nmol/kg PYY3-36 (2*PYY), 
100nmol/kg GLP-17-36(GLP-1), 100nmol/kg GLP-17-36(GLP-1) or 100nmol/kg PYY3-36 + 
I 00nmol/kg GLP- 17-36 (P+G) (n=8-9) a) in the first hour * P<0.05 vs. saline. t P<0.05 for 
P+G vs. all other groups and b) cumulative 24 hour food intake * P<0.05 vs. saline for all 
peptide groups; t P<0.05 for P+G vs. all other groups, * P<0.05 for all groups vs. saline § 
P<0.05 for P+G vs. saline. 
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From these studies, the only combination 
' 
resulting in significantly greater inhibition of 
feeding than single or double doses of the individual peptides was PYY3-36 and GLP- 17-36- 
Therefore, this combination was further investigated. PYY3-36 and GLP-17-36 were 
administered to genetically obese oblob and dbldb mice to determine whether their effect 
on food intake was independent of leptin. A chronic study was performed to investigate 
the effect of repeated administration Of PYY3-36 and GLP-17-36 on body weight and 
cumulative food intake. PYY3-36 and GLP-17-36 were also co-administered in another 
species (the rat) and in another feeding phase (the dark-phase). 
Z3.5 Co-administration Of PIT3-36 and GLP-17-36 in oblob and dbldb mice 
Prior to the study, food intake and body weights were measured in these genetically obese 
mice. By the time these mice were available they were 20 weeks old and the dbldb mice 
were clinically diabetic with polyuria and polydipsia. Loss of energy in their urine and 
the cachectic effect of a deficiency in insulin could explain their increased food intake 
compared with the heavier oblob mice. 
Mean weight (g) Mean 24h food intake 
oblob 54.5 ± 1.4 6.92 d: 0.27 
WT littermates of oblob 32.5± 1.0 5.36± 0.21 
dbldb 41.8 ± 1.1 9.54± 0.5 
WT littermates of dbldb 31.0± 0.5 4.79± 0.15 
Table 2.5 
Baseline body weight and food intake of genetically obese and WT mice. 
In the studies, mice were randomised to receive saline, 200nmol/kg GLP-17.36, 
200nmol/kg PYY3-36 or I 00nmoVkg PYY3-36 +I 00nmoUkg GLP- 17-36- 
Co-administration Of PYY3-36 and GLP-17-36 in oblob mice and their WT littermates led to 
significant inhibition of feeding compared with saline and both peptides alone. The 
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percentage reduction in food intake with the co-administration treatment compared with 
saline was similar in oblob (74 ± 4%) and WT mice (70 ± 6%) (figure 2.13A). 
Co-administration Of PYY3-36 and GLP-17-36 was also associated with significant 
reductions in food intake in dhldb mice and their WT littermates compared with saline and 
both peptides alone. The percentage reduction in food intake with the co-administration 
treatment compared with saline was similar in dbldb (65 ± 7%) and WT mice (63 ± 6%) 
(figure 2.13B). 
saline P+G pyy GLP-1 
Nff 1.3 ± 0.11 0.33 ± 0.05 t 0.78 ± 0.08 0.68 ± 0.09 
oblob 0.4810.09 0.14 ± 0.03 t 0.32 ± 0.04 0.25 ± 0.03 * 
Nw 1.16± 0.08 0.43 0.06 f 0.76 ± 0.06 * 0.91 ± 0.09 
dbldb 0.59± 0.10 0.20 0.04 f 0.36 ± 0.04 * 0.45 ± 0.05 
Table 2.6 
Food intake in the first hour (g) following IP saline, 200nmoVkg GLP-17-36,200nmol/kg 
PYY3-36 and I 00nmoL/kg PYY3-36 + 100 nmoL/kg GLP- 17-36 (P+G) (n=9-1 0) in oblob, 
dbldb and WT mice. * P<0.05 vs. saline, t P<0.05 vs. all other groups. 
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Figure 2.13 
Food intake in the first hour following IP saline, 200nmol/kg GLP-17-36,200nmol/kg 
PYY3-36 and I 00nmol/kg PYY3-36 + 100 nmol/kg GLP- 17-36 (P+G) (n=9-1 0) in (A) fasted 
WT and oblob mice and (B) fasted WT and dbldb mice. Results are presented as a 
percentage of the mean food intake on the saline day. *P<0.05 v. v. saline. tP<0.05 
compared with all other groups. 
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2.3.6 Chronic co-adminisiralion QfP YY3-36 and GLP- 17-36 10 lean mice 
Mice were randomised into 4 groups and received two injections per 24 hours - one 
between 08: 00 and 08: 30 in the early light phase and the other between 20: 30 and 21: 00 
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immediately before the dark phase. Mice were randomised into 4 groups to receive saline, 
200nmol/kg GLP-17-36,200nmol/kg PYY3-36 or 100nmol/kg PYY3-36 + 100nmol/kg GLP- 
17-36 (n--12). Each mouse received the same treatment throughout the study. All three 
peptide groups inhibited feeding acutely in the first hour of the dark phase following the 
pre-dark-phase injection compared with saline on every evening investigated. The effect 
Of PYY3-36 on food intake in the first hour appeared to be more potent than in the previous 
studies (Percentage reduction in I hour feeding with PYY3-36 compared with saline: 
previous acute study 31%; first dark-phase of this study 53%). The percentage reduction 
in feeding with PYY3_36 appeared to become greater as the study progressed (percentage 
reduction with PYY3-36: 53% on dark-phase I vs. 91% on dark-phase 7; P--0.001). In 
contrast, the percentage reduction in 0-1h dark phase food intake appeared relatively 
constant in the GLP- 17-36 group (22% on dark-phase I vs. 31% on dark-phase 7; 11-NS). 
There was no further inhibition seen with the PYY3-36 + GLP-17-36 co-administration 
group compared with PYY3-36 alone. The percentage reduction in food intake in the first 
hour of the dark-phase in the co-administration increased significantly from dark-phase I 
to dark-phase 7 (53% on dark-phase I vs. 79% on dark-phase 7; P---0.005) in a similar 
fashion to the PYY3-36 group (figure 2.14A). 
As expected, the mean food intake in the first hour following the early light-phase 
injection was low in the saline control group because rodents are nocturnal, dark-phase 
feeders (range 0.01 ± O. Olg on light-phase 4 to 0.13 ± O. Olg on light-phase 1). No 
significant alterations in light-phase food intake in the first hour following injections were 
observed between treatment groups (figure 2.1413). 
Despite these changes in acute energy intake following injections, there were no 
differences in 12-hour energy intake between treatment groups or in cumulative energy 
intake during the study (figure 2.15). On the final early light-phase of the study (light- 
phase 8), there were no differences in the cumulative food intake from the beginning of 
the study between treatment groups (cumulative food intake (g): saline 29.9 ± 0.5, GLP- 
17-36 29.0 ± 0.5, PYY3-36 30.1 ± 0.8, PYY3-36 + GLP-17-36 28.2 ± 0.9g). 
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Figure 2.14 
Food intake in the first hour of A) the dark-phase and B) the light-phase during the 
chronic study following twice daily injections of saline, 200nmol/kg GLP-17-36, 
200nmol/kg PYY3-36 or 100nmol/kg PYY3-36 + 100nmol/kg GLP-17-36 (n=12). * P<0.05 
vs. saline. § P<0.05 vs. saline and vs. GLP-17-36- 
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Figure 2.15 
Cumulative food intake during the chronic co-administration study with twice daily 
injections of saline, 200nmol/kg GLP-17-36,200nmol/kg PYY3-36 or 100nmol/kg PYY3-36 
+I 00nmol/kg GLP- 17-36 (n= 12). 
Analysis of the body weights revealed that in all treatment groups, weight increased over 
the nocturnal feeding period from beginning of the dark-phase until the early-light phase 
(figure 2.16) corresponding with the usual rodent nocturnal feeding pattern. In order to 
illustrate changes in body weights between groups more clearly, graphs have been drawn 
separately for the change from baseline in body weights prior to the dark-phase and for the 
change in body weights prior to the light-phase (figure 2.17A and B). 
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Figure 2.16 
Body weight change during the chronic mouse co-administration study with twice daily IP 
injections of saline, 200nmol/kg GLP-17-36,200nmol/kg PYY3-36 or 100nmoVkg PYY3-36 
+I 00nmol/kg GLP- 17-36 (n= 12). 
In the early light-phase body weights, there was a significant increase in body weight in 
the PYY3-36 group from day 5 which was sustained until the end of the study (body weight 
change from early light phase I to early-light phase 8 (g): saline 0.28 ± 0.20; GLP-17-36 
0.38 :L0.35; Pyy3-36 1-()8 : L- ()-10; Pyy3-36 + 
GLP-17-36 0.52 ± 0.30; P<0.05 for Pyy3-36 
vs. saline) (figure 2.17A). 
In the weights prior to the dark phase, prior to dark-phase I there was a significant 
reduction in body weight change in the combined PYY3-36 + GLP- 17-36 group- However 
this reduction was not significantly sustained over the rest of the study. There were no 
other changes in body weights prior to the dark-phase (figure 2.1713). In particular, there 
was no significant change in weights of the PYY3-36 group prior to the dark-phase despite 
the increase in early light-phase body weights observed in this group. 
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Figure 2.17 
Change from baseline of A) body weights in the early light-phase and B) body weights 
immediately prior to the dark-phase with twice daily IP injections of saline, 200nmol/kg 
GLP- 17-36,200nmol/kg PYY3-36 or I 00nmol/kg PYY3-36 +I 00nmol/kg GLP- 17-36 (n= 12). 
*P<0.05 vs. saline. 
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Prior to dark-phase 3 of the study, behaviour was assessed over 30 minutes following 
injection. There were no significant differences in the numbers of individual behavioural 
observations between treatment groups. The most frequent observation in all groups was 
'head down' (figure 2.18). 
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Figure 2.18 
Number of behaviour observations (feeding, rearing, locomotion, grooming, burrowing 
and head down) over 30 min in mice following IP saline, 200nmol/kg GLP-17-36, 
200nmol/kg PYY3-36,100nmoVkg PYY3-36 + 100nmoVkg GLP-17-36 (n=12) prior to the 
dark-phase. 
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2.3.7 Co-administration Of P YY3-36 and GLP- 17-36 in MIS 
PYY3-36 and GLP- 17-36 dose response studies were performed in freely feeding rats in the 
dark phase. In the PYY3-36 study, food intake in the first hour of the dark phase was 
significantly inhibited by 3 and lOnmol/kg PYY3-36 but not significantly by the Inmol/kg 
dose (P<0.05 vs. saline) (figure 2.19A). In the GLP-17-36 study, food intake in the first 
hour was significantly inhibited by 30 and 100nmol/kg GLP-17-36 (P<0.05 for 30nmol/kg 
and I 00nmol/kg PYY3-36 VS- saline) (figure 2.1913). 
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Figure 2.19 
The effect on food intake in the first hour of the dark phase in freely feeding rats of A) IP 
PYY3-36 (1,3 and 10nmol/kg) (n=12-13); B) IP GLP-17-36 (3,10,30 and 100nmol/kg) 
(n--9-10). *P<0.05 vs. saline. 
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The doses of peptides selected for the combined study were 3-fold lower than the 
minimum doses found to inhibit food intake significantly in the first hour. Rats received 
IP injections of saline, lnmol/kg PYY3-36,2nmol/kg PYY3-36,10nmol/kg GLP-17-36, 
20nmol/kg GLP-17-36 or lnmol/kg PYY3-36 + l0nmol/kg GLP-17-36. Food intake in the 
first hour of the dark phase was significantly inhibited only in the PYY3-36 + GLP-17-36 
group (figure 2.20). There was significant inhibition of food intake with the combined 
treatment compared with all other groups (P<0.02). Cumulative food intake was inhibited 
in the co-administration group for up to 4 hours compared with saline (figure 2.20b). 
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Figure 2.20 
Food intake in freely feeding rats following IP low dose co-administration Of PYY3-3f, with 
GLP- 17-36 compared with each peptide alone prior to the dark-phase. Rats were injected 
with either saline, P+G (Inmol/kg PYY3-36 + l0nmol/kg GLP-17-36), I*G (10nmol/kg 
GI-P-17-36), 2*G (20nmol/kg GLP-17-36), I*P (Inmol/kg PYY3-36) or 2*P (2nmol/kg 
13YY3-36) (n=19-20) a) in the first hour, tP<0.05 compared with all other groups; b) in the 
first four hours, * P<0.05 vs. saline 
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23.8 Immunocytochemistry 
In order to elucidate a possible mechanism for the additive inhibitory feeding effect of 
PYY3-36 and GLP-17-36,. c-fos was quantified following low dose individual peptide and 
combined peptide administration. Doses Of PYY3-36 and GLP-17-36 were chosen which 
had been found not to alter food intake individually but had led to significant reduction in 
food intake following co-administration. Rats received IP injections of saline, 10nmol/kg 
GLP-17-36, Inmol/kg PYY3-36 or lnmol/kg PYY3-36 + 10nmol/kg GLP-17-36- In the 
hypothalamus, there were no significant differences in the number of fos-like 
immunoreactivity (FLI) counts in the PVN,, VMN, DIAN between treatment groups (table 
2.7). At these low doses, no significant differences were seen in the ARC with either 
PYY3-36 or GLP-17-36 alone compared with saline. However, an 85% increase in the 
number of FLI counts was observed in the ARC following the co-administration treatment 
compared with saline (P<0.05) (figures 2.21 and 2.22). Moreover, following the 
combined PYY3-36 + GLP-17-36 treatment there were significantly more FLI counts than 
following PYY3-36 alone (P<0.05), and a trend for more FLI than following GLP-17-36 
alone (P=0.05). 
In the brainstem no significant differences in FLI counts were observed between these low 
dose treatments in the nucleus of the solitary tract (NTS) or the area postrema (AP) (table 
2.7). 
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Saline 
Counts/section 
GLP- 17-36 
Counts/section 
PYY3-36 
Counts/section 
PYY+GLP- I 
Counts/section 
MPOA 80.0 ± 28.6 81.5 ± 24.0 98.1 ± 18.7 87.9 ± 12.0 
PVN 40.2 ± 10.8 37.2 ± 8.3 41.6 ± 8.3 38.2 ± 12.3 
ARC 35.4 ± 6.2 42.9 ± 1.2 36.2 ± 4.4 65.6 ± 10.0 
VMH 43.2 ± 6.2 40.9 ± 5.5 47.4 ± 9.1 57.0 ± 4.7 
DMH 33.8 ± 4.6 48.5 ± 22.2 51.1 ± 13.6 49.3 ± 8.6 
NTS 6.9 ± 2.3 7.9 ± 1.6 6.5 ± 1.2 7.5 ± 1.5 
AP 26.5 ± 4.9 29.4 ± 4.6 26.3 ± 5.5 35.7 ± 5.8 
Table 2.7 
c-fos counts per section in hypothalamic and brainstern nuclei following IP injection of 
saline, I Onmol/kg GLP- 17-369 1 nmol/kg PYY3-36 and I nmoUkg PYY3-36 +I Onmolikg GLP- 
17-36 (n=5-6). *P <- 0.05 vs. all other groups in the nucleus examined. 
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Figure 2.21 
c-fos counts per section in the ARC in response to III saline, P+G (Inmol/kg PYY3-36 + 
[Onmol/kg GLP-17-36), G (10nmol/kgGLP-17-36) and P (Inmol/kg Pyyi--36) (n=5-6). *P< 
0.05 compared with all other groups. 
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(a) saline 
PYY3-36 
Figure 2.22 
3V 
N ME 
(b) GLP-1 
(d) PYY3-36 + GLP-1 
Representative views of the arcuate nucleus (ARC) following staining for c-fos at 
magnification *10; ME=median eminence, 3V=3d ventricle; (a) IP saline, (b) I Onmol/kg 
GLP- 17-369 WI nmol/kg PYY3-36, (d) I nmol/kg 
PYY3-36 +I Onmol/kg GLP- 17-36- 
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Z3.9 Behavioural studies 
It is possible that the additive inhibitory effect on food intake observed following PYY3.36 
and GLP-17-36 was due to an aversive effect rather than a direct feeding effect. The 
author hypothesised that PYY3-36 and GLP-17-36 inhibited food intake through a direct 
feeding effect. In order to investigate this, ideally a conditioned taste aversion (CTA) 
study would have been performed (Seeley et al, 2000). This would have required 
temporary fluid restriction prior to the introduction of flavoured drinks. Unfortunately the 
laboratory animal project licenses (70/5516,70/5281) did not permit fluid restriction and 
therefore a CTA study could not be carried out. As an alternative observational 
behavioural and locomotion studies were performed. Exendin-4 and lithium chloride at 
doses expected to cause behavioural change (see methods section 2.2.9) were included as 
positive controls. 
In the observational study, fasted rats were IP injected with saline, 10nmol/kg GLP-17-36, 
Imnol/kg PYY3-36, Inmol/kg PYY3, -36 + 10nmol/kg 
GLP-17-36,10nmol/kg exendin4 or 
IM lithium chloride (n--10 per group) and then allowed to re-feed. The groups treated 
with exendin4 and lithium chloride had significantly fewer feeding episodes and 
significantly more head down episodes compared with saline (P<0.05) (figure 2.23). 
However, no significant differences in behaviours were observed following PYY3-36, 
GLP- 17-36 or PYY3-36 + GLP- 17-36- 
ill 
Saline GLP-1 pyy 
PYY+GLP-1 Ex4 
A, 
LiCl 
m feeding 0 drinking 0 rearing 
locomotion grooming 
head down sleeping 
Figure 2.23 
Number of behaviour observations (feeding, drinking, locomotion, grooming, head down, 
sleeping and rearing) over 60 min following IP saline, ]OnmoUkg GLP-17-36, lnmol/kg 
PYY3-36, lnmoVkg PYY3-36 + ]Onmol/kg GLP-17-36,10nmol/kg exendin-4 (ex-4) and 
0.5ml IM lithium chloride (LiCl) (n=10). 
In the locomotion study, movement was assessed in freely feeding rats prior to the dark 
phase following IP saline, I Onmol/kg GLP- 17-367 1 nmol/kg PYY3-36, I nmol/kg PYY3-36 + 
10nmoUg GLP-17-36 and 10nmollkg exendin-4 (n=9-10 per group). No significant 
differences in horizontal movement (x-tot) were observed following the combined PYY3- 
36 + GLP- 17-36 treatment there was but there was a slight reduction in vertical movement 
(z-tot) compared with saline (P--0.04) (table 2.8). There were significant reductions in 
both horizontal and vertical movement following exendin-4 compared with saline (P<0.0 I 
for both comparisons). 
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Horizontal movement 
(X-tot) 
Vertical movement 
(Z-tot) 
Saline 724± 60 357 ± 81 
GLP-17-36 664 76 265: h 56 
PYY3-36 653 88 291 ± 56 
PYY3-36 + GLP- 17-36 517 66 167 ± 25 * 
Exendin-4 442 38 128 ± 19 * 
Table 2.8 
Beam breaks in the first hour of the dark phase following IP saline, 10nmol/kg GLP-17-36,, 
I mnol/kg PYY3-36, I Omnol/kg GLP- 17-36 +I nmol/kg 
PYY3-36 or I Onmol/kg exendin-4 in 
freely feeding lean rats (n--8-10). *P<0.05 vs. saline. 
2.4 Discussion 
In this chapter the effect of the peripheral administration of pairs of gut hormones on food 
intake was investigated in rodents in order to investigate the hypothesis that they inhibit 
feeding additively. Prior to combining peptides, dose response studies were performed 
for each peptide individually. PYY3-36, CCK-8, PP and GLP-17-36 each inhibited food 
intake compared with saline as expected from the results of previously published work. 
All peptides and peptide combinations were administered via IP bolus injection. This 
leads to an acute rise in the plasma concentrations of these hormones rather than the 
sustained rise usually seen after a meal (Anini et al, 1999; Batterham et al, 2002). If the 
peptides; had been administered via an infusion pump over several hours, one could argue 
that the results would be more applicable to human physiology. However Azlet osmotic 
mini-pumps, with which the laboratory has experience, run as soon as they have been 
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implanted and cannot be switched off. Therefore, it would have been difficult to 
administer peptide infusions for a few hours without either tethering the animal or 
disturbing it to disconnect the pump. The advantage of the IP injection protocol used in 
these studies was that once the peptides had been injected, the animals were able to move 
freely around the cage and feed without fijrther disruption. As explained in the methods, 
stress, which could be provoked by disturbance, has been demonstrated to interfere with 
the efficacy Of PYY3-36 in rodents (Halatchev et al, 2004) and could have affected the 
other peptides. Therefore despite the disadvantage of an acute surge in circulating 
peptide, the protocol used in the current studies had significant advantages over the 
alternatives. 
With the exception of the GLP-17-36 and PYY3-36 study in rats, the studies in this chapter 
were performed only once. It is therefore possible that the results of these studies are not 
truly representative of the effects of these peptides, on feeding, and they should be 
interpreted with caution. However, the dose response studies were in line with previously 
published work (see below). Each of the peptide combinations was studied at least twice 
in rodents at different doses, and the results were internally consistent. This consistency 
strengthens the results of this chapter. Nonetheless, further studies are required to confirm 
these results. 
Synthetic human PYY3-36,, GLP-17-36,, CCK-8, and PP were administered to mice and 
synthetic human PYY3-36 and GLP-17-36 were administered to rats. GLP-17-36 and CCK-8 
have identical amino acid sequences in mice, rats and humans (Bachem, 2006). Mouse 
and rat PYY3-36 am identical and differ from human PYY3-36 by only 2 out of 34 amino 
acids (Keire et al, 2000). Peripheral administration of synthetic human (Batterham et al, 
2002) and synthetic rat PYY3-36 (Chelikani et al, 2005) have been reported to inhibit 
feeding in rats. Tberefore, human and rodent PYY3-36 may have similar effects when 
administered to rodents. Of the gut hormones studied, PP exhibits the most divergence 
between species, with mouse and human PP differing by 6 amino acids (Asakawa et al, 
2003). Both human and mouse PP bind to the Y4 receptor within the CNS whereas only 
human PP exhibits significant binding at the Y5 receptor (Asakawa et al, 2003). Given 
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that there is conservation of expression of the Y5 receptor in the hypothalamus between 
rodents and humans (Nichol et al, 1999), it may be that the results of studies administering 
human PP rather than rodent PP to rodents are more applicable to human physiology. 
In the current studies, PYY3-36 inhibited food intake in the first hour in fasted mice at 
doses of I Onmol/kg and above. Batterharn et al. reported a reduction in food intake from 
a lower dose of 0.3ug/100g or 1.2nmol/kg (Batterham et al, 2002). In the current study 
there was no significant further increase in feeding inhibition with increasing doses. 
PYY3-36, from a dose of 30nmol/kg, inhibited cumulative food intake for up to six hours 
after injection. The half life Of PYY3-36 in vivo is only 8 minutes (Lluis et al, 1989), and 
thus it appears that PYY3-36 may influence appetite even after it has been degraded 
peripherally. Indeed PYY3-36 has been reported to inhibit appetite for up to 24 hours post 
injection (Batterham et al, 2002). The mechanism may be through reduced expression of 
NPY in the hypothalamus (Batterharn et al, 2002). 
CCK-8 inhibited feeding from a dose of 3nmoI/kg, but this inhibition was only sustained 
for the first hour following injection. The half life of CCK-8 has been reported to be 17 
minutes in rat plasma (Koulischer et al, 1982). Unlike PYY3-36, it appears that CCK-8 
must be present in the circulation to modulate appetite. Voigt et aL performed a CCK-8 
dose response study in fasted rats and reported that CCK-8 inhibited feeding from a 
slightly higher dose of 8nmol/kg (Voigt et al, 1996) compared with an effective dose of 
3nmol/kg in fasted mice observed in the study described in this chapter. 
PP inhibited food intake in the first hour from a dose of 10nmol/kg. This is consistent 
with Asakawa et aL who reported a reduction in food intake with peripheral 
administration of PP from 0.3nmol/mouse for mice weighing -32-35g (Asakawa et al, 
1999), representing approximately 9nmol/kg. In the current dose response, the maximal 
inhibition was observed following the 10 and 30nmol/kg doses. Although the higher dose 
of 100nmol/kg inhibited food intake compared with saline, the reduction was significantly 
less than that following 30nmol/kg PP. ICV administration of PP has been reported to 
increase food intake in mice (Asakawa, et al, 1999), and it could be that higher dose 
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peripheral administration activates similar neuronal pathways. Inhibition of cumulative 
food intake following 30nmol/kg PP was sustained for up to 24 hours post injection. This 
was the longest inhibition of feeding observed in the dose response series. Interestingly 
the half-life of PP in plasma is only 7 minutes (Adrian et al, 1978) and yet PP inhibits 
energy intake in humans for up to 24 hours (Batterharn et al, 2003b). Thus, like PYY3-36, 
it appears that PP alters appetite after it has been degraded in the plasma. 
GLP-17-36 inhibited food intake in the first hour from a dose of 100nmol/kg. Muchofthe 
previous work in mice and rats has been -performed using the longer acting GLP-I 
receptor agonist, exendin-4 and it is therefore difficult to compare doses. Originally ICV 
administration of GLP-I was first reported to inhibit feeding and it was thought that IP 
administration did not alter food intake (Turton et al, 1996). In a chronic study, daily ICV 
GLP-1 administration lead to a'reduction in food intake and body weight compared with 
saline-treated controls (Meeran et al, 1999). Subsequently Rodiquez et al. observed a 
small but significant'reduction in food intake following subcutaneous administration of 
GLP-1 at*500ng/100g (2runol/kg) (Rodriquez et al, 2000). More recently Dakin et al. 
reported a reduction in food intake following IP GLP-17-36 in rats from a dose of 
100nmol/kg (Dakin et al, 2004). In the current dose response study in mice, enhanced 
inhibition was observed with increasing doses with a minimally effective, dose of 
100nmol/kg. Cumulative food intake was inhibited for up to 8 hours post GLP-17-36 
injection. The half-life of GLP-17-36 in the plasma is only 1-3 minutes (Kieffer et al, 
1995). Unlike the study with CCK-8, the reduction in cumulative food intake which was 
observed in the first hour was subsequently sustained. Thus GLP-17-36 may prevent 
reciprocal increases in food intake to compensate for the reduction in the first hour. 
In the PYY3-36 and CCK-8 co-administration studies the combination treatment was more 
effective at inhibiting appetite than either peptide alone at both high and low doses. At 
high doses, the combined treatment was also compared with double the doses of the 
individual peptides. Although the co-administration treatment inhibited food intake in the 
first hour more than the double dose Of PYY3-36, the comparison between the co- 
administration group and double the dose of CCK-8 was not statistically significant. 
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These findings suggest that PYY3-36 and CCK-8 may inhibit feeding additively but not 
synergistically. 
In contrast with the additive effect observed fOllOWing PYY3-36 and CCK-8, no significant 
difference in the inhibition of food intake was observed with the co-administration of 
PYY3-36 and PP compared with either peptide alone. These findings suggest that PP and 
PYY3-36 do not inhibit feeding additively. PP and PYY are members of the NPY family of 
neuropeptides. Human PP (as used in these studies) binds to the appetite stimulatory Y5 
receptor in addition to the inhibitory Y4 receptor (Katsuura et al, 2002). PYY3-36 also has 
affinity for the Y5 receptor in addition to the Y2 and Y1 receptors (Borowsky et al, 1998). 
Additive stimulation of Y5 receptors following co-administration of PP and PYY3-36 could 
counter-act the inhibitory effects on appetite of the Y2, and Y4 receptors providing an 
explanation for the lack of an inhibitory additive effect on feeding. 
Co-administration Of PYY3-36 and GLP-17-36 in lean mice inhibited food intake 
significantly more than either peptide individually, which indicates that these hormones 
may inhibit food intake additively. Co-administration Of PYY3-36 and GLP-17-36 also 
inhibited feeding significantly more than twice the dose of either peptide alone. This 
suggests that the inhibition of feeding was greater than the sum of the effects due to the 
individual treatmints, and raises the possibility of synergy. In his elegant 
pharmacological article, Tallarida has demonstrated that in order to demonstrate synergy, 
several different ratios of the two individual peptides should be administered in order to 
plot an isobolograrn (Tallarida, 2001). This was beyond the scope of the current 
investigations. ý Therefore, in order to avoid over-claiming, from hereon the text in this 
chapter will refer to the 'additive' inhibitory feeding effect Of PYY3.36 and GLP-17-36- 
PYY3-36 and GLP-17-36 are thought to inhibit food intake through independent receptor 
systems (the Y receptors and GLP-I receptor respectively). Recently the specific Y2 
receptor antagonist, BIIE0246, has been administered to mice in combination with PYY3- 
36 and the GLP-1 receptor agonist, exendin-4. While BlIE0246 completely prevented the 
inhibitory effect seen with PYY3-36 alone, it did not alter the inhibition of feeding 
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observed with exendin4 alone (Talsania et al, 2005). Thus exendin-4 appears to inhibit 
feeding independently of the Y2 receptor. Further studies are required to confirm that 
GLP-17-36 inhibits feeding independent of the Y2 receptor. When the GLP-l receptor 
antagonist, exendin 9-39, was co-administered with PYY3-36 and with exendin4, the 
feeding inhibition Of PYYI-36 was unchanged whereas the feeding inhibition of exendin4 
was blocked (Talsania et al, 2005). Thus PYY3-36 appears to function independently of 
the GLP-l receptor. The hypothesis that PYY3-36 and GLP-17-36 do not inhibit feeding 
through the receptor of the other peptide could be further explored by administering both 
peptides to Y2 receptor and GLP-I receptor knockout mice. 
PYY3-36 and CCK-8 are also thought to inhibit feeding through distinct receptor systems. 
This may explain the additive effect observed in the feeding studies. This hypothesis 
could be further explored by administering Y2 and CCK-A receptor antagonists in 
combination with these peptides, or through the use of Y2 receptor or CCK-A receptor 
knockout mice. 
In the PYY3-36 and GLP-17-36 co-administration studies with genetically obese mice, 
examination of the food intake in the saline-injected groups revealed that the oblob and 
dbldb mice ate less in the first hour of re-feeding than their WT littermates. This 
somewhat surprising finding is consistent with previously published work (Batt, 1983; 
Martin et al, 2004). Genetically obese mice may have exaggerated thermogenic 
adaptation to fasting, and this may reduce their subsequent energy requirement (Dubuc et 
al, 1985). Co-administration Of PYY3-36 and GLP-17-36 treatment led to significantly 
greater reduction in feeding than twice the dose of either peptide alone in the oblob and 
dbldb and WT mice. Thus PYY3-36 and GLP-17-36 inhibited food intake additively in 
genetically obese as well as lean rodents, and their effects on food intake appear to be 
independent of leptin signalling. 
A chronic co-administration study Of PYY3-36 and GLP-17-36 Was undertaken in order to 
investigate whether the acute effects of these peptides would be sustained following 
multiple injections, and whether these would result in changes in body weight. As 
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expected, in the first hour of the light-phase when endogenous levels of these hormones 
were high following the dark feeding phase (Anini et al, 1999; Wynne et al, 2004) no 
significant inhibition of food intake compared with saline was observed. All peptides 
inhibited feeding in the first hour of the dark-phase throughout the study. However, 
PYY3-36 appeared to inhibit food intake more potently than had been observed in the acute 
studies in fasting mice. Moreover, the potency Of PYY3-36 appeared to increase during the 
course of the study. These apparently conflicting results could be explained by 
differences in stress in the mice in these experimental paradigms. It has been recently 
reported that PYY3-36 fails to inhibit feeding in animals unaccustomed to human handling 
and to the experimental protocol (Halatchev et al, 2004). Fasting is inevitably stressful 
for animals (Talsania et al, 2005). In the current chronic study with freely feeding 
animals, the PYY3-36 may have been more effective due lower stress levels. Furthermore, 
as the animals became more used to their twice daily injections, they may have become 
less stressed. This could explain the increasing potency Of PYY3-36 observed as the study 
progressed. 
Stress and feeding are known to be closely inter-related. For example, centrally 
administered CRH inhibits food intake and leads to a stress-like biochemical response, 
including elevated levels of plasma corticosterone, catecholamines and glucose (Morley & 
Levine, 1982). Central administration of CART also modulates food intake (Abbott et al, 
2001) and results in an increase in circulating corticosterone. There is recent evidence 
that NPY and AgRP expression are modulated by stress. Two hours after inescapable foot 
shocks, which would be expected to reduce food intake, hypothalamic Agrp expression 
was down-regulated whereas hypothalamic NPY expression was up-regulated (Kas et al, 
2005). In contrast, expression of both these neuropeptides increases in response to fasting 
(Swart et al, 2002). NPY is thought to play a role in non-feeding circuits in the 
hypothalamus, including stimulation of the HPA axis (Suda et al, 1993) and it may be 
these circuits that are activated by foot-shock. AgRP may have a more specific effect on 
feeding through antagonism of the MC3 and MC4 receptors. 'Thus variation in the level 
of stress may lead to complex changes in appetite signals. 
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In contrast with the enhanced feeding suppression observed with repeated PYY3-36 
administration, a similar percentage reduction in food intake following GLP-17-36 injection 
was observed in the chronic as in the acute studies in fasted mice. In the chronic study, 
the percentage reduction following GLP-17-36 appeared to be consistent throughout the 
study. This might suggest that GLP-17-36 inhibits food intake more robustly in the face of 
stress than PYY3-36- 
In the chronic study, no further inhibition in acute dark phase food intake was observed 
with the co-administration treatment compared with PYY3-36 alone. It may be that the 
inhibition of food intake by PYY3-36 was sufficient to preclude further reduction with the 
addition of GLP-17-36- 
Reductions in food intake in the first hour of the dark phase following GLP-17-36,, PYY3-36 
and PYY3-36 + GLP-17-36 were not sustained over the subsequent II hours and there were 
no significant differences in cumulative food intake over the course of the study. It 
appears that acute elevations in PYY and GLP- I plasma levels are not sufficient to sustain 
a reduction in food intake. Recent studies by Talsania. et al published after the 
completion of the current studies, have reported that while acute administration of the 
GLP-I receptor agonistý exendin4, and PYY3-36 inhibited food intake synergistically 
when administered acutely, neither peptide alone or their combination led to significant 
change in body weight when administered chronically (Talsania et al,, 2005). Perhaps 
administration of these peptides in a form that would resist degradation via a pump would 
result in changes in body weight. Indeed Pittner et aL have reported a reduction in body 
weight following continuous subcutaneous administration Of PYY3-36 to oblob mice 
(Pittner et al, 2004). 1 
Apart from the -first early light-phase body weight measurements, when a transient 
reduction in body weight was seen in the group treated with PYY3-36 + GLP-17-36, neither 
GLP-17-36 alone nor PYY3-36 + GLP-17-36 were associated with alteration in body weight 
during the course of the study. It was surprising, given the inhibition of food intake 
observed in these and other studies following acute administration Of PYY3-36 (Chelikani 
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et al, 2005; Halatchev el al, 2004), that there was an increase in the body weights of the 
animals treated with PYY3-36 compared with mice treated with saline in the last four early 
light-phase body weights. No such increases in body weight were observed in the body 
weights prior to the dark-phase. One explanation could be that these observations were a 
type I statistical error. If these rapid shifts in body weight are truly representative of 
repeated administration Of PYY3-36, then the most likely explanation is alteration in water 
intake and fluid balance. Were PYY3-36 to lead to an increase in fluid intake, then this 
might explain these results. This effect would be the most pronounced prior to the dark 
phase when endogenous PYY3-36 tone is low, and might explain the accumulation of body 
weight seen over the final four dark-phase periods of this study. On the other hand, this 
does not explain why such an effect was not observed over the first four dark-phase 
periods of this study. Further studies are needed to investigate the effect of acute PYY3-36 
on water intake and urine output. In the studies in this chapter the animals received water 
through freely dripping bottles and therefore water intake was not measured. 
Peripheral administration of GLP-17-36 has been reported to inhibit water intake (Tang- 
Christensen et al, 1998). It might be that in the co-administration group, the inhibitory 
effect of GLP-17-36 opposed a possible stimulatory action of PYY3ý-36 on water intake, 
resulting in no significant changes in body weight. This chronic study could be repeated 
using PYY3-36, GLP-17-36 and PYY3-36 + GLP-17-36 at the same doses, and the effect on 
body weight, food intake and water intake quantified. This would enable the results of the 
current study to be confirmed or refuted, and the effect of repeated administration of these 
peptides on fluid intake examined. 
C-fos immunoreactivity was quantified fOllOWing PYY3-36,, GLP-17-36 and PYY3-36 + GLP- 
17-36 administration in rats in order to determine a possible mechanism for their acute 
additive effect on feeding. Within the arcuate nucleus of the hypothalamus, there was a 
significant increase in c-fos following low dose combination PYY3-36 + GLP-17-36 
treatment, but no changes in the other treatment groups. Previous peripheral c-fos 
analyses have usually been performed with much higher individual doses of PYY3-36 and 
GLP-17-36 than those used in the current study. For example, IP administration of 
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20nmol/kg PYY3-36 was associated with a two-fold increase in the number of fos-positive 
nuclei in the ARC (Batterham et al, 2002). It is therefore not surprising that the lower 
dose Of PYY3-36 (Inmol/kg) used in this study (which did not alter feeding), did not result 
in changes in FLL The finding that low dose GLP-17-36 alone did not increase c-fos in the 
nuclei examined is consistent with Rowland et aL who reported no changes in FLI in 
hypothalamic or bminstem nuclei with a similar IP dose (Rowland et al, 1997). These co- 
administration results suggest that PYY3-36 and GLP-17-36 may inhibit food intake through 
additive stimulation of ARC neurons. In contrast, no significant alteration in FLI was 
observed in the brain-stem. These results suggest that the additive inhibitory feeding 
effect Of PYY3-36 and GLP-17-36 at low doses may be mediated primarily via the arcuate 
nucleus of the hypothalamus rather than the bmin-stem. It would be interesting to quantify 
c-fos following higher doses Of PYY3-36 and GLP-17-36, at which an additive effect was 
also seen, to determine whether a similar pattern of staining would be observed. 
However, c-fos staining can only indicate a possible anatomical location of neuronal 
activation rather than the ftinction of these neurones and so these results should be 
interpreted with caution. 
The gut hormone cholecystokinin (CCK) has been reported to potentiate the appetite 
inhibitory effects of the adipocyte hormone, leptin, in rodents. C-fos analysis at these 
doses revealed significant fos-like immunoreactivity in the NTS and AP and to a lesser 
extent in the PVN following CCK-8 alone but no changes in FLI following leptin alone 
(Wang et al, 1998). The addition of leptin to CCK-8 resulted in a significant increase in 
FLI in the PVN (Wang el al, 1998). Whereas CCK-8 and leptin appear to inhibit 
additively through enhanced activation of PVN neurons, PYY3-36 and GLP-17-36 may do so 
through enhanced stimulation of ARC neurons. 
It should be noted that the experiments in this chapter were performed in males and, with 
the exception of the study in adult oblob and dbldb mice, to young rodents. The majority 
of male laboratory mice go through puberty from post natal day 34 (P34) to P38 (Silver, 
1995) with a range from P28 - P49 (Fox, 1984). The lean mice used in the feeding 
studies were aged 49 - 63 days in early adulthood. It is interesting that a similar feeding 
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response to PYY3-36 and GLP-17-36 was observed in the WT littermates of the oblob and 
dbldb mice aged 20 weeks. Further work is needed to examine the effects of the other 
peptide combinations in older mice. In male rats, plasma LH becomes pulsatile around 
P25 and testosterone increases dramatically from P40 - P55 when adulthood is attained 
(Dutlow et al, 1992). The feeding and behaviour studies were performed in immature 
mice aged 6-8 weeks and immature rats aged 6-7 weeks. These rats were subsequently 
used for the c-fos immunocytochemistry study when they were 8-9 weeks old in order to 
reduce the number of animals required according to the 'Reduce, refine, replace' principle 
of animal care under the Animals (Scientific Procedures) Act 1986. It is possible that the 
results obtained are only applicable to mice and rats of a similar developmental stage as 
used in these studies. Nonetheless the consistency of the results for PYY3-36 and GLP-17- 
36 in rodents of varying ages suggests a relatively stable response for these peptides from 
puberty into adulthood. 
It was possible that the inhibition in food intake observed in these studies were part of an 
aversive response rather than due to a specific feeding effect. Indeed PYY3-36 has been 
reported to be associated with conditioned taste aversion in mice at a dose of 1.511g/100g 
(4nmol/kg) (Halatchev & Cone, 2005)., However in another study a lower dose Of P)(Y3- 
36 was not associated with significant CTA whereas high dose exendin-4 caused CTA in 
mice at a dose of 30nmol/kg (Talsania et al, 2005). CNS administration of GLP-17-36 is 
associated with CTA in rats (Thiele et al, 1997), although the effect of Peripheral GLP-17- 
36 on taste aversion has not been examined. As explained in the methods section, as part 
of the current studies, ideally conditioned taste aversion studies would have been 
performed but were not permitted by the laboratory animal project licenses. Instead 
formal observational studies were performed in rats and mice. There were no significant 
differences in observed behaviour in mice or rats following PYY3-36, GLP-17-36 or PYY3-36 
+ GLP-17-36 at doses at which the combination inhibited feeding. However it may be that 
observational studies are less sensitive in detecting aversive change than CTA studies. 
In the locomotion study in rats, no significant differences in horizontal beam breaks were 
observed following the combined PYY3-36 + GLP-17-36 treatment, but there were 
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marginally fewer vertical beam breaks. In their recent publication, Talsania et al. have 
suggested that low dose exendin-4 together with PYY3-36 may increase the suppression of 
food intake in rodents without inducing significant side effects (Talsania. et al, 2005). 
Taken together these results suggest that altered behaviour is unlikely to account for the 
feeding inhibition observed with co-administration of PYY3-36 and GLP-17-36. Thus these 
peptides may have specific effects on feeding. 
In summary, the effects of co-administration of three pairs of gut hormones on food intake 
have been investigated in rodents. The combination of PP and PYY3-36 was not associated 
with additive inhibition of food intake. However additive inhibition was observed 
following combinations Of PYY3-36 + CCK-8 and PYY3-36 + GLP-17-36- Ile combination 
Of PYY3-36 and GLP-17-36 appeared to be the more effective and inhibited feeding 
significantly more than double the dose of either peptide alone in lean and obese rodents. 
The e-fos analysis suggested that inhibition of food intake following co-administration of 
PYY3-36 and GLP-17-36 may be mediated via enhanced activation of ARC neurons. 
However, repeated injections Of PYY3-36 and GLP-17-36 did not result in changes in 
cumulative food intake or in body weight. It may be that the duration of action of these 
peptides is too short to achieve changes in body weight following twice daily IP 
injections. It would be interesting to administer continuous PYY3-36 and a GLP-I receptor 
agonist via a peripheral pump and to examine their combined effect on body weight. 
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Chapter 3 
Co-administration of 
PYY3-36and GLP-17-36 inMan 
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3.1 Introduction 
In chapter 2, pairs of gut hormones known to inhibit feeding were co-administered to 
rodents and their effects on food intake examined. Exogenous administration Of PYY3-36 
with GLP-17-36 inhibited feeding additively at both high and low doses. These results 
suggest that the endogenous post-prandial rise in PYY and GLP-I may act together to 
inhibit further feeding in rodents. In order to test the hypothesis that PYY and GLP-I 
inhibit feeding additively in man and to enhance our understanding of physiological 
appetite regulation, PYY3-36 and GLP-17.36 were co-administered to healthy lean human 
volunteers and their effects on energy intake examined. 
Both PYY and GLP- I had been previously administered to humans. PYYI-36 and GLP- 17- 
36 had been co-administered to man and an additive inhibitory effect on pentagastrin- 
induced gastric acid secretion was observed (Wettergren et al, 1997) although their 
combined effect on appetite was not examined. Subsequently intravenous infusion of 
PYY3-36 alone at 0.8pmol/kg/min was associated with a 36% reduction in energy intake in 
6 men and 6 women at a free buffet meal (Batterham et al, 2002). In a later study graded 
PYY3-36 intravenous infusions resulted in a dose-dependent reduction in energy intake in 
16 men with a significant reduction observed at 0.4 and 0.8 pmol/kg/min (Degen et al, 
2005). Side effects of nausea, fullness and abdominal discomfort were observed, largely 
at the 0.8pmol/kgtmin dose. The authors observed that these occurred when the plasma 
concentration of PYY was greater than 300pg/ml. In a recent PYY3-36 intravenous 
infusion study in 12 lean men, significant reduction in energy intake was observed at 0.7 
and 0.8pmol/kg/min but not at lower doses of 0.2,0.4,0.5 and 0.6pmol/kglmin (le Roux et 
al, 2006). No side effects were observed at any dose in this study on visual analogue 
scales (VAS). PYY3-36 intravenous infusion has also been reported to inhibit food intake 
in obese men and women (Batterham et al, 2003a). 
The effect of GLP-17-36 on energy intake in humans is more controversial. In 1998 GLP- 
17-36 was administered via intravenous infusion, which was continued through the meal, to 
20 lean men at 50pmol/kg/h (0.8pmol/kg/min). A significant 12% reduction in energy 
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intake observed was compared with the saline control day (Flint et al, 1998). However, in 
another study in which GLP-17-36 was infused at a rate of 0.75pmol/kg/min to 6 obese 
men, but commencing only at the start of the buffet meal, no alteration in energy intake 
was observed (Naslund et al, 1998). The following year, these authors administered GLP- 
17-36 at a rate of 0.75pmol/kglmin to 8 obese men commencing at 8arn with a fixed 
breakfast and continuing for 8 hours, during which time ad libitum lunch and dinner were 
served and energy intake quantified. 'Mere were significant reductions in energy intake at 
both lunch and dinner. In another study intravenous GLP-17-36 was infiised at a similar rate 
of 0.8pmol/kg/min, starting 40 minutes before the buffet meal, to 10 lean men but did not 
significantly alter energy intake (Long et al, 1999). 
In the same year, Gutzwiller et al. administered GLP-17-36 in graded doses and observed a 
dose dependent reduction in energy intake in 16 lean men. GLP-17-36 did not significantly 
reduce energy intake at 0.375pmol/kgtmin but did so at 0.75 and 1.5pmol/kg/min 
(Gutzwiller et al, 1999). In this study, the GLP-17-36 infusion was commenced 60 minutes 
before the meal and continued through the meal for a total of 120 minutes. In 2001 Flint 
et al. infused GLP-17-36 at a rate of 45pmol/kg/h (0.75pmol/kg/min) to 18 -obese men 
(Flint et al, 2001) in a similar protocol, but at slightly lower dose than in their previous 
study in lean men (Flint et al, 1998). Although a reduction in the rate of gastric empyting 
was observed, there was no significant alteration in energy intake with the GLP-17-36 
infusion. 
A meta-analysis of these papers suggested that intravenous infusion of GLP-17-36 was 
associated with a small dose-dependent reduction in energy intake in both lean and obese 
subjects (Verdich etal, 2001a). Stepwise regression analysis revealed that the GLP-17-36 
infusion rate was the only independent predictor of the reduction in energy intake. In all 
the studies examined, the GLP-17-36 infusion was continued through the ad libitum meal. 
However, in two of the three studies in which GLP-17-36 infusion was given at a rate of 
0.75pmol/kg1min or 0.8prnol/kg/min and a reduction in energy intake not observed, the 
infusion was either started simultaneously with the meal or only 40 minutes prior to the 
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meal (Naslund et al, 1998; Long et al, 1999). Tbus the duration of GLP-17-36 infusion 
prior to the meal may also be an important factor. 
GLP-17-36 is thought to function as an incretin in humans. The plasma insulin response to 
a given rise in plasma glucose is much greater when the glucose is given orally rather than 
intravenously. Following this observation, Moore postulated in 1906 that there was a 
hormonal factor in the gut that enhanced nutrient disposal. This factor was later named 
incretin (Moore et al, 1906; Zunz & La Barre, 1929). Exogenous administration of GLP- 
17-36 and glucose-dependent insulinotropic peptide (GIP) stimulate insulin release more 
potently in the presence of a glucose load (Kreymann et al, 1987). Of these two peptide 
hormones, GLP-17-36 has been reported to be the more potent incretin (Kreymann et al, 
1987). In contrast, infusion Of PYY3-36 was reported to cause no change in plasma insulin 
or glucose compared with saline control either with or without a nutrient load (Batterham 
et al, 2002). The effect of the combination Of PYY3-36 with GLP-17-36 on plasma insulin 
and glucose was unknown. 
In order to determine the effect of the co-administration Of PYY3-36 with GLP-17-36 on 
energy intake, appetite, insulin and glucose, a randomised double-blind placebo-controlled 
trial was performed in healthy human volunteers. 
3.2 Methods 
3. ZI Materials 
Synthetic human PYY3-36 and GLP-17-36 were purchased from Phoenix Pharmaceuticals, 
Belmont, CA, USA). Unless otherwise stated all chemicals were purchased from Merck, 
Poole, Dorset, UK. 
3.2.2 Study Protocol 
The study was approved by the Hammersmith, Queen Charlotte's and Chelsea Ethics 
Committee (reference number 2002/6261) and performed in accordance with the 
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principles of the Declaration of Helsinki. Healthy volunteers were recruited through 
advertisement. Inclusion criteria were a body mass index (BMI) between 20 and 27 kg/M 2 
and exclusion criteria were substance abuse, pregnancy, regular medication except the oral 
contraceptive pill and significant medical or psychiatric illness. 
Subjects were given an information sheet (appendix 3). They were screened by a doctor 
(the author) and a dietician. They completed the Dutch Eating Behaviour Questionnaire 
(DEBQ) (appendix 4) which has 33 questions to which the subject should respond never 
(score 0), seldom (1), sometimes (2) often (3) or very often (4). These 33 questions may 
be subdivided into those that focus on restrained eating (questions 1-10), those focussing 
on emotional eating (11-23) and those biased towards external influences on eating (24- 
33) (van Strien et al, 1986). The main aim of dietary screening was to exclude sub ects j 
with restrained eating. Subjects who scored 5 or more from the first 10 questions were 
excluded from the study. For subjects who scored between 3 and 5, the screening 
dietician also took account of their reported eating behaviour and the rest of the questions 
of the DEBQ before recommending who should be included. Subjects had to be 
comfortable with having intravenous cannulae inserted, infusions running and blood being 
withdrawn. Twelve subjects were recruited, each of whom gave their informed consent to 
participate in the study. One subject was withdrawn due to violation of the protocol. 
Following his first infusion, he reported that he had run 3 miles on his way to the infusion 
room when strenuous exercise was prohibited (see below). Another was withdrawn due to 
nausea on a study morning. Thus ten subjects (4 men and 6 women) completed the study 
(table 3.1). Their ages ranged from 22-29 with an average of 25.6 d: 2.3 years (mean± 
SD) and BMIs ranged from 20.5-26A with a mean of 23.0 ± 2.4 kgIm 2. 
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Subject 
number 
Sex Age 
(yean) 
BMI 
(k gIM2) 
Units 
alcohol 
per week 
Cigarettes 
per day 
Medications Medical history 
I F 23 21.4 9 0 none 
2 F 26 26.1 2 0 salbutamol inhaler 
once/ month 
Exercise-induced 
asthma 
3 F 24 21.5 14 8 OCP 
microgynon 30 
4 M 27 22.6 20 0 none 
5 M 26 26A 16 18 none mild asthma 
6 F 24 20.5 9 8 OCP 
microgynon 30 
7 F 27 23.0 2 0 none 
8 M 28 26.3 18 8 none 
9 M 22 21.0 2 0 none 
10 F 29 22.1 to 12 none 
Table 3.1 
Baseline characteristics of the lean healthy volunteers recruited to the human co- 
administration study. Sex -F female, M male; OCP - oral contraceptive pill. 
Two of the subjects suffered from mild asthma, and one of these used a salbutamol inhaler 
approximately once per month but not within 3 days of any infusion. While there may be 
a mild increase in asthma incidence in the obese, body mass index does not appear to be 
related to asthma severity (Beuther et al, 2006). However, the effect of PYY3-36 and 
GLP-17-36 in patients with mild asthma was unknown. Salbutamol (Allen and Hanburys, 
Middlesex, UK) is a short acting [6 agonist which acts as a bronchodilator. Following 
salbutamol inhalation, approximately 10-201/o of the dose reaches the lower airways and 
the remainder is retained in the delivery system of deposited in the oropharynx from 
where it is swallowed (Allen and Hanburys product information, 2006). The swallowed 
portion of an inhaled dose is absorbed from the gastrointestinal tract and undergoes 
considerable first pass metabolism to phenolic sulphate. Both unchanged drug and 
conjugate are excreted primarily in the urine. The plasma half life of salbutamol is 4-6 
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hours (Sweetman, 2005) and therefore by 72 hours (at least 12 half lives), little if any 
active drug should have been present in the circulation. 
Two of the female subjects were taking microgynon 30 ED and took their tablets in the 
mornings (Schering Health Care Ltd, West Sussex, UK). This is a synthetic combined 
oestrogen and progesterone oral contraceptive pill. The patient takes active medication 
for the first 21 days, and then a placebo for the final 7 days of the cycle to permit a 
withdrawal bleed. Both ethinylestradiol (synthetic oestrogen) and levonorgestrel 
(progestogen) are rapidly absorbed from the GI tract, with maximum plasma levels of 
both substances being reached within 1-2 hours. Thereafter, both undergo 2 phases of 
elimination of 1-2 hours and 20 hours for ethinylestradiol and 0.5 hours and 20 hours for 
levonorgestrel (Schering Health Care Ltd product information, 2002). Therefore, active 
ethinylestradiol and levonorgestrel would be present during the infusions. Oestrogen has 
been observed to reduce meal size in rats, and the mechanism may be through increasing 
the potency of gut hormones such as CCK (Geary, 1998; Geary et al, 1994). The 
synthetic progestogen, megestrol acetate, is well-known to stimulate appetite and the 
mechanism may be, at least in part, through stimulating hypothalamic NPY release 
(McCarthy et al, 1994), and it is possible that levonorgestrel acts similarly. 
All of the subjects drank alcohol moderately and within UK government guidelines for 
their sex (Department of Health, UK, alcohol guidelines, 2006). Alcohol consumption 
may lead to short and long term increases in energy intake (Yeomans, 2004). In the 
current study all subjects refmined from drinking for 24 hours before and after each 
infusion. Therefore by the time the inftisions started, negligible ethanol would be present 
in the circulation (Paton, 2005). 
Five of the ten subjects smoked cigarettes. These subjects reported at screening that they 
would be comfortable without smoking while in the infusion room. An inverse 
relationship has been documented between smoking habit and body weight in several 
studies (Albanes, et al, 1987; Perkins, 1992). When rats were exposed to cigarette smoke 
three times per day for four consecutive days there was a reduction in body weight, food 
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intake and fat mass compared with control rats (Chen et al, 2005). In this study, no 
differences in NPY concentrations were observed between different hypothalamic regions. 
However in a subsequent study, lower NPY concentrations within the PVN of the 
hypothalamus were observed in rats exposed to cigarette smoke (Chen et al, 2006), which 
suggests an alteration in CNS appetite signalling. The effects of cigarette smoking in 
combination with PYY3-36 and GLP-17-36 were unknown. 
The study was randomised and double-blinded. Every volunteer received four 
intravenous infusions - saline, GLP-17-36, PYY3-36 or PYY3-36 with GLP-17-36, each on a 
separate day at least 5 days apart. In the 24 hours before and after infusions, subjects were 
asked to abstain from alcohol and strenuous exercise which could confound energy intake 
results. On the evening before each infusion, subjects ate a fixed meal at 20: 00 and then 
fasted and drank only water until attending the Clinical Investigations Unit, Hammersmith 
Hospital the following morning. On each study day two venous cannulae were inserted - 
one for blood sampling and one for the infusion. 
Both PYY3-36 and GLP-17-36 were sterile on culture and limulus amoebocyte lysate assays 
for pyrogen (Karplus et al, 1987) were negative. Two vials were used for each infusion 
(saline + saline, saline + GLP-17-36,, saline + PYY3-36, and PYY3-36 + GLP-17-36). Both 
vials were dissolved in 2.5ml haemcel (Beacon, Tunbridge Wells, Kent, UK) to minimise 
peptide adsorption to the syringe and connecting tube, drawn up in a single syringe and 
diluted in 0.9% saline (Bayer, Newbury, Berkshire, UK) (total volume 50ml). 
The infusion rates were chosen from previous studies (see introduction section 3.1). 
PYY3-36 at 0.8pmol/kg/min was associated with a 36% reduction in food intake 
(Batterham et al, 2002). At the time this study was undertaken there were no reports of 
the effect of lower dose PYY3-36 on energy intake in humans in the literature. The lowest 
rate of GLP-17-36 which had been shown to inhibit energy intake significantly was 
0.75pmol/kg/min. In one study a 21% reduction in energy intake was observed (Naslund 
et al, 1999a) and in another a reduction of 11% reported (Gutzwiller et al, 1999). In the 
current study the aim was to achieve a submaximal effect for each individual peptide. 
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Therefore rates of 0.4pmol/kglmin for both GLP-17-36 and PYY3-36 infusions and a rate of 
0.4pmol/kgImin PYY3-36 + 0.4pmol/kg/min GLP-17-36'for the combined infusion were 
selected. 
As in the previous PYY3-36 and GLP-17-36 intravenous studies in the literature, peptides 
were administered via continuous infusion rather than by a loading dose. The half lives of 
PYY and GLP- I in human plasma have been reported as 9.2 minutes (Adrian et al, 1986) 
and 3.9 minutes (Kreymann et al, 1987) respectively. Following commencement of a 
continuous intravenous infusion, after 5 half lives of a peptide or drug (46 minutes for 
PYY and 20 minutes for GLP-I), 97% of steady state concentration is predicted (Clinical 
Pharmacokinetics, 2006). Therefore the infusion duration before the meal was set at 90 
minutes to enable steady state of both peptides to have been reached for a minimum of 30 
minutes. 
In the GLP-I papers described above, there was no significant effects on well-being or 
feelings of nausea, nor were any side-effects reported during GLP-17-36 infusion (Verdich 
et al, 2001a). At the time of the study, no side-effects had been observed with PYY3-36 
infusion (Batterham et al, 2002; Batterham. et al, 2003a). However, PYY3-36 had only 
been infused to 36 volunteers at the time of the study, and thus a significant possibility of 
side-effects remained., Although full length PYYI-36 and GLP-17-36 had been previously 
co-administered to humans without systemic adverse effects (Wettergren et al, 1997), the 
possibility of adverse effects with truncated PYY3-36 and GLP-17.36 remained. The 
advantage of a continuous infusion over a loading dose was that should side effects have 
occurred, the infiision could be terminated before steady state had been reached. All 
infusions were performed in the Hammersmith Hospital where medical assistance and full 
resuscitation facilities were available. 
Pulse and blood pressure were monitored every 30 minutes in order to ensure that the 
subjects were cardiovascularly stable during and after infusions. Full lengh PYYI-36 at 
0.57pmol/kgtmin had been reported to lead to significant increases in systolic and 
diastolic blood pressure of 9 and II mmHg respectively (Adrian et al, 1986). However in 
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a later study, no significant effect on blood pressure was observed with truncated PYY3-36 
infusion at 0.8pmol/kg/min (personal communication with Dr R Batterham). The GLP-I 
receptor agonist, exendin-4, has been reported to increase heart rate and blood pressure in 
rats (Yamamoto H et al, 2002a). However continuous GLP-17-36 infusion to human 
volunteers at 0.5pmol/kg/min was not associated with changes in pulse or blood pressure 
(Kreymann et al, 1987). Therefore clinically significant effects on pulse and blood 
pressure were not expected with infusion Of PYY3-36 or GLP-17-36 alone, but the effect of 
the combined infusion on these cardiovascular parameters was unknown. 
In all of the GLP-17-36 studies described in the introduction, the infusion was continued 
throughout the meal. In the PYY3-36 study published when the experiment described in 
this thesis was undertaken there was an interval of 2 hours between the end of the infusion 
and the buffet meal (Batterham. et al, 2002). The aim was to select. an infusion protocol in 
which both PYY3-36 and GLP-17-36 would be active at the time of the meal. Thus a total 
infusion length of 120 minutes was selected with lunch served at 90 minutes. This 
protocol had the disadvantage that the subjects would have to be attached to an 
intravenous drip during the buffet meal which could make eating difficult. However this 
would be the case on all infusion days. In addition to the GLP-17-36 studies above, 
significant alteration in energy intake in a human ghrelin study was observed with the 
infiision running during the buffet meal (Wren et al, 2001a). In order to allow free 
movement at the elbow, cannulae were placed in the dorsum of the hand or in the forearm 
rather than the ante cubital fossa where possible. 
The infusion protocol is summarised in figure 3.1. Subjects arrived for their infusions at 
9: 30 (t--60 minutes). They were encouraged to relax by reading or watching videos. All 
time cues were removed. 'Me infusion was started 60 minutes later at 10: 30 (t--O). The 
reason for this delay was to allow subjects to recover from the stress of cannulation and to 
enable them to acclimatise to the infusion room prior to the start of the infusion. Blood 
samples (I Oml) were taken every thirty minutes until two hours after the meal into heparin 
coated tubes containing 2000 Kallikrein inhibitor units (0.2ml) of aprotonin (Bayer). 
Following centrifugation, plasma was separated and stored immediately at -70*C until 
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radioimmunoassay for PYY, GLP- I and insulin. Subjective hunger, sickness and fullness 
were assessed every 30 minutes using visual analogue scales (VAS) (max score 100mm) 
(appendix 6) (Flint et al, 2000). Meal palatability was assessed following the meal by 
asking the subjects to respond on a visual analogue scale to the question, 'How pleasant 
did you find this mealT. 
INFUSION 
Buffet 
Lunch 
I 
I 
09: 30 
t 
Subject 
arrives 
10: 30 12: 00 12: 30 14.30 
t 
Subject 
home 
Figure 3.1 
Infusion protocol for the co-administration Of PYY3-36 and GLP- 17-36 study in healthy lean 
human volunteers. 
After 90 minutes infusion, a buffet lunch of food in excess was served, consisting of pre- 
weighed quantities of Sainsburys chicken or vegetable korma (1200-1300g), boiled rice 
(400450g), tinned fruit salad (340-360g) and sweets (90g). One subject was vegetarian 
and was given vegetable korma on all infusion days. The remaining 9 subjects were given 
chicken korma. The macronutrient compositions of all these foods are presented in table 
3.2. All food was weighed using a Soehnle Vera food balance (Austin White Ltd, 
Northamptonshire, UK) (detection limit Ig). The food was presented in separate bowls 
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and the subjects were given plates on which to serve themselves. There were no large 
discrete portions which subjects might have finished once they had started independent of 
their satiety. Thus energy intake was viewed as a continuous variable. 
Subjects were instructed to eat until they were comfortably full. They were told that they 
could take away any unfinished food at the end of the day. Thirty minutes later, the 
remaining food was removed and weighed and the infusion discontinued. The remaining 
foods were weighed individually. Any curry and rice which were left together were 
separated as much as possible and similarly on each infiision day. Subjects were allowed 
to leave two hours after the meal and instructed to eat ad libitum and to complete a food 
diary for the following 24 hours. The buffet meal and food diaries were kindly assessed 
by our dietician, who was blinded to which treatment had been given, using Dietplan-5 
nutritional software (Forestfield software Ltd, West Sussex, UK). 
Chicken 
korma 
Vegetable 
korma 
Boiled 
rice 
Fruit 
salad 
Sweets 
Energy (KJ) 610 624 587 186 1933 
Protein (g) 14.1 2.7 2.6 0.6 4.1 
Fat (g) 8.5 12.6 1.3 0.1 16.6 
Saturated fatty acids (g) 3.0 4.9 0.3 0.0 12.5 
Mono-unsaturated (g) 2.5 5.4 0.3 0.0 2.0 
Poly-unsaturated (g) 3.0 2.3 0.5 0.0 2.1 
Carbohydrate (g) 3.3 6.6 30.9 10.5 73.5 
Starch (g) 0.4 3.8 30.9 0.5 1.0 
Total sugars (g) 2.9 2.8 0.0 10.0 72.5 
Dietary fibre (g) 0.7 1.0 1.0 1.5 0.1 
Table 3.2 
Macronutrient composition of the foods provided at the buffet meal per 100g to lean 
healthy human volunteers following saline, PYY3-36,, GLP-17-36 and PYY3-36 + GLP-17-36 
infusions. 
136 
3.2.3 Radio-immunoassays 
All sam ples were assayed in duplicate and in single assays to eliminate the effects of inter- 
assay variation. PYY, GLP-l and insulin concentrations were assayed using established 
in-house radioimmunoassays and antibodies (Adrian et al, 1985a; Kreymann et al, 1987; 
Ghatei et al, 1983). The detection limits and intra and inter-assay coefficients of variation 
of these assays are listed in table 3.3. The PYY antibody bound PYYI-36 and PYY3-36 but 
not neurotensin, glicentin or vasoactive intestinal peptide. Similarly the GLP-I antibody 
cross-reacted with synthetic entire GLP-11-36 in addition to GLP-17-36, but not with 
glucagon or other pancreatic peptides. Glucose concentrations were measured using a 
YSI-2300STAT analyser (YSI, Yellow Springs, Ohio, USA). Post-prandial insulin and 
glucose levels were not measured due to the variability of energy intake at the buffet meal. 
Detection limit 
(95% confidence) 
Intra-assay co- 
efficient of variation 
Inter-assay co- 
efficient of variation 
pyy 2.5 pmol/I 5.8% 9.8% 
GLP-1 3 pmol/l 6.1% 10% 
Insulin 6 pmol/I 5.4% 12.6% 
Table 3.3 
Detection limits and intra- and inter-assay coefficients of variation of PYY, GLP-I and 
insulin assays. 
3.2.4 Statistical Analysis 
Subject characteristics (age and BMI) are reported as mean ± standard deviation (SD). 
Results are shown as mean values ± SEM. The primary outcome was energy intake at the 
buffet meal. Secondary outcomes were 24 hour energy intake, visual analogue scale 
scores, vital signs and plasma hormone levels. A random effect repeated measures 
ANOVA was performed for all comparisons and 'within subject' effect examined under a 
Greenhouse-Geisser correction. P<0.05 was considered to be statistically significant. 
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3.3 Results 
There were significant increases in PYY plasma levels with PYY3-36 and PYY3-36 + GLP- 
17-36 infusions, and in GLP-I plasma levels with GLP-17-36 and PYY3-36 + GLP-17-36 
infusions (Tables 3.4 and 3.5). Interestingly, the GLP-17-36 infiision inhibited circulating 
PYY (PYY pmol/I at 90 min: saline infusion 10.3 ± 1.2, GLP-17-36 infusion 7.7 ± 0.8) 
(P<0.05). However, no significant changes in circulating GLP-I were observed during 
PYY3-36 infusion. 
Infusion PYY levels (pmoIA) pre- 
infusion (fasting) 
PYY levels (pmoL/I) after 
90 min infusion (pre-meal) 
PYY levels (pmoIA) 
2 hours after the meal 
Saline 10.511.4 10.3 ± 1.2 163 ± 1.4 
GLP-1 10.9 ± 0.9 7.7 ± 0.8 16.0-+1.6 
PYY3-36 8.9* 0.7 59.8 ± 4.2 18.0 ± 1.3 
PYY3-36 + GLP-1 11.1± 1.2 58.4± 43 23.1 ± 3.3 
Table 3.4 
Plasma levels of PYY in healthy lean human volunteers with saline, PYY3-36, GLP-17-36 
and PYY3-36 + GLP-17-36 infusions. * P<0.05 wt. saline, ** P<0.005 vs. saline. 
Infusion GLP-1 levels (pmoUl) 
pro-infusion (fasting) 
GLP-1 levels (pmolA) after 
90 min infusion (pre-meal) 
GLP-1 levels (pmolfi) 
2 hours after the meat 
Saline 24.6 ± 2.8 18.8: k 4.4 62.8110.4 
GLP-1 21.5 ± 1.6 61.5 + 3.7 78.4+12.3 
PYY3-36 18.311.5 18.2 ± 1.6 47.5 ± 2.9 
PYY3-36 + GLP-I 23.0± 2.2 62.5 ± 5.2 56.8 ± 5.8 
Table 3.5 
Plasma levels of GLP-1 in healthy lean human volunteers with saline, PYY3-36, GLP-17-36 
and PYY3-36 + GLP-17-36 infusions. ** P<0.005 vs. saline. 
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Fasting plasma insulin was increased by GLP-17-36 infusion at 90 minutes compared with 
saline. No changes in insulin secretion were observed with PYY3-36 alone. While the 
joint PYY3-36 + GLP-17-36 infusion enhanced insulin secretion there was no additional 
secretion compared with GLP-17-36 alone (Table 3.6). Consistent with these changes in 
insulin levels, fasting plasma glucose was reduced by GLP-17-36 infusion and by the joint 
PYY3-36 + GLP- 17-36 infusion but was unchanged by PYY3-36 alone (Table 3.7). 
Insulin levels (pmoVI) 
pre-infusion (fasting) 
Insulin levels (pmoVI) after 
90 min infusion (pre-meal) 
Saline 5 8.7 4.0 53.2 ± 4.9 
GLP-1 56.6 4.4 63.0 ± 3.5 
PYY3-36 57.3 4.0 51.2: E 5.5 
PYY3-36 + GLP-1 58.1 ±4.0 66.2 ± 4.3 
Table 3.6 
Plasma levels of insulin in healthy lean human volunteers with saline, PYY3-36,. -GLP-17-36 
and PYY3-36 + GLP-17-36 infusions. * P<0.05 vs. saline. 
Glucose levels (mmoIA) 
pre-infusion (fasting) 
Glucose levels (mmoIA) after 
90min infusion (pre-meal) 
Saline 4.44 ± 0.70 4.56 ± 0.07 
GLP-1 4.54 ± 0.13 4.22 + 0.95 * 
PYY3-36 4.55 ± 0.58 4.52+ 0.07 
PYY3-36 + GLP-I 4.49 ± 0.59 4.11 ± 0.09 * 
Table 3.7 
Plasma levels of glucose in healthy lean human volunteers with saline, PYY3-36, GLP-17-36 
and PYY3-36 + GLP-17-36 infusions. * P<0.05 vs. saline. 
Analysis of the buffet meal data revealed significant variation between subjects on the 
saline infusion day (mean 4661 ± SEM 57 KJ) (range 719 - 1358KJ). This variation was 
similar to that seen in previous human infusion studies (personal communications with Dr 
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Alison Wren and Dr Rachel Batterham). Because each subject received saline, each 
peptide alone and the combined infusion, the energy intake on the peptide infusion days 
could be compared with that of the saline control group. Thus the effect of variation in 
individual appetite on the results of the study was minimised. 
A 15% reduction in energy intake was observed with infusion Of PYY3-36 alone 
(0.4pmol/kg/min) compared with saline, although this reduction achieved only borderline 
statistical significance (P--0.07). There was no significant difference in energy intake 
with GLP-17-36 infusion (0.4pmol/kg/min) in keeping with previously published results 
(Kreymann et al, 1987). With the combined PYY3-36 and GLP-17-36 infusion, caloric 
intake at the buffet meal was reduced by 27% (Buffet meal energy intake (KJ): saline 
4174± 285, GLP-17-36 3978± 340, PYY3-36 3551 ±441, PYY3-36+GLP-17-363033 ± 279) 
(Percentage change from saline day: GLP-17-36 -5 ± 5%, PYY3-36 -15 ± 9%, PYY3-36 + 
GLP-17-36 -27 ± 3%) (Figure 3.2). There was a statistical difference in energy intake 
between the four infusion groups (P<0.01). The buffet caloric intake on the PYY3-36 + 
GLP- 17-36 day was significantly less than on all other infusion days (P<0.05). 
Figure 3.2 
Energy intake at the buffet lunch with infusion of saline, G (0.4pmol/kg/min GLP- 17-36), P 
(0.4pmol/kg/min PYY3-36) and P+G (0.4pmol/kg/min PYY3-36 + 0.4pmol/kg/min GLP-17- 
36). Results are presented as absolute difference in energy intake from the saline infusion 
day. f P<0.05 compared with al I other groups. 
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Cumulative energy intake over 24 hours (buffet + food intake from rest of day as assessed 
by food diary) was significantly reduced with the combined PYY3-36 + GLP-17-36 
compared with the all other groups. (Cumulative 24 hour energy intake (MJ): saline 13.7 
± 0.6, GLP- 17-36 13.6 ± 1.3, PYY3-36 13.5 ± 0.9, PYY3-36 + GLP- 17-36 12.0 ± 0.7) (P<0.05 
for PYY3-36 + GLP-17-36 vs. all other groups) (Percentage change from saline day: GLP- 
17-36 
-2 ± 7%, 
PYY3-36 
-1 ± 5%, PYY3-36 + GLP- 17-36 -13 ± 5%) (Figure 3.3). 
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Figure 3.3 
Cumulative 24 hour energy intake following infusion of saline, G (0.4pmolikg/min GLP- 
17-36)ý P (0.4pmol/kg/min PYY3-36) and P+G (0.4pmol/kg/min PYY3-36 + 0.4pmol/kg/min 
GLP-17-36). Results are presented as absolute difference in energy intake from the saline 
infusion day. tP<0.05 compared with all other groups. 
There were no significant differences in the percentage of energy obtained from 
macronutrient groups between infusion days (table 3.8). Five of the ten subjects smoked 
cigarettes, and it is possible that cigarette smoking could have confounded the results of 
this study. However given that each subject received all four infusions, this should have 
been similar between infusion days. There were no significant differences in energy 
intake between the smokers and the non-smokers in the study (table 3.9). The energy 
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intakes of the two female subjects taking the oral contraceptive pill were broadly similar 
to the other participants in the study (table 3.10). However this small number did not 
permit formal statistical comparison. 
saline GLP-I PYY PYY+GLP-1 
protein 19.2±1.2 % 19.5 ± 1.3 % 20.1±1.6 % 20.3 1.6 % 
fat 32.2: h 1.7 % 32.6±2.5 % 32.6±2.0 % 33.2 3.0 % 
carbohydrate 48.7± 1.4 47.8±1.9 % 47.3 ±2.4 % 46.5 ±2.8 % 
Table 3.8 
Percentage of energy intake from Protein, fat and carbohydrate with saline, GLP-17-36, 
PYY3-36 and PYY3-36 + GLP-17-36 infusions in healthy lean human volunteers. P--NS for 
all comparisons. 
saline GLP-1 pyy PYY+GLP-1 
non-smokers 4.45 ± 0.24 MJ 3.83 ± 0.3 MJ 3.79± 0.44 MJ 3.30 ± 0.34 MJ 
smokers 3.92 ± 0.52 MJ 4.15 ± 0.65 MJ 3.33 ± 0.81 MJ 2.80 ± 0.45 MJ 
P value 0.39 0.67 0.63 0.39 
Table 3.9 
Energy intake (MJ) consumed by the non-smokers (n=5) and smokers (n=5) in the human 
co-administration study on different infusion days. There were no significant differences 
between these two groups. 
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saline GLP-1 pyy PYY+GLP-1 
Subject 3 2.8 MJ 2.4 MJ 3.1 MJ 2.4 MJ 
Subject 6 3.8 MJ 4.6 MJ 2.0 MJ 2.4 MJ 
Table 3.10 
Energy intake of the two subjects taking the oral contraceptive pill with saline. Although 
this small number did not permit statistical analysis, the results appeared broadly similar 
with the rest of the subjects. 
Despite these significant and sustained changes in overall energy intake, no significant 
differences in subjective hunger or fullness were observed on the visual analogue scales. 
'Mere were no significant differences in nausea scores between infusion days (Table 
3.11). At the end of lunch, subjects were asked to rate the pleasantness of the meal. 
There were no significant differences in these scores (pleasant score (mm): saline 77 ± 3, 
GLIP-17-36 71 ± 4, PYY3-36 71 ± 6, PYY3-36+ GLP-17-36 68 ±5; P--NS forall comparisons). 
No signiricant differences in pulse and blood pressure were observed between infusion 
days (table 3.12). 
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Saline GLP-1 pyy PYY+GLP-1 
Hunger score (mm) 73 ±3 68 ±5 75 ±5 62± 9 
P vs. saline - n/a 1.00 0.89 0.79 
Nausea score (mm) 9.4 ± 0.83 1.2 ± 0.5 3.8 ± 0.18 6.3 ± 2.2 
P vs. saline n/a 0.43 0.70 0.93 
Full score (mm) 15 ±7 9± 3 ll± 4 14 ±4 
P vs. saline n1a 0.24 OA7 0.8 
Table 3.11 
Hunger, nausea and subjective fullness scores after 90 minutes infusion, prior to the buffet 
meal. Possible scores Omm (minimum) to I 00mm (maximum). 
Saline GLP-1 pyy PYY+GLP-1 
Pulse (beats/min) 73 ±3 68 ±5 75 ±5 62 ±9 
P vs. saline n/a 1.00 0.37 0.43 
Systolic BP (mmHg) 113 ±2 112: k 2 118±3 1 10± 3 
P vs. saline n/a 0.90 0.58 0.69 
Diastolic BP (mmHg) 65 ±2 65 ±2 6512 65: E 3 
P vs. saline n1a, 1.00 1.00 1.00 
Table 3.12 
Pulse, systolic and diastolic pressure after 90 minutes infusion of saline, GLP-17-36, PYY3- 
36 and PYY3-36 + GLP- 17-36 prior to the buffet meal in healthy lean human volunteers. 
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3.4 Discussion 
In this study the effects of the co-administration Of PYY3-36 and GLP-17-36 on energy 
intake were investigated in humans. These results are of physiological interest as these 
hormones are co-secreted after a meal (Anini et al, 1999). 
GLP-17-36 alone (0.4pmol/kg/min) did not lead to a significant change in energy intake. 
The lowest dose of GLP-17-36 that has been reported to be associated with a change in 
energy intake is 0.75pmol/kg/min (Gutzwiller et al, 1999). However, incretin effects have 
been observed with a lower rate of GLP-17-36 of O. Spmol/kg/min (Kreymann et al, 1987). 
In the current study there was a small but significant reduction in fasting glucose levels 
and an increase in the fasting insulin concentration with GLP-17-36 infusion. 
PYY3-36 infusion (0.4prnol/kg/min) was associated with a trend towards reduction in 
energy intbke (15%) compared with saline infusion. The magnitude of this reduction is in 
keeping with the larger reduction of 36% reported following higher-rate PYY infusions 
(0.8prnol/kg/min) (Batterhain et al, 2002). At this relatively low dose Of PYY3-36, no 
adverse effects were observed. 
Co-administration, Of PYY3-36 with GLP-17-36 was associated with a 27% reduction in 
energy intake from the buffet meal. Moreover, the combination was more effective in 
inhibiting appetite then either peptide alone. Cumulative energy intake for the whole day 
was reduced by 13% by the combined infusion compared with the saline infusion and was 
significantly less than on all other infusion days. These represent significant decreases in 
energy intake which if sustained might lead to changes in body weight. 
The mechanism of this reduction in energy intake could either be through a direct appetite 
effect or through local effects such as changes in the rate of gastric empyting. GLP-17-36 
infusion has been reported to inhibit gastric empyting in humans (Verdich et al, 2001a). 
However no effect on gastric emptying, as measured by the paracetamol absorption 
method, was observed in humans with PYY3-36 infusion (Batterham et al, 2002). This 
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group also reported that IP administration Of PYY3-36 did not alter gastric emptying in rats 
(Batterham et al, 2002). In contrast, significant reduction in the rate of gastric empyting 
was observed following IP PYY3-36 in mice (Talsania et al, 2005). Both rodent studies 
assessed gastric emptying from percentage of food remaining in the stomach 3 hours after 
PYY3-36 injection. These apparently conflicting results could be explained by the 
relatively higher dose Of PYY3-36 in mice 3ug per mouse (approximately 30nmol/kg) 
compared with 0.3pg/100g in rats (Inmol/kg) or inter-species variation. Interestingly 
when PYY3-36 at this dose and the relatively potent GLP-I receptor agonist, exendin-4, 
were co-administered in mice, additive inhibition of gastric empyting was reported 
(Talsania et al, 2005). Thus inhibition of gastric empyting could have contributed to the 
reduction in energy intake observed in this study. In order to investigate, a further study 
could be performed with these peptides and gastric emptying assessed following a fixed 
meal. 
The current study was performed with a relatively small number of 10 subjects, and thus it 
is possible that these results are not representative of those which would be observed in a 
larger number of healthy volunteers. A study with a greater number of subjects could 
confirm whether PYY3-36 and GLP-17-36 inhibit feeding additively in humans. As in 
previous human infusion studies (Wren et al, 200 1 a; Batterharn et al, - 2002), there was 
considerable individual variation in food intake at the buffet meal between subjects on the 
saline infusion day. However energy intakes on peptide infusion days were compared 
with the saline control day for each individual subject and therefore the effect of such 
variation was reduced. Despite efforts to make the infusion room as relaxed as possible, it 
was a clinical setting which differed from the circumstances in which subjects would 
normally eat. As explained in the methods section, the infusion ran while the subjects ate 
their meal. Ilis was because there was no evidence that GLP-17-36 infusion terminating 
before the meal would be biologically active. , The setting and infusion protocol were 
identical between infusion days and thus should not have impacted on the results of any 
one peptide or saline infusion. 
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The subjects were offered four different food choices in excess - chicken curry 
(predominantly protein and fat), rice (predominantly carbohydrate), fruit salad (relatively 
low in energy and predominantly carbohydrate) and sweets (relatively high in energy and 
predominantly fat and carbohydrate). It is possible that subject choices at the buffet meal 
could have influenced their satiety. When isocaloric portions of three 'spoonable creams' 
(pure carbohydrate, pure fat and pure protein) were given to another group of human 
subjects, subjective hunger was significantly less with protein than with carbohydrate or 
fat (Fischer et al, 2004). Therefore subjects who ate a greater proportion of chicken curry 
at the buffet meal may have had reduced hunger subsequently. However there were no 
significant differences between the percentage of energy obtained from protein, fat and 
carbohydrate between infusion days. Therefore, subject macronutrient choice is unlikely 
to have had a major impact on the results of this study. 
Two of the subjects were taking a combined oral contraceptive pill. As explained in the 
methods section, the progestin component may lead to an increase in food intake 
(McCarthy et al, 1994) whereas the oestrogen component may lead to a reduction in food 
intake (Geary, 1998). Thus this medication, which would have been active at the time of 
the study, could have confounded the results. The energy intakes for both these subjects 
were broadly similar to the other subjects in the study. However a larger study with more 
participants off and on the combined oral contraceptive pill would be required to 
investigate the possibility of interaction of the combined oral contraceptive pill with the 
gut hormones PYY3-36 and GLP-17-36 ftu-ther. 
Five of the ten subjects in the study smoked cigarettes, and this could also have 
confounded the results of the study. Subgroup analysis did not reveal significant 
differences in energy intake between the smokers and non-smokers on different infusion 
days. However a larger study with a greater number of smokers and non-smokers would 
be required to investigate whether cigarette smoking affects the response to PYY3-36 and 
GLP-17-36- 
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It has recently been reported that, while infusion of CCK-33 or GLP-17-36 inhibited food 
intake when administered individually in humans, no enhanced inhibition was observed 
when they were infused together (Gutzwiller et al, 2004). Thus is appears that not all gut 
hormones inhibit food intake additively. Further work is needed to determine whether the 
other combinations of gut hormones lead to alterations in food intake. 
Given the statistically and clinically significant reductions in food intake in this study, it 
may seem surprising that there were no significant differences in subjective hunger. 
Measurement of perception of hunger is inherently less accurate than measurement of 
energy intake at a buffet meal. The absence of a statistically significant difference could 
therefore reflect a type 11 error. Alternatively, it may be that despite the reduction in 
energy intake, there is no difference in subjective hunger associated with the combination 
of these hormones. Another study with a larger n number would be needed to determine 
the answer to this question. 
Importantly there were also no significant differences in subjective nausea VAS scores 
between infusions. Any substance that inhibits appetite may do so through aversive 
effects rather than directly via appetite signalling circuits. In the rodent studies in chapter 
2, no behaviours, suggestive of an aversive response were observed. However, rodents do 
not vomit (Yamamoto K et al, 2002b), and extrapolation from these studies to the effects 
of these peptides in vomiting species such as humans should only be made with caution. 
in addition, humans are able to report subtle changes in hunger and nausea. Therefore, the 
sensitivity in detecting visceral illness may be greater with visual analogue scales in 
humans than with observational studies in animals. The absence of an effect on nausea in 
the current human study is further evidence that PYY3-36 and GLP- 17-36 may have specific 
effects on satiety. 
There were no significant differences in pulse and blood pressure between infusions. 
Peripheral bolus administration of the GLP-I-R agonist, exendin-4, has been reported to 
increase pulse and blood pressure in rodents (Yamamoto H et al, 2002a). However no 
significant differences in vital signs were observed during a 48 hour subcutaneous GLP- 
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17-36 infusion in humans (Toft-Nielsen et al, 1999). This apparent disparity could be 
explained by the greater potency of exendin4 than GLP-17-36 (Yamamoto et al, 2002a), 
differences in the pharmacokinetics of bolus and continuous administration, and inter- 
species variation. Infusion of full length PYYI-36 to humans was reported to increase both 
systolic and diastolic blood pressure (Adrian et al, 1986a). However, no differences in 
blood pressure were observed when PYY3-36 was infused to humans at a dose 
(0.8pmol/kg/min) which inhibited energy intake (Personal communication with Dr Rachel 
Batterham). In the light of all these publications, it is not surprising that there was no 
significant alteration in pulse and blood pressure with the relatively low doses Of PYY3-36 
and GLP-17-36 in the current infusions. From a practical point of view, if PYY3-36 and 
GLP- 17-36 were to be developed as a therapy, it would be important to confirm that they do 
not cause significant side effects. The 27% reduction in energy intake associated with the 
absence of effects on heart rate, blood pressure and nausea in this study suggests that they 
might prove a suitable therapeutic target. 
GLP-17-36 infusion was associated with a small but statistically significant increase in 
plasma insulin and a decrease in plasma glucose. PYY3-36 was not associated with 
changes in plasma insulin and glucose, which is consistent with another human study 
(Batterham et al, 2003a). In the current study, co-administration Of PYY3-36 with GLP-17- 
36 led to similar plasma concentrations of insulin and glucose as seen with GLP-17-36 
infusion alone. In contrast with the additive inhibition of energy intake, there was no 
evidence of an enhanced incretin effect with the combination treatment. Post-prandial 
glucose and insulin were not assessed due to the variability of energy and nutrient intake 
at the buffet meal. However, it is likely that the incretin effects seen with GLP-17-36 and 
PYY3-36 with GLP-17-36 would be more marked post-prandially than in the fasting state 
(Kreymann et al, 1987). A fiirther study with fixed isocaloric meal would be required to 
assess the effect Of PYY3-36 with GLP-17-36 on post-prandial plasma insulin and glucose. 
Significant inhibition of circulating PYY was observed with the GLP-17-36 infusion. This 
has been previously demonstrated at a higher dose of peripheral GLP-17-3,5 administration 
(Naslund et al, 1999b). Inhibition of endogenous PYY could oppose the anorexic action 
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of GLP-17-36- In contrast, as in previous work (Batterham et al, 2003a), no changes in 
circulating GLP- I concentrations were observed following PYY3-36 infusion. 
GLP-17-36 has been reported to improve glycaemic control in patients with type II diabetes 
(Todd et al, 1998). However it is rapidly degraded in vivo (Hui et al, 2002). Treatment 
strategies include the use of exenatide (synthetic exendin4) (Nielsen et al, 2004) and 
inhibition of dipeptidyl peptidase IV (DPP-IV) (Ahren et at, 2002), the protease that 
inactivates GLP-17-36- It could be that these treatments also reduce circulating PYY3-36 
leading to reduction of the appetite inhibitory effects of GLP-17-36 alone. Thus overweight 
patients with type 11 diabetes could benefit from the addition Of PYY3-36 treatment to 
either a GLP- IR agonist or DPP-IV inhibitor. 
The results of this study suggest that low-dose PYY3-36 and GLP-17-36 inhibit appetite 
additively in man. These findings are consistent with the observation -that PYY3-36 and 
GLP-17-36 inhibit food intake in rodents, and support the hypothesis that these hormones 
may act in concert as physiological post-prandial satiety signals. Reduction in energy 
intake and increase in insulin secretion would make this combination a particularly 
attractive therapy for patients with type 2 diabetes. 
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Chapter 4 
Ghrelin Stimulates Energy Intake in 
Cancer Patients with Impaired Appetite 
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4.1 Introduction 
The growing obesity pandernic has recently received much media attention including the 
recent House of Commons select committee report (House of Commons, 2004). Greater 
understanding of the regulation of appetite control is also important in other clinical 
conditions. Loss of appetite and loss of weight are major causes of morbidity and 
mortality affecting many patients, including those with cancer, HIV, cardiac cachexia, 
chronic renal failure, inflammatory conditions such as sepsis and bums, and in post- 
operative patients. Weight loss also has an important impact on health economics. 
Under-nutrition may account for an additional 5 days' admission for 10% of hospital 
patients, costing approximately L266 million annually in Britain (Kings Fund: report of 
working party chaired by JE Lennard-Jones, 2003). 
Up to 50% of cancer patients report changes in eating behaviour at the time of diagnosis, 
'leading to weight loss (Dewys et al, 1980). Loss of appetite and decreased caloric intake 
frequently affect the quality of patients' lives. These symptoms may lead to cancer 
cachexia, a complex metabolic condition resulting in skeletal muscle wasting, which adds 
significantly to morbidity and mortality. Cancer patients receiving chemotherapy also 
frequently experience debilitating loss of appetite and weight, which may limit the dose 
and duration of a potentially curative or disease-modifying treatment (Tominaga, et al, 
1994). 
Currently prescribed appetite-stimulatory drugs include steroids, progestogens such as 
megesterol acetate (megace) and prokinetic agents such as metoclopramide. While these 
drugs may achieve modest weight gain or at least reduce the rate of weight loss, they are 
associated with significant side effects. Steroids such as dexamethasone may improve 
both quality of life and appetite but are associated with significant metabolic, infectious 
and psychiatric side effects. Tbus their use is usually limited to the short term. 
Megesterol acetate has also been observed to improve appetite (Bruera, 1998), but it is 
associated with water retention and increases the risk of venous thromboembolism which 
is higher in patients with cancer. Prokinetic agents have been reported to reduce chronic 
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nausea (Bruera et al, 2000). However they have no proven effect on appetite and are 
associated with dose-limiting extra-pyramidal side effects. Clearly some patients are not 
helped by, or cannot tolerate currently available treatments for appetite loss. There is a 
need for a safe appetite stimulatory treatment that can be commenced early in a patient's 
therapy before significant weight loss occurs. 
Possible novel therapeutic targets for cachexia could be the gut hormones. Whereas 
increasing the circulating levels of inhibitory gut hormones could be used to treat obesity, 
enhanced levels of gut hormones which increase appetite could be used to treat cachexia. 
As explained in chapter 1, ghrelin is the only circulating hormone identified to date which 
is thought to increase appetite at physiological concentrations. Ghrelin is expressed in the 
stomach and activates neurones of the hypothalamus, an area of the brain known to be 
important in the regulation of feeding (Nakazato et al, 2001). Supra-physiological 
concentrations of other hormones, such as corticosteroids and thyroid hormones, may lead 
to metabolic changes associated with a secondary increase in appetite. In contrast ghrelin 
appears to increase feeding at concentrations within the normal fasting range (Wren et al, 
2001b). 
This laboratory has previously reported that ghrelin increases energy intake by 28% in 
healthy volunteers in a double-blind randomised controlled trial. No adverse events were 
observed. However baseline endogenous ghrelin increases with weight loss (Cummings 
et al, 2002) and falls with weight gain (Levin et al, 2003). Rats with prostate cancer have 
been observed to have higher fasting ghrelin levels than in rats without cancer, although 
these levels were comparable with those of pair-fed controls. Similarly, patients with lung 
cancer and cachexia have been reported to have higher fasting circulating ghrelin levels 
than lung cancer patients without cachexia (Shimizu et al, 2003). Patients in negative 
energy balance, with associated elevated endogenous ghrelin levels, could be resistant to 
the appetite-stimulatory effects of exogenous ghrelin. The question remained as to 
whether a further increase in plasma ghrelin through exogenous treatment would increase 
energy intake. In order to test the hypothesis that supra-physiological levels of ghrelin 
would stimulate energy intake in patients with appetite loss, a group of patients with 
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cancer and anorexia were recruited. In a double-blind cross-over study, these subjects 
were infused with ghrelin and saline control and energy intake from a buffet meal and 
measures of hunger and meal appreciation were compared. 
4.2 Methods 
ZI Materials 
Synthetic human acylated ghrelin was purchased from Bachem, (Merseyside, UK). Unless 
otherwise stated all chemicals were purchased from Merck (Poole, Dorset, UK). 
4.22 Studyprotocol 
The study was approved by the Hammersmith, Queen Charlotte's and Chelsea Ethics' 
committee under number 2002/6316, and performed in accordance with the principles of 
the Declaration of Helsinki. Because patients rather than volunteers were to be 
administered with ghrelin, permission was also required from Medicines Control Agency. 
This was granted as a drugs and therapeutic exemption certificate (DDX) under reference 
number (MF8000/11855). Patients with known cancer reporting loss of appetite were 
recruited from Charing Cross Hospital oncology clinics. 
Ghrelin is primarily secreted in the stomach (Date et al, 2000). Rodents with vagotomy 
have been reported to be insensitive to exogenous ghrelin (Date et al, 2002) and patients 
with gastric bypass surgery have been observed to have reduced circulating ghrelin 
(Cummings et al, 2002). Thus patients with gastric or oesophageal cancer could have an 
altered response to ghrelin compared with patients with other cancers and were therefore 
excluded from the trial. This important subgroup of patients will be discussed in chapter 
six. 
Further exclusion criteria included surgery or radiotherapy within the previous month. 
Had such patients been investigated, difference in energy intake on infusion days could 
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have reflected response to treatment rather than to ghrelin infusion. In practice, these 
patients were recruited and infusion delayed until the one month time limit had expired. 
Patients on regular systemic steroids or progestins such as megestrol acetate were also 
excluded, as both these classes of drugs may stimulate appetite and could have interfered 
with the effect of ghrelin on energy intake. Patients established on chemotherapy with 
sustained appetite loss were included in the study (see below). 
Clinical reduction in appetite was confirmed by dietetic consultation using the Edmonton 
Symptom Assessment Scale, in which subjects were asked to rate the severity of the 
following nine symptoms on a 100mm. visual analogue scale: pain, tiredness, nausea, 
depression, anxiety, drowsiness, lack of appetite, lack of well-being, and shortness of 
breath (Chang et al, 2000) (appendix 6). Subjects also selected the food to be served to 
them on both their infusion days, and tasted -it to confirm palatability. Although the 
patients had significant chronic illness, it was important to determine that they were well 
enough to participate, and that their health was likely to be reasonably consistent over the 
two infusion days. This was especially important for the patients on chemotherapy who 
had 3 weeks between their two infusions. Patients were screened medically with history, 
examination and electrocardiogram (ECG). Blood tests were performed, including full 
blood count (FBC) looking particularly for anaemia and leucopenia, urea and electrolytes 
to investigate renal function and liver function tests for evidence of metastases. One 
patient was excluded due to anaemia (haemoglobin 8.5g/dl), and two others on 
chemotherapy were excluded due to persistent neutropenia (neutrophils 1.2 and 1.5 x 
101) 
Following screening, seven patients were recruited (six women and one man) with a mean 
weight loss from their pre-cancer weight of 13% and mean current BMI of 22.6 kg/M2 
(table 4.1). All patients had metastatic cancer. At recruitment the mean Edmonton 
Symptom Assessment score for lack of appetite was 70mm/100mm and the mean total 
score for all 9 questions representing poor quality of life was 230mm/900mm. The 
patients scored that lack of appetite was the main contributor to their overall poorer 
quality of life. Each patient gave their written, informed consent to participate in the 
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study and attended for two infusion days at least 3 days apart (range 3-21 days), one for 
ghrelin and one for saline control. Patients on chemotherapy attended for their first 
infusion as long after their chemotherapy cycle as possible (at least 17 days) and then the 
same number of days after their subsequent cycle. Although these patients took an anti- 
emetic in the few days after their chemotherapy, this was no longer taken nor required 
from 7 days prior to ghrelin or saline infusion. 
The study was randomised and double-blinded. Subjects were randomised to receive 
intravenous ghrelin then saline (4 patients) or saline then ghrelin (3 patients) using the 
statistics Package Sigma stat v2.0 (SPSS Science, Chicago, IL). Vials of ghrelin and 
saline were indistinguishable visually and were labelled by subject number and infusion 
number and stored in a sealed container. Subjects, investigators and dieticians were 
blinded to the infusion order until study completion. Both ghrelin and saline vials were 
sterile on culture, and the limulus amoebocyte lysate assays for pyrogen (Karplus et al, 
1987) were negative. 
The infusion day protocol was similar to that of the infusions Of PYY3-36 and GLP-17-36 in 
healthy volunteers (chapter 3). In the current study, fasted patients had two intravenous 
cannulae (one for infusion and one for blood sampling) placed at 09: 00 (t = -30 minutes) 
(See the protocol in figure 4.1). Patients were encouraged to relax by reading or watching 
television or videos. At 09: 30 (t--O) a fixed breakfast was served in order to standardise 
food intake prior to the infusion. This consisted of 15g Kellogg's cornflakes, 75ml whole 
milk, 4g white sugar, I 00ml unsweetened orange juice and optional decaffeinated coffee 
or herbal tea (total energy content 657 KJ) (table 4.2). A small breakfast of relatively low 
energy content was selected to ensure that patients could finish it. Circulating ghrelin 
peaks in the fasting state, and falls within one hour after a meal (Cummings et al, 2001). 
The light breakfast was included in order to reduce endogenous ghrelin from its high 
fasting level. It also enabled patients to eat breakfast close to their customary time. 
Ghrelin or saline infiision was commenced at 11: 00 (t--90). 
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Patient 
No. 
Age Sex Pre- 
cancer 
weight 
(kg) 
Current 
weight 
(kg) 
Current 
BMI 
(kg/m2) 
Cancer On 
Chemotherapy? 
1 52 F 
1 
58 44.3 17.3 Malignant 
melanoma 0 
2 63 F 64 57.5 21.4 Breast Yes 
3 66 F 67 52.7 21.1 Breast No 
4 55 F 58 54.8 25.7 Breast No 
5 54 F 65 64.6 24.3 Breast No 
6 49 M 80 59 19.0 Colon No 
7 41 F 86 83.8 29.3 Breast Yes 
Table 4.1 
Details of patients with cancer and impaired appetite recruited to the study. 
Com flakes 
(15g) 
Whole 
milk 
(75ml) 
Sugar 
(4g) 
Orange 
Juice 
(100ml) 
Total 
Energy (KJ) 230 206 67 153 657 
Protein (g) 1.2 2.4 0.0 0.5 4.1 
Fat (g) 0.1 2.9 0.0 0.1 3.1 
Saturated fatty acids (g) 0.0 1.8 0.0 0.0 1.8 
Mono-unsaturated (g) 0.0 0.8 0.0 0.0 0.8 
Poly-unsaturated (g) 0.0 0.1 0.0 0.0 0.1 
Carbohydrate (g) 12.9 3.6 4.0 8.8 29.3 
Starch (g) 11.7 0.0 0.0 0.0 11.7 
Total sugars (g) 1.2 3.6 4.0 8.8 17.6 
Dietary fibre (g) 0.5 0.0 0.0 0.0 0.5 
Table 4.2 
Macronutrient composition of the fixed breakfast served to patients with cancer and 
impaired appetite 30 minutes after arrival on each study day. 
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The rate of ghrelin infusion (5pmol/kg/min) was chosen because it had previously been 
reported to increase food intake in healthy volunteers (Wren et al, 2001a). At 12: 30 
(t=180) a buffet lunch was served of pre-weighed food in excess. This consisted of 
Sainsburys spaghetti bolognaise, fruit salad and sweets (table 4.3). As in the ghrelin study 
in healthy volunteers (Wren et al, 2001a), ghrelin or saline infusion was continued 
through the meal. Being attached to an intravenous infusion could have affected patients 
while they were eating. However, this was the case on both ghrelin and saline infusion 
days. Following the meal, the remaining food was removed and weighed, and the infusion 
discontinued. A Soehnle Vera food balance (Austin White Ltd, Northamptonshire, UK) 
(detection limit Ig) was used for the measurement of food weights of the fixed breakfast 
and the buffet meal before and after presentation to the subjects. The energy intake and 
nutrient content of the food consumed at the buffet lunch was kindly calculated by a 
dietician, who was blind to which treatment had been given, using dietplan-5 nutritional 
analysis software. 
INFUSION 
Patient 
arrives 
Fixed 
Breakfast 
I 
Buffet 
Lunch 
I 
Patient 
home 
II 
09: 00 09: 30 11: 00 
III -IF 
-30 0 45 90 
Blood sampling 
Figure 4.1 
Infusion protocol of ghrelin or saline in patients with cancer and impaired appetite. 
12: 30 13: 00 14: 00 
II11 
150 180 210 270 (min) 
+++++ 
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Blood samples (each 10ml) were collected into heparin-coated tubes containing 2000 
Kallikrein inhibitor units (0.2ml) aprotinin (Bayer, Newbury, Berkshire, UK). Samples 
were taken before breakfast (t--O minutes) and at 45,90,150 and 180 minutes. Fewer 
blood samples were taken from these patients than from the healthy volunteers in the co- 
administration Of PYY3-36 and GLP-17-36 study (chapter 3) because the patients with 
cancer were at higher risk of becoming anaemic. Therefore the total blood volume 
withdrawn was restricted to 50ml per infusion day or 100ml in the whole study. Each 
sample was immediately centrifuged, the plasma separated and stored at -70'C until being 
assayed for ghrelin, GH, insulin and glucose. 
Spaghetti 
bolognaise 
Fruit Salad Sweets 
per I OOg 
Energy (KJ) 563 186 1933 
Protein (g) 7.8 0.6 4.1 
Fat (g) 5.6 0.1 16.6 
Saturated fatty acids (g) 1.8 0.0 12.5 
Mono-unsaturated (g) 3.3 0.0 2.0 
Poly-unsaturated (g) 0.5 0.0 2.1 
Carbohydrate (g) 13.1 10.5 73.5 
Starch (g) 12.3 0.5 1.0 
Total sugars (g) 0.8 10.0 72.5 
Dietary fibre (g) 0.4 1.5 0.1 
Table 4.3 
Macronutrient composition of the foods provided at the unlimited buffet meal per I OOg to 
patients with cancer and impaired appetite on each study day. 
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In addition to the primary end point of energy intake, subjective hunger was also 
quantified. It was also important to assess whether or not ghrelin was associated with 
sickness. This was assessed using visual analogue scales (VAS) (Flint et al, 2000). 
Patients were asked to rate hunger, sickness, fullness, how pleasant it would be to eat, how 
much they thought they could eat, and how full they felt on 100min scales (appendix 5). 
They were given these questionnaires before breakfast (t=O), before the start of the 
infusion (t--90), after 60 minutes' infusion (t--150), immediately before lunch (t--180) and 
prior to going home (t--270). Additionally, in order to assess meal appreciation, after the 
buffet lunch patients were asked to score on a VAS "How pleasant was this meal? " At the 
end of the study, positions in min on all VAS were measured prior to unblinding of the 
data. 
Pulse and blood pressure were measured every 30 minutes during the protocol. In the 
event of a clinically significant alteration in these vital signs, the infiision was to be 
discontinued. These measurements also enabled quantification of the effect of ghrelin on 
the cardiovascular system. An intravenous ghrelin injection reduced the difference in 
mean arterial blood pressure from baseline compared'with saline injection(Nagaya et al, 
2001a). Therefore, in addition to reporting absolute values, difference from baseline was 
calculated for pulse, systoliC'and diastolic pressures by subtracting the mean of the values 
at t=-30 and t=O minutes at each subsequent time point. 
In order to assess the effect of ghrelin on energy intake following the infusion, patients 
were asked to complete a food diary for 24 hours after each infusion. One patient (patient 
7) failed to complete the food diary after her second infusion. Unfortunately one month 
after she had. completed the study, she became extremely unwell, and it would have been 
inappropriate to have asked her or her family again about the food diary. Completed food 
diaries were kindly assessed by our dietician using dietplan-5 nutritional analysis 
software. 
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4.2.3 Plasma hormone measurement 
Plasma ghrelin was measured by radio-immunoassay (Phoenix Pharmaceuticals). The 
limit of detection was 3pmol/1 and the intra- and inter-assay coefficients of variation were 
5 and 14% respectively. The antibody binds 100% with des-acylated ghrelin in addition 
to acylated ghrelin and the assay measures total ghrelin rather than the acylated fraction. 
Plasma GH was analysed using Advantage automated chemiluminescent immunoassay 
(Nichols Institute Diagnostics, San Juan Capistrano, California, USA). Glucose and 
insulin were measured using an Olympus AU640 clinical chemistry analyser (Melville, 
New York State, USA) and insulin was measured using an automated microparticle 
enzyme immunoassay. The relationship between baseline ghrelin levels and alteration in 
energy intake with ghrelin infusion was also quantified. 
4.2.4 Statistical analysis 
Patient characteristics (age and BMI) are presented as mean ± SD. Results are presented 
as mean I SEM. Statistical comparisons between treatments for food intake, visual 
analogue scores, plasma ghrelin and GH levels, and pulse and blood pressure were made 
using paired t-tests. For correlations between ghrelin levels and alteration in energy 
intake in response to ghrelin infusion, linear regression was performed using the statistics 
package SPSS for windows. For all statistical tests, significance was set at P<0.05. 
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4.3 Results 
4.3.1 Ghrelin and GHplasma levels 
Mean fasting plasma ghrelin concentration was 538 ± 49 pmol/l, with levels ranging from 
350 to 938 pmol/l. Ghrelin infusion achieved steady state within 60 minutes of infusion 
with a mean plasma ghrelin of 1718 ± 169 pmol/l (table 4.4a). However, following the 
light fixed breakfast and prior to the start of the infusion at t--90 minutes, no significant 
fall in circulating ghrelin was observed (Pý-0.08 on saline day). The expected GH rise 
associated with acute ghrelin administration was observed (table 4.4b), confirming that the 
ghrelin inftision was biologically active. 
4.3.2 Energy intake 
Energy intake from the buffet lunch was increased by 31% during ghrelin infusion 
compared with saline control (Energy intake KJ: saline infusion 2156 ± 365, ghrelin 
infusion 2820 ± 519; P--0.005), (figure 4.2a). Moreover every patient consumed more on 
his or her ghrelin administration day compared with the saline infusion day (figure 4.2b) 
(range 7-59% increase). No side effects were observed. There was no evidence of a 
compensatory decrease in food intake following ghrelin treatment as assessed by 24-hour 
food diary. Total energy intake over the 24-hour period including the buffet was 9271 ± 
2342 KJ following ghrelin treatment versus 6854 A: 1251 KJ following saline (Pý-0.09) 
(figure 4.3a). Cumulative individual energy intakes for the buffet meal and subsequent 24 
hours are illustrated in figure 4.3b. 
162 
(a) 
0 minutes 
(pre-breakfast) 
(PMOIA) 
90 minutes 
(infusion start) 
(PMOIA) 
150 minutes 
(PMOIA) 
180 minutes 
(pre-lunch) 
(PMOIA) 
Saline infusion 545 ± 58 440 ± 59 509± 97 490 ± 63 
Ghrelin infusion 531 ± 83 505 ± 90 1718 ± 169 1840 ± 221 
rval-ue) P=0.71 P=0.20 P<0.001 P<0.001 
(b) 
0 minutes 
(pre-breakfast) 
(iU/I) 
90 minutes 
(infusion start) 
(iU/I) 
150 minutes 
(iU/I) 
180 minutes 
(pre-lunch) 
(iU/I) 
Saline infusion 6.5 ± 3.3 6.5 ± 2.9 2.6 ± 1.0 3.8 ± 1.9 
Ghrelin infusion 10.9± 3.4 9.4 ± 3.3 72.5 ± 26.4 39.7+12.4 
(P value) P=0.08 P=0.08 P=0.03 P=0.02 
Table 4.4 
(a) Plasma ghrelin levels and (b) plasma GH levels in subjects with cancer and impaired 
appetite at t--O, 90,150 and 180 minutes on saline and ghrelin infusion days. A light fixed 
breakfast was given at t--O, ghrelin or saline infusion started at t--90 and buffet lunch 
served at t--180 minutes. P values compare ghrelin and GH levels at each time point 
between infusion days. 
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% energy intake of saline day 
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saline ghrelin 
Figure 4.2a 
Percentage increase in energy intake from an unlimited buffet meal in patients with cancer 
and impaired appetite following ghrelin infusion. Energy intake on the saline inftision day 
is shown as baseline at 100%. * P--0.005. 
Energy intake (MJ) 
5r 
4 
3 
2 
I 
0 
Figure 4.2b 
saline ghrelin 
Energy intake at an unlimited buffet meal in individual patients with cancer and impaired 
appetite following ghrelin and saline infusions. The bold line represents mean energy 
intake. 
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%energy intake of saline day 
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saline ghrelin 
Figure 4.3a 
Percentage increase in cumulative 24-hour energy intake including the unlimited breakfast 
meal following ghrelin infusion in cancer patients with impaired appetite. Energy intake 
on the saline day is shown as baseline at 100%. 
Energy intake (MJ) 
20 F 
16 
12 
8 
4 
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saline ghrelin 
Figure 4.3b 
Individual 24-hour cumulative energy intake including the breakfast meal following 
ghrelin and saline infusions in cancer patients with impaired appetite. The bold line 
represents mean energy intake. 
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There were no significant differences in the percentage of energy intake at the buffet meal 
obtained from different macronutrients between saline and ghrelin infusions (table 4.5). 
saline ghrelin P value 
protein 15.7 ± 1.6 % 15.2 ± 1.3 % 0.60 
fat 24.8 ±2.7 % 26.0±2.6 % 0.33 
carbohydrate 59.5 ±4.0% 5 8.7 ± 3.6 % 0.70 
Table 4.5 
Percentage of energy intake at the unlimited buffet meal from protein, fat and 
carbohydrate with saline and ghrelin infusions in cancer patients with impaired appetite. 
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In order to detennine whether there was a relationship between baseline endogenous 
ghrelin levels and energy intake in response to the ghrelin infusion, these variables were 
plotted (figure 4.4). No significant relationship or correlation was observed; P---0.67. 
60 ý 
50 ý 
30 ý 
10-1 
0. 
increase in energy intake 
0 
0 
Observed 
Linear 
40 ý 
20 ý 
0 
0 
0 
III U------l -Iy 
300 400 500 600 700 800 900 
Fasting ghrelin. (pmol/1) 
Figure 4.4 
Scatter graph of fasting ghrelin levels (X-axis) and percentage increase in energy intake 
with ghrelin inftision compared with saline infusion (Y-axis) - no significant correlation 
(le =0.02; P=0.67). 
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4.3.3 Visual analogue scales 
Analysis of the visual analogues scores revealed no significant differences in hunger, 
sickness, nor answers to the questions 'how pleasant would it be to eat right nowT, 'how 
much could you eat right nowT and how full do you feel right nowT between ghrelin and 
saline infusions (table 4.6). 
Saline infusion Ghrelin infusion P value 
Hungry? 5.71-12 63 ± 10 0.8 
Sick? 9±4 10 ±6 0.5 
Pleasant to eat now? 60 ± 11 66± 10 0.5 
Much could you eat? 49 ±8 60 ± 12 0.2 
Full right now? 27 ± 11 10±5 0.1 
Table 4.6 
Visual analogue scores (mm) immediately before lunch at t--180 minutes on saline and 
ghrelin infusion days in subjects with cancer and impaired appetite. Subjects were asked 
to rate their responses from 0 to I 00mm. 
Analysis of the meal appreciation VAS, 'How pleasant did you find this mealT revealed a 
significant increase in the perceived pleasantriess of the meal on the ghrelin administration 
day compared with the saline administration day (pleasant score (mm): saline infusion 63 
: 1: 8, ghrelin infusion 76 ± 7; P=0.02). This represented at 23% increase in how pleasant 
the subjects found the meal on the ghrelin infusion day. 
168 
4.3.4 Plasma insulin and glucose levels 
As expected, plasma insulin and plasma glucose increased following the fixed breakfast 
(figures 4.5 and 4.6). Using paired Mest analysis, at t--150 minutes (150 minutes after 
breakfast and 60 minutes into the infusion), there were trends for a decrease in plasma 
insulin and an increase in circulating glucose with ghrelin infusion compared with saline 
(Plasma insulin iU/l at t-- 150 min: saline infusion 8.0 ± 2.0, ghrelin infusion 5.0 ± 1.3; P= 
0.05) (Plasma glucose mmol/l at t=150 minutes: saline infusion 4.610.3, ghrelin infusion 
5.3 ± 0.2; P=0.09). However immediately prior to the buffet lunch at t--180 minutes, 
insulin and glucose levels were similar on both infusion days (Plasma insulin iU/l at t-- 180 
min: saline infusion 6.6 ± 1.5, ghrelin infusion 5.2 + 1.4; P=0.6) (Plasma glucose mmol/l 
at t--180 minutes: saline infusion 4.9± 0.2, ghrelin infusion 5.0 10.2; P=0.9). 
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Figure 4.5 
Plasma insulin with saline and ghrelin infusion in patients with cancer and impaired 
appetite. 
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Figure 4.6 
Plasma glucose with saline and ghrelin infusion in patients with cancer and impaired 
appetite. 
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4.3.5 Pulse and bloodpressure measurements 
There were no statistically significant alterations in pulse and blood pressure recordings 
between inflision days (table 4.7). Differences from baseline were calculated on both 
saline and ghrelin infusion days as in previous publications (Nagaya et at, 2001a; Wynne 
et al, 2005a) and compared, but no statistically significant alterations were observed (table 
4.8). 
Pulse 
beats/min 
Systolic BP 
mmHg 
Diastolic BP 
mmHg 
Saline infusion 78 ±3 136 ±7 74± 4 
Ghrelin infusion 79 ±4 123 ±5 67 ±3 
P value 0.84 0.15 0.10 
Table 4.7 
Absolute pulse and blood pressure readings after 90 minutes infiision in patients with 
cancer and impaired appetite, immediately before the meal at t-- 180 minutes. 
Pulse 
(beats/min) 
Systolic BP 
(rnrnHg) 
Diastolic BP 
(mmHg) 
Saline infusion -3.9± 1.4 11.7 =I-- 5.6 8.0 ± 7.6 
Ghrelin infusion -2.4± 1.1 4.4 ± 2.8 0.0 ± 4.8 
P value 0.47 0.36 0.23 
Table 4.8 
Difference from baseline (t--O) of pulse and blood pressure readings after 90 minutes 
infusion in patients with cancer and impaired appetite immediately before the meal at 
t-- 180 minutes. 
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4.4 Discussion 
The results of this study suggest that ghrelin stimulates appetite acutely in cancer patients 
with appetite loss. The 31% increase in energy intake observed with ghrelin infusion is 
comparable with the 28% increase previously reported in healthy volunteers (Wren et al, 
2001a). In practice, smaller increases in energy intake (-I%) are associated with 
significant weight change when sustained (Schutz & Garrow, 2000). Although baseline 
energy intake and endogenous plasma ghrelin varied widely, ghrelin infusion stimulated 
appetite in all the patients investigated. Interestingly there was no correlation between 
fasting ghrelin levels and the percentage increase in energy intake with ghrelin infusion. 
Instead it appears that the response to ghrelin infusion is dependent on the peak ghrelin 
plasma concentration achieved prior to the meal. 
There was a trend for an increase in cumulative 24-hour energy intake after ghrelin 
treatment from a mean of 6854 KJ with saline to 9270 KJ with ghrelin. Home diaries 
completed by patients are inevitably less accurate than buffet food intake assessment in 
the controlled conditions of the infusion room. Patient recruitment proved challenging, 
and while an n number of 7 had sufficient power to detect a significant difference in 
energy intake at the buffet meal (the primary end-point), this may have been insufficient 
to detect a significant difference between home food diaries and could represent a type 11 
statistical error. This small sample size means that the results of this study should be 
interpreted with caution and a larger study is required for confirmation. 
With the observed increase in energy intake, it is perhaps surprising that no differences in 
subjective hunger were observed. Indeed with 9 healthy volunteers who were infused 
with intravenous ghrelin at the same dose as in the current study a significant increase in 
subjective hunger as measured by VAS has been previously reported (Wren et al, 200 1 a). 
It may be that hunger is inherently more variable in patients reporting appetite loss 
compared with that of healthy volunteers. 
172 
Fasting plasma ghrelin concentrations in the cancer patients were higher than those 
reported in healthy reference populations of similar body mass index which were also 
measured using the commercial Phoenix assay (Cummings et al, 2001). This finding is 
consistent with previous work (Shimizu et al, 2003). Surprisingly endogenous ghrelin 
levels in the current study did not fall significantly following the light fixed breakfast. It 
may be that the energy content of the breakfast was too small to affect circulating ghrelin. 
However, in the food diaries it appeared that several patients ate breakfast at home of a 
similar size and energy content. Further work is needed to determine the 24 hour profile 
of ghrelin in patients with appetite loss. If there is loss of peak and trough amplitude, this 
could explain at least in part why the endogenous rise in plasma ghrelin in response to 
negative energy balance fails to restore appetite. 
As expected the ghrelin levels achieved in the current study with ghrelin infusion were 
supra-physiological (1718 ± 169 pmoIA) and approximately Mold higher than fasting 
endogenous levels. However, no side effects were seen or reported. There was no 
significant correlation between fasting ghrelin levels, which ranged from 418-880 pmol/l, 
and response to ghrelin infusion. This could be explained by the fact that ghrelin levels 
achieved with the infusion were much greater than endogenous levels making differences 
from baseline between patients relatively small. The observation that every patient ate 
more with ghrelin infusion suggests that peripheral ghrelin is effective in stimulating 
appetite despite elevated endogenous baselines. The patients in this study found the meal 
significantly more pleasant with ghrelin infusion. In addition to stimulating appetite, 
ghrelin may improve appreciation of food. 
Analysis of the pulse and blood pressure recordings revealed no statistically significant 
differences between infusion days. Nagaya et al. reported a reduction in mean arterial 
blood pressure in response to intravenous ghrelin in healthy volunteers (Nagaya et al, 
2001a) and Wynne et al. observed a reduction in diastolic pressure in patients with 
chronic renal failure (Wynne et al, 2005a). In the current study, diastolic blood pressure 
from baseline was lower with ghrelin infusion, although this did not reach statistical 
significance (P--0.2). It is difficult to draw definitive conclusions about the effect of 
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ghrelin administration on blood pressure in patients with cancer with the relatively small 
number of patients in this study. A larger study would be required to address this 
question. 
It is not yet established whether ghrelin has any long-term adverse effects. A brief rise in 
GH was observed with ghrelin infusion. Theoretically, through increasing GH, ghrelin 
could promote tumour growth. Data on the effect of ghrelin on cell lines are conflicting. 
Whereas ghrelin promoted prostate cancer cells (Jeffery et al, 2002), it inhibited breast 
cancer cells (Cassoni et al, 2001). Further work is needed to determine the effect of 
ghrelin on tumours in vivo. 
In this study, ghrelin infusion administered 90 minutes after a small fixed breakfast had no 
significant effect of plasma insulin and glucose. Wren et aL have previously reported that 
immediately following a fixed breakfast, ghrelin infusion was associated with a decrease 
in plasma insulin and an increase in plasma glucose in healthy volunteers (Wren et al, 
2001a). However ghrelin was found to have no effect on plasma insulin or glucose in the 
fasting state (personal communication with Dr Alison Wren). From the current study, it 
appears that ghrelin also has no cffect on insulin and glucose 90 minutes after a light meal. 
Were ghrelin to become a chronic treatment for appetite loss, it would be administered 
prior to a meal and usually more than 90 minutes after the preceding meal. Thus ghrelin 
could have a positive effect on appetite without altering insulin and glucose. - 
Ghrelin has now been administered acutely to more than 100 human subjects worldwide 
(Wren et al, 2001a; Broglio et al, 2001; Nagaya et al, 2001b). It is also worthy of note 
that synthetic agonists of the ghrelin (GH secretagogue) receptor have been administered 
to adults with GH deficiency and children with idiopathic short stature for up to 2 years 
with no reported adverse effects (Muller et al, 1999). Nonetheless, chronic ghrelin 
administration in patients with normal growth axis could lead to supra-physiological 
levels of GH, causing acromegaly and its associated complications, such as joint pain, 
headaches and visual field defects. 
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Ghrelin may promote gastric emptying in addition to stimulating appetite. An increase in 
gastric emptying was reported following peripheral ghrelin in rodents (Domonville de la 
Cour et al, 2004). Wren et aL measured gastric emptying in human volunteers following 
a fixed breakfast (Wren et al, 200 1 a) using the paracetamol absorption method (Tarling et 
al, 1997) and observed no significant change with ghrelin infusion. Recently Murray et 
al. have reported that intravenous ghrelin infusion, as the same rate as in the current study, 
stimulates gastric emptying in patients with diabetic gastroparesis using the more sensitive 
technique of real-time ultrasound (Murray et al, 2005; Darwiche et al, 2003). Thus 
patients with loss of appetite could benefit from ghrelin's effect as a prokinetic in addition 
to its effect on appetite. 
Unlike currently available appetite stimulatory treatments, administration of ghrelin 
boosts an endogenous appetite-regulating system. Ghrelin stimulated appetite in healthy 
volunteers (Wren et al, 2001 a) and in the current study in cancer patients with anorexia. 
In both groups, food intake was increased in every individual studied. It is also possible 
that ghrelin may have a potential therapeutic benefit in patients with other causes of 
cachexia. Preliminary studies suggest that ghrelin improves cardiac function and protects 
against cardiac ischaemia (Nagaya et al, 2001b) making a therapeutic role in cardiac 
cachexia particularly attractive. This acute study highlights the need for further 
investigation to establish whether long-term ghrelin can be used effectively in the 
palliation of appetite loss. 
175 
Chapter 5 
Subcutaneous Ghrelin Stimulates 
Energy Intake in Healthy Volunteers 
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5.1 Introduction 
Intravenous infusion of ghrelin stimulated energy intake in cancer patients with loss of 
appetite in the study described in chapter 4. Patients may suffer loss of appetite from 
various causes (Neary et al, 2004; le Roux et at, 2005a) and ghrelin might prove a suitable 
treatment for them. However, intravenous administration is cumbersome and unsuited to 
outpatient clinical practice. If ghrelin is to be used as an appetite-stimulatory treatment 
then a more practical means of delivery which retains bioactivity is required. 
Ghrelin has a unique biological structure with an acyl side chain on the P amino acid 
residue (figure 1.3 in introduction). Acylated and des-acylated ghrelin both circulate 
endogenously (Akamizu et al, 2005), but it is only acylated ghrelin which has affinity for 
the growth hormone secretagogue receptor (GHS-R la) (Kojima et al, 1999). Acylated 
ghrelin had been reported to stimulate GH release and food intake in vivo (Wren et al, 
2000). At this point in the studies described in this thesis the effect of des-acylated 
ghrelin on food intake had not been examined. 
Peptide hormones including insulin and glucagon are not active when given orally due to 
digestion. Subcutaneous ghrelin injection might result in inactivation due to loss of the 
acyl group. In order to determine whether des-acylated ghrelin would alter feeding, 
acylated ghrelin and des-acylated ghrelin were administered to mice in the fed and fasting 
states and their effect on food intake measured. Given that the effect of exogenous des- 
acyl ghrelin in vivo was unknown and might, like any novel substance, lead to toxic 
effects, this study was performed in mice rather than humans. 
Subsequently a pilot human study was performed to select a dose of ghrelin administered 
subcutaneously which would be suitable to increase GH release and food intake. The 
ethical approval process favoured administration to volunteers rather than patients prior to 
consideration for a therapeutic trial. Therefore healthy volunteers were recruited for this 
study. Given that patients with appetite loss had responded similarly to ghrelin as had 
healthy volunteers (Wren et al, 2001a; Neary et al, 2004), it is likely that they would also 
177 
respond similarly to subcutaneous ghrelin. A randomised placebo-controlled cross-over 
trial was performed using a dose of ghrelin selected from the pilot study in healthy 
volunteers to determine the effect of subcutaneous ghrelin on food intake in man. 
5.2 Methods for rodent des-acylated ghrelin study 
Male C5713116 mice aged 7-8 weeks weighing 20-25g were individually housed, fed with 
standard rodent chow (RM1 diet, SDS Ltd, Witham, Essex, UK), given free access to 
water and acclimatised to the experimental procedure as described in chapter 2. A dose of 
0.3 nmol/g acylated ghrelin consistently stimulated food intake in lean mice in the fed 
state (Druce el al, 2005a), and this dose was selected for acylated and des-acylated 
ghrelin. Mice were randomised to receive an IP injection of saline, 0.3nrnol/g acylated 
ghrelin (AG), 0.3nmol/g des-acylated ghrelin (DAG) and 0.3nmol/g AG + 0.3nmol/g 
DAG (n=11-12 per treatment group). The combined group was pre-mixed prior to 
injection, and the maximum injection volume was O. Iml. This study was performed twice 
- first in the fed state and secondly following a 20 hour fast. In the fasting experiment, 
0.03nmol/g PYY3-36 was also injected as a positive control for appetite inhibition., Food 
intake was measured at 1,2,4,6 and 24 hours post injection. 
5.3 Methods for human subcutaneous study 
The study was approved by the Hammersmith, Queen Charlotte's and Chelsea Ethics 
Committee (reference number 2003/6558) and performed in accordance with the 
principles of the Declaration of Helsinki. Synthetic human ghrelin was purchased from 
Bachem (Merseyside, UK). All subjects in the study gave their written informed consent 
to participate. Ghrelin was dissolved in saline 0.9% (Bayer, Haywards Heath, UK) for 
subcutaneous administration (maximum injection volume 0.4ml). As in the previous 
human study, ghrelin and saline were cultured for seven days and limulocyte amoebocyte 
lysate (LAL) assays (Karplus et al, 1987) were performed in order to confirTn sterility and 
the absence of endotoxin. 
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5.3.1 Pilot injitsion study 
In order to select a suitable dose of ghrelin, a pilot study was performed using stepwise 
escalation of dose administered. The starting dose of ghrelin was 0.225 nmol/kg, which 
was equivalent to half of the total ghrelin dose administered intravenously prior to the 
meal in the study to cancer patients (chapter 4). Eight subjects were recruited for the pilot 
study and these were divided into two groups of four. Each subject attended on four 
occasions having fasted overnight. For the first group, subjects were randomised to 
receive either saline on the first day and 0.225nmol/kg ghrelin on the second, or 
0.225nmol/kg ghrelin on the first day and saline on the second. A cautious starting dose 
was chosen because, unlike an intra-venous infusion which may be switched off in the 
event of an adverse reaction, once administered the total subcutaneous ghrelin dose would 
remain in the tissues. For the following two visits the dose was increased by a factor of 
two on each occasion. Thus the dose on the third visit was 0.45nmol/kg and the dose on 
the fourth visit was 0.9nmol/kg (table 5.1). Group 2 commenced studies after completion 
of studies on group 1. Group 2 were randomised to receive either 0.9nmol/kg ghrelin or 
saline on visits one and two. Doses on their third and fourth visits were 1.8 and 
3.6runol/kg. One subject in the second pilot group left the study after two injections due 
to a change in personal circumstances. Thirty minutes after injection subjects received 
breakfast (herbal tea or decaffeinated coffee and cinnamon loaf) and energy intake was 
measured. The aim was to find a dose of ghrelin which tended to increase energy intake 
and then to investigate this formally in a randomised double-blind cross-over trial. 
Group I (n=4) Group 2 (n=4) 
Visit I Saline or 0.225 nmol/kg ghrelin Saline or 0.9 nmol/kg ghrelin 
Visit 2 0.225 nmol/kg ghrelin or saline 0.9 runong ghrelin or saline 
Visit 3 0.45 tunol/kg ghrelin 1.8 nmol/kg ghrelin 
Visit 4 0.9 nmol/kg ghrelin 3.6 nmol/kg ghrelin 
Table 5.1 
Doses of ghrelin administered via subcutaneous injection in the pilot study to healthy 
human volunteers. 
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5.3.2 Double-blind randomised controlled trial 
The inclusion criteria were an age between 18 and 55 years, BMI between 19 and 26 
kg/m2 and the absence of disease or medication likely to interfere with the study. Sixteen 
healthy volunteers (8 men and 8 women) were recruited to the main study. At screening, 
subjects were asked if they found cinnamon loaf palatable. Two out of the sixteen 
subjects reported that they disliked cinnamon loaf but that they liked Madeira cake. on 
the study days, these two volunteers were given Madeira cake, and the remaining 14 were 
given cinnamon loaf. The macronutrient composition of these foods is listed in table 5.2. 
The mean age of the volunteers was 25.412.9 years (mean _+ SD) (range 19 - 31 years) 
and mean BMI 22.5 ± 1.5 k g/M2 (range 19.8 - 25.1 k g/M 2). 
Cinnamon Loaf Madeira cake 
per I OOg 
Energy (KJ) 1525 1655 
Protein (g) 6.4 5.5 
Carbohydrate (g) 54.6 57.9 
of which sugars (g) 28.6 37 
Fat (g) 13.2 15.6 
of which saturates (g) 4.6 8.7 
monounsaturates (g) 5.6 5.1 
polyunsaturates (g) 2.1 1.1 
Fibre (g) 1.5 1.2 
Table 5.2 
Macronutrient composition of the food offered to healthy lean human volunteers at the 
unlimited breakfast per 100g. 
Subjects attended following an overnight fast on two mornings at least two days apart. 
Druce et al. had recently observed that intravenous ghrelin stimulates energy intake in 
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fasting lean and obese healthy volunteers (Druce et al, 2005b). - If ghrelin is to be used as 
a therapy, it is likely to be injected in the fasting and pre-prandial states. Therefore in this 
study, subcutaneous ghrelin infusion was administered to subjects in the fasting state. A 
dose of ghrelin of 3.6nmol/kg was selected from the pilot study (see results section). At 
08: 30 (t--O minutes), subjects received a subcutaneous injection of ghrclin or saline. At 
09: 00 (t--30), breakfast was served, comprising pre-weighed cinnamon loaf or Madeira 
cake (table 5.2) presented in excess, herbal tea or decaffeinated coffee, and water. The 
cakes were cut into small pieces to prevent subjects eating in discrete portions of 
significant size. Subjects were instructed to eat until they felt comfortably full. At 09: 30 
(t--60), by which time all subjects had completed their meal, the remaining food was 
removed and weighed. Ile balance used was a Soehnle Vera food balance (Austin White 
Ltd, Northamptonshire, UK) (detection limit I g). 
During the study, subjects were asked to rate subjective hunger, nausea and fullness on 
100mm visual analogue scales (VAS) (appendix 5) (Flint et al, 2000) at times -15,0,15, 
30 and 60 minutes. A 10ml blood sample was also taken at each time point. Plasma for 
ghrelin assay (Iml) was collected with 501il IM HCL and 10pl 10mglml phenyl methyl 
sulphonyl fluoride (PMSF) as recommended by Linco prior to radioimmunoassay. 
Acylated ghrelin is readily broken down with freeze-thawing and when kept at room 
temperature (Hosoda et al, 2004). The reason for acidifying the samples was that 
acidified acylated ghrelin is relatively resistant to such degradation (Hosoda et al, 2004). 
At t--60, subjects were asked to rate the pleasantness of the meal on a VAS. They were 
then allowed home and were asked to record their food intake for the rest of the day. 
Food diaries were assessed using Dietplan-5 nutritional software (Forestfield Software 
Ltd, West Sussex, UK) by a dietician who was unaware of which treatment had been 
given. 
An intravenous ghrelin bolus of 10lig/kg (3nmol/kg) in human healthy volunteers was 
reported to reduce mean arterial blood pressure by 9mm Hg but without significant 
alteration in heart rate (Nagaya et al, 2001a). In order to determine whether subcutaneous 
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ghrelin would have similar effect, pulse and blood pressure were measured at each time 
point after subjects had filled in their visual analogues scales. 
5.3.3 Honnone assays 
Ghrelin-like immunoreactivity was measured with an established sensitive and specific 
radioimmunoassay (Martin et al, 2004; le Roux et al, 2005b; Druce et al, 2005b). This 
assay measures both acylated and des-acylated (total) ghrelin and without cross-reacting 
with other known gastrointestinal or pancreatic peptide hormones. The antiserurn (SC- 
10368) was obtained from Santa Cruz Biotechnology (Santa Cruz, California, USA) and 
used at a final dilution of 1: 50,000. The 1251 ghrelin was prepared using Bolton & Hunter 
reagent (Amersham International, Chalfont St. Giles, Buckinghamshire, UK) and purified 
by RP-HPLC using a linear gradient from 10 to 40% acetonitrile, 0.05% tri-fluroacetic 
acid (TFA) over 90 minutes. The specific activity of ghrelin label was 48 Bq/finol. The 
buffer was 0.06 M phosphate, pH 7.2, containing 0.3% bovine serum albumin (BSA). 
The sample volume was 25pl and the total volume per assay tube was 0.7 ml. The assay 
was incubated for 3 days at 4C before separation of free and antibody-bound ghrelin by 
charcoal adsorption. This assay detected changes of 25 pmol/l of plasma ghrelin with a 
95% confidence limit, with intra- and inter-assay coefficients of variation of 5.5 and 
10.1% respectively. This radioimmunoassay was developed in this laboratory while the 
study in cancer patients (chapter 4) was ongoing. Therefore, due to in-house experience, 
availability and lower cost, this assay was used rather than the commercial Phoenix 
ghrelin assay employed in chapter 4. 
In order to determine whether ghrelin would reach the circulation in the acylated form an 
assay for acylated ghrelin was performed in addition to that for total ghrelin. Plasma 
acylated ghrelin was quantified using the active ghrelin Linco radioimmunoassay (RIA) 
(product no GHRA-88HK) (Marzullo et al, 2004). The limit of detection of this assay 
was 2pmol/l and the intra- and inter-coefficients of variation were 7.5% and 13.5% 
respectively. In order to assess the bioactivity of ghrelin administered subcutaneously, 
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plasma GH was analysed with the Advantage automated chemi-luminescent immunoassay 
(Nichols Institute Diagnostics). 
5.3.4 Statistical analysis 
Patient characteristics are presented as mean ± SD. All results are presented as mean 
SEM. In the rodent study, treatment groups were compared using a one-way ANOVA. 
The primary outcome of the human subcutaneous injection study was energy intake at the 
unlimited breakfast. Comparisons between ghrelin and saline injection days for energy 
intake, VAS, plasma ghrelin levels, pulse and blood pressure readings were made using 
paired Mests. Mean arterial blood pressure (MAP) was calculated using the standard 
formula (Ganong, 2003): 
MAP 1/3 systolic BP + 2/3 diastolic BP 
The effect of ghrelin on energy intake in the men and the women in the study was 
compared using an unpaired West (n=8 per group). This subgroup analysis should 
however be viewed with caution, as the study was powered for 16 subjects. In all cases 
P<0.05 was considered to be statistically significant. 
183 
5.4 Results 
5.4.1 Acylated and des-acylatedghrelinfeeding studies in mice 
Acylated ghrelin (AG) stimulated feeding in mice in the fed state (as previously reported 
(Asakawa et al, 2001)). Des-acylated ghrelin (DAG) had no effect on food intake in the 
fed state, nor did it attenuate the stimulatory feeding effect of ghrelin (figures 5.1a and 
5.2a). The combined AG+DAG treatment stimulated feeding in the fed state similarly to 
AG alone. 
In the fasting study, PYY3-36, the positive control, significantly inhibited cumulative food 
intake up to 6 hours post injection. In contrast, AG stimulated cumulative food intake in 
the, fasted mice for up to 6 hours following injection. DAG alone had no significant 
effects on food intake. During the first hour of re-feeding, the combined AG+DAG 
treatment was associated with a similar increase in re-feeding as seen with AG alone 
(figure 5.1b). However, two hours post-injection, des-acylated ghrelin significantly 
attenuated the increase in cumulative food intake seen with acylated ghrelin alone (figure 
5.2b) (P<0.05). At four and six hours post injection, AG alone significantly increased 
food intake, and DAG alone and AG+DAG did not lead to significant alterations. 
However comparisons of AG group with the combined DAG+AG group were not 
statistically significant (Food intake (0-6h) (g) following IP saline 2.18 ± 0.05, PYY 1.68 
± 0.15, AG 2.52 ± 0.08, DAG 2.18 ± 0.06, AG+DAG 2.29 ± 0.08); P<0.05 for PYY vs. 
saline and AG vs. saline. P=0.2 for DAG+AG vs. AG). 
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Figure 5.1 
Food intake in the first hour in mice following IP injection of saline, 0.3nmol/g acylated 
ghrelin (AG), 0.3nmol/g des-acylated ghrelin (DAG), 0.3nmol/g acylated ghrelin + 
0.3nmol/g des-acylated ghrelin (AG+DAG) and 0.03nmol/g PYY3-36 (PYY) in the a) fed 
and b) fasted states. **P<0.005 vs. saline. 
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Figure 5.2 
Food intake in the first two hours following injection of saline, 0.3nmol/g acylated ghrelin 
(AG), 0.3nmol/g des-acylated ghrelin (DAG), 0.3nmol/g acylated ghrelin + 0.3nmol/g 
des-acylated ghrelin (AG+DAG) and 0.03nmol/g PYY3-36 (Pyy) in the in the a) fed and 
b) fasted states. * P<0.05 vs. group indicated. **P<0.005 vs. saline. 
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5.4.2 Pilot human injection study 
In the pilot study, the maximum dose of ghrelin injected subcutaneously was 3.6nmol/kg. 
One of the subjects in the second group left the study after two visits due to a change in 
personal circumstances. No side effects were observed or reported at any dose of ghrelin 
administered. A trend for an increase in food intake was observed at a dose of 3.6nmol/kg 
and therefore this dose was selected for the randoMised controlled study (figure 5.3). 
Energy intake (KJ) 
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Figure 53 
Energy intake at breakfast from pilot group 2 of lean healthy subjects (n=4) (Y-axis) 
against dose of subcutaneous ghrelin (X-axis). Each line represents an individual subject. 
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5.4.3 Randomised controlled human subcutaneous ghrelin study 
Fasting ghrelin levels were comparable on the saline and ghrelin injection days (total 
ghrelin 176 ± 16.3 and 192± 11.4 pmol/l respectively, P--0.1, acylated. ghrelin levels 36.7 
± 3. lpmoill and 34.7 ± 2. lpmol/l respectively, P =0.7). The ratio of acylated to total 
fasting ghrelin was approximately 1: 5. Endogenous ghrelin decreased after breakfast on 
the saline injection day (total ghrelin fell from 198 ± 22.1 pmol/l to 161 ± 15.5 pmol/l P 
<0.05, and acylated ghrelin from 34.5: 1: 3.2 pmol/l to 29.2 ± 2.1 pmol/l, P <0.05). On the 
ghrelin day, total ghrelin peaked 15 minutes after subcutaneous injection at 988 ± 89.4 
pmol/l. Acylated ghrelin peaked 30 minutes after injection at 355 1 66.3pmol/I (figure 
5.4a). The ratio of acylated to total ghrelin following ghrelin injection was approximately 
1: 3. Subcutaneous ghrelin stimulated GH release, confirming bioactivity. GH peaked at 
30 minutes following ghrelin injection: saline day 5.6 ± 1.7 mIU/1, ghrelin day 126 ± 18.3 
mIU/1, *P<0.05 (figure 5.4b). 
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Figure 5.4 
a) Mean active and total plasma ghrelin levels and b) mean growth hormone following 
ghrelin or saline injection in healthy lean human volunteers following subcutaneous 
ghrelin or saline injection, *P<0.001 vs. saline. 
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Energy intake at the unlimited breakfast was increased by 27% following ghrelin injection 
(Energy intake [KJ]: saline 4230 ± 607, ghrelin 5076 ± 69 1, P=0.04) (figure 5.5). Twelve 
of the sixteen volunteers ate more with ghrelin than with saline infusion. There was no 
significant alteration in energy intake for the rest of the day following ghrelin injection 
(Energy intake [KJ]: saline day 6697 ± 860, ghrelin day 6630 ± 727, P=0.9). Subgroup 
analysis of the data revealed that the men ate more than the women on the saline control 
day (5620 ± 943 vs. 2841 ± 378 U, P<0.05). However similar percentage increases in 
food intake were observed following ghrelin injection in both sexes (% increase energy 
intake: men 23 ± 14%, women 30 ± 14%, P=0.7). 
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Figure 5.5 
Percentage increase in energy intake at an unlimited breakfast meal following 
subcutaneous ghrelin injection in human healthy lean volunteers. Energy intake following 
saline injection is shown at baseline at 100%. *P<0.05. 
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No adverse effects were observed by the investigators or reported by the subjects. There 
were no significant differences in the VAS nausea, hunger or fullness scores following 
saline and ghrelin injection (table 5.3). However, subjects found the meal more pleasant 
following ghrelin injection (mean score [mm]: ghrelin day 81 ± 4, saline day 70 ± 4, P 
=0.03). 
Saline injection Ghrelin injection P value 
Hunger score (mm) 69 ±6 72 ±5 0.56 
Nausea score (mm) 11 ±5 13 ±4 0.58 
Full score (mm) 17 ±5 14 ±4 0.31 
Table 5.3 
Hunger, nausea and subjective fullness scores 30 minutes after ghrelin or saline injection 
prior to the unlimited breakfast in lean healthy volunteers. Subjects were asked to rate 
these measures on visual analogue scales ranging between 0 to 100 mm. 
After saline injection the mean change in systolic blood pressure from baseline to 30 
minutes after injection was 0.9 ± 1.9 mmHg to an absolute systolic pressure of 1] 7±2.7 
mmHg. After ghrelin injection the mean change was -5.4 ± 2.8 mmHg to 108 ± 3.9 
mmHg (P<0.05 vs. saline day). Although there was no significant changes in diastolic 
blood pressure, there was a significant reduction in mean arterial blood pressure (P=0.04). 
As in previous studies (Nagaya el al, 2001 a; Enomoto el al, 2003), no alteration in heart 
rate was observed following ghrelin injection (table 5.4). 
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Saline injection Ghrelin injection P value 
Heart rate (beats/min) -4.5 ±2.6 -5.7 ± 2.9 0.6 
Systolic BP (mmHg) 0.9± 1.9 -5.4+2.8 0.03 
Diastolic BP (mmHg) 0.2 ± 2.0 -3.8 ± 1.8 0.19 
Mean arterial BP (mmHg) -0.59 ±- 1.32 -5.17 ± 1.6 0.04 
Table 5.4 
Change in heart rate, systolic, diastolic and calculated mean arterial blood pressure 
readings from baseline at 30 minutes following saline or ghrelin injection in lean healthy 
human volunteers. 
5.5 Discussion 
These results suggest that ghrelin increases food intake in healthy human volunteers 
following subcutaneous administration. Subsequently Wynne et aL reported that 
subcutaneous ghrelin increases energy intake in malnourished patients with chronic renal 
failure on peritoneal dialysis (Wynne et al, 2005a). Therefore this practical route of 
administration has potential therapeutic benefits. 
It was possible that significant breakdown of acylated to des-acylated ghrelin would occur 
in the tissues following subcutaneous injection. Although des-acylated ghrelin has no 
binding affinity for the growth hormone secretagogue receptor (GHSR-1a) (Kojima et al, 
1999), the effect of des-acylated ghrelin on food intake had not been reported when the 
current study was designed. The effect of des-acylated ghrelin on feeding was 
investigated in order to determine whether any breakdown of acylated to des-acylated 
ghrelin in the tissues might alter the feeding response to acylated ghrelin administered 
subcutaneously. Acylated ghrelin stimulated feeding in both the fed and fasted states in 
mice, although the relative increase to saline was lower in the fasted than the fed state. 
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The effect of peripheral ghrelin administration to rodents in the fasted state had not been 
previously reported. Des-acylated ghrelin alone had no effect on feeding in the fed or 
fasted states. While these rodent studies were in progress, Asakawa et al. reported that 
intracerebroventricular (ICV) and peripheral administration of des-acylated (DAG) 
ghrelin inhibited feeding in fasted mice (Asakawa et al, 2005). In the current rodent 
study, a higher dose of IP des-acylated ghrelin was given that that administered by 
Asakawa et aL (approximately 7.5nmol vs. 3nmol Per mouse) and therefore the absence of 
a feeding effect associated with DAG is unlikely to be explained by differences in doses. 
When DAG was co-administered with acylated ghrelin (AG), no effect on the feeding 
response to ghrelin was observed in the fed state. However when administered to mice in 
the fasted state, DAG + AG attenuated the feeding effect of ghrelin from 2 to 6 hours post 
injection. These results suggest the possibility that the presence of des-acylated ghrelin in 
the circulation, where it is present in higher concentration than AG (Akamizu et al, 2005), 
may modulate the physiological feeding effect of acylated ghrelin. Des-acylated ghrelin 
has no binding affinity for the GHS-Rla (Kojima et al, 1999), the receptor through which 
ghrelin is thought to increase feeding and GH release. Therefore any alteration in the 
feeding response to des-acylated ghrelin is likely to be mediated via an alternative 
receptor. From a therapeutic perspective, this study suggests that ghrelin needs to reach 
the circulation in the acylated form for it to stimulate food intake. 
In the subcutaneous ghrelin injections study in human lean healthy volunteers, the dose of 
ghrelin was chosen from the pilot study which suggested that a subcutaneous dose of 
3.6nmol/kg was likely to stimulate food intake. Given that there were no reports of the 
effects of subcutaneous ghrelin on energy intake in the literature when this study was 
designed, the dose was chosen primarily from the pilot study. Subcutaneous ghrelin at a 
similar dose of 10mg/kg (3nmol/kg) had been reported to lead to a significant increase in 
the cardiac left ventricular fraction without adverse effects, although food intake was not 
assessed (Enomoto et al, 2003). 
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Plasma samples from the main randomised controlled study of subcutaneous ghrelin 
versus saline were assayed for acylated and total ghrelin in order to determine whether 
acylated ghrelin increased in the circulation following subcutaneous injection. 
Tbeoretically the difference between these levels should represent des-acylated ghrelin, 
although comparison is limited between different assays using different antibodies. In the 
baseline levels of fasted subjects, the ratio of acylated to total ghrelin was 1: 5. Marzullo 
et al. have reported a lower ratio of acylated to total ghrelin of approximately 1: 15 
measured with radioimmunoassays (Marzullo et al, 2004). Recently Akamizu et aL have 
reported a 1: 5 ratio, as in the current study, using enzyme linked immunosorbant assays 
(ELISA) (Akamizu et al, 2005). 
On the saline control day, a significant fall in plasma total ghrelin levels following 
breakfast was observed in keeping with previously published work (Cummings et al, 
2001). There was also a similar decrease in acylated ghrelin levels following the meal. 
The response of acylated ghrelin to consumption of food had not been previously 
reported. It should be noted that the breakfast offered to the subjects was relatively high 
in simple carbohydrate compared with the test meals offered to volunteers and patients in 
chapters 3 and 4. Breakfast high in simple carbohydrate has been reported to lead to 
significantly greater reduction in total circulating ghrelin levels compared with an 
isocaloric meal high in complex carbohydrate (Blom et al, 2005). Thus the high simple 
carbohydrate component of the breakfast in the current study may have contributed to the 
fall in circulating ghrelin levels observed on the saline infusion day. 
Following subcutaneous ghrelin injection there were significant increases in acylated and 
total ghrelin levels., The rise in GH observed is further evidence of the bioactivity of 
subcutaneous ghrelin. Plasma acylated ghrelin levels had risen by 15 minutes following 
subcutaneous injection and were similarly elevated at 30 minutes. This suggests that 
ghrelin injection 30 minutes before a meal might be the optimal time for stimulation of 
food intake. This would be a similar therapeutic pattern to pre-meal short acting insulin 
injections in patients with diabetes. 
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The increase in energy intake following subcutaneous ghrelin injection was of a similar 
magnitude to that reported following intravenous ghrelin infusion. Such comparison 
should however be made with caution because of differences in the administration route 
and subsequent timing of the meal. Wren et al. reported a 28%* increase in food intake 
following a total intravenous dose of 1.4nmoVkg (Wren et al, 2001a). In the present 
study, 3.6nmol/kg ghrelin was administered via subcutaneous injection and a comparable 
27% increase in food intake was observed. The feeding response to ghrelin (percentage 
increase in energy intake on ghrelin injection day relative to the saline injection day) 
appeared to be similar in the men and women in the current study. However this subgroup 
analysis with only 8 men and 8 women should be viewed with caution. 
Looking at the visual analogue scores in the men and women together, there were no 
significant alterations in subjective perceptions of hunger or fullness. In contrast, Wren et 
al. reported significant increases in hunger scores with intravenous ghrelin in healthy 
human subjects. It is possible that only the more sustained elevation in plasma ghrelin 
associated with intravenous infusion leads to increases in subjective hunger. A further 
study in which both subcutaneous and intravenous ghrelin and saline were administered to 
the same subjects would be required to investigate this formally. In the current study, as 
in the intravenous ghrelin study in cancer patients (chapter 4), there was an increase in the 
perceived palatability of the meal following ghrelin treatment. An enhanced appreciation 
of the palatability of a meal could contribute to the increase in energy intake following 
ghrelin injection. 
Food choice may influence appetite and satiety, as explained in chapter 3 in which several 
options were available at the unlimited meal. Alterations in macronutrients could have 
confounded the total energy intake results. Therefore in this study only one food was 
presented to the subjects at the unlimited meal (cinnamon loaf or Madeira cake) and thus 
the proportions of macronutrients of the varying sized breakfasts were fixed, albeit with a 
relatively high proportion of carbohydrate. A finther study would be required to assess 
the effect of subcutaneous ghrelin on macronutrient preference. 
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The high content of carbohydrate and simple sugars in the food offered could have led to 
reduced satiety following the meal (Fischer et al, 2004), but should have been equivalent 
between the infusion days. A ftirther limitation is the relatively small sample size of 16 
volunteers. Thus these results should be viewed with caution. It is however reassuring 
that the energy intake results of the current study appear broadly in line with previous 
ghrelin studies (Wren et al, 2001a; Neary et al, 2004; Wynne et al, 2005a; Druce et al, 
2005b). 
There were no reported or observed side effects with subcutaneous ghrelin or saline on 
study days. No significant differences in the visual analogue scores for nausea were 
observed between infusion days. There were no instances of a clinically significant 
decrease in blood pressure or symptomatic hypotension. However, analysis of the blood 
pressure recordings revealed a small reduction in mean arterial blood pressure following 
subcutaneous ghrelin but no significant alteration in heart rate, as previously reported 
following intravenous ghrelin (Nagaya el al, 200 1 a). 
Ghrelin and its receptor, the GHS-R are expressed in the vasculature and the heart 
(Kojima et al, 2001; Howard et al, 1996). Thus the GHS-R may mediate changes in blood 
pressure in addition to altering GH and appetite. An intra-arterial infusion of ghrelin 
resulted in an increase in forearm blood flow which was not blocked with pre-treatment 
with a nitric oxide inhibitor (Okumura et al, 2002). Thus ghrelin may have a direct 
vasodilatory effect which is independent of nitric oxide. Ghrelin administration has also 
been reported to improve cardiac function by increasing the left ventricular ejection 
fraction (LVEF) in patients with heart failure (Nagaya et al, 2001b) and in healthy human 
volunteers (Enomoto et al, 2003). The mechanism of ghrelin's cardiac effects may be, at 
least in part, through its stimulation of GH. Growth hormone has been reported to up- 
regulate cardiac sarcoplasmic reticulum calcium-ATPase activity and to enhance 
myocardial contractility (Taj ima et al, 1999). 
Analysis of the food diaries of the current subcutaneous study revealed that, as with 
intravenous ghrelin (Wren et al, 2001a) (chapter 4), the increase in food intake observed 
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at the unlimited meal was not sustained for the rest of the day. However there was no 
evidence of a subsequent reduction in energy intake to compensate for the increased food 
intake at the breakfast meal. Further work is needed to determine the effect of repeated 
ghrelin injections on food intake and body weight in humans. 
This study suggests that acute subcutaneous administration of ghrelin stimulates food 
intake in man. This work can now lead to further trials in patients in whom anorexia is a 
significant impediment to recovery. 
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Chapter 6 
Ghrelin does not Stimulate Food Intake in 
Patients with Surgical Procedures 
ý involving Vagotomy 
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6.1 Introduction 
Patients who have had gastric or oesophageal surgery with transection of the vagus nerve 
frequently suffer from loss of appetite and loss of weight (King et al, 1987). In a series of 
patients who had Ivor Lewis oesophagogastrectomy, 60% lost weight whereas only 40% 
suffered from dysphagia (King et al, 1987). This disparity suggests that mechanical 
obstruction alone may not fully explain the weight loss seen following such surgery. In 
the intravenous ghrelin study in cancer patients with loss of appetite (chapter 4), patients 
with gastric surgery, including patients with vagotomy were excluded. Ghrelin is 
primarily secreted by the stomach and following gastrectomy plasma ghrplin levels are 
reduced by at least 50% (Asakawa et al, 2001). Therefore patients with gastric surgery 
might have had an altered response to ghrelin and this was the reason for their exclusion. 
In 2001 it was reported that administration of ghrelin into the inferior vena cava of mice 
resulted in marked suppression of gastric vagal afferent discharge rates. In addition 
truncal vagotomy prevented feeding stimulation by intraperitoneal ghrelin (Asakawa et al, 
2001). However in these studies, there was marked reduction of food intake by vagotomy 
per se, and no positive controls to demonstrate that vagotomised mice were able to 
respond to a vagus-independent orexigenic challenge. Thus the lack of response to 
systemic ghrelin may have been due to non-specific ill health. 
Subsequently, Date et al, reported that intraperitoneal ghrelin did not stimulate feeding in 
rats with surgical and chemical truncal vagotomy (Date et al, 2002). In contrast the 
feeding response to ICV ghrelin remained intact. Vagotomised animals receiving 
peripheral ghrelin displayed a significant but attenuated GH response compared with 
sham-operated controls. These results suggest that ghrelin's feeding effects in rodents are 
mediated via the vagus. These authors also reported that intravenous ghrelin 
administration to intact rats suppressed vagal afferent activity. GHS-R mRNA expression 
was demonstrated in the nodose ganglion, while autographs demonstrated accumulation of 
ghrelin binding sites proximal to the site of vagal ligation, suggesting that the GHS-R is 
transported distally along vagal neurones. CNS signalling following peripheral ghrelin 
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administration to rodents appears to be dependent on the vagus nerve, as the increase in c- 
fos staining observed in sharn-operated rats was not observed in the vagotomised rats 
(Date et al, 2002). 
In the past vagotomy was performed in humans as an isolated procedure in order to reduce 
gastric acid secretion for the treatment of gastrointestinal ulcers. However, following the 
development of the proton pump inhibitors which effectively reduce gastric acid secretion 
pharmacologically, such surgery is no longer routinely performed. Vagotomy is currently 
performed as part of an oesophageal or total gastric resection for malignancy because 
transection of the oesophagus results in complete anterior and posterior truncal vagotomy. 
In 2004 an intravenous ghrelin bolus injection of 0.2[tg/kg (60nmol/kg) to human patients 
who had undergone vagotomy was reported to lead to a significant rise in GH which was 
of similar magnitude as observed in non-vagotomised controls (Takeno et al, 2004). 
Subsequently it was'reported that the rise in GH following an intravenous ghrelin boluses 
of 0.1 and Ipg/kg (30 and 300nmol/kg) to patients with total gastrectomy and vagotomy 
were significantly greater than in control subjects (Popovic et al, 2005). This suggested 
that patients with gastrectomy might have increased sensitivity to exogenous ghrelin. 
However in neither of these human studies was the effect of ghrelin on energy intake 
investigated. 
In order to investigate the hypothesis that the feeding effect of peripheral ghrelin is 
dependent upon the vagus nerve in humans, a double-blind randomised controlled study 
was performed in patients with vagotomy, comparing energy intake following ghrelin and 
saline infusion. 
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6.2 Methods 
6 2.1 Erperimental subjects 
All studies were performed according to the principles of the Declaration of Helsinki and 
approved by the local research and ethics committee (reference number 2002/6316). The 
aim was to recruit two groups of patients - patients with total gastrectomy and/or 
oesophagectomy with vagotomy, and patients with partial gastrectomy with their vagus 
nerve intact. Written informed consent was obtained from all subjects. Exclusion criteria 
included pregnancy, chronic medical illness likely to interfere with the study, and surgery, 
radiotherapy or chemotherapy within the past month. 
Nine men and one woman were recruited. Three patients were excluded prior to the 
commencement of the study due to significant co-morbidity. There was evidence of a 
previously undiagnosed anterior myocardial infarction on the ECG of one patient and two 
patients suffered from dementia which prevented them from giving adequate informed 
consent to participate. The remaining seven patients (six men and one woman) entered 
and completed the study (tables 6.1 and 6.2). All patients had undergone transection of 
anterior and posterior trunks of the vagus nerve as part of gastric or oesophageal surgery 
for proven or suspected malignancy. Patients 1,2 and 3 had undergone total gastrectomy. 
All patients were operated on by a single surgeon. The mean time between surgery and 
infusions was 13 ± 16 months (mean ±SD). Themean agewas 63 ± 11 years and mean 
BMI 21.2 ± 2.9 kghn2. All patients had lost weight (mean 16 ± 9kg) from their pre-cancer 
weight at the time of the study. No patients with partial gastrectomy and their vagus nerve 
intact were recruited to the study. 
The highest content of ghrelin is present in the fiandus of the stomach (Date et al, 2000), 
and patients with total gastrectomy have been reported to have only 35% of the circulating 
ghrelin levels compared with control subjects (Ariyasu el al, 2001). In a subsequent 
study in gastric cancer patients, I hour following partial gastrectomy ghrelin levels were 
reported to be 39% of their pre-operative levels (Jeon et al, 2004). By 7 days, ghrelin 
levels in these patients had recovered to 88% of their pre-operative levels. In contrast, in 
patients who had undergone total gastrectomy, ghrelin levels were 29% of the pre- 
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operative levels I hour after surgery but only 30% of the pre-operative levels after 7 days 
(Jeon et al, 2004). Thus patients recruited with total gastrectomy were expected to have 
lower circulating ghrelin than those with partial gastrectomy or oesophagectomy. 
Therefore subgroup analysis on ghrelin levels and the GH response and energy intake 
response to ghrelin infusion was performed in order to compare patients with total 
gastrectomy and patients with oesophagectomy or partial gastrectomy. 
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6Z2Materials 
Human ghrelin was purchased from Penninsula Laboratories (Merseyside, UK) and 0.9% 
saline from Bayer (Haywards Heath, UK). The Limulus Amoebocyte Lysate assay test 
for pyrogen was negative (Karplus et al, 1987) and the peptide was sterile following 
culture for 7 days. 
6.2.3 Infusion protocol 
Fasted subjects had two intravenous carmulae inserted at 09: 00; one for the infusion and 
the other for blood sampling. Intravenous infusions of ghrelin or saline were started at 
10: 00 (t--O minutes). Each subject received inftision of saline, ghrelin Ipmol/kg/min or 
ghrelin 5pmol/kg/min on three separate days at least 48 hours apart in a double-blind 
randomised cross-over design. Continuous intravenous infusion rates were chosen from 
previous studies. Ghrelin 5pmol/kg/min had been reported to increase energy intake in 
healthy volunteers (Wren et al, 200 1 a) and in cancer patients with their vagus nerve intact 
(chapter 4) (Neary et al, 2004). However, patients with gastrectomy and associated 
reduction in endogenous ghrelin (Asakawa, et al, 2001) might have enhanced sensitivity to 
exogenous ghrelin. Hence a lower rate of Ipmol/kg/min was also included. Recently 
Druce et al. reported that ghrelin (5pmol/kg/min) stimulated energy intake in lean and 
obese volunteers in the fasted state (Druce et al, 2005b). Tberefore in the current 
investigation, a fixed breakfast was not included in the protocol and ghrelin was 
administered in the fasting state in order to make the visit as short and simple as possible 
for the patients. 
The infusion duration was 120 minutes, as had been administered to the cancer patients. 
After 90 minutes, lunch was served, comprising pre-weighed Sainsbury's spaghetti 
bolognaise (table 6.3) presented in excess, and water. A Soehnle Vera food balance 
(Austin White Ltd, Northamptonshire, UK) (detection limit Ig) was used to weigh the 
food before and after presentation to the subjects. As in the subcutaneous ghrelin study 
(chapter 5), only one food choice was available to subjects to prevent subject 
macronutrient preference from confounding the energy intake results of the study. 
Subjects were asked to 'eat until they were comfortably full'. All subjects finished eating 
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within 20 minutes. The remaining food was weighed after the meal and energy intake 
calculated. Venous blood was collected at -60,0,60,90,120 and 150 minutes. Plasma 
was separated following centrifugation and stored immediately at -20"C. Patients were 
asked to complete visual analogue scales (VAS) (possible scores 0-100 mm) rating 
hunger, sickness and satiety at baseline (t = 0), before lunch (t = 90) and after lunch (t = 
150) (appendix 5) (Flint et al, 2000). Positions on these scales were measured by an 
observer unaware of the treatment administered. As explained in chapter 5, ghrelin has 
been reported to reduce mean arterial blood pressure in healthy volunteers (Nagaya et al, 
200 1 a), and the author wished to determine whether patients with vagotomy would have a 
similar cardiovascular response. Therefore pulse and blood pressure were measured every 
30 minutes. Mean arterial blood pressure (MAP) was calculated according to the formula 
(Ganong, 2003): 
MAP (mmHg) = 1/3 Systolic BP (mmHg) + 1/3 Diastolic BP (mmHg). 
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Spaghetti bolognaise 
per I OOg 
Energy (KJ) 563 
Protein (g) 7.8 
Fat (g) 5.6 
Saturated fatty acids (g) 1.8 
Mono-unsaturated (g) 3.3 
Poly-unsaturated (g) 0.5 
Carbohydrate (g) 13.1 
Starch (g) 12.3 
Total sugars (g) 0.8 
Dietary fibre (g) 0.4 
Table 6.3 
Macronutrient composition (per 100g) of the Sainsbury's spaghetti bolognaise provided at 
the buffet meal. 
The original plan was that the-patients with partial gastrectomy would act as controls, and 
be infused with ghrelin alongside patients with total gastrectomy/oesophagectomy and 
vagotomy. However as the study neared completion, it became apparent that few if any 
such subjects would be recruited. Therefore a group of healthy volunteers was also 
recruited. Although permission had not been granted from the ethics committee to infuse 
them with ghrelin, blood samples could be taken from them before and after a meal. Nine 
volunteers (5 men and 4 women) of mean age 29 ±5 years (mean ± SD) and BMI 23.1 ± 
1.7 k g/M2 gave blood samples at 09: 00 following an'OVemight fast. They received a fixed 
breakfast of orange juice, decaffeinated tea or coffee and cinnamon loaf (table 6.4) which 
was calorie matched to the mean energy intake at the buffet lunch of the patients with 
vagotomy. Sixty minutes later, a post-prandial blood sample was taken. Blood samples 
were immediately centrifuged and separated and 'plasma stored at -20'C until 
radioimmunoassay. 
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Cinnamon loaf 
(159g) 
Orangejuice 
(250ml) 
Total 
Energy (KJ) 2422 383 2805 
Protein (g) 10.2 1.3 11.4 
Fat (g) 21.0 0.3 21.2 
of which saturates (g) 7.3 0.0 7.3 
monounsaturates (g) 8.9 0.0 8.9 
polyunsaturates (g) 3.3 0.0 3.3 
Carbohydrate (g) 86.7 22.0 108.7 
starch (g) 41.3 0.0 41.3 
total sugars (g) 45.4 22.0 67.4 
Fat (g) 21.0 0.3 21.2 
Fibre (g) 2.4 0.0 2.4 
Table 6.4 
Macronutrient content of the fixed breakfast given to the healthy volunteers. 
6.2.4 Hormone assays 
All samples were assayed simultaneously and in duplicate to eliminate the effect of inter- 
assay variation. Ghrelin-like immunoreactivity was measured with the specific and 
sensitive radioimmunoassay using antisera (SC-10368) described in chapter 5. Using the 
standard sample volume of 251il in a pilot assay, while samples during ghrelin infusion 
could be quantified, basal plasma ghrelin levels in several patients with gastro- 
oesophagectomy were below the lower limit of detection of the assay. Therefore in the 
main assay two volumes of plasma sample were assayed: one of 25 and one of I 00pl. The 
total volume per tube was 0.7 ml. Plasma PYY and GLP- I concentrations were quantified 
using established in-house radioimmunoassays, and antibodies as described in chapter 3 
(Adrian et al, 1985a; Kreymann et al, 1987). The limits of detection and intra- and inter- 
coefficients of variation of the ghrelin, PYY and GLP-I assays are listed in table 6.5. 
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Growth hormone (GH) was measured by Advantage automated chemi-luminescent 
immunoassay (Nichols Institute Diagnostics). 
Detection limit 
(95% confidence) 
Intra-assay co- 
efficient of variation 
Inter-assay co- 
efificient of variation 
Ghrelin 25 pmol/1 5.5% 10.1% 
pyy 2.5 pmol/l 5.8% 9.8% 
GLP-I 3 pmol/l 6.1% 10.0% 
Table 6.5 
Detection limits and intra- and inter-assay coefficients of variation of the ghrelin, PYY 
and GLP-l radioimmunoassays. 
6.2.5 Statistical analysis 
Patient characteristics (age, BMI and time to surgery) are presented as mean ± SD. 
Results are expressed as means d: SEM. Energy intake, plasma ghrelin and GH 
concentrations, and visual analogue scales were compared using paired t-tests. Ghrelin 
levels between the patients and the healthy volunteers were compared using unpaired t- 
tests. Subgroup analysis was performed between vagotomy patients with total 
gastrectomy (n=3) and vagotomy patients with oesophagectomy and partial gastrectomy 
(n=l) using unpaired t-tests. However in view of the very small numbers in these 
subgroups, this analysis should be viewed with caution. In all cases P<0.05 was 
considered to be statistically significant. 
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6.3 Results 
No adverse events were observed or reported on any infusion day. 
Baseline fasting plasma ghrelin levels were similar on all infusion days. Fasting ghrelin 
levels were significantly lower in the vagotomy patients than in the fasting samples of the 
healthy volunteers (Plasma ghrelin pmol/l: vagotomy patients 295 1 50, healthy 
volunteers 680 ± 17; P<0.0001). The vagotomy patients who had undergone total 
gastrectomy had significantly lower fasting ghrelin levels than the vagotomy patients who 
had undergone oesophagectomy or partial gastrectomy (Plasma ghrelin pmol/l: vagotomy 
patients with total gastrectomy (n=3) 106 1 18, vagotomy patients with oesophagectomy 
(n--3) or partial gastrectomy (n= 1) 437: 1: 54; P<0.0005). 
On the saline infiision day, there was no significant change in the plasma ghrelin of the 
vagotomy patients following the buffet lunch. In contrast, the usual post-prandial fall in 
plasma ghrelin was observed 60 minutes after the meal in the healthy volunteers (figure 
6.1). Plasma ghrelin was significantly elevated in the vagotomy patients with ghrelin 
infusion at ]Pmol/kg/min compared with saline and increased further with ghrelin infusion 
at 5pmol/kg1min (figure 6.2). 
A significant and dose-dependent rise in GH was associated with ghrelin infusion 
confirming that the ghrelin was biologically active (GH iU/I at 90 min: saline 1.2 d: 0.5; 
ghrelin Ipmol/kg/min 32.6 ± 6.2; ghrelin 5pmol/kglmin 60.9 :h 12.7; P<0.005) (figure 
6.3). Subgroup analysis revealed no significant differences in baseline GH or GH in 
response to either dose of ghrelin between patients with total gastrectomy and 
oesophagectomy or partial gastrectomy (table 6-6). 
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1000 
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0 
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Figure 6.1 
Plasma ghrelin levels in the fasting state (clear bars) and 60 minutes after a meal (hashed 
bars) in patients with vagotomy and healthy volunteers. * P<0.0001. 
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Figure 6.2 
Plasma ghrelin with after 90 minutes intravenous infusion of saline, I and 5pmol/kg/min 
ghrelin in patient with vagotomy. *P<0.05. 
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Figure 6.3 
Plasma GH at 90 minutes with saline, I and 5pmol/kg/min ghrelin infusion in patients 
with vagotomy. *P<0.05. 
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saline ghrelin ghrelin 
lpmol/Wmin 5pmoVkg/min 
Total gastrectomy 0.9 ± 0.5 W/l 32.5 ± 12.9 W/l 55.2 ± 25.7 iU/I 
patients 
Patients with 1.5 ± 0.9 W/l 32.6 ± 7.4 W/l 65.2 ± 15.1 M/I 
oesophagectomy or 
partial gastrectomy 
P value comparing 0.60 1.00 0.74 
patient subgroups I I I 
Table 6.6 
Subgroup analysis of GH levels at 90 minutes immediately prior to the buffet meal with 
saline, Ipmol/kg/min ghrelin and 5pmol/kg/min ghrelin infiisions between patients with 
total gastrectomy (n=3) and patients with oesophagectomy or partial gastrectomy (n=4). 
Plasma PYY concentrations were similar during all three infusions (PYY (Pmol/1) at 90 
min: saline 22.6 13.5, ghrelin Ipmol/kg/min 23.3 ± 3.5, ghrelin 5pmol/kg/min 23.7 ± 
5.5). There were also no significant differences in GLP-I concentrations between 
infusions (GLP-1 (pmol/1) at 90 min: saline 53.0 ± 9.0, ghrelin Ipmol/kg/min 54.9: L 10.5, 
ghrelin 5pmol/kg/min 57.7 ± 14.1). As expected plasma PYY and GLP- I increased on all 
infusion days following the buffet lunch (figure 6.4). 
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PYY (pmol/l) 
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GLP-1 (pmol/1) 
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Figure 6.4 
A) PYY and B) GLP- I plasma levels immediately before (clear bars) and 60 minutes after 
the beginning of the buffet lunch (hashed bars). *P<0.05 vs. plasma level before lunch. 
There were no statistically significant differences in energy intake between the three 
infusion days (figure 6.5). (Energy intake (KJ): saline 2805 ± 812, ghrelin Ipmol/kg/min 
2486 ± 767, ghrelin 5pmol/kg/min 2382 543; P=NS) (Percentage change from saline 
infusion day: ghrelin lpmol/kg/min -4 11%, ghrelin 5pmol/kg/min -5 ± 8%). The 
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patients with gastrectomy tended to eat less on the saline control day than the patients with 
oesophagectomy or partial gastrectomy, although this did not reach statistical significance 
(P--0.08). In both subgroups there was no significant alteration in energy intake with 
ghrelin infusion (table 6.7). 
energy intake saline day 
120 
100 
80 
60 
40 
20 
0 
T- -ý:: F 
saline I 5 
Ghrelin (pmoUkg/min) 
Figure 6.5 
Percentage alteration in buffet meal energy intake following infusion of 0.9% saline, 
I pmol/kg/min ghrelin and 5pmol/kg/min ghrelin. Food intake on the saline day is shown 
as baseline at 100%. 
Analysis of the VAS revealed no significant differences in hunger or sickness ratings 
between the three infusion days (hunger score at 90 min (min): saline 70 ± 9; ghrelin 
I pmol/kg/min 62 ± 9; ghrelin 5pmol/kg/min 61 ± 10) (sickness score at 90 minutes (min) 
saline 6.0 ± 1.4; ghrelin Ipmol/kg/min 6.01 1.5; ghrelin 5pmol/kg/min 5.8 ± 1.5). While 
there were no differences in how full subjects felt before the meal, patients reported 
feeling less full after the meal on the 5pmol/kg/min ghrelin infusion day (satiety score 
(min) at 150 min: saline 65 ± 10; ghrelin 5pmol/kg/min 56 ± 11; P<0.05). There was no 
difference in the meal appreciation score following the buffet lunch (Meal appreciation 
score (mm): saline 68 ± 9, ghrelin I pmol/kg/min 71 ± 8, ghrelin 5 pmollkg/min 68 ± 8; 
P--NS for ghrelin I pmoVkg/min and ghrelin 5pmol/kg/min vs. saline). 
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saline ghrelin P value ghrelin P value 
Ipmol/kgtmin Ipmol/kg/min 5pmol/kg/min 5pmol/kgImin 
vs. saline vs. saline 
Total gastrectomy 1203 ± 148 1462: 1: 323 KJ 0.50 1376 ± 189 KJ 0.51 
patients KJ 
Patients with 4006 ±1083 3253 ± 1244 KJ 0.66 3137 ± 756 KJ 0.53 
oesophagectomy or KJ 
partial gastrectomy 
P value comparing 0.08 0.28 Oil 
patient subgroups 
Table 6.7 
Energy intake at the buffet meal following saline, *ghrelin Ipmol/kg/min and ghrelin 
5pmol/kg/min infusions in vagotomy patients with total gastrectomy (n--3) and vagotomy 
patients with oesophagectomy or partial gastrectomy (n=4). 
Analysis of the pulse recordings revealed a reduction in pulse rate with ghrelin 
5pmol/kgImin immediately before the buffet lunch, but not at the lower dose of 
Ipmol/kg/min (figure 6.6A). However, significant reduction in pulse rate was not 
observed at other time points and so could have represented a type I statistical error. As 
illustrated in figure 6.6A, the usual post-prandial rise in pulse rate after a meal was 
observed following all infusions. There were no significant differences in systolic blood 
pressures between infusion days. However significant reductions in diastolic blood 
pressure were observed with the higher dose ghrelin infusion compared with saline at 60, 
90 and 120 minutes. (Difference in diastolic blood pressure at 90 min from baseline 
(mmHg): saline 4.2± 2.6, ghrelin I pmol/kg/min -1.1 ± 2.0, ghrelin 5 pmovkg/min -6.8: L 
2.2; P< 0001 for ghrelin 5pmol/kg/min vs. saline. ) There was also a significant reduction 
in mean arterial blood pressure with ghrelin (5pmol/kg/min) compared with saline (figure 
6.613). 
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Figure 6.6 
Difference from baseline with saline and ghrelin (5pmol/kgImin) infusions in patients with 
vagotomy of A) pulse and B) mean arterial blood pressure. * P<0.05 vs. saline. 
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6.4 Discussion 
In this study intravenous ghrelin infusion did not alter appetite or energy intake in patients 
with vagotomy and partial or total gastrectomy or oesophagectomy. However, as with 
vagotomised rodents (Date et al, 2002), the rise in GH following ghrelin administration 
was present. 
Ghrelin was associated with small but statistically significant reductions in pulse rate and 
mean arterial blood pressure in patients with vagotomy, the latter as previously reported 
(Nagaya et al, 2001a). There were no differences in the hunger, fullness or sickness 
scores during ghrelin infusion. There was however a significant reduction in the post- 
prandial fullness score following ghrelin (5pmol/kg/min) infusion. In addition to its 
effects on appetite and GH release, ghrelin has been reported to stimulate gastric motility 
in rodents (Masuda et al, 2000) and humans (Murray et al, 2005). The reduction in post- 
prandial satiety observed in the current study might be explained by an alteration in 
gastric motility associated with ghrelin infusion. Thus ghrelin stimulated GH release and 
may have stimulated gastric motility but did not alter appetite or energy intake. The lack 
of a feeding response could be explained by the absence of afferent vagal nerve signals. 
These findings are in marked contrast with the 31% increase in energy intake in similar 
aged cancer patients with intact vagus nerves (chapter 4). The protocols in both these 
studies were similar with the same ghrelin infusion rate (5pmol/kg/min) and duration (120 
minutes). 
Ghrelin is not the only gut hormones which is thought to signal alterations in appetite via 
the vagus nerve. Over 20 years ago it was reported that the feeding inhibition of CCK-8 
was absent in vagotomised rodents (Smith et al, 1981). Recently it has been reported that 
the anorectic action Of PYY3-36 was absent in re-feeding vagotomised rats following a fast 
(Koda et al, 2005; Abbott et al, 2005). However in another study PYY3-36 inhibited food 
intake in freely feeding mice prior to the dark phase and this inhibition may even have 
been sustained for longer than in the inhibition observed in sham-operated controls 
(Halatchev & Cone, 2005). The freely feeding rodents were likely to have been less 
stressed than the fasted rodents, and the difference in the results of these studies could be 
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explained if vagotomised rodents were more prone to stress-induced attenuation of the 
feeding effect Of PYY3-36 (Halatchev et al, 2004). Alternatively these results could be 
explained by inter-species variation. GLP-17-36 has also been reported not to inhibit 
feeding in fasted vagotomised rats (Abbott et al, 2005). Further work is needed to 
determine the effect Of PYY3-36 and other inhibitory gut hormones on energy intake in 
vagotomised patients. If the appetite inhibition effect of endogenous PYY3-36 is absent in 
humans with vagotomy, this might counter the effects of a lack of orexigenic activity due 
to endogenous ghrelin. All the patients in the current study had lost weight following 
their surgery but the majority were able to maintain their reduced weight. This could be 
explained by an altered balance of appetite stimulation and inhibition associated with 
changes in the neuronal response to ghrelin and PYY3-36- 
The fasting ghrelin levels of the patients with gastro-oesophagectomy and vagotomy in 
were 57% lower than those of the healthy volunteers. It should be noted that although the 
patients had similar BMI to the volunteers (22.2 ± 1.5 vs. 23.0 ± 0.2 kg/m2), they were 
older (63 ±4 vs. 29 :hI years). Rigamonti et aL reported that fasting plasma ghrelin levels 
were 37% lower in older volunteers with a mean BMI 25.0 ± 1.7 k g/M 2 than younger 
volunteers of mean BMI 21.2 ± 0.9 kg/m2 (Rigamonti et al, 2002). However this 
reduction in plasma ghrelin could have reflected the increased body mass index of the 
older patients rather than their age per se. Nevertheless the difference in age between the 
patients with vagotomy and the healthy volunteers of the current study could have 
contributed to the reduction in ghrelin levels. However,, the magnitude of this reduction 
suggests that age was unlikely to have been the sole factor. All the patients in the study 
had undergone either gastric or oesophageal surgery, and this in itself could explain the 
reduction in plasma ghrelin (Ariyasu et al, 200 1). 
It might have been hypothesised that reduced plasma ghrelin concentrations would lead to 
up-regulation of ghrelin growth hormone secretagogue receptors (GHS-R), and that 
intravenous ghrelin would be associated with an enhanced appetite responseý In fact the 
converse was observed in the current study, with no significant feeding response in the 
patients with gastro-oesophagectomy and vagotomy following ghrelin infusion. One 
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explanation could be that instead of up-regulation of GHS receptors in response to a 
reduction in plasma ghrelin, following prolonged absence of stimulation from endogenous 
hormone, down-regulation occurs. However the normal GH response of these patients to 
ghrelin suggests the presence of functioning GHS receptors. Subgroup analysis of the 
patients in the study revealed that the patients who had undergone total gastrectomy had 
significantly lower fasting ghrelin levels than the patients who had undergone partial 
gastrectomy or oesophagectomy. However in neither subgroup was there a significant 
increase in energy intake with ghrelin infusion. 
The rise in plasma GH associated with ghrelin infusion in the current study was similar to 
that of the cancer patients without vagotomy (chapter 4) and to that previously reported in 
healthy volunteers (Wren et al, 2001a). This confirmed the bioactivity of the ghrelin. 
Thus the GH response to ghrelin in patients with vagotomy appears to remain intact, as 
previously reported (Takeno et al, 2004). In contrast Date et al. observed a present but 
attenuated GH response to ghrelin in vagotomised rats (Date et al, 2002). It could be that 
the GH response to ghrelin depends in part on the vagus nerve in rodents but does not do 
so in humans. Alternatively, the dose of ghrelin in the human studies may have been 
sufficient to achieve a high level of GH via direct action on the hypothalamus or pituitary 
without the effect of ghrelin on GH transmitted via the vagus. A ghrelin dose response 
study in humans to assess GH response would be required to answer this question. 
It should be noted that relatively few patients were recruited to the current study and thus 
these results should be viewed with caution. Moreover, as listed in tables 6.1 and 6.2, 
there were significant differences in the clinical characteristics of the patients recruited 
which could have confounded the results. In particular, fasting ghrelin levels were 
significantly lower in the patients who had undergone total gastrectomy than the other 
patients in the trial, although this did not appear to affect the GH or feeding response to 
exogenous ghrelin. Overall these results are strikingly different from those obtained 
following intravenous ghrelin in healthy volunteers (Wren et al, 2001a) and cancer 
patients (chapter 4) (Neary et al, 2004) and from those observed following subcutaneous 
ghrelin in healthy volunteers (chapter 5) (Druce et al, 2006) and patients with chrq . 
'Pig 
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renal failure (Wynne et al, 2005a). In these studies, there were marked increases in both 
energy intake and GH, whereas in the vagotomy patients of the current study, while there 
was a marked dose dependent increase in GH, there was no alteration in energy intake 
with either rate of ghrelin infusion compared with saline. 
Patients frequently suffer from profound weight loss following gastric surgery and 
vagotomy (King et al, 1987). Indeed the absolute energy intake at the buffet meal of this 
group on the saline infusion day was similar to that seen in the cancer patients selected 
because they reported loss of appetite, and considerably less than that seen in a previous 
study of healthy volunteers (Wren et al, 2001a) (energy intake (KJ): patients with 
vagotomy 2805 ± 812, cancer patients 2156 ± 365, healthy volunteers: 4713 ± 344). It 
may be that reduction or even absence of a feeding response to endogenous ghrelin in 
patients with vagotomy contributes to their weight loss. Weight gain could be beneficial 
to support recovery of post-operative and cachectic patients. From a treatment perspective 
these results suggest that ghrelin is unlikely to be an effective appetite-stimulatory 
treatment for patients who have had oesophageal or gastric surgery with vagotomy. From 
a mechanistic perspective this study suggests that in humans, as in rodents, an intact vagus 
nerve is required for exogenous ghrelin to stimulate food intake. 
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Chapter 7 
General Discussion and Conclusions 
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The programme of work described in this thesis investigates the effects of specific gut 
hormones on energy intake and body weight in rodents and man. When this work began 
in 2001, the anorectic effects of the gut hormones GLP-17-36 (Turton et al, 1996) and 
CCK-8 (Moran, 2000) were relatively well characterised. Peripheral administration of 
pancreatic polypeptide had first been reported to inhibit feeding in rodents in 1999 
(Asakawa et al, 1999). Ghrelin was the first gastric hormone demonstrated to stimulate 
food intake in rodents (Tschop et al, 2000; Wren et al, 2000). In 2001, the effects of 
ghrelin on appetite in humans were being investigated (Wren et al, 2001a). In addition, 
the role Of PYY3-36 on food intake was also being examined. 
7.1 Co-administration of anorectic gut hormones 
Ghrelin is the only orexigenic gut hormone identified to date, but there are several gut 
hormones including PYY3-36, GLP-17-36, PP and CCK-8 which are known to inhibit 
appetite. These appetite inhibitory gut hormones had been well studied individually but 
their combined effect on appetite had not been investigated. In this thesis the hypothesis 
that anorectic gut hormones may inhibit energy intake additively was explored. 
Dose response studies were performed for each peptide individually in order to determine 
doses for the combined studies. There was a 27% reduction in food intake in the first hour 
following IP 30nmol/kg PYY3-36 compared with the saline-treated group. However 
significant Rifther inhibition was not observed with higher doses. These results suggest 
that PYY3-36 inhibits but does not completely suppress food intake. Other groups have 
also observed a reduction in feeding following acute administration Of PYY3-36 (Challis et 
al, 2003; Halatchev et al, 2004). However, several authors have reported that acute 
administration Of PYY3-36 does not reduce food intake in rodents (Tscbop et al, 2004). As 
discussed in chapter 1, it is possible that the animals in these studies were less 
acclimatised to the experimental procedures than those in the studies in which PYY3-36 
inhibited feeding (Halatchev et al, 2004). 
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There is evidence that PYY3-36 inhibits food intake through ý CNS appetite circuits. 
Peripheral P'"3-36 administration reduced hypothalamic NPY mRNA expression and led 
to a non-significant increase in POW mRNA expression (Batterham et al, 2002). There 
was an increase in c-fos in the arcuate nucleus of the hypothalamus following PYY3-36 
injection and a 2.6-fold increase in the proportion of arcuate POMC neurones which 
stained positively for c-fos (Batterham et al, 2002). Another group measured 
neuropeptide message expression in the arcuate nucleus, rather than from the whole of the 
hypothalamus, and reported significant increase in POW mRNA at 6 and 24 hours and a 
significant decrease in NPY expression at 6 hours following PYY3-36 injection (Challis et 
al, 2003). These results suggest that the inhibition of food intake following peripheral 
PYY3-36 administration may be due to an increase in NPY expression and a reduction in 
POW expression in the ARC. 
This theory was subsequently challenged when it was observed that PYY3-36 led to similar 
reductions in feeding in MC4 receptor and POMC knockout mice (which would have 
been expected to have impaired or absent responses to alterations in POMC neuronal 
activation) as in wild-type littermates (Halatchev'et al, 2004; Challis et al, 2004). These 
data suggest that the anorectic effects Of PYY3-36 may not be mediated by POMC 
neurones. In two recent electrophysiological slice preparation studies, PYY3-36 reduced 
the frequency of action potential firing in POMC cells (Ghamari-Langroudi et al, 2005; 
Acuna-Goycolea & van den Pol, 2005). The former group reported that inhibition of 
POMC neuronal action potential firing was attenuated following pre-treatment with the 
Y2 receptor selective antagonist BlIE0246 (Ghamari-Langroudi et al, 2005). Thus PYY3- 
36 may inhibit POMC neurones via the Y2 receptor. The latter group reported that, in 
addition to inhibiting POMC, PYY3-36 inhibited NPY action potential firing (Acuna- 
Goycolea & van den Pol, 2005). 
Comparing these investigations of the effect of peripheral PYY3-36 on the CNS, one study 
has reported a significant increase (Challis et al, 2003) and another study has reported a 
non-significant increase in PONIC expression (Batterhani et al, 2002). One 
electrophysiological, study has reported an increase (Batterharn et al, 2002) and two have 
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reported a decrease (Ghmnari-Langroudi et al, 2005 Acuna-Goycolea & van den Pol, 
2005) in the action potential firing rate of POMC following PYY3-36. Arcuate POMC 
neurones are small, unstable and often fire periodically (Ghamari-Langroudi et al, 2005) 
and may give misleading stationary recording results. This could explain the apparently 
conflicting results in the literature of the effect Of PYY3-36 on POMC action potential 
firing. Further immunological and electrophysiological studies may clarify the effect of 
PYY3-36 on POMC neurons. Currently it appears that PYY3-36 inhibits appetite primarily 
through inhibition of NPY neurones. The magnitude of the maximal feeding reduction 
following PYY3-36 may be dependent on NPY tone. This could explain why further 
inhibition of food intake in the studies in this thesis was not observed with doses of PYY3- 
36 beyond 30nmol/kg. 
It is interesting that PYY3-36 may inhibit both POMC and NPY neurones within the 
arcuate nucleus as these alterations would be expected to lead to opposing changes in 
appetite and food intake. Acuna-Goycolea et al. suggested that these contradictory effects 
might temporarily reduce the contribution of arcuate cells to feeding and enhance the role 
of other CNS loci (Acuna-Goycolea & van den Pol, 2005). In order to investigate this 
hypothesis, further immunological studies could be performed to examine the effect of 
PYY3-36 on other areas of the hypothalamus. Future electrophysiological studies may 
determine whether PYY3-36 alters the signalling of other CNS neurones known to affect 
feeding such as MCH neurones. 
In the PP dose response study in this thesis a 33% reduction in food intake in the first hour 
was observed following doses of 10 and 30nmol/l. This was comparable to the 27% 
reduction seen in the PYY3-36 dose response study. Significantly less reduction in food 
intake was observed with a higher PP dose of 100nmol/kg. As discussed in chapter 2, this 
could have been due to relatively more stimulation of the orexigenic Y5 receptor than the 
anorexigenic Y4 receptor (Asakawa, et al, 2003). 
A reduction of 76% in food intake in the first hour was observed following high dose 
GLP-17-36 (900nmol/kg) in mice. The GLP-I receptor agonist, exendin4, has also been 
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reported to lead to high percentage reductions in food intake (Talsania et, al; 2005). 
Following CCK-8 at high dose (I Oninol/kg), a 42% reduction in food intake was observed 
in the first hour in the study in this thesis. However, other authors have reported that 
peripheral administration of CCK-8 leads to greater reduction in feeding (Ervin et al, 
1995). One of the limitations of this thesis is that experiments, including the CCK-8 dose 
response curve, were largely performed only once. Looking at the CCK-8 study in the 
context of the literature, it may be that high dose peripheral CCK-8, like high dose 
peripheral GLP-17-36, largely suppresses feeding. Taste aversion is thought to contribute 
to these high percentage reductions in food intake (Talsania et al, 2005; Deutsch & Hardy, 
1977) and may have been a factor in the current studies. However lower dose peripheral 
administration of exendin-4 and CCK-8 has been reported to inhibit feeding without 
evidence of associated aversive effects (Talsania et al, 2005; Ervin et al, 1995). 
In the combined studies in this thesis, additive inhibition of feeding was observed in mice 
following PYY3-36 and CCK-8, and PYY3-36 and GLP-17-36 at high and low doses. These 
peptides are thought to inhibit feeding via independent receptor systems. In contrast, 
although PYY3-36 with PP inhibited feeding, this reduction was not significantly greater 
than that following either peptide alone. As discussed in chapter 2, combined Y5 
stimulation following PYY3-36 with PP could have counter-acted some of the inhibitory 
feeding effects mediated via the Y2 and Y4 receptors and explain why an additive 
inhibitory feeding effect was not observed with this combination. Thus gut hormones 
released in response to a meal which function through independent receptor systems may 
inhibit feeding additively. Further studies are required to investigate this hypothesis. It 
would be interesting to investigate comprehensively the effects of the known appetite 
inhibitory gut hormones in pairs and subsequently in triplets. 
PYY3-36 and GLP-17-36 were administered alone and in combination to genetically obese 
mice. Acute peripheral PYY3-36 administration reduced fasting induced re-feeding in the 
first hour in oblob and dbldb mice and their WT littermates, although the reduction in the 
oblob mice was not statistically significant (P=0.16). ý GLP-17-36 led to significant 
reductions in feeding in oblob and WT mice and non-significant reductions in feeding in 
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dbldb mice and their WT littermates (P---0.26 and P'-0.07 respectively). When PYY3-36 
and GLP-17-36 were combined, similar significant reductions in acute feeding were 
observed in oblob and WT mice (74 and 70% respectively) and in dbldb and WT mice (65 
and 63%). In oblob, dbldb and WT mice the reduction in food intake following PYY3-36 
and GLP-17-36 was significantly greater than following either peptide alone. 
Several other studies suggest that PYY3-36 and GLP-17-36 are active when administered 
individually to genetically obese rodents. Continuous subcutaneous PYY3-36 
administration over 4 weeks led to a reduction in weight gain in oblob mice (Pittner et al, 
2004). Subsequently it was reported that acute IP PYY3-36 administration led to similar 
percentage reductions in food intake in the first two hours in oblob and dbldb mice as in 
WT littermates (Halatchev & Cone, 2005). These results support the findings in this 
thesis. Earlier Young et al had reported that IP injection of GLP-17-36 and exendin-4 
reduced plasma glucose in oblob and dbldb mice (Young et al, 1999). In 2006, repeated 
administration of the GLP-I receptor agonist, exendin-4, was observed to reduce body 
weight gain in oblob mice although its effect on food intake was not reported (Ding et al, 
2006). These studies and the results in this thesis suggest that PYY3-36 and GLP-17-36 
alone and in combination inhibit feeding independent of leptin signalling. 
The question remains as to whether PYY3-36 and GLP-17-36 inhibit feeding additively in 
obese rodents and humans with normal leptin signalling. This thesis is limited by the 
absence of these studies. Circulating concentrations of PYY and GLP-I are reduced in 
obese rodents (le Roux et al, 2006; Anini & Brubaker, 2003) and humans (Batterham et 
al, 2003a; Verdich et al, 2001b). The circulating levels of the majority of appetite- 
signalling hormones appear to alter to counter-act changes in body weight. For example, 
circulating leptin increases with weight gain (Rosenbaum et al, 1997) and fasting ghrelin 
concentrations are lower in obese subjects than lean subjects (Batterham et al, 2003a). 
The physiological increase in leptin associated with weight gain may lead to receptor 
down-regulation and resistance to exogenous leptin therapy (Mantzoros & Flier, 2000). In 
contrast, the reduction in plasma inhibitory gut hormones following weight gain may 
reduce satiety following a meal and contribute to -weight gain. Theoretically obese 
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subjects should remain sensitive (or even be super sensitive) to the effects of the 
inhibitory gut hormones. Indeed PYY3-36 (Batterhain et al, 2003a) and GLP- I (Naslund et 
al, 1999a) have been reported to inhibit food intake in obese humans. It would be 
interesting to examine the combined effect Of PYY3-36 and GLP-17-36 on feeding in obese 
rodents and humans. 
In order to determine whether repeated PYY3-36 and GLP-17-36 administration would lead 
to reductions in cumulative food intake and in body weight a chronic study was 
performed. Lean mice received two IP injections per day for one week. Following each 
pre-dark phase injection there were significant reductions in energy intake in the first hour 
of the dark phase in mice treated with GLP-17-36, PYY3-36 and PYY3-36 + GLP-17-36- 
However, by each of the following light phases there were no significant differences in 
cumulative energy intake compared with the saline control group. There were no 
significant overall alterations in body weight during the study. Surprisingly on the last 
four early light-phase body weight measurements of the study, there was a small but 
statistically significant increase in body weight in the PYY3-36-treated group. However no 
difference in body weight was present by the measurements 10 hours later prior to the 
dark phase. As explained in chapter 2, one explanation for the transient increase in body 
weight in the PYY3-36-treated group seen in the early light phase could be an alteration in 
fluid balance. A future study could confirm whether this increase in early light phase 
body weight associated with PYY3-36 is genuine and could quantify the effect of PYY3-36 
on fluid intake. 
The literature on repeated PYY3-36 'bolus administration in rodents is conflicting. 
Batterharn et al. administered IP PYY3-36 twice per day at 5pg/lOOg (13nmol/kg) to lean 
rats for 8 days and observed significant reductions in cumulative food intake and in body 
weight (Batterham el al, 2002). Subsequently Talsania et aL administered 3Pg/mouse 
PYY3-36 (approx 30nmol/kg) and 0.06lig/mouse exendin4 (approximately 0.6nmol/kg) 
alone and in combination twice per day over 14 days to mice on a high fat diet (Talsania 
et al, 2005). Neither peptide alone led to significant reductions in cumulative food intake 
in the 8 hours following injection. Combined PYY3-36 and exendin4 treatment was 
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associated with a significant decrease in food intake at 8 hours but there were no 
significant differences in body weight or overall food intake over the course of the 
experiment. Perhaps differences in responses to repeated PYY3-36 administration may be 
explained by inter-species variation. The study in this thesis and that of Talsania et aL 
were performed in mice and were not associated with significant change in body weight 
whereas the study of Batterharn et aL in which there was a reduction in body weight was 
performed in rats. 
The effect of a continuous peripheral infusion Of PYY3-36 has also been examined in 
rodents. Subcutaneous PYY3-36 infusion for four weeks to male mice on a high fat diet 
reduced cumulative fc*d intake and weight gain (Pittner et al, 2004). Unniappan et al. 
reported that continuous subcutaneous PYY3-36 administration to rats reduced food intake 
for the first 2 days (Unniappan et al, 2005). However over the following 5 days, there 
were no significant differences in body weight or cumulative food intake between the 
PYY3-36 treated animals and the saline-treated controls. After 7 days, all the pumps were 
removed and inserted into new groups of rats which had been acclimatised to the 
experimental conditions. A similar pattern was observed with an initial reduction in food 
intake for the first two days which was not subsequently sustained. The early reduction in 
food intake in the nalve rats suggests that the lack of a sustained anorectic effect of the 
PYY3-36 is not due peptide degradation. This study suggests that continuous PYY3-36 
infusion causes tachyphylaxis. The mechanism of this desensitisation to the anorectic 
effect Of PYY3-36 is unknown. It would be interesting to measure hypothalamic Y2 
mRNA expression following repeated administration Of PYY3-36 of varying durations to 
see if there is evidence of receptor down regulation. 
Recently, Wang et al. administered PYY3-36 by continuous subcutaneous infusion to mice 
and rats on high fat diet for four weeks and observed significant reductions in body weight 
and adiposity (Vrang et al, 2006). These findings are supported by concurrent study 
which reported a reduction in body weight and adiposity in mice fed a high fat diet after 
infusion Of PYY3-36 for one week (Adams et al, 2006). In both studies, there was an initial 
reduction in food intake for the first 3-4 days which was not subsequently sustained. This 
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suggests that the initial reduction in food intake and the absence of a subsequent increase 
in food intake were sufficient to lead to a reduction in body weight that was subsequently 
maintained or that PYY3-36 increases energy expenditure. In the study of Adams et aL, 
PYY3-36 treatment was associated with a significantly lower RQ during the I ight phase and 
reduced adiposity. Surprisingly there were no significant differences in mass specific 
metabolic rates between animals treated with PYY and saline controls (Adams et al, 
2006). It would be interesting to repeat this study to confirm whether PYY3-36 alters 
metabolic rate in rodents. 
The chronic study in this thesis suggests that repeated administration of GLP-17-36 is not 
associated with sustained alterations in food intake and body weight This could be 
explained by the short plasma half live of GLP-I of only 2 minutes (Kieffer et al, 1995). 
There is evidence that repeated administration of the more potent and longer acting GLP-1 
receptor agonist, exendin-4, is more effective. Rodriquez et al. administered exendin-4 
once per day one hour prior to the dark phase for 7 days, at a dose four-fold higher than 
that given by -Talsania et al., and observed a reduction in food intake and weight gain in 
lean and obese rats (Rodriquez et al, 2000). Exendin4 may also reduce weight when 
administered continuously. Subcutaneous exendin-4 infusion over 4 weeks was 
associated with significant reductions in body weight in mice and rats on a high fat diet 
(Mack et al, 2006). 
Looking at these studies together it appears that continuous PYY3-36 infusion is associated 
with more consistent, if transient, decrease in food intake than repeated bolus 
administration and may lead to a reduction in body weight gain. While low dose exendin- 
4 may not modify cumulative food intake and body weight, higher dose exendin-4 appears 
to be effective when administered via repeated bolus injection and via continuous 
infusion. It would be interesting to administer PYY3-36 and exendin-4 alone and in 
combination via continuous infusion in rodents and to investigate their effects on food 
intake and body weight. 
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C-fos was quantified in areas of the hypothalamus and brainstern known to affect feeding 
following low dose peripheral PYY3-36 and GLP-17-36 administration, in rats. No 
significant alterations in c-fos staining were seen following either peptide alone at doses 
which had not individually altered food intake. Co-administration Of PYY3-36 and GLP-17- 
36 was associated with an increase in c-fos staining in the arcuate nucleus. No increases in 
c-fos staining were observed in the PVN or other hypothalamic or brainstern nuclei 
examined. While these findings support the hypothesis that PYY3-36 and GLP-17-36 inhibit 
feeding additively via a CNS mechanism in the ARC, they cannot distinguish which 
neurones are stimulated. In situ hybridisation studies have revealed that the Y2 receptor is 
present at high concentration in the ARC and medial pre-optic areas of the hypothalamus 
(Gustafson et al, 1997) and that the GLP-I receptor is widely distributed in the CNS 
including the ARC (Merchenthaler et al, 1999). Therefore it is plausible that PYY3-36 and 
GLP-17-36 stimulate feeding additively through stimulation of discrete receptor systems in 
the ARC. Future studies could investigate which neuronal types stain for c-fos in the 
ARC. In particular, it would be interesting to examine the proportion of c-fos positive 
nuclei staining for NPY and POMC following PYY3-36 and GLP- 17-36 administration. 
A randomised controlled trial was performed in order to investigate the effect of co- 
administration Of PYY3-36 and GLP-17-36 on energy intake in healthy lean humans. As in 
the rodent studies, PYY3-36 with GLP-17-36 inhibited feeding significantly more than either 
peptide alone. Compared with saline, there was a 27% reduction in energy intake at the 
buffet meal. However, these findings should be interpreted cautiously given the relatively 
small sample size of ten subjects. The consistency between the effects of these hormones 
in rodents and humans, and the similarity between the results Of PYY3-36 and GLP-17-36 
infusions alone in humans with previously reported studies (Batterharn et al, 2002; Degen 
et al, 2005; le Roux et al, 2006; Gutzwiller et al, 1999) support these findings. 
As with all substances which inhibit appetite, it is possible that PYY3-36 and GLP-17-36 
inhibit appetite via aversive effects rather than specific appetite circuits. In chapter 2, 
studies were performed in rodents to determine whether there was evidence of differences 
in observed behaviours (mice and rats) and in locomotion (rats) between animals treated 
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with PYY3-36,, GLP-17-36 and PYY3-36 + GLP-17-36. Doses were chosen from the feeding 
studies at which all peptide groups had inhibited feeding in mice and the combined 
treatment alone had inhibited feeding in rats. There were no significant differences in 
recorded behaviours between treatment groups in the observational studies. Thus PYY3-36 
and GLP- 17-36 appear to inhibit appetite without causing gross behavioural change. 
The locomotion study in rats revealed a small but statistically significant reduction in 
vertical movement in animals treated with PYY3-36 + GLP-17-36 but no significant 
differences in horizontal movement following PYY3-36, GLP-17-36 or PYY3-36 + GLP-17-36 
treatment. One explanation for the reduction in vertical movement in the combined 
treatment group could be that the animals were making fewer visits to the food chamber 
which was situated above ground level in the cage. It would be interesting to assess the 
effects of these peptides more specifically on feeding behaviour and to quantify their 
effects on meal size and meal interval. Using a higher dose Of IP PYY3-36 in rats 
I000mg/kg (250nmol/kg) than given to mts in the studies in this thesis (Inmol/kg), Wang 
et aL observed an increase in locomotion in animals treated with PYY3-36 (Vrang et al, 
2006). Such an increase in locomotion could lead an increase in energy expenditure 
which would favour weight loss. In order to investigate further it would be interesting to 
perform locomotion studies and to measure energy expenditure following PYY3-36 at 
varying doses. 
An alternative and well-validated method of assessing whether peptides are associated 
with aversive effects is conditioned taste aversion (CTA) (Seeley et al, 2000) (see section 
2.2.9). At the time of the investigations in this thesis, fluid restriction was not permitted 
on the laboratory animal licenses and therefore CTA studies were not performed. Several 
other groups have administered PYY3-36, GLP-17-36 and exendin-4 and examined their 
effects on CTA. Acute IP administration Of PYY3-36 at 1.5 and 5 jig/100g (4nmol and 
20nmol/kg) to mice led to significant CTA (Halatchev & Cone, 2005). However in two 
other studies in mice, IP PYY3-36 at higher doses of 3pg/mouse (approximately 
30nmol/kg) (Talsania et al, 2005) and at (250 and 100OAg/kg or 75 and 250nmol/kg) 
(Vrang et al, 2006) did not cause significant taste aversion. There were differences in the 
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protocols of these studies which might explain the apparently conflicting results. 
Halatchev & Cone presented mice with the flavoured drinks for one hour 48 hours after 
the last conditioning trial. Talsania et aL gave the mice flavoured drinks for 24 hours 72 
hours after the last conditioning trial and Wang et aL gave presented the mice with a 
flavoured drink or saline for 12 hours 72 and 96 hours after conditioning. The latter 
studies could have lacked sensitivity because of an extra day between conditioning and 
flavour selection. However other authors observed significant taste aversion in rats with a 
similar time interval (see below) (Chelikani et al, 2006). , 
There may have been an 
alteration in taste selection in the first hour, which was no longer present at 12 and 24 
hours. 
Recently, conditioned taste aversion has been examined in rats with 2-hour intravenous 
PYY3-36 infusions at rates from 2- 30 pmol/kg/min (Chelikani et al, 2006). The protocols 
compared consumption of two flavoured chows, and consumption of two flavoured 
saccharin solutions which were both offered for 2 hours. During conditioning, PYY3-36 or 
saline infusion was started 15 minutes before the presentation of flavoured chow or 
solution rather than being given immediately afterwards as in the injection studies above. 
72 hours later rats were presented with both flavoured chows or solutions for 2 hours 
without infusions and the proportions consumed quantified. PYY3-36 infusion was 
associated with CTA from a rate of 8pmol/kg/min with both flavoured chow and saccharin 
solution protocols. Higher rates Of PYY3-36 were associated with more marked taste 
aversion. Thus these authors ý concluded that PYY3-36 dose dependently causes taste 
aversion. They noted that during conditioning, PYY3-36 at low doses (2 and 
4pmol/kg/min), which were not subsequently associated with taste aversion, led to a 
reduction in flavoured saccharin solution consumption. It would be interesting to 
administer intravenous infusions Of PYY3-36 at the lower doses in this study and examine 
their effect on food intake with normal chow. 
There is also evidence that GLP-17-36 and exendin4 may be associated with CTA. CNS 
administration of GLP-17-36 causes CTA in mice (Thiele et al, 1997; Lachey et al, 2005). 
The effect of peripheral GLP-17-36 on taste aversion has not been reported in the literature. 
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Exendin4 bolus injection at 3gg/mouse (approximately 30nmol/kg) was associated with 
significant CTA, although a lower dose of 0.061Lg/mouse (approximately 6nmol/kg) 
inhibited feeding without producing significant CTA (Talsania et al, 2005). Thus high 
dose exendin4, like PYY3-36, may be associated with CTA. 
Talsania et aL also co-administered exendin-4 with PYY3-36 and observed no significant 
effects on taste aversion. As highlighted above, their protocol could have missed early 
changes in flavoured solution intake as this was only quantified after 24 hours. 
Nonetheless, their results support the hypothesis that PYY3-36 and GLP-17-36 inhibit food 
intake additively in rodents through a specific effect on appetite. It would be interesting 
to investigate CTA following doses Of PYY3-36 and GLP-17-36 used in the studies in this 
thesis in the first hour when these peptides actively inhibited feeding. 
Adverse effects have been associated with PYY3-36 infusion in humans. Nausea, 
abdominal discomfort and fullness were reported with PYY3-36 infusion at a rate of 
0.8pmol/kg/min and also occurred less commonly at a rate of 0.4pmol/kg/min (Degen et 
al, 2005). No such adverse effects were observed at PYY3-36 inftision rates up to 
0.8pmol/kg/min in three other human studies (Batterham et al, 2002; Batterhain et al, 
2003a; le Roux et al, 2006) nor were they reported with PYY3-36 alone at a rate of 
0.4pmol/kg/min in the study in this thesis. 
Differences in protocols might explain these apparently conflicting results. In the study in 
this thesis and that of Degen et al., the buffet meal was presented with the infusion still 
running (Degen et al, 2005) whereas in the other studies there was an interval of 2 hours 
between the end of the PYY infusion and the presentation of the buffet meal (Batterharn et 
al, 2002; Batterham et al, 2003a; le Roux et al, 2006). Thus a delay between the end of 
PYY3-36 infusion and the presentation of food appears to prevent aversive effects. It may 
be that in the presence of elevated PYY from a running or recent infusion, endogenous 
rises in gut hormones associated with cating lead, to adverse effects. In order to 
investigate this hypothesis, a study could be performed in which sub ects receive two j 
PYY3-36 and two saline infusions on four separate days. On one PYY3-36 day and one 
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saline day, the buffet meal would be presented with the infusion running and on the 
remaining two days the meal would be presented 2 hours after the end of the infusion. In 
addition to quantifying nausea and plasma peptide levels, it would be interesting to 
compare the efficacy Of PYY3-36 in reducing food intake between immediate meal 
presentation and after a2 hour delay. 
The GLP-1 receptor antagonist, exendin-4 (exenatide) has recently been approved by the 
FDA as a treatment for type 2 diabetes. Daily exenatide injection may lead to nausea but 
this usually improves with further treatment (Kim et al, 2005). In contrast, GLP-17-36 
infusions, at doses which inhibit energy intake, have not been reported to be associated 
with adverse effects in several studies in humans (Gutzwiller et al, 1999; Naslund et al, 
1999a; Flint et al, 1998). Exendin-4 is relatively resistant to degradation by the enzyme 
DPPIV and has a much longer plasma half life than GLP-1 (Bray, 2006; Kieffer et al, 
1995). This may explain its more potent effect on food intake and adverse effects such as 
nausea. 
When low dose PYY3-36 and GLP-17-36 were co-administered to healthy human volunteers 
in the study described in this thesis no adverse effects were reported. - It may be that 
infusing PYY3-36 at a relatively slow rate of 0.4pmoYkg/min in combination with GLP-17- 
36 leads to significant reduction in energy intake without the adverse effects which may be 
associated with PYY3-36 infusion at a higher rate. While the 27% reduction in energy 
intake following acute PYY3-36 and GLP-17-36 infusion is clinically significant, it will be 
important to determine whether such a reduction in energy intake is sustained and whether 
adverse effects occur following repeated combined peptide administration. 
7.2 Ghrelin studies in human healthy volunteers and patients 
The gastric hormone ghrelin was known to, stimulate appetite in rodents and healthy 
human volunteers but its effect in patients with cancer and loss of appetite had not been 
investigated. Obese people who lose weight (Cummings et at, 2002) and cachectic 
patients with cancer (Shimizu et al, 2003) have elevated circulating ghrelin levels. This 
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increase in plasma ghrelin levels may reflect an attempt to defend body weight. The 
question remained as to whether ftu-ther elevation in plasma ghrelin through peripheral 
ghrelin administration would lead to an increase in energy intake. 
In the study in cancer patients in this thesis, intravenous ghrelin infusion was associated 
with a significant 31% increase in energy intake, at the buffet meal, of comparable 
magnitude to that previously observed in healthy volunteers (Wren etal, 2001a). Fasting 
ghrelin levels were higher in these subjects than had been previously reported in a group 
of healthy volunteers (Cummings et al, 2001). However there was no significant 
relationship between baseline ghrelin levels and the energy intake response to ghrelin 
infusion. These results suggest that intravenous ghrelin stimulates energy intake 
independently of endogenous circulating ghrelin levels. - 
As in a previous study in healthy volunteers (Wren et al, 2001a), ghrelin stimulated GH 
release in cancer patients. This might accelerate tumour growth. In 1999, Torsello et al. 
investigated the effects of four novel growth hormone secretagogues in rats on food intake 
and GH secretion (Torsello et al, 1998). They reported that one of these compounds 
selectively increased GH and another selectively increased food intake. The latter 
compound therefore had potential as an appetite-stimulatory treatment with a favourable 
side-effect profile. The absence of ftirther reports in the literature suggests that these 
compounds may not be as selective for food intake and GH release'as initially hoped. 
One wider question that remains is whether the appetite-loss associated with malignancy 
preferentially restricts tumour growth. Appetite stimulants might, if this is the case, 
increase the rate of tumour growth independent of GH. This possibility requires careful 
analysis, and the pros and cons of treatment under different circumstances would require 
careful evaluation. It should not be forgotten that there are several groups of patients with 
appetite loss who do not have cancer who might also benefit from treatment with an 
appetite-stimulatory hormone such as ghrelin. Examples include patients with chronic 
renal failure, HIV and post-surgical patients. 
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The effect of repeated administration of ghrelin in humans remains to be investigated. 
Studies investigating the effect of chronic ghrelin administration in rodents are promising. 
Wren et aL injected ghrelin three times per day to rats for seven days and observed an 
increase in food intake following each injection and an increase in cumulative food intake 
and body weight at the end of the study (Wren et al, 2001b). Using a similar protocol, 
Tschop et al. reported an increase in body weight, but interestingly without an increase in 
cumulative food intake (Tschop et al, 2000). DEXA scan imaging suggested that the 
increase in body weight was due to an increase in fat accumulation rather than an increase 
in lean body mass. Ghrelin administration was associated with an increase in respiratory 
exchange ratio, indicating a preference for carbohydrate metabolism and therefore lipid 
conservation. This suggests that ghrelin treatment in cachectic patients might lead to an 
increase in body fat but without the benefit of an increase in muscle mass. It remains to 
be seen whether such an alteration in body composition would improve morbidity and 
mortality in cachectic patients. 
Patients would need to self-administer ghrelin as outpatients if ghrelin were to be used as 
an appetite stimulating treatment. The intravenous route is therefore impractical whereas 
the subcutaneous route is more acceptable to patients. Only the acylated form of ghrelin 
has been reported to inhibit feeding whereas the des-acylated form may have no effect 
(chapter 5) or may even inhibit feeding (Asakawa et al, 2005). The mechanism of 
breakdown of acylated to des-acylated ghrelin has yet to be determined. It was possible 
that acylated, ghrelin might be inactivated in the subcutaneous tissues. 
A study was therefore performed to investigate whether subcutaneous ghrelin stimulated 
energy intake in healthy volunteers. A 27% increase in energy, intake was observed, 
although subcutaneous ghrelin only stimulated energy intake in 12 of the 16 subjects. 
17his is in contrast to the previous intravenous studies in healthy volunteers and cancer 
patients when ghrelin had stimulated energy intake acutely in every individual studied 
(Wren et al, 2001 a; Neary et al, 2004). It may be that the response to an acute peak in 
circulating ghrelin levels following subcutaneous ghrelin is less robust than that to the 
steady state achieved with intravenous inftision. Alternatively, it may be that lower 
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plasma ghrelin levels were achieved in the subcutaneous study than in the intravenous 
ghrelin studies. 
Unfortunately, comparison of the plasma ghrelin levels achieved in these two studies is 
not possible. In the intravenous study in cancer patients, total ghrelin was measured using 
the commercial Phoenix assay. However, in the subcutaneous study, total ghrelin was 
quantified with an in-house radioimmunoassay using the SC antibody (see chapter 5). 
Patterson et aL have compared these two assays and reported that ghrelin-like 
immunoreactivity (Ghr-LI) corresponded strongly (Patterson et al, 2005). There appeared 
to be differences between the ghrelin standards supplied in the kit and those prepared in 
the laboratory. Ghrelin levels were approximately Mold higher with bothassays using 
the laboratory standards compared with standards supplied with the Phoenix 
radioimmunoassay. In future, using freeze dried ghrelin standards prepared at the same 
time would allow comparison between assays. 
In both the Phoenix and SC assays, the same single Ghr-LI peak was identified from 
human plasma using gel permeation chromatography with both assays (Patterson et al, 
2005). Its elution position corresponded to that of des-acylated ghrelin. Thus these assays 
detect mainly free des-acylated ghrelin. In contrast, the majority of acylated ghrelin may 
be bound to larger molecules. Patterson et al. detected two peaks with molecular weights 
much larger than acylated ghrelin using an active acylated ghrelin antibody and gel 
permeation chromatography. In an in vitro study, acylated ghrelin bound to several 
plasma proteins including high density lipid associated proteins - apolipoprotein Al and 
paraoxonase-1 (Beaumont et al, 2003). The latter has esterase activity and might 
therefore facilitate the conversion of acylated to des-acylated ghrelin. . 
Given that only acylated ghrelin stimulates feeding (Asakawa et al, 2005; chapter 5), 
quantification of acylated ghrelin levels are arguably more important than total ghrelin 
levels. Using their own antibodies and reverse phase high pressure liquid chromatography 
(HPLC), Yoshimoto et al. reported that less than 10% of plasma Ghr-LI after peptide 
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extraction was acylated ghrelin (Yoshimoto et al, 2002). Therefore subtle alterations in 
acylated ghrelin may be missed when only total Ghr-Ll is measured. 
Plasma samples from the subcutaneous study in this thesis were also assayed with a 
commercial acylated ghrelin radioirnmunoassay (Linko). There was a marked rise in 
acylated ghrelin after subcutaneous ghrelin injection which confirmed that a significant 
proportion of acylated ghrelin was reaching the vasculature. It would be interesting to 
compare levels of acylated ghrelin following subcutaneous and intravenous 
administration. It may be that a higher dose of subcutaneous ghrelin would achieve 
plasma acylated ghrelin levels more comparable to those in the intravenous ghrelin studies 
and lead to more consistent increases in energy intake. When a suitable dose of 
subcutaneous ghrelin has been established, a study could be performed to examine the 
effect of repeated ghrelin administration on food intake and body weight to determine 
whether ghrelin might be a suitable appetite-stimulatory treatment. 
During the course of this thesis, it was reported that ghrelin did not significantly stimulate 
feeding in rodents which had undergone sub-diaphragmatic vagotomy (Date et al, 2002). 
The stimulatory-feeding effect of ghrelin was also nullified following application of the 
specific afferent neurotoxin, capsasin, to the, vagal abdominal trunk. Thus the vagal 
afferent appears to be critical to the feeding effect of ghrelin in rodents. 
In order to determine whether energy intake would be stimulated by ghrelin in patients 
with vagotomy, patients who had undergone vagotomy with gastrectomy or 
oesophagectomy were recruited and infused with ghrelin (chapter 6). As expected, the 
patients with total gastrectomy had lower baseline ghrelin levels than the patients with 
oesophagectomy or partial gastrectomy. In marked contrast with previous ghrelin studies 
in humans, there was no increase in energy intake in these patients with vagotomy 
although, as in the rodent vagotomy study (Date et al, 2002), the GH response was 
present. When this study was designed, the plan was to recruit two groups of patients - 
patients with vagotomy with total gastrectomy or oesophagectomy and patients with their 
vagus nerve in tact with partial gastrectomy. The patients with intact vagus nerves would 
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have acted as controls. However, no such patients were successfWly recruited to the 
study. Furthermore, only seven patients with vagotomy were recruited. Thus it is 
possible that the failure of a feeding response to ghrelin was due to a small sample size 
rather than the absence of a functioning vagus nerve. However, the feeding results are 
strikingly different from other intravenous studies (Wren et al, 2001 a; Neary et al, 2004) 
in which ghrelin stimulated energy intake in every individual studied. Thus it seems 
likely that a functioning vagus nerve is required for the feeding effect of ghrelin in 
humans as well as in rodents. 
Recently Date et aL administered intravenous ghrelin to rats which had undergone 
bilateral midbrain transections and to sham-operated controls (Date et al, 2006). Ghrelin 
only stimulated feeding in the sham-operated controls. In contrast ghrelin injected into 
the lateral cerebral ventricle stimulated feeding in all animals. These findings support the 
hypothesis that neuronal pathways from the hindbrain through the midbrain (to the 
hypothalamus) are critical for ghrelin's effect on feeding. These authors also investigated 
the effect of peripheral ghrelin administration on norepinephrine (NE) within the CNS. 
There was a significant increase in the dopamine P hydroxylase, which is required to 
convert dopamine to NE in the NTS following ghrelin administration. Norepinephrine 
overflow within or near the ARC was quantified using a microdialysis system and found 
to be stimulated by ghrelin in sham-operated controls but not in transected rats (Date et al, 
2006). In another study, the effects of NE on the electrophysiological activities of single 
hypothalamic arcuate neurons were studied using extracellular recordings (Kang et al, 
2000). Of 236 neurones examined, 58% were excited with NE, 28% were inhibited and 
14% failed to respond. It is possible that peripheral ghrelin enhances NE release from the 
NTS which in turn stimulates arcuate NPY/Agrp neurones. In order to investigate this 
hypothesis, a double-staining c-fos study could be performed to determine which ARC 
neurones are stimulated and which are inhibited by NE. 
There is evidence that a functioning vagus nerve may also be required for inhibitory gut 
hormones to modulate food intake. The feeding response to CCK-8 is absent in 
vagotomised rats (Smith et al, 198 1). More recently two groups have reported that PYY3- 
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36 failed to inhibit food intake in vagotomised rats but did so in sham-operated controls 
(Koda et al, 2005; Abbott et al, 2005). The latter group also observed that GLP-17-36 did 
not inhibit feeding in vagotomised rats. However in a study in freely feeding mice, PYY3. 
36 reduced food intake prior at the beginning of the dark phase and this inhibition may 
even have been sustained for longer than in the inhibition observed in sham-operated 
controls. As discussed in chapter 6, these apparently conflicting results could be 
explained by the fact that the animals in this study were freely feeding rather than fasted 
or by inter-species variation. Further studies could help to determine the effect Of PYY3-36 
in vagotomised mice and rats. It would also be interesting to investigate the effect of 
anorectic gut hormones in patients with vagotomy. 
7.3 Clinical applications 
During the course of the studies described in this thesis, reaching completion in 2006, no 
new appetite-stimulatory treatment has been licensed for use. Current treatments include 
the progestin, megestrol acetate (megace), and steroids such as dexamethasone. As 
explained in chapter 4, these drugs have limited efficacy and are associated with 
significant side effects. While ghrelin has promise, the effects of chronic administration 
need to be investigated before formal drug trials could be considered. 
in contrast, new evidence has become available about existing anti-obesity treatments and 
new anti-obesity therapies are being developed. Knowler et al. investigated the effect of 
life-style modification with an intense caloric restriction and increased exercise 
programme or treatment with metformin, a well known oral hypoglycaemic agent, in 
patients with impaired glucose tolerance (Knowler el al, 2002). They reported that both 
treatments improved glycaemic control (the life-style treatment significantly more than 
metformin) and delayed the onset of type 2 diabetes. Both the life-style treatment and 
metformin were associated with a significant weight loss (5.6 kg and 2.1 kg respectively) 
compared with placebo over an average follow-up period of 2.8 years. While the intense 
life-style treatment in this study is likely to be challenging to achieve in clinical practice, 
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these results suggest that early measures to prevent the development of diabetes, including 
weight reduction, may be effective. 
Recently the novel selective cannabinoid CB I receptor antagonist, rimonobant, has been 
developed as an anti-obesity therapy. Rimonobant, in combination with a calorie- 
restricted diet, was reported to lead to significant weight loss at I year of 6.3kg more than 
placebo in obese patients without diabetes (Van Gaal et al, 2005) and 5.3kg more than 
placebo in obese patients with diabetes (Scheen et al, 2006). However there were more 
side effects in the patients treated with rimonobant including nausea, diarrhoea, vomiting, 
dizziness, and anxiety. Only one reported study has looked at the effects of rimonobant 
treatment over a period two years (Pi-Sunyer et al, 2006). These authors reported similar 
weight loss at one year as in the studies above of 6.3kg more than placebo. In the second 
year, this weight loss was maintained but not increased further. The effects of taking 
rimonobant for more than two years remain to be seen. 
In 2005, the synthetic GLP- I receptor agonist, exendin4 (exenatide) was approved by the 
FDA for the treatment of patients with type 2 diabetes. Exenatide acts as an incretin and 
has been demonstrated to improve glycaemic control in overweight or obese diabetic 
patients established on metformin and a sulphonylurea. After treatment for 30 weeks with 
exenatide or placebo twice per day before meals in addition to existing treatments, there 
was reduction in glycosylated haemoglobin (HbAlc) in the exendin-treated group of 1% 
compared with placebo (Kendall et al, 2005). There was also small reduction in body 
weight in the exendin-treated group of 1.6kg. The most frequent side effect was mild or 
moderate nausea which occurred in 30% of the patients on exenatide but this tended to 
improve after the first 8 weeks of therapy. , Other treatments for diabetes, including 
insulin and the sulphonylureas but excluding metformin, tend to lead to weight gain which 
may worsen insulin resistance (Kendall et al, 2005). Therefore exenatide, which 
stimulates insulin release without weight gain (or even with weight loss), is a potentially 
exciting new development in the treatment of diabetes. Further studies which evaluate the 
effect of exenatide on glycaemic control and adverse effects for a longer period of time 
are awaited (Blonde et al, 2006). Studies to date suggest that the effect of exenatide on 
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plasma insulin and glucose are more potent than its effect on body weight. Therefore 
exenatide should be thought of as a treatment for type 2 diabetes with the benefit of small 
degree of weight loss rather than as a primary anti-obesity therapy. 
The only treatment which has been proven to achieve lasting weight reduction in obese 
patients is gastric and intestinal bypass surgery. In 2002, Cummings et al. reported that 
circulating ghrelin levels were suppressed in patients with gastric bypass and the usual 
pre-meal peaks in circulating ghrelin were absent (Cummings et al, 2002). Subsequently 
other authors have measured serial - ghrelin circulating concentrations before and after 
gastric bypass (Stoeckli et al, 2004). Although no change in ghrelin levels were observed 
following surgery, the patients lost weight and the usual associated rise in ghrelin levels 
was not observed (Stoeckli et al, 2004). Tbus it appears that the elevation in circulating 
ghrelin associated with weight loss, which may act to oppose weight loss, is lost in 
patients who have undergone gastric bypass. In addition to suppressed ghrelin levels, 
gastric bypass patients have been reported to have an exaggerated early post-prandial 
PYY response (Korner J et al, 2005b) and this may also contribute to the reduction in their 
appetite. In the UK, the National Service of Clinical Excellence (NICE) has now 
approved gastric bypass treatment for patients with a BMI over 40 kg/m: 2 and or for those 
with a BMI over 35kg/M2 associated with a medical complication. If the hormonal 
changes observed following gastric bypass could be achieved using pharmacological 
therapy this might lead to an effective and more widely available therapy without the 
morbidity and mortality associated with surgery. 
In the quest for an effective anti-obesity agent, it is pertinent to examine the tight 
physiological regulation of body weight. Despite significant day to day variation in 
energy intake, the majority of healthy people retain their body weight remarkably 
accurately (Edholm, 1977) with a slight tendency to gain weight as they age (Koh- 
Banedee et al, 2004). The thrifty gene hypothesis postulates that certain genes in humans 
have evolved to maximise metabolic efficiency and food searching behaviour (Neel, 
1962). This could explain the progressive prevalence of obesity in the western world. 
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The tendency to gain rather than lose weight suggests that appetite regulating circuits may 
overall play a more critical role in the protection against starvation rather than obesity. 
It is possible that the body 'acclimatises' to the associated alterations in circulating 
hormones after many years of being overweight, and then acts to defend the increased 
weight. This could explain why people find it so difficult to lose weight and to maintain a 
lower weight through lifestyle change and currently available pharmacological agents. in 
general it might prove beneficial to intervene earlier when people are overweight, rather 
than obese, so that only moderate weight loss, associated with a less dramatic shift in 
eating behaviour and circulating hormones, would be required. The challenge for the 
future is to find a pharmacological therapy with which to treat the widespread medical and 
social problem of obesity. Gut hormones represent promising targets for the design of 
future appetite and weight-modulating therapies. 
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Appendix 1- Amino Acid Codes 
Amino Acid 
Glycine 
Proline 
Alanine 
Valine 
Leucine 
Isoleucine 
Methionine 
Cysteine 
Pheynlalanine 
Tyrosine 
Tryptophan 
Histidine 
Lysine 
Arginine 
Glutamine 
Asparganine 
Glutamic acid 
Aspartic acid 
Serine 
Threonine 
Three letter 
Gly 
Pro 
Ala 
Val 
Leu 
Ile 
Met 
Cys 
Phe 
Try 
Trp 
His 
Lys 
Arg 
Glu 
Asn 
Glu 
Asp 
Ser 
Thr 
Codes 
Single letter 
G 
p 
A 
V 
L 
I 
M 
C 
F 
Y 
w 
H 
K 
R 
Q 
N 
E 
D 
S 
T 
244 
(D 
CD 
I=. 
1-1 
II II 
(D 
110 S, 
aq 
0 
0t 
tlj t) 
ILA C) 
I 
0. - 1. - ul C) I 
0 
t! h 
Appendix 3- Information Sheet for Human Subjects 
Registration No: 2002\6261 
Information Sheet for Research Participants 
You will be given a copy of this Information Sheet and a signed copy of your consent 
form to keep, should you decide to participate in the study. 
Study title: 
Investigation of the effects of glucagon-like-peptide-1 and peptide YY on appetite. 
You are being invited to take part in a research study. Before you decide it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with friends, relatives and your GP if you wish. Ask 
us if there is anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part. 
We will be happy to let you have a copy of the leaflet entitled 'Medical Research and You' 
published by Consumers for Ethics in Research (CERES). This leaflet gives more information 
about medical research and looks at some questions you may want to ask. 
If you do decide to take part, please let us know beforehand if you have been involved in any other 
study during the last year. You are free to withdraw at any time without explanation. 
Thank you for reading this. 
What is the purpose of the studv? 
Glucagon-like-peptide-I (GLP-1) and peptide YY (PYY) are naturally occurring substances found 
in the blood of healthy people. GLP-I and PYY are made in the gut and released into the blood 
stream after a meal. The aim of this study is to assess whether GLP-I and PYY act together to 
influence appetite in healthy individuals. This study may help to determine if GLP-1 and PYY 
can be used to treat people who are overweight, or if drugs which block the action of naturally 
occurring GLP- I and PYY can be used to treat people who are underweight. 
Why have I been chosen? 
You have been chosen because you are in good health and are on no regular medication. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be given 
this information sheet to keep and be asked to sign a consent form. If you decide to take part you 
are still free to withdraw at any time and without giving a reason. 
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You should not take part in this study if you 
I) have any illness 
2) if you take any regular medication (except the oral contraceptive pill) 
3) if you are pregnant or breast feeding 
4) if you have given blood in the last three months 
5) It is important that you should not become pregnant during the course of the study or for 
one month following the study, as the effects of GLP-I and PYY in pregnancy are not 
known. It is therefore important that you have adequate and reliable contraception during 
this period. 
What will happen to me if I take part? 
If you agree to take part in this study, you will first be examined by one of the doctors and have 
a number of blood tests and a heart recording (ECG) to ensure you are fit and healthy. You 
will also be asked to complete a questionnaire about your eating habits. 
You will be asked to attend the Department of Medicine for studies on four different days. 
On each occasion, you will be asked to eat nothing and to drink only water from 9pm the 
evening before the study day. You will then attend the Clinical Investigation Unit at the 
Hammersmith Hospital the next morning. For one day before each visit and for one day 
afterwards, you will be requested to keep a record of all food and drink consumed so that we 
have a record of your usual diet before each treatment, and a record of any longer lasting 
effects. Each study will take approximately 6 hours and during this you will be seated, or 
lying on a couch, but may read or watch videos. Throughout the study, we will monitor your 
heart rate and blood pressure. 
A plastic cannula will be placed into a vein in each arm, one to administer GLP-I, PYY, or saline 
(salt water) and one to collect blood samples. You may feel a little discomfort when the cannulae 
are inserted (under local anaesthetic). The amount taken in the blood samples is approximately 
equivalent to one and a half teaspoonfuls on each occasion. The total amount taken during all four 
study days will be approximately 440 ml. This is about the same as the amount taken during a 
blood donation session. 
You will receive four different treatments on four separate days. Each treatment consists of an 
infusion lasting 90 minutes. One of these will be an infusion of saline as a control. One treatment 
will be an infusion of GLP-I and another infusion of PYY. The remaining treatment will be an 
infusion of GLP-I with PYY. 
The study design is known as a double blind cross-over trial. In a crossover trial the participants 
each have the different treatments in turn (saline, GLP-1, PYY and GLP-I with PYY). There will 
be a break of at least 3 days between these study days so that each treatment is cleared from your 
body before you start the new treatment. The order in which you receive the treatments will be 
decided randomly and you will not be aware which treatment you are receiving on each occasion. 
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This is called a double blind trial, which means neither you nor your doctor will know in which 
treatment group you are (although, if your doctor needs to find out he/she can do so). 
After the study you will need to remain at the hospital to have lunch for continued observation. 
What do I have to do? 
The only restrictions on your lifestyle are that you will be asked to have nothing to eat and only 
water to drink from 9pm on the days before the study days. You will need to keep a record of all 
food and drinks consumed in the two days before every visit and for the twenty-four hours 
afterwards. For twenty-four hours before each treatment you will be asked to refrain from taking 
strenuous exercise and drinking alcohol. 
Pregnancy will be excluded in female volunteers at the start of the study by questioning and also a 
pregnancy test You should have adequate contraception for the period of the study and for I 
month afterwards as the effects of GLP- I and PYY in pregnancy are not known. 
What is the dru2 or procedure that is beins! tested? 
GLP-I and PYY are naturally occurring hormones found in the circulation of healthy people. 
They are simultaneously released from the same cells in the gut following a meal. GLP-I and 
PYY have both been used many times worldwide in healthy mean and women without harmful 
effects. We know from previous work what doses we need to give to mimic the natural levels of 
both these levels following a meal. Hence the doses of both GLP-I and PYY that you will be 
given will be small, and will increase the levels of GLP-I and PYY in your body to levels seen 
naturally in people after a meal. 
What are the side effects of takine part? 
From our previous studies we do not expect any side effects, but the unexpected can occur. 
During the study, two experienced doctors will monitor you closely. If you suffer from any ill 
effects during the study you should report them to the doctors monitoring you immediately. If you 
suffer from any ill effects afterwards you should report them to one of the research doctors at the 
contact number below or when you next see them. You may ask for the study to stop at any time. 
If there are any side effects, the study will be stopped. 
What are the vossible disadvantages and risks of taking part? 
It is always possible that any treatment given to a pregnant woman will harm the unborn child. 
Pregnant women must not therefore take part in this study; neither should women who plan to 
become pregnant during the study. Women who are at risk of pregnancy will be asked to have a 
pregnancy test before taking part to exclude the possibility of pregnancy. Women who could 
become pregnant must use an effective contraceptive during the course of this study. Any woman 
who finds that she has become pregnant while taking part in the study should immediately tell her 
research doctor. 
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What are the possible benefits of takiniz part? 
The information that we get fi-om this study may help us to better treat future patients who suffer 
from being overweight or underweight. 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available about the 
treatment that is being studied. If this happens, your research doctor will tell you about it and 
discuss with you whether you want to continue in the study. If you decide to continue in the study 
you will be asked to sign an updated consent form. 
Also, on receiving new information your research doctor might consider it to be in your best 
interests to withdraw you from the study. 
What happens when the research studv stops? 
Once the study has finished, the results of the study can be made available to you and/or your GP 
should you wish. If you have any problems immediately following the study, then you should 
contact one of the research doctors on the numbers provided below. 
What if something goes wrona? 
In the event of any adverse events occurring as a consequence of your participation in this study, 
you will be compensated through the Imperial College Faculty of Medicine's 'No-fault' 
Compensation scheme. 
Will mv taking part in this studv be kept confidential? 
All information, which is collected, about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital will have your name 
and address removed so that you cannot be recognised from it. 
It is a requirement that your GP is informed, with your consent, of your participation in this study. 
What will happen to the results of the research studv? 
The results are likely to be published in the six months following the study. Your confidentiality 
will be ensured at all times and you will not be identified in any publication. At the end of the 
study, the results of the study can be made available to you and/or your GP should you wish. 
Who is organising and funding the research? 
This study is being funded in part by a medical charity, the Wellcome Trust, and by the Medical 
Research Council. They will pay the Endocrine Unit, Hammersmith Hospital, for including you in 
this study. 
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Registration No: 2002\6261 
Who has reviewed the studv? 
This study has been reviewed by Hammersmith, Queen Charlotte's and Chelsea and Acton 
Hospitals Research Ethics Committee. 
Contact for Further Information 
If you experience any problems during the study, you may withdraw at any stage. The doctors 
involved in the study, Dr Neary and Dr Park (bleep 4732) will be available by telephone at any 
time and can be contacted through Professor Bloom's secretary (020 8383 3242). The hospital 
switchboard (020 8383 1000) has home and mobile phone numbers for all the doctors involved in 
the study and can contact them at any time outside normal working hours. 
You will receive payment for your participation in this study. 
THIS INFORMATION SHEET IS VALID FOR USE UNTIL: 04-10-2005 
-elzýý 
Signed (REC Chairman) Date: 05-10-01 
TMS INFORMATION SHEET IS VALID FOR USE UNTIL: 04-10-2005 
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Appendix 4- Dutch Eating Questionnaire 
Volunteer Name ..................... Volunteer No . .............. 
Date // 
1. If you have put on weight, do you eat less than you usually do? 
Never Seldom I I Sometimes I Often Very Often 
2. Do you try to eat less at mealtimes than you would like to eat? 
Never Seldom r-] Sometimes Often [--] Very Often 
r--i 
F7 
3. How often do you refuse food or drink offered because you are concerned about 
your weight? 
Never Seldom Sometimes 
4. Do you watch exactly what you eat? 
Never I Seldom Sometimes 
5. Do you deliberately eat foods that are slimming? 
Never I Seldom Sometimes 
Often 
Often 
Often 
r-1 
F-I 
II 
6. When you have eaten too much, do you eat less than usual the following days? 
Never Seldom Sometimes Often Very 
Often 
Very Often 
Very Often 
Very Often 
Not 
Relevant 
Do you deliberately eat less in order not to become heavier? 
Never F--j Seldom I Sometimes Often r--ý Very Often F7 
8. How often do you try not to eat between meals because you are watching your 
weight? 
Never Seldom Sometimes Often F-ý Very Often 
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VolunteerName ..................... 
Volunteer No . .............. 
Date // 
9. How often in the evening do you try not to eat because you are watching your 
weight? 
Never Seldom Sometimes Often 
10. Do you take into account your weight with what you eat? 
Never F--j Seldom I Sometimes Often 
11. Do you have the desire to eat when you are irritated? 
Never Seldom Sometimes Often Very 
Often 
12. Do you have a desire to eat when you have nothing to do? 
Never Seldom Sometimes Often Very 
Often 
I 
I 
Very Often 
Very Often 
Not 
Relevant 
Not 
Relevant 
13. Do you have a desire to eat when you are depressed or discouraged? 
Never Seldom Sometimes Often Very 
Often 
14. Do you have a desire to eat when you are feeling lonely? 
Never Seldom Sometimes Often Very 
Often 
15. Do you have a desire to eat when somebody lets you down? 
Never Seldom Sometimes Often 
16. Do you have a desire to eat when you are cross? 
Never Seldom Sometimes Often 
Very 
Often 
Very 
Often 
Not 
Relevant 
Not 
Relevant 
Not 
Relevant 
Not 
Relevant 
r7 
L-1 
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VolunteerName ..................... Volunteer No . .............. 
Often 
17. Do you have a desire to eat when you are approaching something unpleasant to 
happen? 
Never Seldom I Sometimes 
Often 
I 
18. Do you get the desire to eat when you are anxious, worried or tense? 
Never I Seldom F--] Sometimes I 
Often 
19. Do you have a desire to eat when things are going against you or when things have 
gone wrong? 
Never I Seldom Sometimes 
20. Do you have a desire to eat when you are frightened? 
Never Seldom Sometimes Often 
Date // 
I 
Very 
Often 
21. Do you have a desire to eat when you are disappointed? 
Ncvcr Seldom Sometimes Often Very 
Often 
22. Do you have a desire to eat when you are bored or restless? 
Never Seldom Sometimes Often Very 
Often 
23. Do you have a desire to eat when you are emotionally upset? 
Never Seldom Sometimes Often Vcry 
Often 
Very Often 
Very Often 
Very Often 
Not 
Relevant 
Not 
Relevant 
Not , 
Relevant 
Not 
Relevant 
F7 
ED 
II 
24. If food tastes good to you, do you eat more than usual? 
Never F--] Seldom Sometimes Often r-ý Very Often 
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VolunteerName ..................... Volunteer No . ............... 
Date // 
25. If food smells and looks good do you eat more than usual? 
Never Seldom F--j Sometimes Often 
26. If you see or smell something delicious, do you have the desire to eat it? 
Never[--] Seldom Sometimes Often 
27. If you have something delicious to eat, do you eat it straight away? 
Never I Seldom Sometimes Often I 
28. If you walk past the baker do you have the desire to buy something delicious? 
Never I Seldom F--j SometimesF--] Often 
Often 
I 
71 
F-I 
1-1 
II 
29. If you walk past a snackbar or a cafd, do you have the desire to buy something 
delicious? 
Never I Seldom Sometimes 
30. If you see others eating, do you also have the desire to eat? 
Never[--] Seldom Sometimes 
31. Can you resist eating delicious foods? 
Never Seldom F--] Sometimes 
Very Often 
Very Often 
Very Often 
Very Often 
Very Often 
Often F--ý Very Often 
Often 
32. Do you eat more than usual, when you see others eating? 
Never [--ý Seldom Sometimes I Often 
33. When preparing a meal are you inclined to eat something? 
Never Seldom Sometimes F--j Often I 
I 
Very Often 
Very Often 
Very Often 
F-1 
II 
F-I 
II 
F--i 
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Appendix 5- Visual Analogue Scales 
HOW HUNGRY DO YOU FEEL RIGHT NOW? 
II ZZIZZ= 
NOT AT ALL 
HOW SICK DO YOU FEEL RIGHT NOW? 
I 
NOT AT ALL 
HOW PLEASANT WOULD IT BE TO EAT RIGHT NOW? 
I 
NOT AT ALL 
EXTREMELY 
EXTREMELY 
I 
EXTREMELY 
HOW MUCH DO YOU THINK YOU COULD EAT RIGHT NOW? 
I 
NOTHING A LARGE AMOUNT 
HOW FULL DO YOU FEEL RIGHT NOW? 
I I 
NOTHING A LARGE AMOUNT 
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Edmonton Symptom Assessment Scale (ESAS Modified) 
Modified Edmonton Symptom Assessment Scale 
1 a. Please rate your pain now. 
1. No pain 
2. Mild pain 
3. Moderate pain 
4. Severe pain 
1 b. Please rate your pain over the past three days. 
1. No pain 
2. Mild pain 
3. Moderate pain 
4. Severe pain 
I c. Is your vain contro acceptable to you? 
1. Very acceptable 
2. Acceptable 
3. Not acceptable 
2. How would you describe your activity leve during your last three days? 
1. Very active 
2. Somewhat active 
3. Minimally active 
4. Not active 
3. How would you describe the amount of nausea during the last three days? 
1. Not nauseated 
2. Mildly nauseated 
3. Moderately nauseated 
4. Very nauseated 
4. How would you describe your. level of constipatio in the last three days? 
1. No constipation 
2. Mild constipation 
3. Moderate constipation 
4. Severe constipation 
4a. When was your last bowel movement? 
1. Today 
2. Yesterday 
3. Two-three days ago 
4. More than four days ago 
How would you describe your feelings of degressio during the last three days? 
1. Not depressed 
2. Mildly depressed 
3. Moderately depressed 
4. Very depressed 
How would you describe your feelings of anxie during the last three days? 
1. Not anxious 
2. Mildly anxious 
3. Moderately anxious 
4. Very anxious 
How would you describe your level of fatiqu during the last three days? 
1. Not fatigued 
2. Mildly fatigued 
3. Moderately fatigued 
4. Very fatigued 
How has your appetit been during the last three days? 
1. Very good appetite 
2. Moderate appetite 
3. Poor appetite 
4. No appetite 
How would you describe your sensation of wellbein during the last three days? 
1.1. Very good sensation of wellbeing 
2.2. Moderately good sensation of wellbeing 
3.3. Not very good sensation of wellbeing 
4.4. Poor sensation of wellbeing 
How short of breath have you been during the last three days? 
1. No shortness of breath 
2. Mild shortness of breath 
3. Moderate shortness of breath 
4. Very short of breath 
How has your physical discomfort been during the last three days? 
1. No physical discomfort 
2. Mild physical discomfort 
3. Moderate physical discomfort 
4. Severe physical discomfort 
Visual Analogue Scale 
Name: 
Room #: 
Please cross the line at the point that best describes: (for coding) 
No Pain Worst Possible Pain 
Not Tired Worst Possible Tiredness 
Not Nauseated Worst Possible Nausea 
Not Depressed Worst Possible Depression 
Not Anxious Worst Possible Anxiety 
Not Drows Worst Possible Drowsiness 
Best Appetite Worst Possible Appetite 
Best Feeling of Well-Being _Worst 
Possible Feeling of Well-Being 
No Shortness of Breath Worst Possible Shortness of Breath 
Other Problems 
Assessed by: 
Revised 1/28/2000 
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Ghrelin Increases Energy Intake in Cancer Patients with 
Impaired Appetite: Acute, Randomized, Placebo- 
Controlled Trial 
NICOLA M. NEARY, CAROLINE J. SMALL, ALISON M. WREN, JENNIFER L. LEE, 
MIARALYN R. DRUCE, CARLO PALMIERI, GARY S. FROST, MOHAMMAD A. GHATEI, 
R. CHARLES COOMBES, AND STEPHEN R. BLOOM 
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(J. L. L., G. S. F. ), and Department of Cancer Medicine (C. P., R. C. C. ), Faculty ofMedicine, Imperial College London, London, 
United Kingdom W12 ONN 
There is a pressing need for more effective appetite-stimula- 
tory therapies for many patient groups including those with 
cancer. We have previously demonstrated that the gastric hor- 
mone ghrelin potently enhances appetite in healthy volun- 
teers. Here, we performed an acute, randomized, placebo-con. 
trolled, cross-over clinical trial to determine whether ghrelin 
stimulates appetite in cancer patients with anorexia. Seven 
cancer patients who reported loss of appetite were recruited 
from oncology clinics at Charing Cross Hospital. The main 
outcome measures were energy intake from a buffet meal 
during ghrelin or saline infusion and meal appreciation as 
assessed by visual analog scale. A marked increase in energy 
intake (31 :t 7%; P=0.005) was observed with ghrelin infusion 
compared with saline control, and every patient ate more. The 
meal appreciation score was greater by 28 :t 8% (P = 0.02) *ith 
ghrelin treatment. No side effects were observed. The stimu. 
latory effects of ghrelin on food intake and meal appreciation 
seen in this preliminary study suggest that ghrelin could be an 
effective treatment for cancir anorexia and possibly for ap- 
petite loss in other patient groups. W Clin Endocrinol Metab 
89: 2832-2836,2004) 
T HERE IS A pressing need for more effective, better- 
tolerated, appetite stimulatory treatments. Loss of ap- 
petite and loss of weight are major causes of morbidity and 
mortality affecting many patients, including those with can- 
cer, HIV, cardiac cachexia, inflammatory conditions such as 
sepsis and burns, and postoperative patients. Weight loss 
also has an important impact on health economics. Under- 
nutrition may account for an additional 5-d admission for 
10% of hospital admissions costing approximately E266 mil- 
lion annually in Britain (1). 
Up to 50% of cancer patients report changes in eating 
behavior at the time of diagnosis, leading to weight loss (2). 
Loss of appetite, decreased caloric intake, and associated 
symptoms are among the most frequent factors affecting the 
quality of patients' lives. These symptoms can be associated 
with cancer cachexia, a complex metabolic condition result- 
ing in anorexia, weight loss, and skeletal muscle wasting, 
which adds significantly to morbidity and mortality (3). Can- 
cer patients receiving chemotherapy also frequently experi- 
ence debilitating loss of appetite and weight, which may limit 
the dose and duration of a potentially curative or disease- 
modifying treatment. 
Currently prescribed appetite stimulatory drugs include 
steroids, progestogens such as megesterol acetate (megace), 
and prokinetic agents such as metoclopramide. Although 
Abbreviation: Cl, Confidence interval. 
JCEM is published monthly by The Endocrine Society (http: //www. 
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docrine community. 
steroids may improve quality of life and appetite, their met- 
abolic, infectious, and psychiatric side-effects usually limit 
their use to the short term. Megestrol acetate has been found 
to improve appetite (3), but is associated with water retention 
and increases the already elevated risk of venous thrombo- 
embolism. A recent meta-analysis reported that megestrol 
acetate treatment produced a modest weight gain of 0.42 kg 
or 0.9 lb (4). Prokinetic agents have been shown to improve 
chronic nausea (5), but they have no proven effect on appetite 
and are associated with dose-limiting extrapyramidal side- 
effects. Clearly some patients are not helped by or cannot 
tolerate currently available treatments. There is a need for a 
safe appetite stimulatory treatment that can be commenced 
early in a patient's therapy to improve nutritional status 
before significant weight loss occurs. 
Chrelin is the only circulating appetite-stimulating hor- 
mone identified to date. Ghrelin is expressed in the stomach 
and activates neurons of the arcuate nucleus of the hypo- 
thalamus, an area of the brain known to be important in the 
regulation of feeding (6). Supraphysiological concentrations 
of other hormones, such as corticosteroids and thyroid hor- 
mones, may lead to metabolic changes associated with a 
secondary increase in appetite. In contrast, ghrelin appears 
to have a direct effect on appetite at concentrations within the 
normal fasting range (7). 
Endogenous ghrelin levels peak before each meal and fall 
within Ih of eating, thus supporting the hypothesis that 
ghrelin is a hormone that stimulates hunger (8). Plasma 
ghrelin is inversely proportional to body weight and fat mass 
and is increased by weight loss and decreased by weight gain 
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(9). These findings suggest that ghrelin is part of a dynamic 
feedback system in the regulation of body weight. 
We have previously reported that ghrelin infusion in- 
creases food intake by 28% (95% confidence interval, 19- 
37%) in male and female healthy volunteers in a double- 
blind, randomized, controlled trial (7). No adverse events 
were observed. However, subjects in negative energy bal- 
ance, including patients with cancer and anorexia, have el- 
evated endogenous plasma ghrelin (9,10) and thus might be 
resistant to the appetite-stimulating effects of exogenous 
ghrelin. To determine whether ghrelin is effective pharma- 
cologically in patients with appetite loss, we recruited a 
group of patients with cancer and anorexia. In this prelim- 
inary study we investigated the effect of ghrelin on energy 
intake and appreciation of food in cancer patients with ap- 
petite loss. 
Patients and Methods 
The aim of the study was to determine whether ghrelin stimulates 
food intake in cancer patients with anorexia. The primary outcome was 
energy intake from a buffet meal designed to be in excess. Secondary 
outcomes were visual analog scores of meal appreciation, 24-h food 
intake as assessed by food diary, and plasma ghrelin and GH levels. 
Synthetic human ghrelin was purchased from Bachem (UK) Ltd. 
(Merseyside, UK). The Limulus amebocyte lysate assay test for pyrogen 
was negative (Associates of Cape Cod UY, Liverpool, UK), and the 
peptide was sterile on culture. The study was approved by our research 
ethics committee and was performed in accordance with the Declaration 
of Helsinki. 
Cancer patients reporting appetite loss were recruited from oncology 
clinics at Charing Cross Hospital between September 10,2002, and 
January 6,2003, and assigned subject numbers in order of recruitment. 
Clinical reduction in appetite was confirmed by dietetic consultation 
using the Edmonton Symptom Assessment Scale, in which they were 
asked to rate the severity of the following nine symptoms on a 100-mm 
visual analog scale: pain, tiredness, nausea, depression, anxiety, drows- 
iness, lack of appetite, lack of well-being, and shortness of breath (11). 
Exclusion criteria were any of the following within the previous month: 
surgery, radiotherapy, and regular use of systemic steroids or proges- 
tins. Patients established on chemotherapy with sustained appetite loss 
were included in the study. At screening, subjects selected the food to 
be served to them in the study from four possible options and tasted it 
to confirm palatability. 
Seven patients were recruited (six women and one man) with a mean 
weight loss from their precancer weight of 13% and mean current body 
mass index of 22.6 kg/m' (Table 1). All patients had metastatic cancer. 
At recruitment the mean Edmonton Symptom Assessment score for lack 
of appetite was 70 mm/100 mm, and the mean total score for all nine 
questions representing poor quality of life was 230 mm/900 mm. Thus, 
patients reported that lack of appetite was the main contributor to their 
overall poorer quality of life. Each patient gave their written, informed 
consent and attended for 2 infusion days at least 3d apart (range, 3-21 
d), 1d for ghrelin and Id for saline control. Patients receiving chemo- 
therapy attended for their first infusion as long after their chemotherapy 
TA13LE 1. Patient details 
Patient Age 
no, (yr) 
Sex Precancer 
weight (kg) 
Current 
weight 
(kg) 
1 52 F 58 44.3 
2 63 F 64 57.5 
3 66 F 67 52.7 
4 55 F 58 54.8 
5 54 F 65 64.6 
6 49 m 80 59 
7 41 F 86 83.8 
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cycle as possible (at least 17 d) and then the same number of days after 
their subsequent cycle. Although these patients took an antiernetic in the 
few days after their chemotherapy, this was no longer taken or required 
before ghrelin or saline infusion. 
On infusion days, fasted patients had two iv cannulas (one for in- 
fusion and one for blood sampling) placed at 0900 h (t = -30 min). Pulse 
and blood pressure readings were taken every 30 min during the study. 
At 0930 h (time zero) a fixed breakfast was served (energy content, 703 
KJ) to standardize food intake before infusion. Ghrelin or saline infusion 
was commenced at 1100 h (t = 90 min). The rate of ghrelin infusion (5 
pmol/kg-min) was that which significantly increased food intake in 
healthy volunteers in our previous study (7). At 1230 h (t - 180 min) a 
buffet lunch was served of preweighed food in excess. After the meal, 
the remaining food was removed and weighed, and the infusion was 
discontinued. Blood samples (each 10 ml) were collected into plastic 
lithium heparin tubes containing 0.6 mg aprotinin. Samples were taken 
before breakfast (0 min) and at 45,90,150, and 180 min. Samples were 
immediately centrifuged, and plasma was separated and stored at -70 
C until immunoassay. To assess meal appreciation, after lunch patients 
were asked to respond on a visual analog scale (possible score, 0-100 
mm), to the prompt "how pleasant was this meal? " (11). Positions on the 
scale were measured in millimeters by a blinded observer. Patients 
completed a 24-h food diary after each infusion. One patient (patient 7) 
failed to complete a food diary after one of her infusions. Completed 
food diaries were assessed with Dietplan-5 nutritional analysis soffWare 
(Forestfield Software, Horsham, West Sussex, UK). 
Plasma ghrelin was measured by RIA (Phoenix Pharmaceuticals: 
intra- and interassay coefficients of variance, 5% and 141/6, respectively). 
Plasma GH was analyzed using Advantage automated chemilumines- 
cent immunoassay (Nichols Institute Diagnostics, San Juan Capistrano, 
CA). Glucose and triglycerides were measured using an Olympus 
AU640 clinical chemistry analyzer (Melville, NY), and insulin was mea- 
sured using an automated microparticle enzyme immunoassay. 
The study was randomized and double-blinded. Subjects were ran- 
domized to receive ghrelin then saline (four patients) or saline then 
ghrelin (three patients) using the statistics package, SigmaStat version 
2.0 (SPSS, Inc., Chicago, IL). Vials of ghreIin and saline were indistin- 
guishable visually; they were labeled by subject and infusion numbers 
and stored in a sealed container. Subjects, investigators, and dieticians 
were blinded to the infusion order until study completion. 
Statistical comparisons between treatments for food intake, visual 
analog scores, and plasma ghrelin and GH levels were made using a 
paired t test, having ascertained that the data were normally distributed. 
Statistically significance was set at P<0.05. Confidence intervals (CI) 
are reported at 95%. 
Results 
The mean fasting plasma ghrelin concentration was 538 
(Cl, 433-643) pmol/liter, with levels ranging from 350-938 
pmol/liter. Ghrelin infusion achieved steady state within 60 
min of infusion, with a mean plasma ghrelin of 1718 (CI, 
1303-2132) pmol/liter (Table 2). The expected GH rise as- 
sociated with acute ghrelin administration was observed 
(Table 3), confirming that the ghrelin infusion was biologi- 
cally active. There was no significant change in plasma glu- 
Current 
BMI 
(kgIM2) 
Cancer 
On 
chemotherapy? 
17.3 Malignant melanoma No 
21.4 Breast Yes 
21.1 Breast No 
25.7 Breast No 
24.3 Breast No 
19.0 Colon No 
29.3 Breast Yes 
BMI, Body mass index; F, female; M, male. 
2834 J Clin Endocrinol Metab, June 2004,89(6): 2832-2836 Neary et al. o Ghrelin Increases Energy Intake in Cancer Patients 
TABLE 2. Plasma ghrelin levels with saline and ghrelin infusions at 0,90,150, and 180 min 
Treatment 
0 min (prebreakfast) 
Saline 545 58 
Ghrelin 531 83 
P value 0.7102 
Ghrelin (pmoVliter) 
90 min (infusion start) 150 min 
Ghrelin values are the mean ± SEM. P values compare ghrelin levels at each time point. 
TABLE 3. Plasma GII levels with saline and ghrelin infusions at 0,90,150, and 180 min 
Treatment 
0 min (prebreakfast) 
Saline 6.5 3.3 
Ghrelin 10.9 3.4 
P value 0.0810 
GH OnIll/liter) 
440 59 509 97 490 63 
505 90 1718 169 1840 221 
0.2004 0.0009 0.0006 
90 nim (infusion start) 150 mill 
GH values are the mean -' SEM. 
P values compare GII levels at each time point. 
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FIG. 1. Percentage increase in energy intake from a buffet meat after 
ghrelin compared with saline infusion. 
cose, insulin, or triglycerides with ghrelin infusion at any of 
the time points studied (data not shown). 
Energy intake from the buffet lunch was increased by 31% 
(Cl, 14-49%6; P=0.005) during ghrelin infusion compared 
with the saline control (Fig. 1). Moreover, every patient con- 
surned more on his/her ghrelin administration day (Fig. 2A) 
(range, 7-59'% increase). No side effects were observed In 
particular, there were no differences in pulse and blood pres- 
sure recordings between ghrelin and saline infusion days. 
There was no evidence of a compensatory decrease in food 
intake after ghrelin treatment as assessed by 24-h food diary 
(Fig. 213). Total energy intake over the 24-h period including 
the buffet was 9,270 Kj (Cl, 3,249-15,290 Kj) after ghrelin 
treatment vs. 6,854 Kj (Cl, 3,634-10,070 Kj) after saline (P 
0.09). 
Analysis of the visual analog score revealed a significant 
increase of 23% in the perceived pleasantness of the meal on 
the ghrelin administration dav compared with the saline 
administration day (Cl, 4-41(%; P-0.02). 
Discussion 
We demonstrated a 31% increase in energy intake with 
ghrelin infusion associated with a significant increase in meal 
appreciation in cancer patients with appetite loss. This is 
comparable with the 28% increase previously observed in 
Energy intake (MJ) 
'[ A 
6.5 2.9 2.6 ± 1.0 3.8 - 1.9 
9.4 3.3 72.5 t 26A 39.7 ' 12.4 
0.0847 0.0341 0.0195 
4 
3 
2 
180 min (prelunch) 
180 min (prelunch) 
Energy intake (MJ) 
20 FB 
16 
12 
8 
4 
01. --01 
saline ghrelin saline gbrelin 
FIG. 2. Energy intakes (megajoules) in individual subjects receiving 
ghrelin compared with saline infusion. The bold line represents mean 
energy intakes. A, Energy intakes for the buffet meal (n = 7). B, 
Energy intakes for the 24 h after ghrelin or saline infusion (n ý 6, as 
one patient failed to complete the diary). 
healthy volunteers (7). Small daily increases in energy intake 
(--P'. ) are associated with significant weight gain when sus- 
tained (12). Thus, the 31"% increase observed in this stuciv 
represents a large increase in energy intake. Although base- 
line energy intake and piasnia ghrelin varied among the 
patients Studied, ghrelin StIMUlated appetite in all patients. 
There was a trend for an increase in 24-hr energy intake after 
ghrelin treatment from a mean of 6854 Kj with saline tO 9270 
Kj with ghrelin. 
The effect of ghrelin on feeding appears to be more sus- 
tained than its effect on GI I release. After peripheral ghrelin 
administration to rodents three times per day for 7 d, no 
attenuation in ghrelin-induced food intake was observed 
(13). However, after an initial rise, plasma GH and IGF-I were 
not significantly differunt from levels in ýahnt-hcated coll- 
trols (13). Further, chronic ghrelin administration to animals 
with absent (; I I nicreased body weight ( 11). '1 Ims, 
stimulatory effect on food intake appears to be independent 
of GI I. 
The effect of chronic ghrelin administration on body 
weight, morbidity, mortality, and quality of life in patient.,, -, 
with loss of appetite remains to he investigated. ', tudies have 
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shown that when patients with cancer anorexia were given 
artificial enteral nutrition body weight, fat mass, and nitro- 
gen balance improved (15). Thus, if ghrelin were to achieve 
long-term increases in voluntary food intake, it could in- 
crease body protein, fat, and total weight as well as improve 
quality of life. 
It is not yet established whether ghrelin has any long-term 
adverse effects. A brief rise in GH was observed with ghrelin 
infusion. I lowever, acromegalic patients who have chroni- 
cally elevated GH only have a small increase in absolute risk 
of bowel cancer with no increased risk of other tumors (16). 
Data about the effect of ghrelin on cell lines is conflicting, 
with some studies suggesting an increase (17,18) and some 
a decrease (19-21) in the rate of cell growth. Further work is 
needed to determine the effect of ghrelin on tumors in vivo. 
In this acute study no changes were observed in plasma 
insulin, glucose, or triglycerides with ghrelin infusion. How- 
ever, an iv bolus of ghrelin in humans has been reported to 
increase plasma glucose and decrease plasma insulin (22). 
Thus, chronic ghrelin could affect metabolic parameters such 
as insulin, glucose, and lipids. 
Interestingly, fasting plasma ghrelin concentrations in the 
present study were higher than those reported in healthy 
reference populations of similar body mass index (8). This is 
consistent with a study performed by Wisse et al. (23) that 
found high ghrelin levels in rats with prostate cancer, al- 
though these levels were similar to those in pair-fed controls. 
This suggests that elevated ghrelin levels in cancer may re- 
flect on-going negative energy balance. When glirelin was 
administered directly into the intracerebroventricular space 
of these animals with prostate cancer, food intake increased 
(23). A human study reported that plasma ghrelin levels were 
higher in lung cancer patients with cachexia than in those 
without (10). Our study shows that peripheral ghrelin is 
effective in stimulating appetite in patients with various en- 
dogenous ghrelin baselines. Thus, sufficient exogenous 
ghrelin appears to overcome any resistance to the appetite- 
stimulating effects of ghrelin in these patients. The patients 
in this trial found the meal more pleasant with ghrelin in- 
fusion. In addition to stimulating appetite, ghrelin may im- 
prove appreciation of food and enhance quality of life. 
Ghrulin has now been administered acutely to more than 
100 human subjects worldwide at doses up to 6-fold higher 
than those used in the current study (24) with no reported 
side-effects other than hunger. It is also worthy of note that 
synthetic agonists of the ghrelin (GI I secretagogue) receptor 
have been administered to adults with GI-1 deficiency and 
children with idiopathic short stature for up to 2 yr with no 
reported adverse effects (25). Nonetheless, chronic ghrelin 
administration in patients with normal growth axis could 
lead to supraphysiological levels of GH, causing acromegaly 
and its associated complications, such as joint pain, head- 
aches, and visual field defects. Flowever, the normal phe- 
notype, length, and weight of the ghrelin-null mouse (26) 
suggest that ghrelin is not the main regulator of G1 I release. 
Unlike currently available appetite stimulatory treat- 
ments, administration of ghrelin directly boosts an endoge- 
nous appetite-regulating system. We have demonstrated that 
ghrelin stimulates appetite and food intake in both healthy 
volunteers and cancer patients with anorexia. In both groups 
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food intake was increased in every individual studied. There- 
fore, it seems likely that ghrelin will be effective in other 
conditions associated with anorexia, and its potential ther- 
apeutic benefits need not be limited to patients with cancer. 
Preliminary studies suggest that ghrelin improves cardiac 
function and protects against cardiac ischernia (24), making 
a therapeutic role in cardiac cachexia particularly attractive. 
This acute study highlights the need for further investiga- 
tions to establish whether long-term ghrelin can be used 
effectively in the palliation of appetite loss. 
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Ghrelin Does Not Stimulate Food Intake in Patients with 
Surgical Procedures Involving Vagotomy 
C. W. le Roux, N. M. Neary, T. J. Halsey, C. J. Small, A. M. Alartinez-1sla, M. A. Gliatei, 
N. A. Theodorou, and S. R. Bloorn 
Department of Metabolic Medicine (C. IVIR., N. M. N., C. J. S., M. A. G., S. R. B. ), Imperial College, and Department of Surgery 
(T. J. H., A. M. M. -I., N. A. T. ), Hammersmith Hospital Trust, London W12 ONN, United Kingdom 
Context: Patients with gastric or esophageal surgery and transection 
of the vagus nerve may suffer from appetite and weight loss but 
without dysphagia or mechanical obstruction to eating. The gastric 
hormone ghrelin stimulates food intake and GH release in rodents 
and man. However, rodents with vagotomy are not sensitive to the 
feeding effects of ghrelin. 
Intervention: Each patient received 120-min infusions of saline, 1 
pmoUkg-min ghrelin, and 5 pmoL/kg-min ghrelin on 3 separate days. 
After 90 min, a buffet meal was served. 
Main Outcome Measure: Energy intake at the buffet meal was 
measured. 
Objective: The objective of the study was to determine whether 
humans with vagotomy are sensitive to ghrelin. 
Study Design: The design was a double-blind, randomized, placebo- 
controlled trial. 
Setting: This was a hospital-based study. 
Patients: Six men and one woman who all had a previous complete 
truncal vagotomy with lower esophageal or gastric surgery entered 
and completed the study. 
P ATIENTS WHO HAVE had gastric or esophageal sur- 
gery with transection of the vagus nerve frequently 
suffer from loss of appetite and loss of weight (1). In a 
series of patients who had Ivor Lewis esophagogastrec- 
tomy, 60% lost weight, whereas onlv 40% suffered from 
dysphagia (1). This disparity suggests that mechanical 
obstruction alone may not full), explain the weight loss 
seen after such surgery. 
A better understanding of the mechanism underlying 
this weight loss would allow development of more effec- 
tive treatments. Ghrelin, the endogenous ligand for the 
GH secretagogue (GHS) receptor, is a 28-arnino-acid pep- 
tide produced primarily in the stomach (2). After gastrec- 
tomy, plasma ghrelin levels were reported to be decreased 
by at least 50'% (3). 
Peripheral ghrelin administration leads to increases in 
food intake and GI-I release in rodents (4,5) and humans 
(6). Circulating plasnia ghrelin levels increase before a 
meal and decrease after the consumption of nutrients (7). 
Therefore, ghrelin has been postulated to increase appetite 
First Published Online May 24,2005 
C VVIR. and N Nl N )rjtrjj)jjted to thk paper. 
Abbreviationý: IiNli, Body mass index; GIIS, (Al secretagogue; 
GLP-1, glucagon-like pej, tid(. -l-(7-36)-armde; NS, not significant; PYY, 
plasma peptide YY; VAS, vi. sual analog scale. 
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Results: Ghrelin-stimulated GH release in a dose-dependent maziner 
was measured, confirming bioactivity. However, no change in energy 
intake was observed with either dose of ghrelin Jenergy intake 
(kilojoules): saline 2805 ± 812; ghrelin 1 pmoUkg-min, 2486 ± 767; 
ghrelin 5 pmoVkg-min, 2382 _- 543; 
P= not significant]. 
Conclusions: Ghrelin is unlikely to be an effective appetite-stimu- 
latory treatment for patients with vagotomy and esophageal or gastric 
surgery. Our results suggest that an intact vagus nerve may be re- 
quired for exogenous ghrelin to increase appetite and food intake in 
man. W Clin Endocrinol Metah 90: 4521-4524,2005) 
and act as a meal initiator (7). Ghrelin may also play a role 
in body weight regulation because plasma ghrelin de- 
creases with weight gain and increases with weight loss 
(8). 
Evidence that ghrelin stimulates motor activity in the gas- 
trointestinal tract is mounting. Ghrelin may affect gastroin- 
testinal motility via specific ghrelin receptors located on 
myenteric, vagal, and central neurons (9). Ghrelin also mod- 
ulates the cardiovascular system. Injection of ghrelin was 
reported to decrease mean arterial pressure without a sig- 
nificant change in heart rate and increase the cardiac index 
and stroke volume index (10). 
Transection of the vagus nerve has been reported to abol- 
ish the orexigenic effect of glirelin in rodents (11,12). In the 
latter study, the postghrelin Gf I response in vagotomized 
rodents remained present but was attenuated. Recently it has 
been reported that patients who have had a vagotomy retain 
their GH response to exogenous ghrelin, although appetite 
was not assessed (13). 
We previously reported that ghrelin stimulates energy 
intake in cancer patient,; with appetite loss (14). However, 
patients with gastric surgery or vagotorn), were excluded. 
The effect of ghrelin on food intake in patients with vagot- 
orny remained to be determined. 
The aim of the current study was to compare appetite and 
food intake in patients who had undergone vagotomy after 
either saline or glirelin infusion. 
4521 
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Subjects and Methods 
Experimental subjects 
All studies were performed according to the principles of the Dec- 
laration of Helsinki and approved by our local research and ethics 
committee (reference no. 2002/6316). Written informed consent was 
obtained from all subjects. Exclusion criteria included pregnancy, 
chronic medical illness likely to interfere with the study and surgery, or 
radiotherapy or chemotherapy within the past month. 
Nine men and one %voinan were recruited. Three patients were ex- 
cluded before the commencement of the study due to significant co- 
morbidity. The remaining seven patients (six men and one woman) 
entered and completed the study (Table 1). All patients had undergone 
transection of anterior and posteriOr trunks of the vagus nerve and 
removal of the funclus of the stomach for proven or suspected malig- 
nancy. Patients 1-3 underwent total gastrectomy. The anatomy of the 
vagotomy was similar in all cases and all were operated on by a single 
surgeon. The mean time between surgery and infusions was 13 ±6 
months (mean -- 5Em). The mean age was 63 -- 4 yr and mean body mass 
index (BMI) 22.2 ± 1.5 kg/M2. 
Methods 
Human ghrelin was purchased from Peninsula Laboratories (St. 
Helens, Merseyside, UK) and 0.9% saline from Bayer (Haywards Heath, 
UK). The limulus amoebocyte lysate assay test for pyrogen was negative 
and the pepticle was sterile on culture. Fasted subjects had two iv 
cannulae placed at 0900 h, one for infusion and the other for blood 
sampling. The infusions of ghrelin or saline were started at 1000 h (t = 
0 min). Each subject received infusion of saline, 1 pmol/kg-min ghrelin, 
or 5 pmol/kg-min ghrelin on three separate days at least 48 h apart in 
a double-blind, randomized, cross-over design. The infusion rates were 
chosen from previous studies. Ghrelin (5 pmol/kg-min) has been Te- 
ported to increase energy intake in healthy volunteers (6) and cancer 
patients with their vagus nerve intact (14). However, patients with 
gastrectomy and associated reduction in enclogenous ghrelin (3) might 
have enhanced sensitivity to exogerious ghrelin. Hence, a lower rate of 
1 pmol/kg-min was also included. Subjects received infusions for 120 
min. After infusion for 90 min, lunch was served, comprising pre- 
weighed pasta lunch presented in excess and water. Subjects were told 
to eat until they were comfortably full. All subjects finished eating within 
20 min. The remaining food was weighed after the meal and energy 
intake calculated. VenOLIs blood was collected at -60,0,60,90,120, and 
150 min. Plasma was separated after centrifugation and stored imme- 
diately at -20 C. Patients were asked to complete visual analog scales 
(VASs) (possible scores 0-100 mm) rating hunger, sickness, and satiety 
at baseline (t ý 0), before lunch (t - 90), and after lunch (t - 150). 
Positions on these scales were measurvc! by a blinded observer. Pulse 
and blood pressure were measure(] every iO min. 
TABLE 1. Details of patients with vagotomy 
Pati, -nt 
Age S, ý 
Weight 
(yr) (kg) 
13 NI I 
kr, 'n, I') 
Surgery 
1 62 NI 801 26.2 Total abdominal 
2 
3 
4 
5 
73 
66 
40 
66 
F 
M 
M 
M 
gastrectomy and 
splenectomy 
60 22.9 Radical total abdominal 
gastrectomy 
58.2 29.6 Total abdominal 
V, ýk, tructoni 
-N 
55.3 17.1 IN-or Lewis 
t.,, )phagectorn. N 
66.7 19.5 Transhiatal 
esophagogastrectomy 
6 74 m 62.5 19,5 Partial gastrectomy 
7 60 M 71 21.9 Ivor Lewis 
esophagectomy 
M, Male; F, female. 
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Hormone assays 
All samples were assayed simultaneously and in duplicate to elim- 
inate the effect of interassay variation. Chrelin-like immuncireactivity 
was measured with a specific and sensitive RIA. The assay measures 
both octanoyl and des octanoyl ghrelin and does not cross-react withany 
known gastrointestinal or pancreatic pepticle hormones. The antisera 
(SC-10368) was obtained from Santa Cruz Biotechnology (Santa Cruz, 
CA) and used at a final dilution of 1: 50,000. The "I ghrelin was prepared 
using Bolton & Hunter reagent (Amersham International, Aylesbury, 
UK) and purified by reverse phase-HI'LC using a linear gradient from 
10 to 40%. acetonitrile, 0,05% trifluoroacetic acid over 90 min. The specific 
activity of ghrelin label was 48 Bq/fmol. Then 25 and 100 pLI of unex- 
tracted plasma was assayed. The assay was performed in a total volume 
of 0.7 ml of 0.06 Ni phosphate buffer (pH 7.2), containing 0.3"/. BSA, and 
incubated for 3d at 4C before separation of free and antibody-bound 
ghrelin by charcoal adsorption. The assay detected changes of 25 pmol/ 
liter of plasma ghrelin with a 95% confidence limit, with an intraassay 
coefficient of variation of 5.5%. Plasma peptide YY (PYY) and glucagon- 
like pep ticle- 1 -(7-36)-amid e (GLP-1) concentrations were quantified us- 
ing established in-house RlAs and antibodies (15,16). 
GH was measured by Advantage automated chemiluminescent im- 
munoassay (Nichols institute Diagnostics, San Clemente, CA). 
Statistical analysis 
Results are expressed as means ± SEM. Energy intake and plasm 
ghrelin and GH levels were compared using a paired t test. VASs were 
analyzed using a Wilcoxon signed rank test, 
Results 
No adverse events were observed or reported on any 
infusion day 
Fasting baseline ghrelin levels were similar on all infusion 
days [ghrelin picomoles per liter: saline day 295 -± 55, glirelin 
I pmol/kg-min day 284 -± 50, ghrelin 5 pmol/kg-min day 
326 ± 57 pmol/liter; P= not significant (NS)I. On the saline 
control day, there was no significant change in plasma 
ghrelin after the meal [ghrelin picomoles per liter: 90 min 
(premeal), 271 -- 70; 150 min 
(60 min postmeal), 236 -_ 48; 
P=0.251. 
Plasma ghrelin was significantly elevated by ghrelin in- 
fusion at 1 prnol/kg-mm and increased further by ghrelin 
infusion at 5 pmol/kg-min (plasma ghrelin picomoles per 
liter at 90 min: saline day 270 ± 70, ghrelin I pmol/kg-min 
day 958 -1- 60, ghrelin 5 pmol/kg-min day 4087 - 253; P< 
0-65). A significant and dose-dependent rise in GH was as- 
sociated with ghrelin infusion, confirming that the ghrelin 
was biologically active (GI I milhinternational Units per liter 
at 90 min: saline, 1.2 ± 0.5; ghrelin 1 pmol/kg-min, 32.6 ± 6.2; 
glirelin 5 pniol/kg-min, 60.9 '- 12.7; P<0.005) (Fig. 1). 
Plasma PYY and GLP-1 concuntrations were similar during 
saline and ghrelin infusions [PYY (picomoles per liter) at 90 
min: saline, 22.6 -_ 3.5; ghrelin I pmol/kg-min, 23.3 - 3.5; 
ghrelin 5 pmol/kg-min, 23.7 ± 5.5; GLP-1 (picomoles per 
liter) at 90 min: saline, 53.0 ± 9.0; ghrelin 1 pmol/kg-min, 
54.9 ± 10.5; ghrelin 5 pmol/kg-min, 57.7 -- 14.11. 
There were no. statistically significant differences in energy 
intake among the three infusion days (Fig. 2) [energy intake 
(kilojoules): saline, 2W5 ý 812, ghrelin I pmol/kg-min, 
2486 ± 767; ghrelin 5 pmol/kg-min, 2382 -_ 543; P= NS; 
percentage change from saline infusion day: ghrelin I pmol/ 
kg-min, -4 ± 11%; ghrelin 5 pmol/kg-min, -5 ± 8%]. These 
findings are in marked contrast with the 31% increase in 
energy intake reported in cancer patients without vagotomy. 
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100 
80 
60 
40 
20 
0 
G" (miU/1) 
saline I5 
Ghrelin (pmoUkg/min) 
FIG. 1. GH response immediately before lunch (t = 90 min) after 
infusion of 0.9% saline, 1 pmoUkg-min ghrelin, and 5 pmoUkg-min 
ghrelin. *, P<0.05. 
Analysis of the VAS revealed no significant differences in 
hunger or sickness ratings among the three infusion days 
[hunger score at 90 min (millimeters): saline, 70 ± 9; ghrelin 
1 pmol/kg-min, 62 t 9; ghrelin 5 pmol/kg-min, 61 ± 10; 
sickness score at 90 min (millimeters) saline, 6.0 ±- 1.4; ghrelin 
1 pmol/kg-min, 6.0 ± 1.5; ghrelin 5 pmol/kg-min, 5.8 ± 1.51. 
Although there were no differences in how full they felt 
before the meal between infusions, patients reported feeling 
less full after the meal on the 5 pmol/kg-min ghrelin infusion 
day, compared with saline [satiety score (millimeters) at 150 
min: saline, 65 -- 10; ghrelin 5 pmol/kg-min, 56 -- 11; P< 
0.05]. There was no difference in the meal appreciation score 
after the meal [meal appreciation score (millimeters): saline, 
68 -1 9, ghrelin 
1 pmol/kg-min, 71 ± 8, ghrelin 5 pmol/ 
kg-min, 68 ± 8; Pý NIS for ghrelin I pmol/kg-min and 
ghrelin 5 pmol/kg-min vs. saline]. 
Analysis of the pulse recordings revealed a reduction in 
pulse rate with 5 pmol/kg-min ghrelin but not at the lower 
dose of 1 pmol/kg-min. [difference in pulse rate at 90 min 
from baseline (beats/min): saline, 0.6 ± 2.0; ghrelin 1 pmol/ 
kg-min, 0.4 ± 1.2; ghrelin 5 pmol/kg-min, -5.6 -- 1.4, P=0.01 
for ghrelin 5 pmol/kg-min vs. saline]. There were no signif- 
icant differences in systolic blood pressures between infusion 
days. However, a significant reduction in diastolic blood 
pressure v,, as observed with the higher dose glirelin infusion, 
compared with saline [difference in diastolic blood pressure 
at 90 min from baseline (millimeters of mercury): saline, 4.2 ± 
A %energy intake of saline day B energy intake (MJ) 
140 r8r 
120 
100 
80 
60 
40 
241 
0 
Saline 15 
Ghrelin (pmol/kWmin) 
4 
saline 
Ghrelin (pmol/kg/min) 
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2.6; ghrelin 1 pmol/kg-min, -1.1 -1 2.0; ghrelin 5 pmol/ kg-min, -6.8 -- 2.2; P<0.001 for ghrelin 5 pmol/kg-min vs. 
saline]. 
Discussion 
The observation that ghrelin no longer stimulated food 
intake in rodents after vagotomy was initially surprising, but, 
to date, this had not been studied in man. We have observed 
that iv ghrelin did not alter appetite or energy intake in 
patients with vagotomy and partial or total gastrectomy. 
I lowever, we found, as with vagotornized rodents (12), that 
the GH-stimulatory response after ghrelin administration 
was present. Ghrelin was also associated with small but 
statistically significant reductions in pulse rate and mean 
blood pressure, the latter as previously reported by Nagaya 
et al. (10). There were no differences in the hunger, fullness, 
or sickness scores during ghrelin infusion. There was, how- 
ever, a significant reduction in the postprandial fullness 
score after ghrelin (5 pmol/kg-min) infusion. In addition to 
its effects on appetite and GH release, ghrelin has beerr re- 
ported to stimulate gastric motility (17). The reduction in 
postprandial satiety observed in the current study might be 
explained by an alteration in gastric motility associated with 
ghrelin infusion. Thus, ghrelm stimulated GH release and 
may have stimulated gastric motility but did not alter ap- 
petite or energy intake. These findings are in marked contrast 
with the 31% increase in energy intake in similarly aged 
cancer patients with intact vagus nerves (14) and to the 28% 
increase in energy intake observed in healthy volunteers (6). 
Similar to our findings, exogenous ghrelin has been shown 
not to stimulate food intake in vagotornized rodents, al- 
though the GH response was present. These findings were 
attributed to the absence of effective ghrelin receptors that 
are normally present in the afferent vagus (12). Vagotomy 
may affect hypothalamic neuronal activation normally seen 
after peripheral ghrelin administration. In rats that had tin- 
dergone vagotomy, reduced expression of c-fos, a marker of 
early neuronal activation, was observed in neuropeptide Y 
and GIIRH neurons after peripheral ghrelin administration, 
compared with sham-operated controls (12). These change, - 
in hypothalamic activation to glirelin Could be explained by 
the lack of afferent vagal responses. Alternatively, it could be 
that vagotomy is itself associated with alterations in hypo- 
thalamic neuronal circuitry. Further work is needed to elu- 
cidate the role of the ghrelin GI IS receptor of the vagus nerve. 
Patients with total or partial ga-strectonues have decreased 
plasma ghrelin levels despite a low BMI (18). The fundus of 
tile stomach is the single largest source of ghrelin and in its 
absence the other ghrelin producing tissues do not have the 
capacity to compensate fully (3,18). It might have been 
hypothesized that reduced plasma ghrelin concentrations 
would lead to up-regulation of ghrulin receptors and that iv 
ghrelin would be associated with an enhanced appetite re- 
sponse. 1 lie ri,,, c in plasma GI I associated with ghrelin in- 
fusion in the current study was similar to that seen at similar 
rates of ghrelin infusion in previous studies (6,14). Thus, the 
GH response to ghrelin in patients with vagotomy appeared 
to remain intact. This provides evidence of activity at the 
G1 IS ghrelin receptor. The disparity in the absence of a feed- 
FIC,. 2. A, Buffet meal energy intake after infusions of 0.917, saline, 1 
pmoUkg-min ghrelin, and 5 pmol/kg-min ghrelin. Results are pre- 
sented as percent energy intake of saline day. B, Energy intake (mil- 
lijoules) for individual patients. Each line represents one patient. 
Mean energy intake is presented as a bold line. 
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ing but presence of a GH response in our study could be 
explained if ghrelin's feeding effects required an intact vagus 
nerve, but the GH-releasing effects were signaled by direct 
action on the hypothalamus. 
Patients frequently suffer from profound weight loss after 
gastric surgery and vagotomy (1). Indeed the absolute energy 
intake at the buffet meal of this group on the saline infusion 
day was considerably less than that seen in a previous study 
of healthy volunteers (6) [energy intake (kilojoules): patient 
with vagotomy 2805 -± 812 vs. healthy volunteers 4713 ± 
344]. It may be that reduction or even absence of a feeding 
response to endogenous ghrelin in patients with vagotomy 
contributes to their weight loss. Weight gain could be ben- 
eficial to support recovery of postoperative and cachectic 
patients. From a treatment perspective, our results suggest 
that ghrelin is unlikely to be an effective appetite-stimulatory 
treatment for patients who have had esophageal or gastric 
surgery with vagotomy. From a mechanistic perspective, this 
study suggests that in humans, as in rodents, an intact vagus 
nerve may be required for exogenous ghrelin to increase 
appetite and food intake. 
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PeptideYY3-. 36and Glucagon-Like Peptide-17-. 361nhibit Food Intake Additively 
Nicola M. Neary, Caroline J. Small, Maralyn R. Druce, Adrian J. Park, Sandra M. Ellis, 
Nina M. Semjonous, Catherine L. Dakin, Karin Filipsson, Fang Wang, Aysha S. Kent, Gary S. Frost, 
Mohammad A. Ghatei, and Stephen R. Bloom 
Department of Metabolic Medicine, Hammersmith Hospital, Imperial College London, London W12 ONN, United Kingdom 
Peptide YY (PYY) and glucagon like peptide (GLP)-I am cq- 
secreted from intestinal L cells, and plasma levels of both 
hormones rise after a meal. Peripheral administration of 
PYY,,, and GLP-17. u inhibit food intake when administered 
alone. However, their combined effects on appetite are un- 
known. We studied the effects of peripheral oond ministration 
of PYY, -. with 
GLP-1,, -. 
in rodents and man. Whereas high- 
dose PYY,.. (100 nmol/kg) and high-dose GLP-17ýa. (100 nmoll 
kg) inhibited feeding individually, their combination led to 
significantly greater feeding inhibition. Additive inhibition of 
feeding was also obsexved in the genetic obese models, oblob 
and dbldb mice. At low doses of PYY3,. " U nmoVkg) and GLP- 1., -m 
(10 nmoVkg), which alone had no effect on food Intake, 
coadministration led to significant reduction in food intake. 
To investigate potential mechanisms, cý&@ immunoreactivity 
was quantified in the hypothalamus and brain stem. In the 
hypothalamic arcuate nucleus, no changes were observed af- 
ter low-dose PYY4-" or GLP-I, -" 
individually, hut there were 
significantly more fos-positive neurons after coadministrac 
tion. In contrast, there was no evidence of additive fos-stim. 
ulation, In the brain stem. Finally, we coadminifftered. PYY, _. and GLP-17-" in mskn- Ten lean fasted volunteers received 
120-min infusions of saline, GLP-17.... (0.4 pmoVkg-min), 
PYYs-m (0.4 pmo]Vkg. min), and PYY&-" (0.4 pmoVkgmin) + 
GLP-1ý4w (0.4 pmol/kIrmin) on four separate days. Energy In. 
take from a buffet meal after combined PYYsw + GLP-17-m 
treatment was reduced by 27% and was significantly lower 
than that after either treatment alone. Thus, PYY8-" and GLP. 
17_8, cosecreted after a meal, may inhibit food intake 
additively. (&ýrinolov 146- 5120-5127,2005) 
T HE GUT HORMONES peptide YY (PYY) and glucagon- 
like peptide (GLP)-I are cosecreted from endocrine L 
cells of the small and large bowel. Endogenous concentra- 
tions of both hormones are low in the fasting state and rise 
within 30 min of a meal (1). However, whereas these hor- 
mones have been found to inhibit food intake individually (2, 
3), their combined effect has yet to be Investigated. 
It has been reported that peripheral administration of 
PYY3_36 inhibits appetite in rodents (4,5) and man (2). Pe- 
ripheral administration of GLP-17-36 inhibits food intake in 
rodents (6,7) and man (8). GLP-17-36 and the GLP-I receptor 
agonist exendin-4 also stimulate insulin release and inhibit 
circulating glucagon (6). In contrast, no changes in insulin 
and glucagon concentrations occur after PYY3-36 adminis- 
tration (9). 
PYY and GLP-1 may mediate these peripheral effects by 
altering central nervous system appetite circuits. After ip 
administration of PYY, -w an 
increase in c-fos, a marker of 
neuronal activation, has been reported in the hypothalamic 
arcuate nucleus (ARC) (2). in contrast, GLP-l is reported to 
act primarily on brain stem neurons. After iv exend in4, c-fos 
activation was observed in the area postrema (AP) (10), 
which, like the ARC, has access to the peripheral circulation. 
c-fos immunoreactivity was also detected in the ARC and 
First Published Online September 8,2DOS 
Abbreviations: AP, Area postrema; ARC, arcuate nucleus, FLLjos-like 
inummoreactivity, GLP, glucagon like peptide-1; PB, phosphate buff- 
ered; PVN, paraventricular nucleus; PYY, peptide YY; WT, wild type. 
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paraventricular nucleus (PVN). This hypothalamic activa- 
tion could be mediated via neuronal projections from the 
brain stem to the PVN (11) or directly onto ARC neurons. 
Both PYY,, 6 and GLP-17-36 have been administered to humans. Intravenous infusion of PYY3. -m was associated 
with a 36% reduction in energy intake at a free buffet meal 
(2). PYY&-m has also been reported to inhibit food intake in 
obese subjects (12). A recent metaanalysis reported that in- 
fusion of GLP-17_ý6 was associated with a small dose-depen- 
dent reduction in energy intake in both lean and obese sub- 
jects (8). Interestingly, when PYY and GLP-1 were 
coadministered to man, an additive inhibitory effect on pen- 
tagastrin-induced gastric acid secretion was observed (13), 
although their combined effect on appetite was not examined. 
Much work has been performed investigating the effect of 
exogenous administration of individual gut hormones on 
appetite to determine their potential physiological role in the 
control of food intake (4,14,15). However, after a meal not 
one but several gut hormones are elevated, and It may be that 
the interactions between the changes in levels of different 
hormones influence food intake more than each hormone 
individually. 
The aim of our study was to investigate whether the com- 
bined administration of PYY3-m and GLP-17-36 was more 
effective in inhibiting food intake than either peptide alone. 
First, we examined the effects of coadministration of PYY3. -m 
and GLP-17-m in lean and obese rodents. Second, to inves- 
tigate potential mechanisms, we quantifiedfos-like immuno- 
reactivity (FLI) In the hypothalamus and brain stem after ip 
PYY346 and GLP-l7_a6 alone and PYY3_m + GLP-17-36 co- 
administration. Finally, we performed a randomized, dou- 
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ble-blind, placebo-controlled, crossover trial in healthy vol- 
unteers to compare the effects of PYY3-a6, GLP-17-,, and 
PYY3_36 with GLP-17-3, on energy intake in man. 
Materials and Methods 
Materials 
Synthetic human PYYIm and GLP-17-36 were purchased from Phoe- 
nix Pharmaceuticals (Belmont, CA). Unless otherwise stated, an chem- 
kals were purchased from Merck (Poole, Dorset, UK). 
Animals 
Ali animal procedures were approved by the British I-Tome Office 
Animals (Scientific Procedures) Act 1986 (project license no. 70/5516 and 70/5281). Male mice and rats were maintained in individual cages under 
controlled temperature (21-23 Q and light (12-h lightý 12-h dark cycle; lights on at 0700 h) with ad Wtum access to standard chow (RM1 diet, 
SDS Ltd., WithamEssmUK) and water. All animals werehandled daily for 7d before the first study, particularly in the light of recent evidence 
that peripheral M3-w does not inhibit food iritake in stressed animals 
unaccustomed to their experimental conditions but does so in well- handled, acclimatized animals (5). During the acclimatization period, 
each animal received two saline injections to minimize stress on the 
study days. 
Intraperitoneal injections 
Intraperitoneal injections were administered to ntice via a 0.5 n-d 
syringe with a 29-gauge needle (maximum injection volume, 0.1 ml) and 
rats via aI ml syringe with a 25-gauge needle (maximum volume, 0.5 
ml). Tn each study animals received one Injection only of equivalent 
volume for each treatment group. For the combination treatment, GLP- 
17-a, and PYY, -m were 
drawn up in a single syringe. In all feeding 
studies, food intake was measured 1,2,4,8, and 24 h after injection as 
previously described (7). 
Feeding studies in lean mice 
C57BL/6 mice (20-25 g) were injected after a 20-h fast. To detem-dne 
suitable doses for the combined study, dose-response studies were per- formed for PYY3. w and GLP-17-m individually. For the PYY,,..,, study, 
mice were ip injected with 30,100,150, and 300 nmol/kg Pyy. ý, -M (n = 11-12). For the GLP-17-a6 study, micewere injected with 30,100,300, and 
900 rimol/kg GLP-1, -. (n - 10). For the combined study, mice were injected with saline, 100 nmol/kg PYY, -3& 200 nmol/kg PYY,.., 100 nmol/kg GLP-17-w 200 nmol/kg GLP-17-e& or 100 nmol/kg PYY3-, + 
100 nmol/kg GLP-17-a(, (n = 8-9). 
Feeding studies in oblob and dbldb mice 
To investigate these effects in obese rodents, PYY3-3r, + and GLP-I, -,, were coadministered to oblob and dbldb mice (both on a C5713L/6 back- 
ground) in a four-way crossover design. After a 20-h fast, oblob mice (mean weight 54.5 t 1.4 g) and their wild-type (Wl) littermates (32.5 ± 1.0 g) and dbldb mice (41.8 t 1.12 g) and their WT littermates (31.0 ± 0.5 g) were ip injected with saline, 200 runol/kg PYY3-3,,, 200 nmol/kg GLP-17-, u, or 100 nmol/kg PYY, -. + 100 runol/kg GLP-l7-a6. Four studies were performed withý 72 h between each study so that each 
mouse received all four treatments (n - 10 per treatment group). 
Feeding studies in rats 
To examine the effect of PYY3, u and GLP-17-,, in another species and during another feeding phase, these peptides were coadministered in 
rats in the dark phase. Rodents are nocturnal feeders and eat the majority 
of their food during the night (16). Freely feeding rats (150-200 g) were Injected in the hour before lights off. For the PYY, -M dose-response study, animals received ip saline or 1,3, or 10 nmol/kg PYY (n - 12-13). for GLP-17-.,,; rats received saline or 3,10,30, or 100 r3L-MO6ol/kg GLP-1-y-" (n = 12-13). To investigate the combined effect of low doses, I nmol/kg M3-36 and 10 nmol/kg GLP-17_% were chosen for the joint 
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study (see Results). On two evenin gs, 72 h apart, animals were random- 'zed and injected iP with saline, 10 nfn0l/kg GLP-17-,, 20 nmol/kg GLP-17-3,1 runol/kg PYY,. -,, 
2 nmol/kg pyy3_. or I nmol/kg PYY3-36 + 10 nmol/kg GLP-17-a, (total n= 19-20 per group) before the dark phase. 
Immunocytochemistry 
The protocols for c-fos staining and quantification were similar to 
those described previously (17). Briefly, rats (240-265 g) were each 
handled for 5 min/d for I wk to minimize the stress of the procedure. 
After an overnight fast, rats received ip infections of saline, 10 nmol/kg 
GLP-17-3w I runol/kg PYY3,. or I nmol/kg PYY,,,, + 10 nmol/kg 
GLP-l7_a6 (n - 5-6 per group). Ninety minutes later, they were termi- 
nally anesthetized with ip sodium pentobarbitone (200 mg) (Rh6ne 
Wrieux, Harlow, UK) and transcardially perfused with 0.1 m PBS fol- 
lowed by 41/6 phosphate-buffered (PB)-fonruWn. The brains were re- 
moved and postfixed overnight in MI-formalin and then transferred tq 
PB-sucrose (2D% wt/vol) for 48 h. Serial 40-pan coronal brain sections 
were cut an a freezing n-dcrotome and stained for FU using the avitin- 
biotin-peroxidase method. Fos-positivenucletwerecounted usinga light 
microscope (Eclipse BW; Nikon, Tokyojapan) byan experienced mem- 
ber of the research team with reference to the Rat Brain Atlas (18), who 
was unaware of which treatment had been given. 17* nuclei examined 
were the PVN, ARC, ventromedial and dorsomedial of the hypothala- 
mus, and the nucleus of the solitary tract and the AP of the brain stern. 
Behavioral studies 
To determine whether alterations in behavior were associated with 
treatments of peptides used in the feeding and c-fos studies, an obser- 
vation study was performed (19). After an overnight fast, rats (150-170 
g) were injected ip with Wine, 10 nmol/kg GLP-17-, w I nmol/kg PYYI. a, 1 runol/kg PYY3.. m + 10 nmol/kg GLP-17_w 10 runol/kg 
exendin4, or Im lithium chloride (positive control) (n - 10 per group) 
and their food replaced. Their behavior was assessed for the subsequent 
60 min by two observers who were unaware of which treatment had 
been given. Each observer recorded behaviors of 30 animals (n =5 per 
group per observer). Each rat was observed for 15 sec in every 5 min. The 15-sec periods were subdivided into three 5-sec periods. In each or 
these periods, the observer selected the behavior dot most closely re- 
sembled what the rat was doing. These options were feedin& drinkin& locomotion, groomin& head down, sleepin& and rearing. In a further experiment, freely feeding rats were ip injected before the dark phase with saline, 10 nrnol/kg GLP-17-, w I nmol/kg FYY,,,, 1 mnol/kg PYY3-. + 10 nmol/kg GLP-Iý.. or 10 nmol/kg exendin4. Infrared beam breaks in two planes x-tot (horizontal movement) and 
z-tot (vertical movement) were counted for Ih using an Opto-Max 
system (Columbus InBtruments, Columbus, OH) to assess locomotion. 
Human randomized, double-blind, controlled trial 
The study was approved by the Harnmersmith, Queen Charlotte's, 
and Chelsea Ethics Committee (reference no. 2002/6261) and performed 
In accordance with the principles of the Declaration of Helsinki. Healthy lean volunteers were recruited through advertisement. Exclusion crite- 
ria were substance abuse, pregnancy, significant medical or psychiatric 
illness, or regular medication except the oral contraceptive pill. Twelve 
subjects were recruited, each of whom gave their informed consent to 
participate in the study. One subject was withdrawn due to violation of 
the protocol and another was withdrawn due to nausea on a study 
morning. Thus, 10 subjects (four men and six women) completed the 
study. Their ages ranged from 22 to 29 with a mean age of 25.6 :t0.7 yr, 
and body mass index ranged from 20.5 to 26.4 with a mean of 23D ± 0.7 kg/mý. 
Each volunteer received four infusions, saline, GLP-17-al PYY3-31 or 
PYY,. 
-. 6 with GLP-17-3& each on a separate day at least 5d apart. 
Subjects 
fasted from 2100 h on the evening before infusions. The infusion days 
were run as previously described (20). 
Both PYY3_" and GLP-17-m were sterile on culture, and limulus 
arnoebocyte lysate assay tests for pyrogen were negative. Two vials were 
used for each hifusion (saline + saline, saline + GLP-17-W saline + 
PYY3., 
.w and 
PYY3,, 
6 + GLP-17. a. ). Both vials were dissolved in 2.5 ml 
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herracel (Beacon, Tunbridge Wells, Kent, UK) to minimize peptide ad- 
sorption, diluted in 0.9%. saline (Bayer, Newbury, Berkshire, UK) and 
drawn up in a single syringe (total volume 50 m]), The infusion rates 
chosen were based on the results of previous studies. PYY, at 0,8 
pmol/kg-min was associated with a 36% reduction in food intake (2). 
The lowest rate of GLP-l_, 36 that has been shown to inhibit food intake 
is 0.75 prnol/kg-min (21). We airned for a submaximal effect for each 
individual peptide and so selected rates of 0.4 pmol/kg-n-Lin for both 
GLP-17, and PYY. infusions and a rate of 0.4 pmol/kg-min PYYý 
+ 0.4 pmol/kg. n-dn GLP-17-36 for the combined infusion. Infusions were 
given for 120 min. 
After 90 min infusion, a buffet lunch was served of preweighed food 
in excess consisting of chicken or vegetable curry, rice, fruit salad, and 
sweets. TI-tirty minutes later, the remaining food was removed and 
weighed and the infusion discontinued. BI(x)d sarriples (10 ml) were 
taken 30 min before the start of the infusion, immediately before the 
infusion, and then every 30 min until 2h after the meal. Blood was 
collected into heparin-coated tubes containing 2000 Kallikrein inhibitor 
units (0.2 md) of aprotonin (Bayer). After centrifugation, plasma was 
separated and stored immediately at -70 C until RIA. Subjects were 
asked to score subjective nausea on a visual analog scales (0-100 mm) 
(22) at each time point. Pulse and blood pressure were also measured at 
these time points. Subjects were allowed to leave 2h after the meal and 
instructed to eat ad libitum and complete a food diary for the following 
24 h. 
RIAs 
All samples were assayed in duplicate and single assays to eliminate 
the effects of interassay variation. PYY, GLP-1, and insulin concentra- 
tions were quantified using established in-house RIAs and antibodies 
(23-25). Glucose concentrations were measured using a YSI-2300STAT 
analyzer (Yellow Springs Instruments, Yellow Springs, OH). 
Statistical analysis 
Results are shown as mean values ' SEM. Data from the animal 
feeding and immunocytocliemistry and behavior studies were analyzed 
using a one-way ANOVA with a Dunnett's two-sided post hoc test. For 
the hurnan infusions, a random effect, repeated-measures ANOVA was 
performed and within-subject effect examined under a Greenhouse- 
Geisser correction. To all cases P --- 0.05 was considered to be statistically 
Results 
Coadministration ol high-dose ITY, ; and (ILP-1 in 
lean mice 
In the I1YY-,,,, dose-responsestudy, food intake in the first 
hour was significantly inhibited by all doses of PYY., -, ad- 
ministered Ifood intake 0-1 h (grarns): ýaline, 0.67 1 0.05; 
PYY, 
_, ý 
30 nrnc)]/kg, 0.49 _ý_ 
0.04,100 nmol/kg, 0.44 ý 0.03, 
150rimol/kg, 0.47 I 0.02,300nniol/kg, 0.47 - 0.04](11- 0.05 
for all doses vs, saline) (Fig. ]A). PYY appeared to cause 
maximal feeding inhibition from doses of 100 nmol/kg and 
'111o% 0, '111d 
this doýe ý% 'Is ýelected 
for tile Combitled "ttid ý;. 
Inhibition inctimulative feeding wassustained lvithalldoses 
for Lit) to 8 11 aticr injection (data not shown). 
_36 
dose-response study, food intake in the In the Gl, l'-I,, 
first hour was significantly inhibited by 100,300, and 900 
nmol/kg GLP-17-36 but not significantly by the 30 nmol/kg 
dose [food intake 0-1 h (grams): saline, 0.85 1 0.05; GLP- 
1) nmol/kg, 0.72 , 0.07,1()Oflli)ol/kg, 0.45 0.03, N)O 
nmol/kg, O.: 31 ' ()J)5,9()0nrno1/kg, 0.20 .10.051 
(1) - 0.01, for 
100,300, and 9W nmol/kg ig. I B). In ""'_17-16 7'S- Saline) 0' 
contrast with the PYY study, greater inhibition of feeding 
was observed with increasing doses of GL, I)-I, -,, 
(1) < 0.05 
forl(X)V, S. 30 nmol/kgGLI)-17-,, and for3OOvs. 100nmol/kg 
A '°° 
0.5o 
0.00 
B 1.00 
030 
0.00 
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* ** 
Saline 30 119) 1.14) w 
PYY,, (nnnol/kg) 
§ 
roý 
sulille -M) 
100 
. 
300 ýMkl 
C IT- 1, 
, 
(nmot/kg) 
nG. 1. The effect on food intake in fasted mice in the first hour ofip 
PYY,,,, (30,100,150, and300 amoVkg) Wor GLP-17-36 (30,100,300, 
and 900 nmoVkg) (B). *, P<0.05 vs. sWine. §, P<0.05 for 100 (is. 30 
nmol/kg GLP-17-, 36 and 300 us. 100 nmoVkg GLP-171- 
GLP-17-,, ). A dose of 100nmol/kgGLP-17.,, 6 was selected 
for 
the combined study, which achieved an approximately 50% 
reduction in food intake in the first hour. Inhibition in cu- 
mulative feeding was sustained up to 8h after injection after 
100,300, and 900 nmol/kg GLP-17-ý,,, - 
The doses for the coad ministration study were as follows: 
saline, 100 nmol/kg PYY3-3w 200 nmol/kg PYY,,,,, 100 
nmol/kg GLP-17.. 200 nmol/kg GLI'-l, -,, and 
1W 
nmol/kg PYY, ,, + 100 nmol/kg 
GLP-17-,,, All pepticles 
iniiibited feeding in the first hotir, compared with saline. 
Coadministration of py'Y3-36 Wit" (-"1'1'-17-36 led to S'91"f'- 
cantly greater feeding inhibition dianall otber grOUJIS [food 
intake 0-1 li (grams): saline, 0.74 -1- 
0.07; 100 nrnol/kg (; Ll'- 
0.33 0.05; 200 ninol/kg GLY-1, -,, 0.33 1 0.07; 100 
11111ol/k-g PY)"3w O. W , 0.03; 200 11111ol/k-g PYY; ,,, 
0,51 
0.04; 100nrnoI/k-gPYY, 
-,,, 
i 100iiinol/kg('ýl")-17-1f,, ()()7 
0.07: 1', -. 0.05 for combined gIOLIPS VS, all otlier groups) kFig. 
2). Feeding iniiibition after tl)c, combination treatment was 
sustained up to 24 h after injection [tood intake U-24 li 
(grams): saline, 7.0 1 0.2; 100 nmol/kg Gl. p-17-J6,6.5 -ý 0.2; 
200 nniol/kg GIT- Iý,,, 71.2 - 0.2,100 nrnol/kg PYý ...... 
6.9 , 0.2; 200 nmol/kg PYY,, o. 8 1 0.2; 100 nniol/kg 
f 100 iiniol/kg G1 P-I ,,, 6ý1 ' 03: P 0.0-) for 
combined grotip vs. saline]. 
Coadniinistration ('/"'Yr, --. 16 and 
GLP-17--,,,, in oblob and 
A ldb rn ice 
Mice ", eie randornized to receive saline, 200 nmolji, 
(; LP-I. /-,, 2Wnjnol/kg IIYY, , or lWimiol/kg I')Y,,, i 100 nmol/kg Coadministration of PYYý'_',, and 
GI, P-1,,, in olilob mice and their wr littermates led to sig- 
nificant inhibition of feeding, compared with saline and both 
peptides alone [food intake 0-1 h (grams), ol)lol) mice: saline, 
Nearv et (it. * PYY and GLP- I Inhibit Feeding Additively 
7. 
1.00 
e4 
0.041 
t 
* 
IM-1 -T- 
Saline P+G 11 2.1, C 2*(; 
FiG. 2. The effect of ip coadministration of PYY.,, with G. LP-l, 
in fasted lean mice on feeding in the first hour. Mice were injected with 
saline, P+ G (100 nmoUkg PYY,, + 100 rimoVkg GLP-17., ), G (100 
nroulflig GLP-17--36), 2*G (200 nmoUkg GLP-Ic), P (100 nrnol/kg 
PYY... ), or 2*P (200 nmoVkg PYY,., ). *, P<0.05 vs. saline. t, P< 
0.05, compared with all other groups. 
0.48 ± 0.09; 200nmol/kgGLP-17-3,, 0.25 ± 0.03; 200nmol/kg 
'YYY3-36,0.32 ± 0.05; 100 nmol/kg IIYY, -,, 
+ 100 nmol/kg 
GLP-l7_3,,;, 0.14 ± 0.03; P<0.05 for combined group vs. all 
other groups; food intake 0-1 h (grams), WT mice: saline, 
1.2 ± 0.08; 200 nmol/kg GLP-17-36,0.68 0.09; 200 nmol/kg 
PYY,, 
-3,, 
0.78 ± 0.069; 100 nmol/kg PYY,,, (, + 100 nmol/kg 
GLP-17-3610.33 ± 04; P<0.05 for combined group vs. all other 
groups]. The percentage reduction in food intake with the 
coadministration treatment, compared with saline, was sim- 
ilar in oblob (-74 t 4%) and WF mice (-70 -- 6%) (Fig. 3A). 
Reduction in cumulative food intake was sustained for up to 
24 h in the WT mice and up to 8h in the oblob mice (data not 
shown). 
Coadministration of PYY3-3,, and GI-P-17-36 was also as- 
sociated with significant reductions in food intake in Aldb 
mice and their WT littermates, compared with saline and 
both peptides alone [food intake 0-1 h (grains), effildl; mice: 
A i5o 
W0 
5() 
B 
IN "F 
I- 
59 
f -I- 
-L:,. 
i- 
. 
blob 
-L 
ir 
L-T- 
%VT (I b/d It 
Fi(,,. 3. Food intake in the firit hour after ip coadininistration of 
PN'Y:,,, w it Ii GIT- in fasted Wrand ob /oh inive (A) a nd NVTand 
(Ibldb (B) micv. Results are presented as a perct-11tage ot div Invall 
food intake on the saline day. Mice Were injecte(I with salifit" 100 
nrnoUkg PYY, ýý 1 100 nnioVkg (xLP-17-,,;, 200 muoAg GIT-1., ,,, 
or 200 nnioVkg PYY,,,, *, P<0,05 vs. saline. t, P<0.05, compared 
with all other groups. White column, Saline; hatched column, GLP-1; 
striped colainn, PYY; black column, PYY i GLP-l (100 ninol/kg 
PYY:, ;,, f 100 nrnolIkg 
GLP-Iýý6). 
End,. rinolon, I kývml. -r 2(K)5, IA6 12,512 0 , 127 5 123 
saline, 0.59 ± 0,10; 200 nmol/kg GLP-L 0.45 i 0.05; 200 
nmol/kg lYY, -36,0.36 
ý 0.04; 100 nmol/kg '", 
-% 
+ 100 
nmol/kg GLP-I, 0.2() 4 0.04; P<0.05 for combined group 
vs. all other groups; food intake 0-1 h (grams), VVT mice: 
saline, 1.17 -- 0.09; 200 nniol/kg GLTAý--A, 0.99 - 0.05; 200 
nmol/kg I)W,,,,, 0.76 0.07; IM nmol/kg JINN, -, 
1 100 
nmol/kg GLP-17-, 36,0.41 0.07; P< 
0.05 for combined group 
vs. all other groups]. The percentage reduction in food intake 
with the coadministration treatment, compared with saline, 
was similar in AIM) (-65 ý- 7'/0) and WT mice (-63 ý 6%) 
(Fig. 3B). Reduction in cumulative food intake was sustained 
for up to 8h in both WT and dbldb mice (data not shown). 
Coadministration of low-dose PIT3-,, 6 and GLP- 17-76 
in rats 
PYY,. u, and GLP-17.36 
dose-response studies were per- 
formed in freely feeding rats in the dark phase. In the PYY3-, 3, 
study, food intake in the first hour of the dark phase was 
significantly inhibited by 3 and 10 nmol/kg MY, _, 
but not 
significantly by the I nmol/kg dose [food intake 0-1 h 
(grams): saline, 4.9 ý 0.2; PYY3--, w 1 nmol/kg, 4.5 1 0.5; 3 
nmol/kg, 3.8 ± 0.3; 10 nmol/kg, 3.5 !: 0.3; P<0.05 for 3 and 
10 nmol/kg PYY,,.,,, zK. saline] (Fig. 4A). In the GLI'-I,,, 
study, food intake in the first hourwis significantly inhibited 
by 30 and 100 nmol/kg GLP_17-36 [food intake 0-1 h (grams): 
saline, 5.0 ± 0.3; Gl-P-1 7-3,3 nmol/kg 
4.9 ± 0.5; 10 nmol/kg, 
4.5 1 0.3; 30 nmol/kg, 4.1 1+ 
0.3; 100 nmol/kg, 3.8 1 0.3; P< 
0.05 for 30 and 100 nmol/kg GLP-17.36 VS saline] (Fig. 4B). 
The doses of peptides selected for the combined study 
were 3-fold lower than the minimum doses found to inhibit 
food intake significantly in the first hour. Rats received ip 
injections of saline, I nrýol/kg IIYY,, _ý, 
2 nmol/kg l'YY_, 3,,, 
10-nmol/kg GIT-17-36,20 nmol/kg (-"1-F_l7-.., 6, or I nniol/kg 
PYY, 4ý 4 10 nmol/kg GLP-17-36. Food intake was signifi- 
A6 
B6 
Saliliv 
[IN I mmoUkg) 
-I 
4 
a Salim 
.1 
11) 34) 1110 
ounoVkg) 
Fi(,. 4. The effect on food intake in the first hour nf the dark phase 
in freely feeding raLs of ip PYY: ýýjc (1,3, and 10 nrnoVkg) (A) or ip G1,11-1, 
-, 
(3,10,30, and 100 nmoUkg) (B). *, P -, -, 0.05 vs. Raline. 
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cantly inhibited only in the PYY3-36 + GLP-17-3. group (Fig. 
5) [food intake 0-1 h (grams): saline, 4.1 ± 0.2; 10 nmol/kg 
GLP-17-,, 3.9 ± 0.3; 20 runol/kg GLP-17-36,4.2 0.3; 1 
nmol/kg PYYI. _, (, 
4.2 ± 0.3; 2 nmol/kg PYY,,, _. 
4.1 0.2; 1 
nmol/kg PYY,, -,, 
+ 10 nmol/kg GLP-17-3., 2.8 ± 0.21. There 
was significant inhibition of food intake with the combined 
treatment, compared with all other groups (P < 0.02). This 
effect was most marked in the first hour of the dark phase. 
Cumulative food intake was inhibited in the coadministra- 
tion group for up to 4 h, compared with saline (11 < 0.05) 
[food intake 0-4 h (grams): saline, 9.8 ± 0.3; 10 nmol/kg 
GLP-17ý3ý 9.7 ± 0.4; 20 nmol/kg GLP-17-, 36,10.0 ± 0.2; 1 
10.1 ý 0.4; 9.9 ± 0.5; 2 nmol/kg PYY, ý nmol/kg l'YY, - 1 nmol/kg PYY. -, -., 
+ 10 nmol/kg GLP-17-3,8.9 ± 0.41. At 
these low doses, no differences in food intake were observed 
between groups at later time points (data not shown). 
Immunocytochemistry 
To elucidate a possible mechanism for the additive inhib- 
itory feeding effect of PYY and GLP-1, c-fos was quantified 
after low dose individual peptide and combined peptide 
administration. Doses of PYY and GLP-1 that had been found 
not to alter food intake individually but had led to significant 
reduction in food intake after coadministration were chosen. 
Rats received ip injections of saline, 10 nmol/kg GLP-17, 
1 nmol/kg PYY3-, 3, or 1 nmol/kg PYY_, -, + 
10 nmol/kg 
GLP-17-,, 6. In the hypothalamus, there were no significant 
differences in the number of FLI counts in the PVN, and 
ventromedial and dorsomedial of the hypothalamus be- 
tween treatment groups (data not shown). At these low 
doses, no significant differences were seen in the ARC with 
either PYY., -, or 
GLP-1, 
-, 6 alone, compared with saline. However, an 85% increase in the number of FLI counts was 
observed in the ARC after the coadministration treatment, 
compared with saline (P < 0.05) (Fig. 6). Moreover, after the 
combined PYY3-3, + GLP-17-16 treatment, there were signif- 
icantly more P'Ll than after PYY3,,, alone (P < 0.05) and a 
trend for more FLI after GLP-17-36 alone (P = 0.05) (FLI- 
positive neurons in the ARC per section: saline, 35.4 - 6.18; 
GLP-17-,, 42.9 ± 1.2; PYY3-36,36.2 -- 4.4; 
PYY., 
_- ,6+ 
GLP- 
17_3ý 65.6 ± 10.0). 
In the brain stem, no significant differences in F1.1 counts 
were observed between these low-dose treatments in the 
nucleus of the solitary tract or Al' (data not shown). 
lk 
IAUI 
16 
drinking m icarmp 
hwollkmon g1wililli'm 
91 Saline P. (; I-P Z*P I-C 2-C. 
Fmý 5. Food intake in the first hour of' the dark phase in treely 
feLding rats after ip low-dosp. condministration ofPYY:, -:,,; with 
GLP- 
17, ý, Lompared with each peptide alone. Rats were injected with 
saline, P+G (I nniol/kg PYY_,,,, + 10 nmoVkg GLP-17ý(), G (10 
n. moVkg GLP-17, M), 2*G (20 njnoVkg GLP-17, s), P (I nmoVkg PYY3-3ý), or 2*P (2 nmoVkg PYY,.,, ). t, P<0.06, compared with all 
other groups. 
Fi(;. 7. Number of the following behavior obrervations: foeding, drink- 
ing, locomotion, grooming, head down, sleeping, and re-aring idler ip 
saline, 10 nmol/kgGLP-17_,,, I runoVkg PYY,,., m, I nmol/kg IIW,, w + 
10 nmoVkg (. LP-17-,., 10 nmoVkg exondin4 (exl), and 0.5 ml 1m 
lithium chloride (UCD. The animals were observed over 60 min aft4er 
injection, and the total number of observations per animal was 36. 
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100 
I 
Saline P+(; pG 
FiG. 6. Expression of FU in the ARC in response to ip saline, P+G (1 
runoVkg PYY.. + 10 runol/kg GLP-lýw), G (10 nmol/kg GLP-17,,, ), 
and P (l nmol/kg PYY,,, ). 1, P -z 0.05, compared with all other groups. 
Behamoral studies 
To determine whether behavioral alteration were associ- 
ated with doses of PYYv, 36 and GLP-17-3. at which an ad- 
ditive feeding effect was observed, an observation studywas 
performed. Fasted rats were ip injected with saline, 10 
mnol/kg GLP-17-36,1 rtmol/kg PYY, -3& 
1 nmol/kg PYY,, 6 
+ 10 nmol/kg GLP-17.36,10 nmol/kg exendin-4, or 1m 
lithium chloride (positive control) (n = 10 per group). The 
groups treated with exendin-4 and lithium chloride had sig- 
nificantly fewer feeding episodes and significantly more 
head-down episodes, compared with saline (P < 0.05) (Fig. 
7). However, no significant differences in behavior were ob- 
served after PYY., -,, 
GLP-17-. w or PYY3, m + GLP-17-36. 
In further study, locomotion was assessed in freely feeding 
rats before the dark phase after ip saline, 10nmol/kgGLP-17-3, 
1 runol/kg PYY3-3,1 nmol/kg PYY3,36 + 10 nmol/kg GLP- 
17,1& or 10 nmol/kg exendin4 (n = 9-10 per group). No sig- 
nificant differences in horizontal movement (x-tot) were ob- 
served after the combined PYY, -, + 
GLP-17-,, 6 treatment, but 
there was a slight reduction in vertical movement (z-tot), com- 
pared with saline (P = 0.04) (Table 1). There were significant 
reductions' in both horizontal and vertical movement after ex- 
endin4, compared with saline (P < 0.01 for both comparisons). 
Saline 1, P- I PVY 
P)'N'+(; I, ll-i FN-4 
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Coadministration of PIT, 3, and GLP- 17-,,, in human 
volunteers 
Infusion of llYY-_, (0.4 pmol/kg-min) was associated with 
a 15% reduction in energy intake at the buffet meal, compared 
wifli saline, although this reduction achieved only borderline 
statistical significance (11 - 0.07). There was no significant dif- 
ference in energy intake with GLP-17_3, infusion (0.4 pmol/ 
kg-min), in keeping with previously published results (8). With 
the combined PYYý,.,,, and GI, P-1.7-,, 6 infusion, caloric intake at 
the buffet meal was reduced by 27% (buffet meal energy intake 
(kilojoules): saline, 4174 ý- 285; GIT-17-3,3978 ý 340; PYY, ý, 
3551 , 44I; PYY_3_3, ý I 
GLP-17_w3O33 1 279; percentage change 
from saline day: GLP-17_v, -5 ± 5%; lYY3.. 36, -15 ± 91%; 
ll'YY, 
-,,, -ý 
GI-P-17_,, -27 ± 3%) (Fig. 8). There was a statistical 
difference in energy intake among the four infusion groups (P < 
0.01). The buffet caloric intake on the PYY3-, 3, + GLP-17-3, day 
was significantly less than on all other infusion days (11 < 0.05). 
Cumulative energy intake over 24 h (buffet + food diary) was 
significantly reduced with the combined 12YY, 6 + GLP-17-3& 
compared with all the other groups (cumulative 24-h energy 
intake (megajoules): saline, 13.7 ± 0.6, GLP-17-3& 13.6 + 13; 
IIYY, 1ý16,13.5 1 0.9; PYYý, 36 -ý GI_11-17ý3ý 12.0 ý 0.7,1) < 0.05 
for I"YY,,, + GLP-1, -,,, vs. all other groups; percentage change from saline day: GLJ)-I, _,, -2 
1 7%; PYY:, 
-. w -1 + 
5%; 
I"YY-, 
-, 36 + 
GLP-17_36, -13 ± 5%). Analysis of the visual analog 
scales revealed no significant differences in nausea scores be- 
tween infusion days [nausea score after 90 min infusion (mil- 
limeters): saline, 9.4 _ý 0.83; GLP-17,1& 1.2 4i 0.05; PYY3-3& 3.8 0.18; PYY3, 
-3,, + 
GLP-17-w 6.3 t 2.2, P=NS). 
There were significant increases in plasma FYY levels with 
PYY, and PW,., + GLP-17. ý infusions and pLasn-ta GIT-1 
leveis with (-; Ll'-17-,, and 1"3, -. 6 
+ GIT-17-3., infusions (Ta- 
bles 2 and 3). Interestingly, our GLP-1,., 6 infusion inhibited 
circulating PYY (FYY picomoles per liter at 90 min: saline in- 
fusion, 10.3 - 1.2; GIT-1, _,, 
infusion, 7.7 -1 0.8,11 - O. o5). 
However, no significant changes in LirCUlating GLP-I were 
obsen-ed during l'YY,,,, infusion. 
Fasting plasma insulin was increased by GLI)-17-,, 'nf Us'un 
-it 90 min, compared with saline, and no chanqs, in insulin 
secretion were observed with PYYý., alone. Whereas the co- 
administration PYYý,, v, + GLI1- infusion enhanced insulin 
secietion, there v., as no additional sccretion, corlip'lled with 
(; 1-13-17-. 6 alone (insulin picomoles per 
liter at 90 min: saline, 
53.2 
-1 
4.9; GLP-I 7_ýý 63.0 3.5; In'Y3_3,51.2 -4 
5.5; 11YY3-36 + 
GIT-I, 
ý,, 
66.7 
-1 
4.3; 11 0.05 fur GLI1-I,, and combined 
PYYý,, + GLP-17-,,, infusions vs. saline) (Table 4). Consistent 
%ý Ith thesechaliges in insulin levuls, lasting plasilla gillco. sewas 
TABLE 1. Beam breaks in the finit hour ofthe dark phase 
following If' saline, 10 nrnoVkg (11'P-17.6,1 nmoVkg PYY,. j,;, 10 
nmoUkg GIT-1,4 1 nrnol/kg PYY,,,, or 10 nmoUkg exendin-4 
(n -- 8-10) 
Horizontal moýmünt vertical 
Saline 724 60 367 81 
GLP- 1 664 76 265 56 
pyy_ý,, 653 88 291 56 
IIYY,, + GLP-l 517 t 66 167- 25" 
Exendin 4 442 , 3H,, 128 * IWI 
"P-0.05 us. saline. 
L), ý, -mbvr 2(K), 5.146, U1 5120-5127,5125 
G 1) P+C 
FTC,. 8. Energy intake in human healthy volunteers from a free buffet 
meal with infusion of.. ýaline, G (0.4 puioLIg min GLT- 17-36ý1 P tO. 4 
pmol/kg-min and P-G. (0.4 pmol/kgmin PYY, -,, 4 OA pmoVkg-min GLP-171). Result-s are presented as absolute difference 
in energy intake from tile saline infusion day. t, P<0.05, compared, 
with all other groups. 
reduced by GLI'-I,., 6 infusion and the joint coadministration 
infusion but unchanged by PYY, 36 alone (glucosL millimoles 
per liter at 90 min: saline, 4.6 ý 0.1; GLP-1-1-w 4.2 t 0.1; PYY,. v,, 45 - 0.1; llYY_, -.,, i 
GLII-1, 
-,, 
4.1 0.1; 11 < 0.01 for (A. 11-1 
and combined M_,, +GLP-17-36 infusions vs. saline) (Table 
5). Postprandial insulin and glucose levels were not measured 
due to the variability of energy intake at the buffet meal. 
Discussion 
In this paper we investigated the effects of the coadmin- 
istrafion of and GLP-17-36 on feeding in rodents and 
humans. 
FfY. j. jr, and GLP-17., inhibited food intake individually in 
mice and rats. lYY,, -,,, appeared to cause maximal ttvding inhibition at doses of 100 nmol/kg and above. In contrast, 
feeding inhibition associated with GIJ)-I,,,, was similar to that 
seen with CCK-8, with increasing inhibition seen with increas- 
ing doses (14). In the dose-response studies with low doses, the 
minimum do,, (w, of PYY,, and UY-1, -,, 
found to inhibit food 
intake v; ere 3and V nmol/kg, respectively. Both theA-ý results 
are consiMent with our previously published data (2,7). In both 
high- and low-do-A-, coadministration studies, PYY., and 
GIT-17, v, administered together inhibited food intake signifi- 
cantly more than either peptide alone or more than double the 
dose of either jxptide. Ilius, and alljývared 
to inhibit feeding additivt. -1y. 
PY) 
_,, and 
Gl, l'-I-_, were c(xidministertxi in geneticalk, 
obesemice. Examinationof thefood intake in thesaline injocted 
groups revealed that theoNoband dil/Amiceate less in the first 
hour of refeeding than their WT littermates. This somewhat 
surprisingfilldillg 1., L: o1). SiSjCjjt N%jtjj 1)14'% iously publislicki %%olk 
TABLE 2. Hýilffill It-VVIS ý11 PYY i" 1'ý .... ý'., 'A 
ninollkg GLP- I.,,, OA iinioAg l'YY,,,;, and 0,1 ninolAg PYY, 
-3,1 0.4 iirnoUkg G1,11- Iý:,,; 
pyy level, PYY levels pyy levels 
(pmoUliter) (pmolAiter) (pmolAiter) 
Won- infusion nftA, r 90 min infu. %ion 2 1) affi, r 
fa, 
Saline 10.5 1.4 10.3 1.2 16.3 1.4 
G. III, - 1 10.9 0,9 7.7 0.81,16.0 1.6 
PYY3--36 8.9 0.7 69.8 4.2' 18.0 1.3 
Pyy: ", i + GLP-I 11.1 1.2 58.4 t 4.3h 23.1 3.3 
P<0.05 vs. saline. 
P<0.005 vs. saline. 
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TA13LE & Plasma levels of GLP-1 in human infusions of saline, 
0.4 nmol/kg GLP-17-as, 0.4 tunoL/kg PYY3.,, o, and 0.4 nmoVkg FYY8., s + 0.4 nmol/kg GLP-11-ag 
GLP-1 levels GLP-I levels GLF-I levels 
(pmoVliter) (pmoVliter) (pmoVliter) 
before infusion after 90 min infusion 2h after 
(fasting) (premeal) the meal 
Saline 24.6 ± 2.8 18.8 t 4.4 62.8 ± 10.4 
GLP-1 21.5 :t1.6 61.5 ± 3.71 78.4 ± 12.3 
pyYs46 18.3 ± 1.5 18.2 ± 1.6 47.5 ± 2.9 
PYY3-,, + GLP-I 23.0 ± 2.2 62.5 ± 5.2' 56.8 ± 5.8 
*P<0.005 v$. saline. 
(26,27) and suggests that thermogenic adaptation to fasting 
reduced the subsequent energyrequirement of theobesemouse 
models (28). Coadministration of PYY3. a6 and GLP-17-m treat- 
ment led to significantly greater reduction in feeding than twice 
the dose of either peptide alone in the oblob and JbIdb and Wr 
mice. Thus, PYY3-a6 and GLP-17_36 inNbited food intake addi- 
tively in obese as well as-lean rodents. 
We quantified cps afterPYY,,,, GLP-17-, W and PYY,, m + GLP-l7_a6 administration to determine a possible mechanism 
for their additive effect on feeding. There was a significant 
increase in c-fos in the ARC after low-dose combination FYY3-m 
+ GLP-17_a6 treatinent but no changes in the other treatment 
groups. Therefore, PYY3-m and GLP-17-, * may inhibit food intake through additive stimulation of ARC neurons. However, 
ofis mapping cannot identify the pathway(s) through which 
neuronal activation was mediated. The ARC neuronal activa- 
tion observed in our study could have been mediated through 
the blood-brain barrier via the median eminence (29) or the 
vagus nerve and brain stem (30). 
There were no significant differences in observed behavior in 
rats after PYY3_w GLP-17-, & or PYY3_w + GLP-17-,, at doses 
at which the combination hihibited feeding. Th the locomotion 
study, no significant differences in horizontal beam breaks were 
observed after the combined PYY3.. 36 + GLP-17-m treatrnentý 
but there were marginally fewer vertical beam breaks. In their 
recent publication, Talsania et aL (31) suggested that low-dose 
exendin4 together with PYY3-m may increase the suppression 
of food intake in rodents without inducing significant side 
effects. There were no differences in nausea scores between 
infusions in our human study. Taken together these results 
suggest that behavioral change is unlikely to account for the 
feeding inhibition observed with coadministration of PYY, 3, -U 
and GLP-17-36. Thus, these peptides may have a specific effect 
on feeding independent of behavioral change. 
In our human study, GLP-l7_a6 alone (0.4 pmol/kg-min) did 
not lead to a significant change in energy intake. In human 
TABLE 4. Plasma levels of insulin in human infusions of saline, 
0.4 mnoVkg GLP-17-89,0.4 nmol/kg PYY3-,,, and 0.4 mnollkg 
PW", + 0.4 mnoL'kg GLP-1,.,, 
Insulin levels Insulin levels 
(PmolAiter) (pmoMiter) 
before infusion after 90 min infusion 
(fasting) (premeal) 
Saline 58.7 ± 4.0 53.2 ± 4.9 
GLP-1 56.6 ± 4.4 63.0 ± 3.61 
PYY3-36 57.3 ± 4.0 51J ± 5.5 
PYY3-ae + GLP-1 58.1 ± 4.0 66.2 ± 4.3* 
IP<0.05 m saline. 
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TABLE 5. Plasma levels of glucose in human, infusions of saline, 
0.4 nmoVkg GLP-17-", 0.4 nmolAcg PYY3. -m, and 
0.4 nmoVkg 
PYYS-36 + 0.4 j3znoVkg GLP-17, u 
Glucose levels Glucose levels 
(mmol/liter) (mmol/liter) 
before infusion after 90 min infusion 
(fasting) (premeal) 
Saline 4.44 ± 0.70 4.56 ± 0.07 
GLP-1 4.54 t 0.13 4.22 t 0.951 
PYY3-86 4.55 ± 0.58 4.52 ± 0.07 
PYY&-36 + GLP-l 4.49 ± 0.59 4.11 ± O. OPI 
*P<0.05 vs. saline. 
subjects the lowest reported infusion rate of GLP-17-m assod- 
ated with a change in energy intake is 0.75 pmol/kgm-dn (21). 
However, incretin effects have been observed with a lower rate 
of GLP-17-m of 0-5 pmol/kg-min (24). In the current study, we 
found a small but statistically significant reduction in fasting. 
glucose levels and an increase in the fasting insulin concentra- 
tim with GLP-17., 3c, infusion. 
PYY3-, 6 infusion (0.4 pmol/kg-n-in) was associated with a 
15% reduction in energy intake, compared with saline infusion, 
although fl-ds did not reach statistical significance. The inagni- 
tude of this reduction is in keeping with the larger reduction of 
360/6 reported after higher-rate PYY infusions (0-8 pmol/ 
kg-n-dn) (2). 
Coadministration of PYY, -. 6 with 
GLP-17-36 was associated 
with a 271/6 reduction in energy intake from the buffet meal. The 
combination was more effective in Inhibiting appetite then ei- 
ther peptide alone. Cumulative energy Intake over 24 4 in- 
cluding the buffet meal, was reduced by 13% after combined 
infusion, compared with the saline infusion, and was signifi- 
car; tly less than that after all other treatment groups. In contrast 
with the additive Inhibitory effect on energy intake, the incretin 
effect of GLP-17-36 appeared unchanged with the addition of 
M3-a6. 
Our study involving coadministration of PYY3-36 and GLP- 
17-36 suggests an additive inhibitory feeding effect. Interest- 
ingly, the GLP-1 receptor agonist, exendin-4, and PYY3-36 have 
been reported to inhibit food intake synergistically in rodents 
(31). However, it appears that not all combinations of gut hor- 
mones behave in this way. Indeed, it has recently been reported 
that whereas Infusion of CCK-33 or GLP-17-, 6 inhibited food 
intake when administered individually, no enhanced Inhibition 
was observed when they were infused together (32). Further 
work is needed to determine whether the other combinations 
of gut hormones lead to additive alterations in food intake. 
We observed a reduction of endogenous PW levels with 
GLP-17-36 infusion. 11-ds has been previously demonstrated 
at a higher dose of peripheral GLP-17-36 administration (32). 
Inhibition of endogenous PYY could result in a reduction in 
the anorexic action of GLP-1. In contrast, as in previous work 
(12), no changes in endogenous GLP-1 concentrations were 
observed after PYY3-" Infusion. 
In summary, we have demonstrated that PYY3-m and GLP- 
17-36 may inhibit appetite additively in rodents and man. The 
mechanism may be through enhanced activation of hypotha- 
Iamic arcuate neurons. Reduction in energy intake and increase 
in insulin secretion would make this combination a particularly 
attractive therapy for patients with type 2 diabetes. 
Neary et al. 9 PYY and GLP-I Inhibit Feeding Additively 
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ORIGINAL ARTICLE 
Subcutaneous administration of ghrelin stimulates 
energy intake in healthy lean human volunteers 
MR Druce', NM Neary', Q Small, j Milton, M Monteiro, M Patterson, MA Ghatei and SR Bloom 
Department of Metabolic Medicine, Imperial College, Hammersmith Hospital Campus, London, UK 
Background: The gastric hormone ghrelin appears a useful agent to stimulate food intake in people with anorexia of illness. The 
loss of ghrelin's acyl group renders it inactive, thus it has been thought that subcutaneous administration may be problematic. 
Objective: To investigate whether human subjects are sensitive to the effects of ghrelin administered by single subcutaneous 
Injection. 
Study design: Randomized, double-blind, placebo-controlled trial. 
Subjects: Sixteen healthy lean volunteers (eight men and eight women). 
Protocol: Fasted subjects received subcutaneous injections of ghrelin (3.6 nmol/kg) or saline. After 30 min, a buffet breakfast 
was served. 
Results: Ghrelin injection Increased energy intake by 27% (ghrelin 5076±691 k] versus saline 4230 ±607 k], P= 0.04). Ghrelin 
appeared to enhance the perceived palatability of the food offered (palatability score: ghrelin 81.1 ± 3.6 versus saline 70.0±4.4; 
P=0.03). 
Conclusions: These results suggest that subcutaneous ghrelin is effective at stimulating energy intake and improving palatability 
and may be of direct use in the treatment of appetite loss. 
International Journal of Obesity (2006) 30,293-296. clohl 0.1 038/4. lio. 0803158; published online 25 October 2005 
Keywords: appetite; ghrelin; food intake, growth hormone secretagogues 
Introduction 
Loss of appetite and loss of weight are major causes of 
morbidity and mortality affecting many patients including 
those with cancer, IIIV, cardiac cachexia, Inflammatory 
conditions such as sepsis and burns and postoperative 
patients. ' There Is a need for effective and well-tolerated 
treatments to improve energy intake. We have recently 
reported that acute administration of intravenous ghrelin 
stimulates energy intake In cancer patients with loss of 
appetite .2 However, intravenous administration Is cumber- 
some and unsuited to outpatient clinical practice. A practical 
means of ghrelin delivery which retains bioactivity Is 
required. 
Ghrelln is a gastric hormone first Identified as the 
endogenous ligand for the growth hormone secretagogue 
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receptor. Ghrelin Is a 28 amino-acid peptide, the active form 
of wliich has a novel post-translational addition of an 
octanoyl acyl group on the third residue. 3 Plasma ghrelln 
levels rise after fasting and fall after feeding. 4 In addition to 
stimulating growth hormone (GH) release, ghrelin increases 
food Intake when administered peripherally In rodents and 
man. s-7 Ghrelin has thus been postulated to act as a meal 
Initiator. 4 Chronic ghreIin administration promotes adipo- 
sity and weight gain In rodents. 5,6 
Peptide hormones are not active when given orally due to 
digestion. Ghrelin Is easily Inactivated and subcutaneous 
gh. relin Injection might result In inactivation due to loss 
of the acyl group. Although ghrelin has been administered 
subcutaneously to human subjects for evaluation of cardiac 
effects, the food intake response was not assessed. 6 
We performed a double-blind, randomized, crossover trial 
in order to determine the effect of subcutaneous ghrelin on 
food intake In man. 
Methods 
The study was performed In accordance with the principles 
of the Declaration of Helsinki. All subjects gave their written 
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Informed consent to participate In the study. Synthetic 
human ghrelln was purchased from Bachem (Merseyside, 
UK). Peptide was dissolved In saline 0.9% (Bayer, Haywards 
Heath, UK) for subcutaneous administration. 
In order to select a suitable dose of ghrelin, a pilot study 
was performed. The starting dose of ghrelin was 0.225 nmol/kg 
(equivalent to half ghrelln dose administered prior to the 
meal In our previous Intravenous Infusion study). 2 Doses 
were thereafter Increased by a factor of two. No side effects 
were observed or reported at any dose of ghrelin adminis- 
tered. A tr end for a consistent Increase In food Intake and an 
Increase In GH release was observed at a dose of 3.6 nmol/kg 
(data not shown). We therefore proceeded to perform a 
double-blind, randomized, crossover trial In order to deter- 
mine the effect of this 6te of subcutaneous ghrelin on food 
Intake. 
In total, 16 healthy volunteers (eight men and eight 
women) were recruited to the main study. The inclusion 
criteria were an age between 18 and 55 years, BMI between 
19 and 26kg/m2 and the absence of disease or medication 
likely to interfere with the study. The mean age of the 
volunteers was ZS. 4±2.9 (mean±s. d. ) years (range 19-31 
years) and mean BW 22. S ± LS (range 19.8-25.1) kg1e. 
Fasted subjects attended on two mornings at least 2 days 
apart. At 0830 hours (t=O), they received a subcutaneous 
injection of ghrelin (3.6nmolft) or saline. At 0900 hours 
(t=30), breakfast was served, comprising preweighed cake 
presented in excess, herbal tea or decaffeinated coffee and 
water. At 0930 hours (t=60), the remaining food was 
removed and weighed. During the study, subjects were asked 
to rate subjective hunger and nausea on 100mm visual 
analogue scales (VAS)' at times -15,0,15,30 and 60mIrL 
A 10ml blood sample was also taken at each time point. 
Plasma for ghrelin assay (1 ml) was collected with 50 pl 1m 
HCL and 10pl 10mg/ml phenyl methyl sulphonyl fluoride 
(PMSF). Intravenous ghrelin has been previously reported to 
lower blood pressure"' and we were interested to determine 
whether subcutaneous ghrelin would have a similar effect. 
Therefore blood pressure and pulse were assessed at each 
time point. At t-60, subjects were asked to rate the 
pleasantness of the meal on a VAS, They were then allowed 
to go home and were asked to record their food Intake for the 
rest of the day. Food diaries were assessed using Dietplan-S 
nutritional software (Forestfield software Ltd, West Sussex, 
UK) by a dietician who was unaware of which treatment had 
been given. 
Plasma total ghrelin was measured by radiolmmunoassay 
(RIA) using antiserurn (SC-10368) from Santa Cruz Bio- 
technology (Delaware, California, USA). " Plasma-acylated 
ghrelln was quantified using the active ghrelin Linco RIA 
(product no GHRA-8811K). Iz In order to confirm the 
bloactivity of ghrelin administered subcutaneously, plasma 
GH was analysed with the Advantage automated cheml- 
luminescent immunoassay (Nichols Institute Diagnostics). 
Subject characteristics (age and BMO are presented as 
mean ± standard deviation (s. d. ). The results of the study are 
presented as mean ± standard error of the mean (s. e. m. ). The 
primary outcome of the study was energy intake at breakfast. 
Comparisons between ghrelin and saline Injection days for 
energy intake, VAS and plasma levels were made using paired 
t-tests. We also examined and compared the effect of ghrelin 
on energy intake between the men and the women in the 
study using an unpaired t-test. In all cases, P<0.05 was 
considered to be statistically significant. 
Results 
Basal ghrelln levels were comparable on the saline and ghrelin 
Injection days (total ghrelin 176±16.3 and 192±11.4pmol/I 
respectively, P=0.1, acylated ghrelin levels 36.7±3.1 and 
34.7±2. lpmol/I respectively, P=0.7). The ratio of acylated 
to total basal ghrelin was approidmately 1: 5. Endogenous 
ghrelin decreased after breakfast on the saline Injection day 
(total ghrelln fell from 198±2Z I pmol/I immediately before 
breakfast to 161 ± 1S. S pmol/I 30 min after breakfast, P<O. OS, 
and acylated ghrelin from 34. S±3.2 to 29.2±2. lpmolA, 
P<O. OS). On the ghrelln day, total ghrelln peaked ISmin 
after Injection at 988±89.4pmol/l. Acylated ghrelin peaked 
30min after injection at 355±66.3pmolA (Figure 1). The 
ratio of acylated to total ghrelln following ghrelin. injection 
was approidmately 13. Subcutaneous ghrelin stimulated GH 
release confirming bloactivity. GH peaked at 30 min following 
ghrelln injection: saline day 5.6±1.7mW/l, ghrelln day 
126±18.3 mIU/1, P<0.05. 
Energy Intake at breakfast was Increased by 27% following 
ghrelin injection (energy Intake (kj): saline 4230±607, 
-ghrelin S076±691, P=0.04) (Figure 2). There was no 
significant alteration in energy intake for the rest of the 
day following ghrelin injection (energy intake (kj): saline 
day 6697 ± 860, ghrelin day 6630 ± 727, P=0.9). There were 
no significant differences in hunger scores between Infec- 
tions (mean score (mm) at 30 min: saline day 69 ± 6, ghrelin 
day 72 ± 5, P=0.5). However subjects found the meal more 
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Figure 2 Breakfast energy intake. Figure shows percentage Increase In 
energy intake compared to the saline control day, Error bar represents 
standard error of the mean; *P< 0.05. 
pleasant following ghrelin injection (mean score (mm): 
ghrelin day 81±4, saline day 70±4, P=0.03). Subgroup 
analysis of the data revealed that the men ate more than 
the women on the saline control day (5619±943 versus 
2841±378kj, P<0.05). However, similar percentage In- 
creases in food intake were observed following ghrelln 
injection In both sexes (% increase energy intake: men 
23±14%, women 30±14%, P=0.7). 
-No side effects were reported by the subjects. There were 
no dIfferences in the VAS nausea scores between infusion 
days (data not shown). After saline injection, the mean 
change in systolic blood pressure from basal to 30 min after 
injection was 0.9 ± 1.9 mmHg to an absolute systolic pressure 
of 117 ± 2.7! rnmHg. After ghrelin injection, the mean change 
was -5.4±2.8 to 108±3.9mmHg (P<0.05 versus saline 
day). No changes In diastolic pressure or pulse rate were 
observed following ghrelin Injection (data not shown). 
Discussion 
Out results show that ghrelin Increased food Intake In 
healthy human volunteers following subcutaneous admin- 
istration. Therefore, this practical route of administration 
has potential therapeutic benefits. 
In our study, the ratio of acylated to total plasma ghrelin 
was similar on a saline day to that previously reported. 13 It 
was possible that significant breakdown of acylated to 
desacylated ghrelin would occur in the tissues following 
subcutaneous Injection. Our finding that plasma-acylated 
ghrelln Increased significantly following subcutaneous In- 
jection suggests that acylated ghrelln, can reach the circula- 
tion via the subcutaneous route. The rise in GH observed is 
further evidence of the bloactivity of subcutaneous ghrelln. 
We also observed a small reduction in blood pressure as has 
previously been reported following intravenous ghtelin. 10 
Plasma-acylated ghrelin levels had risen 15 min following 
subcutaneous injection and were similarly elevated at 
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30min. This suggests that ghrelin injection 30 min before a 
meal might be the optimal time for stimulation of food 
Intake. Millions of diabetics self-administer Insulin In this 
way without difficulty. 
While direct comparison would not be valid because of 
differences In the administration route and subsequent 
timing of the meal, it Is helpful to examine the feeding 
response following intravenous ghrelin In published work. 
Wren et al. 7 reported a 28% increase in food intake following 
a total intravenous dose of 1.4 nmol/kg. In our present study, 
we admin. 1stered 3.6 nmoVkg subcutaneous ghrelin and 
observed a comparable 27% Increase In food Intake. We also 
observed an Increase In the perceived palatability of the meal 
following ghrelln Injection. An enhanced appreciation of the 
palatability of a meal could contribute to the Increase in 
energy intake following ghrelin Injection. 
Analysis of the food diaries of the current study revealed 
that, as with Intravenous ghrelin '2.7 the Increase In. 
food 
intake observed at the meal following subcutaneous ghrelin 
was not sustained for the rest of the day. However, there was 
no evidence of a subsequent reduction In energy Intake to 
compensate for the increased food intake at the meal. 
The cake was selected to be given to the subjects for their 
breakfast because of its fixed nutrient components and 
because of the ease of reproducibility of measurement of 
energy intake between infusion days. Previous ghrelin 
studies have demonstrated similar increases in energy intake 
with a lunch-time meal. 2.7 The energy Intake on the saline 
Injection day in the current study was relatively high with 
the men eating more than the women. Despite these high 
baselines, subcutaneous ghrelln significantly stimulated 
energy intake. The feeding response to ghrelin appeared to 
be similar In the men and women In the study. 
The effectiveness of subcutaneous administration of ghre- 
lin on food intake can now lead to further trials in patients in 
whom anorexia Is a significant Impediment to recovery. 
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